0001493152-19-019860.txt : 20191230 0001493152-19-019860.hdr.sgml : 20191230 20191230160654 ACCESSION NUMBER: 0001493152-19-019860 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191230 DATE AS OF CHANGE: 20191230 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rennova Health, Inc. CENTRAL INDEX KEY: 0000931059 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 680370244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35141 FILM NUMBER: 191316711 BUSINESS ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-855-1626 MAIL ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: CollabRx, Inc. DATE OF NAME CHANGE: 20120926 FORMER COMPANY: FORMER CONFORMED NAME: TEGAL CORP /DE/ DATE OF NAME CHANGE: 19950918 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

(Mark one)

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2019

 

OR

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to ______.

 

Commission File Number: 001-35141

 

RENNOVA HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   68-0370244

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

     

931 Village Boulevard, Suite 905

West Palm Beach, FL

  33409
(Address of principal executive offices)   (Zip Code)

 

(561) 855-1626

(Registrant’s telephone number, including area code)

 

Securities registered under Section 12(b) of the Act:

 

Title of Each Class  

Trading Symbol(s)

  Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer [  ] Accelerated filer [  ]
Non-accelerated filer [X] Smaller reporting company [X]

 

  Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

As of December 26, 2019 the registrant had 9,648,936,775 shares of its Common Stock, $0.0001 par value, outstanding

 

 

 

   
 

 

RENNOVA HEALTH, INC.

FORM 10-Q

September 30, 2019

 

TABLE OF CONTENTS

 

    Page No.
PART I – FINANCIAL INFORMATION    
       
Item 1. Financial Statements   3
  Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018 (unaudited)   3
  Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2019 and 2018 (unaudited)   4
  Condensed Consolidated Statements of Changes in Stockholders’ Deficit for each of the quarters in the periods ended September 30, 2019 and 2018 (unaudited)   5
  Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2019 and 2018 (unaudited)   7
  Notes to Condensed Consolidated Financial Statements (unaudited)   8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   38
Item 3. Quantitative and Qualitative Disclosures About Market Risk   50
Item 4. Controls and Procedures   50
       
PART II – OTHER INFORMATION    
       
Item 1. Legal Proceedings   51
Item 1A. Risk Factors   51
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   51
Item 3. Defaults Upon Senior Securities   51
Item 4. Mine Safety Disclosures   52
Item 5. Other Information   52
Item 6. Exhibits   52
       
SIGNATURES   53

 

 2 

 

 

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

 

RENNOVA HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

 

   September 30,   December 31, 
   2019   2018 
ASSETS          
Current assets:          
Cash  $107,472   $6,870 
Accounts receivable, net   5,108,462    3,811,749 
Inventory   688,819    453,402 
Prepaid expenses and other current assets   77,646    78,820 
Income tax refunds receivable   631,077    631,077 
Current assets of AMSG and HTS classified as held for sale   362,146    140,352 
Total current assets   6,975,622    5,122,270 
           
Property and equipment, net   8,467,887    8,526,904 
Right-of-use operating lease assets   328,615    - 
Intangibles, net   509,443    259,443 
Deposits   281,523    278,864 
Non-current assets of AMSG and HTS classified as held for sale   10,975    11,819 
Total assets  $16,574,065   $14,199,300 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable (includes related parties amount of $0.5 million and $0.4 million, respectively)  $13,076,160   $8,155,955 
Checks issued in excess of bank account balance   121,947    109,695 
Accrued expenses (includes related parties amount of $1.8 million and $0.4 million, respectively)   10,542,219    10,711,281 
Income taxes payable   1,355,651    1,400,651 
Current portion of notes payable   3,605,532    7,083,505 
Current portion of notes payable, related party   14,968,104    800,000 
Current portion of right-of-use operating lease obligations   141,830    - 
Current portion of finance lease obligations   589,457    730,665 
Current portion of debentures   28,690,240    12,776,316 
Derivative liabilities   455,336    350,260 
Current liabilities of AMSG and HTS classified as held for sale   2,701,459    2,297,846 
Total current liabilities   76,247,935    44,416,174 
           
Other liabilities:          
Right-of-use operating lease obligations, net of current portion   186,785    - 
Finance lease obligations, net of current portion   28,821    31,543 
Total liabilities   76,463,541    44,447,717 
           
Commitments and contingencies          
           
Redeemable Preferred Stock - Series I-1   5,835,294    5,835,294 
Redeemable Preferred Stock - Series I-2   1,940,179    3,084,153 
           
Stockholders’ deficit:          
Series G preferred stock, $0.01 par value, 14,000 shares authorized, 215 shares issued and outstanding   2    2 
Series H preferred stock, $0.01 par value, 14,202 shares authorized, 10 and 60 shares issued and outstanding   -    - 
Series F preferred stock, $0.01 par value, 1,750,000 shares authorized, 1,750,000 shares issued and outstanding   17,500    17,500 
Series J preferred stock, $0.01 par value, 250,000 shares authorized, 250,000 shares issued and outstanding   2,500    2,500 
Common stock, $0.0001 par value, 10,000,000,000 shares authorized, 8,398,936,775 and 128,567,273 shares issued and outstanding   839,894    12,857 
Additional paid-in-capital   509,515,347    375,845,883 
Accumulated deficit   (578,040,192)   (415,046,606)
Total stockholders’ deficit   (67,664,949)   (39,167,864)
Total liabilities and stockholders’ deficit  $16,574,065   $14,199,300 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 3 

 

 

RENNOVA HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2019   2018   2019   2018 
                 
Net revenues  $3,885,977   $5,039,112   $13,137,816   $9,932,989 
                     
Operating expenses:                    
Direct costs of revenue   3,227,709    3,350,286    12,072,442    7,809,465 
General and administrative   3,163,624    4,351,576    12,730,695    10,240,434 
Depreciation and amortization   199,996    152,825    609,818    804,074 
Total operating expenses   6,591,329    7,854,687    25,412,955    18,853,973 
                     
Loss from continuing operations before other income (expense) and income taxes   (2,705,352)   (2,815,575)   (12,275,139)   (8,920,984)
                     
Other (expense) income:                    
Other (expense) income   (5,784,873)   188,658    (6,980,616)   609,719 
Gain on bargain purchase   -    -    250,000    7,732,302 
Change in fair value of derivative instruments   -    109,305,331    (105,076)   13,688,678 
Interest expense   (3,637,467)   (9,322,333)   (19,229,232)   (17,075,437)
Total other(expense) income, net   (9,422,340)   100,171,656    (26,064,924)   4,955,262 
                     
Net (loss) income from continuing operations before income taxes   (12,127,692)   97,356,081    (38,340,063)   (3,965,722)
Provision for income taxes   -    -    -    76 
Net (loss) income from continuing operations   (12,127,692)   97,356,081    (38,340,063)   (3,965,798)
Net (loss) income from discontinued operations   (138,076)   (159,430)   (791,936)   115,787 
Net (loss) income   (12,265,768)   97,196,651    (39,131,999)   (3,850,011)
Deemed dividend from trigger of down round provision feature   -    (17,942,578)   (123,861,587)   (17,942,578)
Net (loss) income to common shareholders  $(12,265,768)  $79,254,073   $(162,993,586)  $(21,792,589)
                     
Net (loss) income per common share:                    
Basic continuing operations  $(0.00)  $17.60   $(0.01)  $(1.55)
Diluted continuing operations  $(0.00)  $(0.08)  $(0.01)  $(1.55)
Basic discontinued operations  $(0.00)  $(0.03)  $(0.00)  $0.05 
Diluted discontinued operations  $(0.00)  $(0.00)  $(0.00)  $0.05 
Basic net (loss) income  $(0.00)  $14.33   $(0.04)  $(8.54)
Diluted net loss  $(0.00)  $(0.08)  $(0.04)  $(8.54)
Weighted average number of common shares outstanding during the period:                    
Basic   6,634,045,471    5,531,767    4,461,922,587    2,550,632 
Diluted   6,634,045,471    254,654,217    4,461,922,587    2,550,632 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 4 

 

 

RENNOVA HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR EACH OF THE QUARTERS IN THE PERIOD ENDED SEPTEMBER 30, 2019

(unaudited)

 

                   Additional       Total 
   Preferred Stock   Common Stock   paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   capital   Deficit   Deficit 
Balance at December 31, 2018   2,000,225   $20,002    128,567,273   $12,857   $375,845,883   $  (415,046,606)  $    (39,167,864)
Conversion of Series I-2 Preferred Stock into common stock   -    -    3,255,700,000      325,570    318,310    -    643,880 
Common stock issued in cashless exercise of warrants   -    -    119,615,384    11,961    (11,961)   -    - 
Stock-based compensation   -    -    -    -    8,650    -    8,650 
Deemed dividend from trigger of down round provision feature   -    -    -    -    123,861,587    (123,861,587)   - 
Modification of warrants   -    -    -    -    4,056,425    -    4,056,425 
Net loss   -    -    -    -    -    (13,441,404)   (13,441,404)
Balance at March 31, 2019   2,000,225    20,002    3,503,882,657    350,388    504,078,894    (552,349,597)   (47,900,313)
Conversion of Series I-2 Preferred Stock into common stock   -    -    2,505,054,118    250,506    10,587    -    261,093 
Stock-based compensation   -    -    -    -    8,650    -    8,650 
Modification of warrants   -    -    -    -    5,408,566    -    5,408,566 
Net loss   -    -    -    -    -    (13,424,827)   (13,424,827)
Balance at June 30, 2019   2,000,225    20,002    6,008,936,775    600,894    509,506,697    (565,774,424)   (55,646,831)
Conversion of Series I-2 Preferred Stock into common stock   -    -    2,390,000,000    239,000    -    -    239,000 
Stock-based compensation   -    -    -    -    8,650    -    8,650 
Net loss   -    -    -    -    -    (12,265,768)   (12,265,768)
Balance at September 30, 2019   2,000,225   $20,002    8,398,936,775   $839,894   $509,515,347   $(578,040,192)  $(67,664,949)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 5 

 

 

RENNOVA HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR EACH OF THE QUARTERS IN THE PERIOD ENDED SEPTEMBER 30, 2018

(unaudited)

 

                   Additional       Total 
   Preferred Stock   Common Stock   paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   capital   Deficit   Deficit 
Balance at December 31, 2017   1,750,275   $     17,502    39,502   $             4   $128,549,458   $  (169,180,425)  $        (40,613,461)
Common stock issued in cashless exercise of warrants   -    -    151,200    15    (15)   -    - 
Conversion of debentures into common stock   -    -    666,621    67    3,056,607    -    3,056,674 
Stock-based compensation   -    -    -    -    24,196    -    24,196 
Restricted stock issued to employees   -    -    142,667    14    641,096    -    641,110 
Shares returned to treasury   -    -    (5)   -    -    -    - 
Beneficial conversion feature of preferred stock   -    -    -    -    (651,562)   -    (651,562)
Net loss   -    -    -    -    -    (146,364,582)   (146,364,582)
Balance at March 31, 2018   1,750,275    17,502    999,985    100    131,619,780    (315,545,007)   (183,907,625)
Conversion of Series H Preferred Stock into common stock   (50)   -    40,000    4    (4)   -    - 
Common stock issued in cashless exercise of warrants   -    -    572,480    57    3,957,710    -    3,957,767 
Conversion of debentures into common stock   -    -    1,571,000    157    4,036,932    -    4,037,089 
Exchange of debentures into Series I-2 Preferred Stock   -    -    -    -    1,331    -    1,331 
Stock-based compensation   -    -    -    -    24,197    -    24,197 
Shares returned to treasury   -    -    (116)   -    (28,217)   -    (28,217)
Beneficial conversion feature of preferred stock   -    -    -    -    651,562    -    651,562 
Net income   -    -    -    -    -    45,317,921    45,317,921 
Balance at June 30, 2018   1,750,225    17,502    3,183,349    318    140,263,291    (270,227,086)   (129,945,975)
Exchange of note payable and accrued expenses for Series J Preferred Stock   250,000    2,500    -    -    247,500    -    250,000 
Common stock issued in cashless exercise of warrants   -    -    768,548    77    661,304    -    661,381 
Common stock issued for conversion of Series I-2 Preferred Stock   -    -    1,764,927    177    632,924    -    633,101 
Conversion of debentures into common stock   -    -    1,649,059    165    991,413    -    991,578 
Exchange of debentures into Series I-2 Preferred Stock   -    -    -    -    89    -    89 
Stock-based compensation   -    -    -    -    78,444    -    78,444 
Adjust treasury shares   -    -    (2)   -    -    -    - 
Deemed dividend from trigger of down round provision feature   -    -    -    -    17,942,578    (17,942,578)   - 
Net income   -    -    -    -    -    97,196,651    97,196,651 
Balance at September 30, 2018   2,000,225   $20,002    7,365,881   $737   $160,817,543   $(190,973,013)  $(30,134,731)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 6 

 

 

RENNOVA HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

 

   Nine Months Ended September 30, 
   2019   2018 
         
Cash flows from operating activities:          
Net loss from continuing operations  $(38,340,063)  $(3,965,798)
Adjustments to reconcile net loss to net cash (used in) provided by operations:          
Depreciation and amortization   609,818    804,074 
Stock-based compensation   25,950    739,729 
Amortization of debt discount   6,386,305    16,080,270 
Modification of warrants   9,464,991    - 
Penalty for non-payment of debentures   5,710,440    - 
Change in fair value of derivative instruments   105,076    (13,688,678)
Loss on sale of receivables to factor   1,361,053    - 
Gain on disposal of equipment under finance leases   -    (549,524)
Bargain purchase gain for hospitals and medical center   (250,000)   (7,732,302)
(Loss) income from discontinued operations   (791,936)   115,787 
Changes in operating assets and liabilities:          
Accounts receivable   (3,525,152)   (5,648,343)
Inventory   82,010    25,066 
Prepaid expenses and other current assets   (1,485)   113,042 
Accounts payable and checks issued in excess of bank balance   4,932,457    3,497,210 
Accrued expenses   (327,953)   3,728,038 
Income tax assets and liabilities   (45,000)   (12,243)
Net cash used in operating activities of continuing operations   (14,603,489)   (6,493,672)
Net cash provided by (used in) operating activities of discontinued operations   182,663    (628,154)
Net cash used in operating activities   (14,420,826)   (7,121,826)
           
Cash flows from investing activities:          
Purchase of hospitals and medical center   (658,537)   (668,983)
Proceeds from the sale of equipment under finance leases   -    433,612 
Purchase of property and equipment   (50,801)   (103,387)
Net cash used in investing activities of continuing operations   (709,338)   (338,758)
Net cash provided by investing activities of discontinued operations   -    800,000 
Net cash (used in) provided by investing activities   (709,338)   461,242 
           
Cash flows from financing activities:          
Proceeds from issuance of related party note payable and advances   16,478,104    3,582,500 
Payments on related party note payable and advances   (2,310,000)   (4,011,000)
Proceeds from issuance of debentures   3,845,000    8,000,000 
Payments on notes payable   (5,005,794)   (256,481)
Proceeds from issuance of note payable   1,500,000    - 
Proceeds from receivables sold to factors   2,650,000    - 
Receivables paid to factors   (1,782,614)   - 
Payments on finance lease obligations   (143,930)   (654,435)
Net cash provided by financing activities of continuing operations   15,230,766    6,660,584 
Net cash used in financing activities of discontinued operations   -    - 
Net cash provided by financing activities   15,230,766    6,660,584 
           
Net increase in cash   100,602    - 
Cash at beginning of period   6,870    - 
Cash at end of period  $107,472   $- 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 7 

 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 1 – Organization and Summary of Significant Accounting Policies

 

Description of Business

 

Rennova Health, Inc. (“Rennova”), together with its subsidiaries (the “Company”, “we”, “us” or “our”), is a vertically integrated provider of healthcare related products and services. The Company’s principal lines of business are (i) Hospital Operations; and (ii) Clinical Laboratory Operations. The Company presents its financial results based upon these two business segments, which are more fully discussed in Note 16.

 

Reverse Stock Split

 

On November 5, 2018, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-500 reverse stock split effective November 12, 2018 (the “Reverse Stock Split”). The stockholders of the Company had approved the amendment to the Company’s Certificate of Incorporation on August 22, 2018 for the Reverse Stock Split. The Company’s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations, and the timing of the reverse split within certain specified effective dates.

 

As a result of the Reverse Stock Split, every 500 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock on November 12, 2018. In addition, the conversion and exercise prices of all of the Company’s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the applicable reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Split, other than as a result of cash paid in lieu of fractional shares as no fractional shares were issued in connection with the Reverse Stock Split.

 

All share, per share and capital stock amounts as of and for the three and nine months ended September 30, 2018 have been restated to give effect to the Reverse Stock Split.

 

In addition, on September 18, 2018, the Company amended its Certificate of Incorporation to have the authority to issue 10,000,000,000 shares of common stock and the par value of the Company’s common stock was decreased from $0.01 per share to $0.0001 per share. No additional change was made to the terms of the Company’s common stock as a result of the November 12, 2018 reverse stock split and no change was made to the authorized preferred stock, which remains at 5,000,000 shares of preferred stock, par value $0.01 per share.

 

The Reverse Stock Split provided sufficient authorized and unissued shares to allow for the Company’s outstanding and otherwise equity classified instruments to be classified in equity. As a result, the fair value of these instruments was evaluated for reclassification and, as a result, during the third quarter of 2018, the Company reclassified its derivative liabilities previously reported as a current liability to derivative income. On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of its Series K Convertible Preferred Stock (“Series K Preferred Stock”) to Alcimede LLC (“Alcimede”), a related party, as more fully discussed in Note 19. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding.

 

Jamestown Regional Medical Center Medicare Agreement

 

Following an inspection at Jamestown Regional Medical Center on February 5, 2019, the hospital was informed on February 15 that several conditions of participation in its Medicare agreement were deficient. The hospital was informed that if the deficiencies where not corrected by May 16 the Medicare agreement would terminate. A follow-up inspection on May 15 resulted in the determination that the hospital had failed to adequately correct the deficiencies highlighted and a notice of involuntary termination was issued that was effective on June 12, 2019. A significant percentage of patients at Jamestown Regional Medical Center are covered by Medicare and without any ability to get paid for these services the Company suspended operations at the hospital. The hospital received initial approval of its application to reactivate the Medicare agreement in August of 2019 and is currently planning the reopening of the hospital.

 

 8 

 

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the consolidated financial statements as filed on the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on October 21, 2019. In the opinion of management, the unaudited condensed consolidated financial statements included herein contain all adjustments necessary to present fairly the Company’s consolidated financial position as of September 30, 2019, and the results of its operations, changes in stockholders’ deficit and cash flows for the three and nine months ended September 30, 2019 and 2018. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2019 may not be indicative of results for the year ending December 31, 2019.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) include the accounts of Rennova and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in the consolidation.

 

Reclassification

 

For the nine months ended September 30, 2018, the Company has presented the proceeds from related party notes payable and advances that were previously netted against payments on related party notes payable and advances as a separate line item on the Statement of Cash Flows. This reclassification did not have an effect on total cash flow from financing activities for the nine months ended September 30, 2018.

 

Comprehensive Loss

 

During the three and nine months ended September 30, 2019 and 2018, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include the estimates of fair values of assets acquired and liabilities assumed in business combinations, including hospital acquisitions, reserves, contractual allowances and write-downs related to receivables and inventories, the recoverability of long-lived assets, stock based compensation, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and derivative instruments, including modifications thereof, deemed dividends and debt discounts, among others. Actual results could differ from those estimates and would impact future results of operations and cash flows.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had minimal cash equivalents at September 30, 2019 and December 31, 2018.

 

 9 

 

 

Revenue Recognition

 

Hospital Operations

 

Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.

 

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain government programs, primarily Medicare, this is generally referred to as the “cost report” filing and settlement process). There were no adjustments to estimated Medicare and Medicaid reimbursement amounts and disproportionate-share funds related primarily to cost reports filed during the three and nine months ended September 30, 2019 and 2018.

 

The Emergency Medical Treatment and Labor Act (“EMTALA”) requires any hospital participating in the Medicare program to conduct an appropriate medical screening examination of every person who presents to the hospital’s emergency room for treatment and, if the individual is suffering from an emergency medical condition, to either stabilize the condition or make an appropriate transfer of the individual to a facility able to handle the condition. The obligation to screen and stabilize emergency medical conditions exists regardless of an individual’s ability to pay for treatment. Federal and state laws and regulations require, and our commitment to providing quality patient care encourages, us to provide services to patients who are financially unable to pay for the health care services they receive. The federal poverty level is established by the federal government and is based on income and family size. The Company considers the poverty level in determining whether patients qualify for free or reduced cost of care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. We provide discounts to uninsured patients who do not qualify for Medicaid or charity care. In implementing the uninsured discount policy, we may first attempt to provide assistance to uninsured patients to help determine whether they may qualify for Medicaid, other federal or state assistance, or charity care. If an uninsured patient does not qualify for these programs, the uninsured discount is applied.

 

The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management’s assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable (the “hindsight analysis”) as a primary source of information in estimating the collectability of our accounts receivable. We perform the hindsight analysis quarterly, utilizing rolling twelve-months accounts receivable collection and write-off data. We believe our quarterly updates to the estimated contractual allowance amounts at each of our hospital facilities provide reasonable estimates of our revenues and valuations of our accounts receivable.

 

Clinical Laboratory Operations

 

Laboratory testing services include chemical diagnostic tests such as blood analysis and urine analysis. Laboratory service revenues are recognized at the time the testing services are performed and billed and are reported at their estimated net realizable amounts. Net service revenues are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the U.S. have an agreement with a third-party payer such as a commercial insurance provider, Medicaid or Medicare to pay all or a portion of their healthcare expenses; most of the services provided by us are to patients covered under a third-party payer contract. In most cases, the Company is provided the third-party billing information and seeks payment from the third party in accordance with the terms and conditions of the third-party payer for health service providers like us. Each of these third-party payers may differ not only in terms of rates, but also with respect to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payer methods and trends. Despite follow up billing efforts, the Company does not currently anticipate collection of a significant portion of self-pay billings, including the patient responsibility portion of the billing for patients covered by third party payers. The Company currently does not have any capitated agreements.

 

 10 

 

 

We review our calculations for the realizability of gross service revenues monthly to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payer groups. The contractual allowance calculation is made based on historical allowance rates for the various specific payer groups monthly with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions. This calculation is routinely analyzed by us based on actual allowances issued by payers and the actual payments made to determine what adjustments, if any, are needed.

 

Bad Debt and Contractual Allowances

 

Total gross revenues for Hospital and Clinical Laboratory Operations were reduced in the aggregate by approximately $0.9 million and $1.8 million for bad debt for the three months ended September 30, 2019 and 2018, respectively. After bad debt and contractual and related allowance adjustments to revenues of $21.9 million and $25.1 million, for the three months ended September 30, 2019 and 2018, respectively, we reported net revenues of $3.9 million and $5.0 million, respectively.

 

Total gross revenues for Hospital and Clinical Operations were reduced in the aggregate by approximately $4.8 million and $3.1 million for bad debt for the nine months ended September 30, 2019 and 2018, respectively. After bad debt and contractual and related allowance adjustments to revenues of $86.7 million and $43.8 million, for the nine months ended September 30, 2019 and 2018, respectively, we reported net revenues of $13.1 million and $9.9 million, respectively. We continue to review the provision for bad debt and contractual and related allowances.

 

Leases, Including the Adoption of ASU No. 2016-02

 

We adopted ASU No. 2016-02, Leases (Topic 842), which requires leases with durations greater than 12 months to be recognized on the balance sheet, effective January 1, 2019, using the modified retrospective approach. Prior period financial statement amounts and disclosures have not been adjusted to reflect the provisions of the new standard. We elected the package of transition provisions available which allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. We lease property and equipment under finance and operating leases. For leases with terms greater than 12 months, we record the related right-of-use assets and right-of-use obligations at the present value of lease payments over the term. We do not separate lease and non-lease components of contracts. Our operating and finance leases are more fully discussed in Note 10.

 

Derivative Financial Instruments and Fair Value, Including the Adoption of ASU 2017-11

 

We account for warrants issued in conjunction with the issuance of common stock and certain convertible debt instruments in accordance with the guidance contained in Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). For warrant instruments and conversion options embedded in promissory notes that are not deemed to be indexed to the Company’s own stock, we classified such instruments as liabilities at their fair values at the time of issuance and adjusted the instruments to fair value at each reporting period. These liabilities were subject to re-measurement at each balance sheet date until extinguished either through conversion or exercise, and any change in fair value was recognized in our statement of operations. The fair values of these derivative and other financial instruments had been estimated using a Black-Scholes model and other valuation techniques.

 

In July 2017, the FASB issued ASU 2017-11 “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.

 

 11 

 

 

When the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis.

 

The Company has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company’s first fiscal quarter of 2017. The remaining $16 million was offset to additional paid-in-capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million of which $51 million of the deemed dividend was recorded retrospectively as of the beginning of the issuance of the debentures issued in March 2017 where the initial derivative liability was recorded as a result of the down round provision feature. A deemed dividend of $231.8 million was recorded for the year ended December 31, 2018, a deemed dividend of $123.9 million was recorded during the nine months ended September 30, 2019 and a deemed dividend of $17.9 million and $17.9 million was recorded for the three and nine months ended September 30, 2018, respectively, as a result of down round provision features. See Note 11 for an additional discussion of derivative financial instruments.

 

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC Topic 260, “Earnings Per Share”, which establishes standards for computing and presenting earnings per share. Basic earnings (loss) per share of common stock is calculated by dividing net (loss) earnings allocable to common shareholders by the weighted-average shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted earnings (loss) per share is calculated by adjusting the weighted-average shares of common stock outstanding for the dilutive effect of common stock equivalents, including stock options and warrants outstanding for the period as determined using the treasury stock method. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation when their effect would be anti-dilutive. Therefore, basic and diluted net loss per share applicable to common shareholders is the same for periods with a net loss. See Note 3 for the computation of earnings (loss) per share for the three and nine months ended September 30, 2019 and 2018.

 

Note 2 – Liquidity and Financial Condition

 

Under ASU, 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40) (“ASC 205-40”), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued. Management has assessed the Company’s ability to continue as a going concern in accordance with the requirement of ASC 205-40.

 

The Company had a working capital deficit, an accumulated deficit and a stockholders’ deficit of $69.3 million, $578.0 million and $67.7 million, respectively, at September 30, 2019. In addition, the Company had a net loss of approximately $39.1 million and cash used in operating activities of $14.4 million for the nine months ended September 30, 2019. The continued losses and other related factors raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the filing date of this report.

 

The Company’s unaudited condensed consolidated financial statements are prepared assuming the Company can continue as a going concern, which contemplates continuity of operations through realization of assets, and the settling of liabilities in the normal course of business. Initial cost savings were realized by reducing the number of laboratory facilities to one for most of its toxicology diagnostics, thereby reducing the number of employees and associated operating expenses. The Company intends to spin off its Advanced Molecular Services Group (“AMSG”) and Health Technology Solutions, Inc. (“HTS”), as independent publicly traded companies by way of tax-free distributions to its shareholders. While these spin offs have taken longer than anticipated, completion of these spin offs is now expected to occur during the first quarter of 2020. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission and consents, including under various funding agreements previously entered by the Company. The intent of the spin offs of AMSG and HTS is to create three public companies, each of which can focus on its own strengths and operational plans. In accordance with ASC 205-20 and having met the criteria for “held for sale”, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. AMSG and HTS are no longer included in the segment reporting following the reclassification to discontinued operations. The discontinued operations of AMSG and HTS are described further in Note 17.

 

 12 

 

 

The Company’s core business is now rural hospitals which is a specialized marketplace with a requirement for capable and knowledgeable management. The Company’s current financial condition may make it difficult to attract and maintain adequate expertise in its management team to successfully operate the Company’s hospitals.

 

There can be no assurance that the Company will be able to achieve its business plan, which is to acquire and operate clusters of rural hospitals, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to significantly reduce its operating costs, increase its revenues, and eventually achieve profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Note 3 – Earnings (Loss) Per Share

 

Basic and diluted earnings (loss) per share is computed by dividing (i) loss available to common shareholders, by (ii) the weighted-average number of shares of common stock outstanding during the period. Basic loss per share excludes dilution and is computed by dividing loss attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company. The loss per share for the three and nine months ended September 30, 2019 and the nine months ended September 30, 2018 excluded securities or other contracts to issue the Company’s common stock because the results were anti-dilutive.

 

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share for each of the three and nine months ended September 30, 2019 and 2018:

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2019   2018   2019   2018 
Numerator:                    
Net (loss) income from continuing operations  $(12,127,692)  $97,356,081   $(38,340,063)  $(3,965,798)
Net (loss) income from discontinued operations   (138,076)   (159,430)   (791,936)   115,787 
Deemed dividends       (17,942,578)   (123,861,587)   (17,942,578)
Net loss (income) to common shareholders -basic  $(12,265,768)  $79,254,073   $(162,993,586)  $(21,792,589)
Adjustments for diluted calculations:                    
Deduct change in fair value of derivative liabilities       (109,305,331)        
Amortize discounts associated with conversion of dilutive convertible debentures       (7,303,912)        
Remove change in warrant value for diluted       (11,376)        
Add back deemed dividends       17,942,578         
Net loss to common shareholders - diluted  $(12,265,768)  $(19,423,968)  $(162,993,586)  $(21,792,589)
Denominator:                    
Weighted average number of common shares outstanding during the period:                    
Basic   6,634,045,471    5,531,767    4,461,922,587    2,550,632 
Common stock equivalents:                    
Warrants       64,315,740         
Convertible preferred stock       9,505,156         
Convertible debentures       175,301,554         
Diluted   6,634,045,471    254,654,217    4,461,922,587    2,550,632 
Net (loss) income per common share- continuing operations:                    
Basic  $(0.00)  $17.60   $(0.01)  $(1.55)
Diluted  $(0.00)  $(0.08)  $(0.01)  $(1.55)
Net (loss) income per common share- discontinued operations:                    
Basic  $(0.00)  $(0.03)  $(0.00)  $0.05 
Diluted  $(0.00)  $(0.00)  $(0.00)  $0.05 
Total per share net (loss) income to common shareholders:                    
Basic  $(0.00)  $14.33   $(0.04)  $(8.54)
Diluted  $(0.00)  $(0.08)  $(0.04)  $(8.54)

 

 13 

 

 

Diluted loss per share as reflected in the table above excludes all dilutive potential shares if their effect is anti-dilutive. For the nine months ended September 30, 2019 and 2018, the following table sets forth the computation of the following potential common stock equivalents excluded from the calculation of diluted loss per share as their effect was anti-dilutive:

 

   Nine Months Ended September 30, 
   2019   2018 
Warrants   634,525,355,377    463,449,767 
Convertible preferred stock   82,901,785,590    68,344,495 
Convertible debentures   30,634,784,339    214,222,495 
Stock options   77    77 
    748,061,925,383    746,016,834 

 

The terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, many of these equity-based securities contain exercise or conversion prices that vary based upon the price of the Company’s common stock on the date of exercise/conversion (see Notes 12 and 13). These provisions have resulted in significant dilution of the Company’s common stock and have given rise to reverse splits of the Company’s common stock. As a result of these down round provisions, the outstanding common stock and potential common stock equivalents totaled 753.9 billion at December 26, 2019. See Notes 13 and 19 regarding a discussion of the Company’s common stock and potential common stock equivalents.

 

Note 4 – Accounts Receivable

 

Accounts receivable at September 30, 2019 (unaudited) and December 31, 2018 consisted of the following:

 

   September 30,   December 31, 
   2019   2018 
Accounts receivable - Clinical Laboratory Operations  $41,750   $622,009 
Accounts receivable - Hospital Operations   45,804,056    31,607,644 
Accounts receivable - Other   (52,296)   - 
Total accounts receivable   45,793,510    32,229,653 
Less:          
Amount purchased by factors   (1,572,000)   - 
Allowance for discounts - Clinical Laboratory Operations   (26,182)   (573,584)
Allowance for discounts - Hospital Operations   (36,298,972)   (25,066,799)
Allowance for bad debts   (2,787,894)   (2,777,521)
Accounts receivable, net  $5,108,462   $3,811,749 

 

Accounts Receivable Factoring Arrangements

 

During the nine months ended September 30, 2019, the Company entered into five accounts receivable factoring arrangements. Under the terms of the arrangements, the aggregate amount of accounts receivable sold on a non-recourse basis, was $3.9 million. The aggregate purchase price paid to the Company was $2.7 million, the total origination and other fees incurred by the Company were $0.1 million and the Company recorded a loss on sale of the receivables of $1.2 million. As of September 30, 2019, $1.6 million of the outstanding accounts receivable were purchased but not yet paid to the factors.

 

 14 

 

 

Note 5 – Acquisitions

 

Purchase Agreement Re Jamestown Regional Medical Center

 

On June 1, 2018, the Company acquired a business engaging in acute hospital care located in Jamestown, Tennessee under an asset purchase agreement. The acquisition also included a separate physician practice referred to as Mountain View Physician Practice, Inc. This acquisition was made as part of the Company’s business plan to acquire and operate clusters of rural hospitals.

 

Pursuant to the asset purchase agreement, by and among the Company and Jamestown TN Medical Center, Inc., and HMA Fentress County Hospital, LLC, Jamestown HMA Physician Management, LLC and CHS/Community Health Systems, Inc. (the “Sellers”), the purchase price paid for the transaction was an aggregate of $635,096, which includes closing costs of $35,735, legal costs of approximately $115,000, and other diligence related costs, which were expensed in 2018.

 

The fair value of the purchase consideration paid to the Sellers was allocated to the net tangible and intangible assets acquired. The Company accounted for the acquisition as a business combination under U.S. GAAP. In accordance with the acquisition method of accounting under ASC Topic 805, “Business Combinations,” (“ASC 805”) the assets acquired, and liabilities assumed were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company.

 

The fair value of the assets acquired, net of the liabilities assumed, was approximately $8.2 million. The excess of the aggregate fair value of the net tangible assets acquired over the purchase price was $7.6 million and has been treated as a gain on bargain purchase in accordance with ASC 805.

 

The following table shows the allocation of the purchase price of Jamestown Regional Medical Center to the acquired identifiable assets acquired, and liabilities assumed:

 

Total purchase price  $635,096 
Tangible and intangible assets acquired, and liabilities assumed at fair value:     
Cash  $375 
Inventories   450,682 
Prepaids and deposits   310,385 
Property and equipment   7,129,484 
Intangible assets   504,806 
Accrued expenses   (193,966)
Net tangible and intangible assets acquired  $8,201,766 
Gain on bargain purchase (1)  $7,566,670 

 

  (1) Gain was adjusted in the fourth quarter of 2018 from $7,732,302 to $7,566,670 to reflect an adjustment of the value of the property and equipment acquired.

 

As reflected in the table above, the total value of intangible assets acquired in the Jamestown acquisition was $504,806, which included a certificate of need valued at $259,443 and a non-compete intangible asset valued at $245,363. The certificate of need has an indefinite life. During the year ended December 31, 2018, the Company determined that the fair value of the non-compete intangible asset, which was being amortized over two years, was fully impaired and, accordingly, the Company recorded an impairment of approximately $0.2 million in December 31, 2018.

 

Purchase Agreement re Jellico Community Hospital and CarePlus Center

 

Effective March 5, 2019, the Company acquired certain assets related to Jellico Community Hospital and CarePlus Center. Jellico Community Hospital is a fully operational 54-bed acute care facility that offers comprehensive services, including diagnostic imaging, radiology, surgery (general, gynecological and vascular), nuclear medicine, wound care and hyperbaric medicine, intensive care, emergency care and physical therapy. The CarePlus Center offers sophisticated testing capabilities and compassionate care, all in a modern, patient-friendly environment. Services include diagnostic imaging services, x-ray, mammography, bone densitometry, computed tomography (CT), ultrasound, physical therapy and laboratory services on a walk-in basis.

 

The purchase price was $658,537. This purchase price was made available by Mr. Diamantis, a director of the Company. The total cost of the acquisition is estimated to be $908,537, including $250,000 of diligence, legal and other costs associated with the acquisition. The acquisition costs were fully expensed in 2019.

 

The preliminary fair value of the purchase consideration paid to the sellers was allocated to the net tangible and intangible assets acquired. The Company accounted for the acquisition as a business combination under U.S. GAAP. In accordance with the acquisition method of accounting under ASC 805 the assets acquired, and liabilities assumed were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company.

 

 15 

 

 

The Company is currently undertaking a valuation study to determine the fair value of the assets acquired. The preliminary estimated fair value of the assets acquired, net of the liabilities assumed, was approximately $0.9 million. The excess of the aggregate fair value of the net tangible assets acquired over the purchase price is currently estimated to be $0.3 million and has been treated as a gain on bargain purchase in accordance with ASC 805. The gain is primarily due to the value of the intangible assets acquired. In addition, the provisional amounts used for the purchase price allocation are subject to adjustments for a period not to exceed one year from the acquisition date. As a result, upon completion of a valuation study, the gain on bargain purchase presented below may be increased or decreased. The preliminary purchase price allocation was based, in part, on management’s knowledge of hospital operations.

 

The following table shows the preliminary allocation of the purchase price of Jellico Community Hospital and CarePlus Center to the acquired identifiable assets acquired, and liabilities assumed:

 

Total purchase price  $658,537 
Tangible and intangible assets acquired, and liabilities assumed at estimated fair value:     
Inventories  $317,427 
Property and equipment   500,000 
Intangible asset- certificate of need   250,000 
Accrued expenses   (158,890)
Net tangible and intangible assets acquired  $908,537 
Gain on bargain purchase  $250,000 

 

The following presents the unaudited pro-forma combined results of operations of the Company and Jamestown Regional Medical Center and Jellico Community Hospital and CarePlus Center as if the acquisitions had occurred on January 1, 2018. The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the acquisitions been completed as of January 1, 2018 or to project potential operating results as of any future date or for any future periods.

 

   Three Months Ended September 30, 2018  

Nine Months

Ended

September 30,

2019

   Nine Months Ended September 30, 2018 
             
Net revenue  $8,276,112   $14,855,436   $25,499,677 
Net income (loss) from continuing operations   96,879,012    (38,537,422)   (8,151,239)
Deemed dividend from trigger of down round provision feature   (17,942,578)   (123,861,587)   (17,942,578)
Net (loss) income from discontinued operations   (159,430)   (791,936)   115,787 
Net income (loss) to common shareholders - basic   78,777,004    (163,190,945)   (25,978,030)
Adjustments for diluted loss to common shareholders   (98,678,041)        
Net loss to common shareholders - diluted  $(19,901,037)  $(163,190,945)  $(25,978,030)
                
Net income (loss) per common share:               
Basic continuing operations  $17.51   $(0.01)  $(3.20)
Diluted continuing operations  $(0.02)  $(0.01)  $(3.20)
Basic net income (loss) to common shareholders  $14.24   $(0.04)  $(10.18)
Diluted net loss to common shareholders  $(0.24)  $(0.04)  $(10.18)

 

 16 

 

 

Note 6 – Accrued Expenses

 

Accrued expenses at September 30, 2019 (unaudited) and December 31, 2018 consisted of the following:

 

   September 30,   December 31, 
   2019   2018 
Commissions payable  $19,113   $19,113 
Sales tax payable   8,009    8,016 
Accrued payroll and related liabilities   6,761,173    3,400,052 
Accrued property tax   41,784    47,396 
Accrued interest   2,586,652    5,464,837 
Other accrued expenses   1,125,488    1,771,867 
Accrued expenses  $10,542,219   $10,711,281 

 

Accrued expenses at December 31, 2018 included $4.9 million of interest due under the terms of a settlement agreement for a prepaid forward purchase contract related to an accounts receivable financing, which was paid by Mr. Diamantis on behalf of the Company during the nine months ended September 30, 2019, as more fully discussed in Note 7. Accrued expenses at September 30, 2019 and December 31, 2018 included $1.8 million and $0.3 million, respectively, of accrued interest due to Mr. Diamantis related to loans made by Mr. Diamantis to the Company as more fully discussed in Note 7.

 

Note 7 – Notes Payable

 

The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At September 30, 2019 (unaudited) and December 31, 2018, notes payable consisted of the following:

 

Notes Payable – Third Parties

 

   September 30,   December 31, 
   2019   2018 
Loan payable under prepaid forward purchase contract (1)  $-   $5,000,000 
           
Loan payable to TCA Global Master Fund, LP (“TCA”) in the original principal amount of $3 million at 16% interest (the “TCA Debenture”). Principal and interest payments due in various installments through December 31, 2017   1,741,893    1,741,893 
           
Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the “Tegal Notes”). Principal and interest payments due annually from July 12, 2015 through July 12, 2017   335,818   341,612 
           
Note payable to Anthony O’Killough dated September 27, 2019 in the original principal amount of $1.9 million. Interest is due only upon event of default. Issued net of $0.3 million of debt discount and $0.1 million of financing fees with $1.0 million of principal due on November 8, 2019 and $0.9 million of principal due December 26, 2019   1,527,821    - 
    3,605,532    7,083,505 
Less current portion   (3,605,532)   (7,083,505)
Notes payable - third parties, net of current portion  $-   $- 

 

  (1) The loan payable under prepaid forward purchase contract has been fully settled during the nine months ended September 2019 as more fully discussed below under the heading “Notes Payable –Related Party”.

 

 17 

 

 

The Company did not make the required monthly principal and interest payments due under the TCA Debenture for the period from October 2016 through March 2017. On February 2, 2017, the Company made a payment to TCA in the amount of $0.4 million, which was applied to accrued and unpaid interest and fees, including default interest, as of the date of payment. On March 21, 2017, the Company made a payment to TCA in the amount of $0.75 million, of which approximately $0.1 million was applied to accrued and unpaid interest and fees in accordance with the terms of the TCA Debenture. Also on March 21, 2017, the Company entered into a letter agreement with TCA, which (i) waived any payment defaults through March 21, 2017; (ii) provided for the $0.75 million payment discussed above; (iii) set forth a revised repayment schedule whereby the remaining principal plus interest aggregating to approximately $2.6 million was to be repaid in various monthly installments from April of 2017 through September of 2017; and (iv) provided for payment of an additional service fee in the amount of $150,000, which was due on June 27, 2017, the day after the effective date of the registration statement filed by the Company; which amount is reflected in accrued expenses at December 31, 2018. In addition, TCA entered into an inter-creditor agreement with the purchasers of the convertible debentures (see Note 8) which sets forth rights, preferences and priorities with respect to the security interests in the Company’s assets. On September 19, 2017, the Company entered into a new agreement with TCA, which extended the repayment schedule through December 31, 2017. The remaining debt to TCA remains outstanding and TCA has made a demand for payment. The parties are currently working to amend the TCA Debenture to extend the maturity although there can be no assurance that the parties will agree to any such extension.

 

The Company did not make the principal payments under the Tegal Notes that were due on July 12, 2016. On November 3, 2016, the Company received a default notice from the holders of the Tegal Notes demanding immediate repayment of the outstanding principal of $341,612 and accrued interest of $43,000. On December 7, 2016, the Company received a breach of contract complaint with a request for the entry of a default judgment (see Note 15). On April 23, 2018, the holders of the Tegal Notes received a judgment against the Company. To date, the Company has yet to repay this amount.

 

On September 27, 2019, the Company issued a promissory note to a lender in the principal amount of $1.9 million and received proceeds of $1.5 million, which is net of a $0.3 million original issue discount and $0.1 million in financing fees. The first principal payment of $1.0 million was due on November 8, 2019 and has not yet been made and the remaining $0.9 million is due on December 26, 2019. The note does not bear interest except upon the occurrence of an event of default (as defined in the note). The note is unsecured and is guaranteed by Mr. Diamantis.

 

Notes Payable – Related Party

 

   September 30, 2019   December 31, 2018 
         
Loan payable to Christopher Diamantis  $14,968,104   $800,000 
           
Total notes payable, related party   14,968,104    800,000 
           
Less current portion of notes payable, related party   (14,968,104)   (800,000)
Total notes payable, related party, net of current portion  $-   $- 

 

On March 31, 2016, the Company entered into an agreement to pledge certain of its accounts receivable as collateral against a prepaid forward purchase contract whereby the Company received consideration in the amount of $5.0 million. The receivables had an estimated collectable value of $8.7 million which had been adjusted down to $0 as of December 31, 2017. In exchange for the consideration received, the counterparty received the right to: (i) a 20% per annum investment return from the Company on the consideration, with a minimum repayment term of six months and minimum return of $0.5 million, (ii) all payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty had not been paid $6.0 million, the Company was required to pay the difference. Christopher Diamantis, a director of the Company, guaranteed the Company’s obligation. On March 24, 2017, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into an amendment to extend the Company’s obligation to March 31, 2018. Also, what the counterparty was to receive was amended to equal (a) the $5,000,000 purchase price plus a 20% per annum investment return thereon, plus (b) $500,000, plus (c) the product of (i) the proceeds received from the accounts receivable, minus the amount set forth in clauses (a) and (b), multiplied by (ii) 40%. In connection with the extension, the counterparty received a fee of $1,000,000. On April 2, 2018, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into a second amendment to extend further the Company’s obligation to May 30, 2018. In connection with this further extension, the counterparty received a fee of $100,000. The counterparty instituted an arbitration proceeding under the agreement with regard to the outstanding balance. In December 2018, the Company, Mr. Diamantis and the counterparty entered into a preliminary settlement agreement in connection with the arbitration, with the terms of the settlement agreement revised on March 31, 2019. The Company and Mr. Diamantis agreed to pay the counterparty $2,000,000 on or before April 5, 2019 and an additional $7,694,685 plus interest at 10% per annum on or before May 20, 2019, which date was subsequently amended. On April 5, 2019 and May 31, 2019, Mr. Diamantis made payments totaling $5.0 million on behalf of the Company. The final payment of $4,937,105 was due on or before July 28, 2019. Mr. Diamantis made that payment on behalf of the Company on July 26, 2019. The Company and Mr. Diamantis have now complied with all of their obligations under the settlement agreement. As a result, the Company is obligated to repay Mr. Diamantis a total of $9,937,105.

 

 18 

 

 

During the nine months ended September 30, 2019, in addition to the $9,937,105 that Mr. Diamantis loaned the Company in connection with the settlement of the prepaid forward purchase contract discussed above, Mr. Diamantis advanced the Company: (i) $0.7 million for the purchase of Jellico Community Hospital as more fully discussed in Note 5; $1.9 million for fees and expenses incurred in connection with the settlement of the prepaid forward purchase contract; and $4.7 million for working capital purposes. During the three and nine months ended September 30, 2019, we accrued interest of $0.7 million and $1.5 million, respectively, on the advances from Mr. Diamantis. During the nine months ended September 30, 2019, we repaid $2.3 million of principal to Mr. Diamantis. Interest accrues on advances from Mr. Diamantis at a flat rate of 10%. Therefore, the total amount of loans and accrued interest payable to Mr. Diamantis at September 30, 2019 and December 31, 2018, were $16.7 million and $1.1 million, respectively. See Note 19 for the discussion of additional advances made by Mr. Diamantis to the Company subsequent to September 30, 2019.

 

Note 8 – Debentures

 

The carrying amount of all outstanding debentures as of September 30, 2019 (unaudited), and December 31, 2018 is as follows:

 

   September 30, 2019   December 31, 2018 
Debentures  $28,690,240   $19,034,800 
Discount on Debentures   -    (6,247,469)
Deferred financing fees   -    (11,015)
    28,690,240    12,776,316 
Less current portion   (28,690,240)   (12,776,316)
Debentures, long-term  $-   $- 

 

As of September 30, 2019, $2.0 million of outstanding debentures issued in March 2017 were not paid as of March 21, 2019, the maturity date and $17.1 million of outstanding debentures issued during 2017 and 2018 were not paid as of September 19, 2019, the maturity date. The Company has accrued penalties in connection with these non-payments in the amount of $5.7 million as of September 30, 2019. These debentures have still not been paid and remain outstanding, and the Company has been accruing interest on these debentures at the default rate of 18% per annum since the dates of the payment defaults.

 

Debentures Issued in the Nine Months Ended September 30, 2019

 

The Company issued debentures on February 24, 2019 in the aggregate principal amount of $300,000 and on March 27, 2019 in the aggregate principal amount of $300,000. Both of these debentures were guaranteed by Mr. Diamantis and were originally due on June 3, 2019. The maturity dates of these debentures were extended to December 31, 2019 and the terms were changed so that commencing on August 17, 2019 the debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest shall entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law.

 

The Company issued debentures on May 12, 2019 in the aggregate principal amount of $500,000. These debentures were guaranteed by Mr. Diamantis and were due on June 3, 2019. In addition, the Company issued debentures on June 5, 2019 in the aggregate principal amount of $125,000 and on June 7, 2019 in the aggregate principal amount of $200,000. These debentures were also guaranteed by Mr. Diamantis and were due on July 20, 2019. The maturity dates of these debentures were extended to December 31, 2019 and the terms were changed so that commencing on August 17, 2019 the debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest shall entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law.

 

 19 

 

 

On June 13, 2019, the Company closed an offering of $1,250,000 aggregate principal amount of debentures with certain existing institutional investors pursuant to the terms of a Bridge Debenture Agreement, dated as of June 13, 2019 (the “June 13 Agreement”) and received proceeds of $1,250,000. The June 13 Agreement provided that on or prior to June 30, 2019, at the mutual election of the Company and the investors, the investors could purchase an additional $1,250,000 principal amount on the same terms and conditions as provided in the June 13 Agreement. Under the June 13 Agreement, the maturity date of the debentures issued on February 24, 2019, March 27, 2019, May 12, 2019, June 5, 2019 and June 7, 2019 were extended to December 31, 2019 and the terms were changed such that they have the same interest terms as contained in the June 13, 2019 debentures, as more fully discussed below.

 

On June 21, 2019, the Company and the investors agreed that the Company would issue, and the investors would purchase, $250,000 principal amount of debentures and on June 24, 2019 the Company and the investors agreed that the Company would issue, and the investors would purchase, an additional $1,020,000 aggregate principal amount of debentures. In connection with the issuances of the June 21, 2019 and June 24, 2019 debentures, the Company received total proceeds of $1,270,000.

 

The June 13, 2019, June 21, 2019 and June 24, 2019 debentures (collectively, the “June 2019 Debentures”) are secured and guaranteed by the Company’s subsidiaries on the same terms as provided in the Purchase Agreement, dated as of August 31, 2017, which is more fully described in Note 9 to the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2018. At the Company’s option, the June 2019 Debentures may also be exchanged for shares of the Company’s Series I-2 Convertible Preferred Stock under the terms of the previously-announced Exchange Agreement, dated as of October 30, 2017. Commencing on August 17, 2019, the June 2019 Debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law. Christopher Diamantis is a guarantor of the June 2019 Debentures.

 

In addition to the debentures issued in the nine months ended September 30, 2019, during the years ending December 31, 2017 and 2018, the Company issued convertible debentures, which are more fully described in Note 9 to the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2018. Certain of these convertible debentures were issued with warrants to purchase shares of the Company’s common stock. Outstanding warrants are more fully discussed in Note 13.

 

The debentures issued during the nine months ended September 30, 2019 and 2018, were issued at discounts of $0.1 million and $2.9 million, respectively, and accordingly, the Company realized a total of $3.8 million and $8.0 million, respectively, in proceeds from the issuances of the debentures. At September 30, 2019, these discounts have been fully amortized. These discounts represented original issue discounts, the relative fair value of the warrants issued with the debentures and the relative fair value of the beneficial conversion features of the debentures. During the three months ended September 30, 2019 and 2018, the Company recorded approximately $1.4 million and approximately $9.0 million, respectively, of non-cash interest and amortization of debt discount expense in connection with the debentures and warrants. During the nine months ended September 30, 2019 and 2018, the Company recorded approximately $15.8 million and approximately $16.1 million, respectively, of non-cash interest and amortization of debt discount expense primarily in connection with the debentures and warrants. These amounts include non-cash interest expense and debt discount amortization, which resulted from the modification of warrants as more fully discussed in Notes 11 and 13.

 

See Note 13 for summarized information related to warrants issued and the activity during the nine months ended September 30, 2019.

 

See Notes 3, 13 and 19 for a discussion of the dilutive effect of the outstanding convertible debentures, warrants and convertible preferred stock as of September 30, 2019.

 

Note 9 – Related Party Transactions

 

Alcimede billed $0.1 million and $0.1 million for consulting fees for the three months ended September 30, 2019 and 2018, respectively, and $0.3 million and $0.3 million for the nine months ended September 30, 2019 and 2018, respectively. Seamus Lagan, the Company’s President and Chief Executive Officer, is the sole manager of Alcimede (see Note 13).

 

See Notes 5, 7 and 19 for a discussion of amounts advanced to the Company by Mr. Diamantis.

 

The terms of the foregoing transactions, including those discussed in Notes 5, 7, 12 and 19, are not necessarily indicative of those that would have been agreed to with unrelated parties for similar transactions.

 

 20 

 

 

Note 10 – Finance and Operating Lease Obligations

 

As more fully discussed in Note 1, we adopted ASU No. 2016-02, Leases (Topic 842), which requires leases with durations greater than 12 months to be recognized on the balance sheet, effective January 1, 2019, using the modified retrospective approach.

 

Generally, we use our estimated weighted average cost of capital at lease commencement as our interest rate, as most of our operating leases do not provide a readily determinable implicit interest rate.

 

The following table presents our lease-related assets and liabilities at September 30, 2019:

 

    Balance Sheet Classification   September 30, 2019  
Assets:            
Operating leases   Right-of-use operating lease assets   $ 328,615  
Finance leases   Property and equipment, net     618,278  
Total lease assets       $ 946,893  
             
Liabilities:            
Current:            
Operating leases   Right-of-use operating lease assets   $ 141,830  
Finance leases   Current liabilities     589,457  
Noncurrent:            
Operating leases   Right-of-use operating lease obligations     186,785  
Finance leases   Long-term debt     28,821  
             
Total lease liabilities       $ 946,893  
             
Weighted-average remaining term:            
Operating leases         1.98 years  
Finance leases         0.19 years  
Weighted-average discount rate:            
Operating leases (1)         13.0 %
Finance leases         5.122 %

 

(1) Upon adoption of the new lease standard, discount rates used for existing operating leases were established at January 1, 2019.

 

The following table presents certain information related to lease expense for finance and operating leases for the three and nine months ended September 30, 2019:

 

  

Three Months Ended

September 30, 2019

   Nine Months Ended
September 30, 2019
 
Finance lease expense:          
Depreciation/amortization of leased assets (1)  $15,004   $(30,055)
Interest on lease liabilities   704    5,804 
Operating leases:          
Short-term lease expense (2)   76,312    263,713 
Total lease expense  $92,020   $239,462 

 

(1) The depreciation for the nine months ended September 30, 2019 has been adjusted for depreciation recorded in the prior year.

(2) Expenses are included in general and administrative expenses in our condensed consolidated statements of operations.

 

 21 

 

 

Other Information

 

The following table presents supplemental cash flow information for the nine months ended September 30, 2019:

 

    2019  
Cash paid for amounts included in the measurement of lease liabilities:        
Operating cash flows for operating leases   $ 214,357  
Operating cash flows for finance leases   $ 5,800  
Financing cash flows for finance leases payments   $ 143,930  

 

Aggregate future minimum rentals under right-to-use operating and finance leases are as follows:

 

    Right-to-Use        
    Operating Leases     Finance Leases  
October 1, 2019 to September 30, 2020   $ 107,457     $ 604,080  
October 1, 2020 to September 30, 2021     134,776       32,611  
October 1, 2021 to September 30, 2022     110,062        
October 1, 2022 to September 30, 2023     29,247        
October 1, 2023 to September 30, 2024     2,437        
Total     383,979       636,691  
                 
Less interest     (55,364 )     (18,413 )
Present value of minimum lease payments     328,615       618,278  
                 
Less current portion of lease obligations     (141,830 )     (589,457 )
Lease obligations, net of current portion   $ 186,785     $ 28,821  

 

As of September 30, 2019, the Company is in default of substantially all its finance lease obligations, therefore the aggregate future minimum rentals and accrued interest under finance leases in the amount of $0.6 million are deemed to be immediately due.

 

Note 11 – Derivative Financial Instruments and Fair Value

 

The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2019 and December 31, 2018:

 

   Level 1   Level 2   Level 3   Total 
As of December 31, 2018:                    
Embedded conversion options  $    -   $     -   $350,260   $350,260 
Total  $-   $-   $350,260   $350,260 
                     
As of September 30, 2019:                    
Embedded conversion options  $-   $-   $455,336   $455,336 
Total  $-   $-   $455,336   $455,336 

 

The Company utilized the following methods to value its derivative liabilities as of September 30, 2019 and December 31, 2018, for embedded conversion options valued at $455,336 and $350,260, respectively. The Company determined the fair value by comparing the discounted conversion price per share (85% of market price, subject to a floor in certain cases) multiplied by the number of shares issuable at the balance sheet date to the actual price per share of the Company’s common stock multiplied by the number of shares issuable at that date with the difference in value recorded as a liability. All inputs for the derivative liabilities are observable and, therefore, there is no sensitivity in the valuation to unobservable inputs.

 

The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the nine months ended September 30, 2019:

 

Balance at December 31, 2018  $350,260 
Change in fair value of debentures   105,076 
Balance at September 30, 2019  $455,336 

 

 22 

 

 

During the nine months ended September 30, 2019 and the three and nine months ended September 30, 2018, the conversions of preferred stock triggered a further reduction in the exercise prices of any debentures and warrants containing ratchet features that had not already ratcheted down to their floor. In accordance with U.S. GAAP, the incremental fair value of the debentures and warrants was measured, ignoring the down round provision, using Black Scholes. The following assumptions were utilized in the Black Scholes valuation models in the nine months ended September 30, 2019: risk free rates ranging from 2.4% to 2.6% and volatility ranging from 189.5% to 273.1% and weighted average life of 0.3 to 3.2 years. The following assumptions were utilized in the Black Scholes valuation models in the three and nine months ended September 30, 2018: risk free rates ranging from 2.36% to 2.88% and volatility ranging from 163.8% to 234.7% and weighted average life of .73 to 3.5 years. The incremental value of $123.9 million was recorded as a deemed dividend for the nine months ended September 30, 2019 and the incremental value of $17.9 million and $17.9 million was recorded as a deemed dividend in the three and nine months ended September 30, 2018, respectively. Deemed dividends are also discussed in Notes 1 and 3.

 

During the nine months ended September 30, 2019, the Company recorded interest expense of $9.5 million, which represented the fair value of the modification of warrants during the period as more fully discussed in Note 13. The Company used the Black Scholes model to calculate the fair value of the warrants as of the modification dates. Using the pre-modification terms and related assumptions of risk free rates ranging from 2.44% to 2.46%, volatility ranging from 182.9% to 204.4% and weighted average remaining lives of .24 years to .36 years, and the post-modification terms and related assumptions of risk free rates ranging from 2.23% to 2.49%, volatility ranging from 198.3% to 259.4% and weighted average remaining lives of .48 years to 2.89 years, the changes in the fair value of the warrant instruments as a result of the modifications were estimated.

 

During the three and nine months ended September 30, 2018, the Company extended the exercise period of outstanding warrants twice, once to March 21, 2019 and the second time to June 21, 2019 and recorded an additional discount on the debenture issued in connection with the warrants of approximately $8.3 million and $0.3 million as a result of the extensions. The Company amortized approximately $6.4 million of the discount as non-cash interest expense in the nine months ended September 30, 2018. This amount was included in the cash flow statement for the nine months ended September 30, 2018 in amortization of debt discount. The Company used the Black Scholes model to calculate the fair value of the warrants as of the modification dates. Using the pre-modification term and related assumptions of risk free rates ranging from 1.91-2.32%, volatility ranging from 184.0-296.3% and weighted average remaining life of .33 years, and the post-modification term and related assumptions of risk free rates ranging from 2.09-2.56%, volatility ranging from 208.2-249.1% and weighted average remaining life of .65 years, the change in the fair value of the warrant instruments as a result of the modifications was estimated on each date.

 

For the three and nine months ended September 30, 2018, the Company realized income of $109.3 million and $13.7 million, respectively, on instruments valued using Level 3 valuations. On September 23, 2018, the Company’s board of directors approved a reverse split of its common stock, which would provide sufficient authorized and unissued shares to allow for otherwise equity classified instruments to be classified in equity. As of September 23, 2018, the fair value of these instruments was evaluated for reclassification. As a result of the evaluation, the Company reclassified the derivative liability previously reported as a current liability to derivative income.

 

All inputs for the derivative liabilities are observable and, therefore, there is no sensitivity in the valuation to unobservable inputs.

 

On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding. The Series K Preferred Stock is more fully described in Note 19.

 

Note 12 – Redeemable Preferred Stock

 

The Company has 5,000,000 authorized shares of Preferred Stock at a par value of $0.01. Issuances of the Company’s Preferred Stock included as part of stockholders’ deficit are discussed in Note 13. The following is a summary of the issuances of the Company’s Redeemable Preferred Stock.

 

 23 

 

 

Series I-1 Convertible Preferred Stock

 

On October 30, 2017, the Company closed an offering of $4,960,000 stated value of 4,960 shares of a newly-authorized Series I-1 Convertible Preferred Stock (the “Series I-1 Preferred Stock”). Each share of Series I-1 Preferred Stock has a stated value of $1,000. The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of October 30, 2017 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $4.0 million from the offering. The Purchase Agreement gives the investors the right to participate in up to 50% of any offering of common stock or common stock equivalents by the Company. In the event of any such offering, the investors may also exchange all or some of their Series I-1 Preferred Stock for such new securities on an $0.80 stated value of Series I-1 Preferred Stock for $1.00 of new subscription amount basis. Each share of Series I-1 Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-1 Preferred Stock. Upon the occurrence of certain Triggering Events, as defined in the Certificate of Designation of the Series I-1 Preferred Stock, the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-1 Preferred Stock in cash or in certain circumstances in shares of common stock at the redemption prices set forth in the Certificate of Designation.

 

Series I-2 Convertible Preferred Stock

 

On October 30, 2017, the Company entered into Exchange Agreements with the holders of the September Debentures to provide that the holders may, from time to time, exchange their September Debentures for shares of a newly-authorized Series I-2 Preferred Stock. The Exchange Agreements permitted the holders of the September Debentures to exchange specified principal amounts of the September Debentures on various closing dates starting on December 2, 2017 (debentures are more fully discussed in Note 9 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K). At the holder’s option each holder could reduce the principal amount of September Debentures exchanged on any particular closing date, or elect not to exchange any September Debentures at all on a closing date. If a holder chose to exchange less principal amount of September Debentures, or no September Debentures at all, it could carry forward such lesser amount to a future closing date and then exchange more than the originally specified principal amount for that later closing date. For each $0.80 of principal amount of September Debenture surrendered to the Company at any closing date, the Company will issue the holder a share of Series I-2 Preferred Stock with a stated value of $1.00. Each share of Series I-2 Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-2 Preferred Stock. From December 2, 2017 through March 1, 2018, any exchange under the Exchange Agreements was at the option of the holder. Subsequent to March 2018, any exchange is at the option of the Company.

 

The Company’s board of directors has designated up to 21,346 shares of the 5,000,000 authorized shares of preferred stock as the Series I-2 Preferred Stock. Each share of Series I-2 Preferred Stock has a stated value of $1,000. Upon the occurrence of certain Triggering Events (as defined in the Certificate of Designation of the Series I-2 Preferred Stock), the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-2 Preferred Stock in cash or in certain circumstances in shares of common stock at the redemption prices set forth in the Certificate of Designation.

 

On February 9, 2018, the holders exercised their right to exchange a portion of the September Debentures for shares of the Series I-2 Preferred Stock for the first time. On that date, the holders exchanged an aggregate of $1,384,556 principal amount of September Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Preferred Stock. On July 16, 2018, under the Exchange Agreements with the holders of the September Debentures, the holders exchanged a portion of the September Debentures for shares of the Company’s Series I-2 Preferred Stock. On that date, the holders exchanged an aggregate of $1,741,580 principal amount of the September Debentures and the Company issued an aggregate of 2,176.975 shares of its Series I-2 Preferred Stock. During the nine months ended September 30, 2018, the Company recorded a loss on these exchanges of convertible debentures into shares of its Series I-2 Preferred Stock in the aggregate amount of $1.5 million. In 2018, the holder converted 1,286.141 shares of Series I-2 Preferred Stock into 106,335,991 shares of the Company’s common stock and during the nine months ended September 30, 2019, the holder converted 982.101 shares of Series I-2 Preferred Stock into 8,150,754,118 shares of the Company’s common stock.

 

See Notes 3 and 19 for a discussion of the dilutive effect of the Series I-1 Preferred Stock and the Series I-2 Preferred Stock as of September 30, 2019 and December 26, 2019, respectively.

 

Note 13 – Stockholders’ Deficit

 

Authorized Capital

 

The Company has 10,000,000,000 authorized shares of Common Stock at $0.0001 par value and 5,000,000 authorized shares of Preferred Stock at a par value of $0.01.

 

 24 

 

 

Preferred Stock

 

The Company has 5,000,000 shares, par value $0.01, of preferred stock authorized. As of September 30, 2019, the Company had outstanding shares of preferred stock consisting of shares of its Series I-1 Preferred Stock and shares of Series I-2 Preferred Stock (both of which are more fully discussed in Note 12), 215 shares of its Series G Preferred Stock, 10 shares of its Series H Preferred Stock, 1,750,000 shares of its Series F Convertible Preferred Stock and 250,000 shares of its Series J Convertible Preferred Stock.

 

The 215 shares of the Series G Preferred Stock have a stated value of $1,000 per share and are convertible into shares of the Company’s common stock at a price equal to 85% of the volume weighted average price of the Company’s common stock at the time of conversion. See Note 19 regarding the redemption of these shares.

 

The Series H Preferred Stock has a stated value of $1,000 per share and is convertible into shares of the Company’s common stock at a conversion price of 85% of the volume weighted average price of the Company’s common stock at the time of conversion.

 

In September 2017, the Company issued 1,750,000 shares of its Series F Preferred Stock valued at $174,097 in connection with the acquisition of Genomas Inc. Genomas Inc. is included in the Company’s discontinued operations, which are discussed in Note 17. Each share of the Series F Preferred Stock is convertible into shares of our common stock (subject to adjustment as provided in the related certificate of designation) at any time after the first anniversary of the issuance date at the option of the holder at a conversion price equal to the greater of $14,625 or the average closing price of the Company’s common stock for the 10 trading days immediately preceding the conversion. The maximum number of shares of common stock issuable upon the conversion of the Series F Preferred Stock is 120. Any shares of Series F Preferred Stock outstanding on the fifth anniversary of the issuance date will be mandatorily converted into common stock at the applicable conversion price on such date. At any time, from time to time after the first anniversary of the issuance date, the Company has the right to redeem all or any portion of the outstanding Series F Preferred Stock at a price per share equal to $1.95 plus any accrued but unpaid dividends. The Series F Preferred Stock has voting rights. Each share of Series F Preferred Stock has one vote, and the holders of the Series F Preferred Stock shall vote together with the holders of the Company’s common stock as a single class.

 

On July 20, 2018, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware to authorize the issuance of up to 250,000 shares of its Series J Convertible Preferred Stock (the “Series J Preferred Stock”). On July 23, 2018, the Company entered into an Exchange Agreement (the “Agreement”) with Alcimede, of which Seamus Lagan, our Chief Executive Officer, is the sole manager. Pursuant to the Agreement, the Company issued to Alcimede 250,000 shares of the Series J Preferred Stock in exchange for the cancellation of the outstanding principal and interest owed by the Company to Alcimede under the Note, dated February 5, 2015, and the cancellation of certain amounts owed by the Company to Alcimede under a consulting agreement between the parties. The total amount of consideration paid by Alcimede to the Company equaled $250,000. Each share of the Series J Preferred Stock has a stated value of $1.00. The conversion price is equal to the average closing price of the Company’s common stock on the 10 trading days immediately prior to the conversion date. Each holder of the Series J Preferred Stock is entitled to vote on all matters submitted to a vote of the holders of the Company’s common stock. From and after October 1, 2018, each share of the Series J Preferred Stock is entitled to the whole number of votes equal to the number of common shares into which it is then convertible. The full terms of the Series J Preferred Stock are listed in the Certificate of Designations filed as Exhibit 3.16 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 24, 2018. The Series J Preferred Stock is entitled to 8% per annum cumulative dividends at the discretion of the Company’s board of directors. No dividends have been declared by the board as of September 30, 2019.

 

On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement, as more fully described in Note 19.

 

Common Stock

 

The Company has authorized 10,000,000,000 shares of Common Stock, par value $0.0001 per share.

 

The Company had 8,398,936,775 and 128,567,273 shares of common stock issued and outstanding at September 30, 2019 and December 31, 2018, respectively. During the nine months ended September 30, 2019, the Company:

 

Issued 119,615,384 shares of common stock upon exercise of 755,000,000 warrants, on a cashless basis; and
   
Issued 8,150,754,118 shares of common stock upon the conversion of 982.101 shares of its Series I-2 Preferred Stock;

 

 25 

 

 

Restricted Stock

 

On August 14, 2017, the Board of Directors, based on the recommendation of the Compensation Committee of the Board and in accordance with the provisions of the 2007 Equity Plan, approved grants to employees and directors of the Company of an aggregate of 364 shares of restricted common stock of the Company. The grants fully vested on the first anniversary of the date of grant, subject to the grantee’s continued status as an employee or director on the vesting date. During the nine months ended September 30, 2019, 123 shares of the restricted stock were forfeited by their terms and returned to treasury.

 

During the nine months ended September 30, 2018, the Company issued an aggregate of 142,667 shares of restricted stock to employees and directors, based upon the recommendation of the Compensation Committee of the Board of Directors. The grants fully vested immediately. During the nine months ended September 30, 2018, the Company recognized stock-based compensation in the amount of $477,933 for the grant of such restricted stock based on a valuation of $3.35 per share. The value of the common stock issued was based on the fair value of the stock at the time of issuance.

 

Common Stock and Common Stock Equivalents

 

The Company has outstanding options, warrants, convertible preferred stock and convertible debentures. Exercise of the options and warrants, and conversions of the convertible preferred stock and debentures could result in substantial dilution of our common stock and a decline in its market price. In addition, the terms of certain of the warrants, convertible preferred stock and convertible debentures issued by us provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that we issue common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. These provisions, as well as the issuances of debentures and preferred stock with conversion prices that vary based upon the price of our common stock on the date of conversion, have resulted in significant dilution of our common stock and have given rise to reverse splits of our common stock.

 

On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement. The Series K Preferred Stock is more fully described in Note 19. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares. These potentially dilutive shares are presented in Note 19.

 

The Company maintained and sponsored the Tegal Corporation 2007 Incentive Award Plan (the “2007 Equity Plan”). Tegal Corporation is the prior name of the Company. The 2007 Equity Plan, as amended, provided for the issuance of stock options and other equity awards to the Company’s officers, directors, employees and consultants. The 2007 Equity Plan terminated pursuant to its terms in September 2017. The following table summarizes the stock option activity for the nine months ended September 30, 2019:

 

Stock Options

 

   Number of options   Weighted-average exercise price   Weighted-average contractual term 
Outstanding at December 31, 2018   77   $1,036,375    7.33 
Granted    -           
Expired   -           
Forfeit   -           
Outstanding at September 30, 2019   77   $1,036,375    6.50 
                
Exercisable at September 30, 2019   68   $1,152,616      

 

The Company recognized stock option expense of approximately $25,950 and $72,590 for the nine months ended September 30, 2019 and 2018, respectively. As of September 30, 2019, the weighted average remaining contractual life was 6.50 years for options outstanding and exercisable. The intrinsic value of options exercisable at September 30, 2019 was $0. As of September 30, 2019, the remaining compensation expense of approximately $8,650 will be amortized over the remaining vesting period, which is approximately three months.

 

 26 

 

 

Warrants

 

The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company’s common stock.

 

During the nine months ended September 30, 2019, the number of shares issuable pursuant to outstanding warrants increased by 582.2 billion as a result of the anti-dilution provisions of outstanding warrants that were issued in connection with the issuances of debentures as more fully discussed in Note 9 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K. The number of shares issued and issuable as well as the exercise prices of the warrants reflected in the table below have been adjusted to reflect the full ratchet and other dilutive and down round provisions pursuant to the warrant agreements. As a result of the current exercise prices for the majority of the outstanding warrants (subject to a floor in some cases), as well as the full ratchet provisions of the majority of the outstanding warrants (again, subject to a floor in some cases), subsequent decreases in the price of the Company’s common stock and subsequent issuances of the Company’s common stock or common stock equivalents at prices below the current exercise prices of the warrants will result in increases in the number of shares issuable pursuant to the warrants and decreases in the exercise prices.

 

The following summarizes the information related to warrants issued and the activity during the nine months ended September 30, 2019:

 

   Number of shares issuable pursuant to warrants   Weighted average exercise price 
Balance at December 31, 2018   53,130,510,439   $0.00172 
Increase during the period as a result of down round provisions   582,209,844,938      
Shares issued pursuant to Warrants exercised during the period   (755,000,000)  $0.00034 
Balance at September 30, 2019   634,585,355,377   $0.00014 

 

On March 27, 2019, the expiration dates of certain warrants issued in March 2017 and September 2017 with convertible debentures, referred to as the March 2017 Series B Warrants and the September 2017 Series B Warrants, were extended from June 2019 to September 2019. On May 12, 2019, the expiration date of these warrants was further extended to March 31, 2022. The Company used the Black Scholes model to calculate the fair value of the warrants as of the modification date. Using the pre-modification terms and related assumptions, and the post-modification terms and related assumptions, the Company determined that the change in fair value of the warrants as a result of the March 27th modification was $4.1 million and the May 12th modification was $5.4 million. Accordingly, the Company recorded the modification value of $5.4 and $9.5 million as interest expense in the three and nine months ended September 30, 2019, respectively. See Note 11 for the assumptions used in the Black Scholes valuation models.

 

During the three and nine months ended September 30, 2018, the Company extended the exercise period of outstanding warrants twice, once to March 21, 2019 and the second time to June 21, 2019 and recorded an additional discount on the debenture issued in connection with the warrants of approximately $8.3 million and $0.3 million as a result of the extensions. The Company amortized approximately $6.4 million of the discount as non-cash interest expense in the nine months ended September 30, 2018. This amount was included in the cash flow statement for the nine months ended September 30, 2018 in amortization of debt discount. See Note 11 for the assumptions used in the Black Scholes valuation models.

 

See Note 19 for a discussion of the dilutive effect of the outstanding warrants as of December 26, 2019.

 

 27 

 

 

Note 14 – Supplemental Disclosure of Cash Flow Information

 

   Nine Months Ended September 30, 
   2019   2018 
Cash paid for interest  $-   $303,208 
Cash paid for income taxes   45,000    20,000 
           
Acquisitions of Hospitals and Medical Center:          
Cash  $-   $375 
Inventory   317,427    450,682 
Prepaid expenses and other current assets   -    310,385 
Property and equipment   500,000    7,129,484 
Intangible assets   250,000    504,806 
Accrued expenses   158,890    193,966 
           
Non-cash investing and financing activities:          
Exchange of Series I-2 Preferred Stock for common stock  $1,143,974   $633,101 
Cashless exercise of warrants   11,961    4,619,150 
Debentures converted into common stock   -    8,085,342 
Common stock issued in cashless exercise of warrants   11,961    - 
Exchange of debentures into Series I-2 Preferred Stock   -    1,420 
Conversions of Series H Preferred Stock into common stock   -    50,000 
Original issue discount of debentures and notes payable   400,000    1,920,000 
Deemed dividend for trigger of down round provision features   123,861,587    17,942,578 
Issuance of Series J Preferred Stock in settlement of note payable to related party   -    250,000 

 

Note 15 – Commitments and Contingencies

 

Concentration of Credit Risk

 

Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base. The Company does have significant receivable balances with government payers and various insurance carriers. Generally, the Company does not require collateral or other security to support customer receivables. However, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.

 

A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid (CMS) reimbursements to hospitals and clinical laboratories. Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in revenues from Medicare and Medicaid (CMS), which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

 

The Company maintains its cash balances in high credit quality financial institutions. The Company’s cash balances may, at times, exceed the deposit insurance limits provided by the Federal Deposit Insurance Corporation.

 

 28 

 

 

Legal Matters

 

From time-to-time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. The Company’s policy is to expense legal fees and expenses incurred in connection with the legal proceedings in the period in which the expense is incurred. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.

 

Biohealth Medical Laboratory, Inc. and PB Laboratories, LLC (the “Companies”) filed suit against CIGNA Health in 2015 alleging that CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA - issued and CIGNA - administered plans. In 2016, the U.S. District Court dismissed part of the Companies’ claims for lack of standing. The Companies appealed that decision to the Eleventh Circuit Court of Appeals, which in late 2017 reversed the District Court’s decision and found that the Companies have standing to raise claims arising out of traditional insurance plans as well as self-funded plans. In July 2019, the Companies and EPIC Reference Labs, Inc. filed suit against Cigna Health for failure to pay claims for laboratory services provided. Cigna Health, in turn, sued for improper billing practices. Both cases are in the early stages.

 

The Company’s Epinex Diagnostics Laboratories, Inc. subsidiary was sued in a California state court by two former employees who alleged that they were wrongfully terminated, as well as for a variety of unpaid wage claims. The parties entered into a settlement agreement of this matter on July 29, 2016 for approximately $0.2 million, and the settlement was consummated on August 25, 2016. In October of 2016, the plaintiffs in this matter filed a motion with the court seeking payment for attorneys’ fees in the approximate amount of $0.7 million. On March 24, 2017, the court granted plaintiffs’ motion for payment of attorneys’ fees in the amount of $0.3 million, and the Company accrued this amount in its consolidated financial statements. Additionally, the Company is seeking indemnification for these amounts from Epinex Diagnostics, Inc., the seller of Epinex Diagnostic Laboratories, Inc., pursuant to a Stock Purchase Agreement entered into by and among the parties.

 

In February 2016, the Company received notice that the Internal Revenue Service (the “IRS”) placed a lien against Medytox Solutions, Inc. and its subsidiaries relating to unpaid 2014 taxes due, plus penalties and interest, in the amount of $5.0 million. The Company paid $0.1 million toward its 2014 tax liability in March 2016. The Company filed its 2015 Federal tax return on March 15, 2016 and the accompanying election to carryback the reported net operating losses was filed in April 2016. On August 24, 2016, the lien was released, and in September of 2016 the Company received a refund from the IRS in the amount of $1.9 million. In November of 2016, the IRS commenced an audit of the Company’s 2015 Federal tax return. Based upon the audit results, the Company has made provisions of approximately $1.0 million as a liability in its financial statements as well as an estimated $0.6 million of receivables for an additional refund that it believes is due.

 

On September 27, 2016, a tax warrant was issued against the Company by the Florida Department of Revenue (the “DOR”) for unpaid 2014 state income taxes in the approximate amount of $0.9 million, including penalties and interest. The Company entered into a Stipulation Agreement with the DOR allowing the Company to make monthly installments until July 2019. The Company has made payments to reduce the amount owed to approximately $$0.4 million as of September 30, 2019. The Company intends to renegotiate another Stipulation agreement. However, there can be no assurance the Company will be successful. The remaining balance accrued of approximately $0.4 million remained outstanding to the DOR at September 30, 2019.

 

In December of 2016, TCS-Florida, L.P. (“Tetra”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with Tetra (see Note 10). On January 3, 2017, Tetra received a Default Judgment against the Company in the amount of $2.6 million, representing the balance owed on the leases, as well as additional interest, penalties and fees. In January and February of 2017, the Company made payments to Tetra relating to this judgment aggregating $0.7 million, and on February 15, 2017, the Company entered into a forbearance agreement with Tetra whereby the remaining $1.9 million due would be paid in 24 equal monthly installments. The Company has not maintained the payment schedule to Tetra. As a result of this default, in May 2018, Tetra and the Company agreed to dispose of certain equipment and the proceeds from the sale have been applied to the outstanding balance. The balance owed to Tetra at September 30, 2019 was $0.3 million and the Company remains in default.

 

In December of 2016, DeLage Landen Financial Services, Inc. (“DeLage”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with DeLage (see Note 10). On January 24, 2017, DeLage received a default judgment against the Company in the approximate amount of $1.0 million, representing the balance owed on the lease, as well as additional interest, penalties and fees. The Company recognized this amount in its consolidated financial statements as of December 31, 2016. On February 8, 2017, a Stay of Execution was filed and under its terms the balance due was to be paid in variable monthly installments through January of 2019, with an implicit interest rate of 4.97%. The Company and DeLage have now disposed of certain equipment and reduced the balance owed to DeLage. A balance of $0.2 million remained outstanding at September 30, 2019.

 

 29 

 

 

On December 7, 2016, the holders of the Tegal Notes (see Note 7) filed suit against the Company seeking payment for the amounts due under the notes in the aggregate of the principal of $341,612, and accrued interest of $43,000. A request for entry of default judgment was filed on January 24, 2017. On April 23, 2018, the holders of the Tegal Notes received a judgment against the Company. To date, the Company has repaid $5,513 of this amount.

 

In November 2017, a former shareholder of Genomas, Inc., Phenomas, LLC, filed suit against the Company for payment of a $200,000 note payable by the Company’s subsidiary, Genomas. This note is recorded in the financial statements of the subsidiary and is not payable directly from the Company. The Company has made payments totaling $120,000 against this note and agreed to a payment schedule in order to dismiss the legal action. On November 12, 2018, Phenomas, LLC filed a motion to voluntarily dismiss the suit without prejudice.

 

The counterparty to the prepaid forward purchase agreement entered into by the Company on March 31, 2016, as amended, filed an arbitration proceeding under the agreement with regard to the outstanding balance. During the nine months ended September 30, 2019, Mr. Diamantis advanced the Company $9.9 million, which was used to repay all obligations under the prepaid forward purchase agreement, as more fully discussed in Note 7.

 

Two former employees of the Company’s CollabRx, Inc. subsidiary have filed suits in a California state court in connection with amounts claimed to be owed under their respective employment agreements with the subsidiary. One former employee received a judgment in October 2018 for approximately $253,000. The other former employee’s claim is for approximately $110,000. The Company is considering its options to refute these matters and believes the claims against the Company to be frivolous and outside of entitlement and contractual agreements.

 

The Company, as well as many of our subsidiaries, are defendants in a case filed in Broward County Circuit Court by TCA Global Credit Master Fund, L.P. The plaintiff alleges a breach by Medytox Solutions, Inc. of its obligations under a debenture and claims damages of approximately $2,030,000 plus interest, costs and fees. The Company and the other subsidiaries are sued as alleged guarantors of the debenture. The complaint was filed on August 1, 2018. The Company has recorded the principal balance and interest owed under the debenture agreement for the period ended September 30, 2019. The Company and all defendants have filed a motion to dismiss the complaint, but have not recorded any potential liability related to any further damages.

 

On September 13, 2018, Laboratory Corporation of America sued EPIC Reference Labs, Inc., a subsidiary of the Company, in Palm Beach County Circuit Court for amounts claimed to be owed of approximately $148,000. The Company has recorded the amount owed in accrued expenses at September 30, 2019. The court awarded a judgment against EPIC Reference Labs, Inc. in May 2019 for approximately $155,000.

 

In July 2019, Roche Diagnostics Corporation sued EPIC Reference Labs, Inc. in the Circuit Court for Palm Beach County claiming approximately $240,000 under an agreement to purchase laboratory supplies. This suit is in the early stages.

 

In August 2019, EPIC Reference Labs, Inc. and Medytox Diagnostics, Inc. were sued by Beckman Coulter, Inc. in the same court under an agreement to purchase laboratory supplies. The plaintiff claims damages of approximately $106,000. This case is in the early stages.

 

In July 2019, the landlord of Medytox Solutions, Inc. received a judgment in the amount of approximately $413,000 in connection with failure to pay under an office lease in West Palm Beach, Florida.

 

In February 2018, Techlogix, Inc. received a judgment of approximately $72,000 against the Company and HTS in the Superior Court of Middlesex County Massachusetts.

 

Following the Company’s decision to suspend operations at Jamestown Regional Medical Center in June 2019 a number of vendors remain unpaid. A number have initiated or threatened legal actions. The Company believes it will come to satisfactory arrangements with these parties as it works towards reopening the hospital. On June 10, 2019, the Company hired a new CEO to oversee the reopening of the hospital and took steps to re-enter the Medicare program. The hospital received initial approval of its application to reactivate the Medicare agreement in August and is currently planning the reopening of the hospital. Negotiations with vendors are ongoing.

 

 30 

 

 

Note 16– Segment Reporting

 

Operating segments are defined under U.S. GAAP as components of an enterprise for which discrete financial information is available and are evaluated regularly by the enterprise’s chief operating decision maker in determining how to allocate resources and assess performance. The Company operates in two reportable business segments:

 

  Hospital Operations, which reflects the operations of Jamestown Regional Medical Center, Big South Fork Medical Center and Jellico Community Hospital and CarePlus Center.
  Clinical Laboratory Operations, which specializes in providing urine and blood toxicology and pain medication testing to physicians, clinics and rehabilitation facilities in the United States.

 

The Company’s Corporate expenses reflect consolidated company-wide support services such as finance, legal counsel, human resources, and payroll.

 

The Company’s Decision Support and Informatics segment and its Supportive Software Solutions segment are now included in discontinued operations as they have been classified as held for sale as of September 30, 2019. The accounting policies of the reportable segments are the same as those described in Note 1.

 

Selected financial information for the Company’s operating segments is as follows:

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2019   2018   2019   2018 
Net revenues - External                    
Hospital Operations  $3,920,608   $5,021,543   $13,081,647   $9,755,099 
Clinical Laboratory Operations   (34,631)   17,569    56,169    177,890 
   $3,885,977   $5,039,112   $13,137,816   $9,932,989 
(Loss) income from continuing operations before income taxes:                    
Hospital Operations  $(1,769,400)  $(1,294,581)  $(8,946,720)   (3,998,943)
Clinical Laboratory Operations   (295,908)   (547,041)   (701,466)   (1,765,395)
Corporate   (640,044)   (973,953)   (2,626,953)   (3,156,646)
Other income (expense), net   (9,422,340)   100,171,656    (26,064,924)   4,955,262 
   $(12,127,692)  $97,356,081   $(38,340,063)  $(3,965,722)
Depreciation and amortization                    
Hospital Operations   182,832   $39,669   $532,979   $177,386 
Clinical Laboratory Operations   10,036    112,908    69,381    625,877 
Corporate   7,128    248    7,458    811 
   $199,996   $152,825   $609,818   $804,074 
Capital expenditures                    
Hospital Operations  $7,086   $103,387   $50,801   $103,387 
Clinical Laboratory Operations   -    -    -    - 
   $7,086   $103,387   $50,801   $103,387 

 

   As of 
   September 30, 2019   December 31, 2018 
Total assets          
Hospital Operations  $16,831,443   $13,568,933 
Clinical Laboratory Operations   356,854    271,426 
Corporate   1,821,952    2,707,416 
Assets of AMSG and HTS classified as held for sale   373,121    152,171 
Eliminations   (2,809,305)   (2,500,646)
   $16,574,065   $14,199,300 

 

 31 

 

 

Note 17 – Discontinued Operations

 

On July 12, 2017, the Company announced plans to spin off AMSG and in the third quarter of 2017, the Company’s Board of Directors voted unanimously to spin off HTS as independent publicly traded companies by way of tax-free distributions to the Company’s stockholders. While the spin offs have taken longer than anticipated, completion of these spin offs is now expected to occur in the first quarter of 2020. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission, and consents, including under various funding agreements previously entered into by the Company. A record date to determine those stockholders entitled to receive shares in the spin offs should be approximately 30 to 60 days prior to the dates of the spin offs. The strategic goal of the spin offs is to create three public companies, each of which can focus on its own strengths and operational plans.

 

In accordance with ASC 205-20 and having met the criteria for “held for sale”, as the Company reached this decision prior to December 31, 2017, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. Prior to being classified as “held for sale,” AMSG had been the Company’s Decision Support and Informatics segment, except for the Company’s subsidiary, Alethea Laboratories, Inc., which had been included in the Clinical Laboratory Operations segment and now is part of AMSG, and HTS had been the Company’s Supportive Software Solutions segment. Segment disclosures in Note 16 no longer include amounts relating to AMSG and HTS following the reclassification to discontinued operations.

 

Carrying amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the condensed consolidated balance sheets consisted of the following:

 

AMSG Assets and Liabilities:

 

   September 30, 2019   December 31, 2018 
   (unaudited)   (unaudited) 
Cash  $220   $4,471 
Accounts receivable, net   22,523    6,838 
Prepaid expenses and other current assets   -    25,477 
Current assets classified as held for sale  $22,743   $36,786 
           
Accounts payable (includes related parties)  $514,415   $532,858 
Accrued expenses   493,356    418,932 
Income taxes payable   -    - 
Current portion of notes payable   268,851    278,836 
Current liabilities classified as held for sale  $1,276,622   $1,230,626 
           
Non-current liabilities classified as held for sale  $-   $- 

 

HTS Assets and Liabilities:

 

   September 30, 2019   December 31, 2018 
   (unaudited)   (unaudited) 
Cash  $2,298   $2,523 
Accounts receivable, net   330,238    90,743 
Prepaid expenses and other current assets   6,867    10,300 
Current assets classified as held for sale  $339,403   $103,566 
           
Property and equipment, net  $4,946   $5,790 
Deposits   6,029    6,029 
Non-current assets classified as held for sale  $10,975   $11,819 
           
Accounts payable (includes related parties)  $710,709   $546,969 
Accrued expenses   714,128    520,251 
Current portion of notes payable   -    - 
Current liabilities classified as held for sale  $1,424,837   $1,067,220 

 

 32 

 

 

Total Discontinued Assets and Liabilities:

 

   September 30, 2019   December 31, 2018 
   (unaudited)   (unaudited) 
Cash  $2,518   $6,994 
Accounts receivable, net   352,761    97,581 
Prepaid expenses and other current assets   6,867    35,777 
Current assets classified as held for sale  $362,146   $140,352 
           
Property and equipment, net  $4,946   $5,790 
Deposits   6,029    6,029 
Non-current assets classified as held for sale  $10,975   $11,819 
           
Accounts payable (includes related parties)  $1,225,124   $1,079,827 
Accrued expenses   1,207,484    939,183 
Current portion of notes payable   268,851    278,836 
Current liabilities classified as held for sale  $2,701,459   $2,297,846 

 

Major line items constituting loss from discontinued operations in the condensed consolidated statements of operations for the three months ended September 30, 2019 and 2018 consisted of the following:

 

AMSG Loss from Discontinued Operations:

 

   Three Months Ended 
   September 30, 2019   September 30, 2018 
   (unaudited)   (unaudited) 
Revenue from services  $11,350   $13,249 
Cost of services   5,878    15,559 
Gross profit (loss)   5,472    (2,310)
Operating expenses   60,424    93,059 
Other income (expenses)   2,912    (5,748)
Provision for income taxes   -    - 
Loss from discontinued operations  $(57,864)  $(89,621)

 

HTS Loss from Discontinued Operations:

 

   Three Months Ended 
   September 30, 2019   September 30, 2018 
   (unaudited)   (unaudited) 
Revenue from services  $235,326   $499,317 
Cost of services   20,134    30,082 
Gross profit   215,192    469,235 
Operating expenses   295,404    532,892 
Other income   -    6,152 
Provision for income taxes   -    - 
Loss from discontinued operations  $(80,212)  $(69,809)

 

 33 

 

 

Consolidated Loss from Discontinued Operations:

 

   Three Months Ended 
   September 30, 2019   September 30, 2018 
   (unaudited)   (unaudited) 
Revenue from services  $246,676   $512,566 
Cost of services   26,012    45,641 
Gross profit   220,664    466,925 
Operating expenses   355,828    625,951 
Other expense   2,912    404 
Provision for income taxes   -    - 
Loss from discontinued operations  $(138,076)  $(159,430)

 

Major line items constituting (loss) income from discontinued operations in the condensed consolidated statements of operations for the nine months ended September 30, 2019 and 2018 consisted of the following:

 

AMSG (Loss) Income from Discontinued Operations:

 

   Nine Months Ended 
   September 30, 2019   September 30, 2018 
   (unaudited)   (unaudited) 
Revenue from services  $59,832   $92,090 
Cost of services   29,638    37,773 
Gross profit   30,194    54,317 
Operating expenses   237,042    363,944 
Other (income) expense   31,874    (819,258)
Provision for income taxes   -    - 
(Loss) income from discontinued operations  $(238,722)  $509,631 

 

HTS Loss from Discontinued Operations:

 

   Nine Months Ended 
   September 30, 2019   September 30, 2018 
   (unaudited)   (unaudited) 
Revenue from services  $706,795   $1,291,288 
Cost of services   83,628    95,965 
Gross profit   623,167    1,195,323 
Operating expenses   1,176,381    1,577,046 
Other income   -    12,121 
Provision for income taxes   -    - 
Loss from discontinued operations  $(553,214)  $(393,844)

 

 34 

 

 

Consolidated (Loss) Income from Discontinued Operations:

 

   Nine Months Ended 
   September 30, 2019   September 30, 2018 
   (unaudited)   (unaudited) 
Revenue from services  $766,627   $1,383,378 
Cost of services   113,266    133,738 
Gross profit   653,361    1,249,640 
Operating expenses   1,413,423    1,940,990 
Other (income) expense   31,874    (807,137)
Provision for income taxes   -    - 
(Loss) income from discontinued operations  $(791,936)  $115,787 

 

Note 18 – Recent Accounting Pronouncements

 

Accounting Pronouncements Adopted

 

In addition to the adoption of pronouncements related to derivative liabilities discussed in Note 1, and ASU 2018-02, Leases (Topic 842) discussed in Notes 1 and 10, the Company adopted the following pronouncements:

 

In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This standard provides companies with an option to reclassify stranded tax effects resulting from enactment of the Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income to retained earnings. Early adoption of this standard is permitted and may be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the tax rate as a result of TCJA is recognized. This ASU became effective for us for annual and interim periods beginning after December 15, 2018. The adoption of this ASU did not have a material impact on our results of operations, financial position and cash flows.

 

In February 2018, the FASB issued ASU 2018-03; Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. These technical corrections and improvements are intended to clarify certain aspects of the guidance on recognizing and measuring financial assets and liabilities in ASU 2016-01. This includes equity securities without a readily determinable fair value, forward contracts and purchased options, presentation requirements for certain fair value option liabilities, fair value option liabilities denominated in foreign currency and transition guidance for equity securities without a readily determinable fair value. We were required to adopt these standards starting in the first quarter of fiscal year 2019. The implementation did not have a material impact on our consolidated financial statements.

 

In March 2018, the FASB issued ASU 2018-05; “Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update)”, which amended ASC 740 to incorporate the requirements of Staff Accounting Bulletin (“SAB”) 118. Issued in December 2017 by the SEC, SAB 118 addresses the application of U.S. GAAP in situations in which a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the TCJA which was signed into law on December 22, 2017. The adoption did not have a material impact on our consolidated financial statements.

 

In June 2018, the FASB issued ASU 2018-07 to expand the scope of ASC Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The adoption did not have a material impact on our consolidated financial statements.

 

Accounting Pronouncements Not Yet Adopted

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard will require entities to disclose the amount of total gains or losses for the period recognized in other comprehensive income that is attributable to fair value changes in assets and liabilities held as of the balance sheet date and categorized within Level 3 of the fair value hierarchy. This ASU will be effective for us for annual and interim periods beginning after December 31, 2020. Early adoption of this standard is permitted. We have not yet determined the impact of the adoption of this ASU on our results of operations, financial position and cash flows.

 

 35 

 

 

In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. Under this standard customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. The adoption of this new guidance prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and additional quantitative and qualitative disclosures. This ASU will be effective for us for annual and interim periods beginning after December 30, 2020. Early adoption of this standard is permitted and may be applied either prospectively to eligible costs incurred on or after the date of the new guidance or retrospectively. We have not yet determined the impact of the adoption of this ASU on our results of operations, financial position and cash flows.

 

Other recent accounting standards issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

Note 19 – Subsequent Events

 

Loans From Mr. Diamantis

 

Subsequent to September 30, 2019 and through November 30, 2019, Mr. Diamantis advanced the Company $0.7 million for working capital purposes. The Company incurred interest of $65,000 on the advance.

 

Issuance of Common Stock

 

Subsequent to September 30, 2019 and through December 26, 2019, the Company issued an aggregate of 1,250,000,000 shares of common stock for conversions of preferred stock. The following table presents the dilutive effect of our various potential common shares as of December 26, 2019.

 

   December 26, 2019 
Common shares outstanding   9,648,936,775 
Dilutive potential shares:     
Stock options   77 
Warrants   634,525,355,377 
Convertible debt   30,634,784,339 
Convertible preferred stock   79,122,373,825 
Total dilutive potential common shares, including outstanding common stock   753,931,450,393 

 

On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding. Following is a summary of certain terms of the Series K Preferred Stock:

 

General. The Company’s Board of Directors has designated 250,000 shares of the 5,000,000 authorized shares of preferred stock as the Series K Preferred Stock. Each share of the Series K Preferred Stock has a stated value of $1.00.

 

Voting Rights. Each holder of the Series K Preferred Stock shall be entitled to vote on all matters submitted to a vote of the holders of the Company’s common stock. With respect to a vote of stockholders to approve either or both a reverse stock split of the Company’s common stock (and any reduction in the authorized shares) and an increase in the authorized shares of common stock from 10 billion shares to up to 12.5 billion shares, no later than December 31, 2019 only, each share of the Series K Preferred Stock shall be entitled to the whole number of votes equal to 40,000 shares of common stock. With respect to all other matters, and from and after December 31, 2019, each share of the Series K Preferred Stock shall be entitled to the whole number of votes equal to the number of shares of common stock into which it is then convertible. The Series K Preferred Stock shall vote with the common stock as if they were a single class of securities.

 

Dividends. Holders of the Series K Preferred Stock shall be entitled to receive dividends on shares of the Series K Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of common stock when, as and if dividends are paid on shares of common stock.

 

 36 

 

 

Rank. The Series K Preferred Stock ranks with respect to dividends or a liquidation, (i) on parity with the common stock, the Company’s Series G Convertible Preferred Stock and the Company’s Series H Convertible Preferred Stock, (ii) senior to the Company’s Series F Convertible Preferred Stock, and (iii) junior to the Company’s Series I-1 Convertible Preferred Stock and the Company’s Series 1-2 Convertible Preferred Stock.

 

Conversion. Each share of the Series K Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder, into that number of shares of common stock determined by dividing the stated value of such share of Preferred Stock plus any accrued and unpaid dividends thereon, by the conversion price. The conversion price is equal to the average closing price of the common stock on the 10 trading days immediately prior to the conversion date.

 

Liquidation Preference. Upon any liquidation, dissolution or winding up of the Company, the holders of the Series K Preferred Stock shall be entitled to receive an amount equal to the stated value of the Series K Preferred Stock, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon for each share of the Series K Preferred Stock before any distribution or payment shall be made on any junior securities.

 

Redemption. At any time the Company shall have the right to redeem all, or any part, of the Series K Preferred Stock then outstanding. The Series K Preferred Stock subject to redemption shall be redeemed by the Company in cash in an amount equal to the stated value of the shares of the Series K Preferred Stock being redeemed plus all accrued and unpaid dividends.

 

Exchange of Series J Preferred Stock for Series K Preferred Stock

 

On December 23, 2019, the Company entered into an Exchange Agreement (the “Agreement”) with Alcimede. Pursuant to the Agreement, the Company issued to Alcimede 250,000 shares of its Series K Preferred Stock in exchange for the 250,000 shares of the Company’s Series J Preferred Stock. The holder of the Series J Preferred Stock was entitled to receive, when and as declared by the Board of Directors of the Company, but only out of funds that were legally available therefore, cumulative cash dividends at the rate of 8% of the stated value per annum on each share of Series J Preferred Stock. The Series J Preferred Stock had been issued to Alcimede on July 23, 2018 and upon the issuance of the Series K Preferred Stock to Alcimede, the shares of Series J Preferred Stock were cancelled. Under the Agreement, Alcimede relinquished all rights to any cumulative dividends on the Series J Preferred Stock. The terms of the Series K Preferred Stock do not provide for cumulative dividends.

 

Redemption of Series G Preferred Stock

 

On December 9, 2019, the Company redeemed all 215 shares of its Series G Preferred Stock that were outstanding.

 

 37 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

SPECIAL NOTE CONCERNING FORWARD-LOOKING STATEMENTS

 

Certain statements made in this Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company’s plans and objectives are based, in part, on assumptions involving its continued business operations. Assumptions related to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove to be inaccurate and, therefore, there can be no assurance the forward-looking statements included in this report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

 

The forward-looking statements included in this Form 10-Q and referred to elsewhere are related to future events or our strategies or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “believe,” “anticipate,” “future,” “potential,” “estimate,” “expect,” “intend,” “plan,” or the negative of such terms or comparable terminology. All forward-looking statements included in this Form 10-Q are based on information available to us as of the filing date of this report, and the Company assumes no obligation to update any such forward-looking statements, except as required by law. Our actual results could differ materially from the forward-looking statements.

 

Important factors that might cause our actual results to differ materially from the results contemplated by the forward-looking statements are contained in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the “2018 Form 10-K”) and in our subsequent filings with the Securities and Exchange Commission. The following discussion of our results of operations should be read in conjunction with the audited financial statements contained within the 2018 Form 10-K and with our unaudited condensed consolidated financial statements and related notes thereto included elsewhere in this report.

 

 38 

 

 

COMPANY OVERVIEW

 

Our Services

 

We have operated in two business segments: Hospital Operations and Clinical Laboratory Operations.

 

Our Hospital Operations net revenues were $3.9 million and $13.1 million for the three and nine months ended September 30, 2019, respectively, as compared to $5.0 million and $9.8 million for the three and nine months ended September 30, 2018, respectively. Our hospital operations began with the opening of our Big South Fork Medical Center on August 8, 2017, following the receipt of the required licenses and regulatory approvals. Our clinical laboratory operations outside of our hospitals are now minimal and the Company is actively discussing the disposal of the laboratory operations outside of the hospital locations. There can be no guarantee that any discussions will lead to a successful sale.

 

On January 31, 2018, the Company entered into an asset purchase agreement to acquire from Community Health Systems, Inc. certain assets related to an acute care hospital located in Jamestown, Tennessee, referred to as Jamestown Regional Medical Center. The purchase was completed on June 1, 2018. The hospital was acquired by a newly formed subsidiary, Jamestown TN Medical Center, Inc., and is an 85-bed facility of approximately 90,000 square feet on over eight acres of land, which offers, when operating, a 24-hour Emergency Department with two spacious trauma bays and seven private exam rooms, inpatient and outpatient medical services and a Progressive Care Unit providing telemetry services. The Company suspended operations of the hospital in June 2019 but is currently planning the reopening of the hospital. The acquisition also included a separate physician practice which now operates under Rennova as Mountain View Physician Practice, Inc. Jamestown is located 38 miles west of Big South Fork Medical Center.

 

In addition, on March 5, 2019, we closed an asset purchase agreement (the “Purchase Agreement”) whereby we acquired certain assets related to an acute care hospital located in Jellico, Tennessee and an outpatient clinic located in Williamsburg, Kentucky. The hospital is known as Jellico Community Hospital and the clinic is known as the CarePlus Center. The hospital and the clinic and their associated assets were acquired from Jellico Community Hospital, Inc. and CarePlus Rural Health Clinic, LLC, respectively. Jellico Community Hospital is a fully operational 54-bed acute care facility that offers comprehensive services, including diagnostic imaging, radiology, surgery (general, gynecological and vascular), nuclear medicine, wound care and hyperbaric medicine, intensive care, emergency care and physical therapy. Jellico is located 33 miles east of our Big South Fork Medical Center. The CarePlus Center offers sophisticated testing capabilities and compassionate care, all in a modern, patient-friendly environment. Services include diagnostic imaging services, x-ray, mammography, bone densitometry, computed tomography (CT), ultrasound, physical therapy and laboratory services on a walk-in basis. We refer to the Jellico Community Hospital and CarePlus Center collectively as Jellico Community Hospital. The purchase price was approximately $0.7 million. This purchase price was made available by Mr. Diamantis, a director of the Company. Annual net revenues in recent years have been approximately $12.0 million, with government payors, including Medicare and Medicaid, accounting for in excess of 70% of the payor mix. The Company does not expect that payor mix to change in the near future.

 

Going forward, we expect our Hospital Operations to provide us with a stable revenue base, as well as the potential for significant synergistic opportunities with our Clinical Laboratory Operations business segment.

 

Prior to our focus on our Hospital Operations, our principal line of business had been clinical laboratory blood and urine testing services, with a particular emphasis on the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Our Clinical Laboratory Operations net revenues were $(34,631) and $56,169 for the three and nine months ended September 30, 2019, respectively as compared to $17,569 and $177,890 for the three and nine months ended September 30, 2018. Our clinical laboratory operations outside of our hospitals are now minimal and the Company is actively discussing the disposal of the laboratory operations outside of the hospital locations. There can be no guarantee that any discussions will lead to a successful sale.

 

Departure of Director

 

On December 11, 2019, Dr. Kamran Ajami resigned as a director of the Company. In submitting his resignation; Dr. Ajami did not express any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr. Ajami had served as a director since April 9, 2017.

 

Discontinued Operations

 

On July 12, 2017, the Company announced plans to spin off its Advanced Molecular Services Group (“AMSG”) and in the third quarter 2017 the Company’s Board of Directors voted unanimously to spin off the Company’s wholly-owned subsidiary, Health Technology Solutions, Inc. (“HTS”), as independent publicly traded companies by way of tax-free distributions to the Company’s stockholders. While these spin offs have taken longer than anticipated, completion of these spin offs is now expected to occur in the first quarter of 2020. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission, and consents, including under various funding agreements previously entered into by the Company. A record date to determine those stockholders entitled to receive shares in the spin offs should be approximately 30 to 60 days prior to the dates of the spin offs. The strategic goal of the spin offs is to create three public companies, each of which can focus on its own strengths and operational plans. In addition, after the spin offs, each company will provide a distinct and targeted investment opportunity. The Company has reflected the amounts relating to AMSG and HTS as disposal groups classified as held for sale and included in discontinued operations in the Company’s accompanying unaudited condensed consolidated financial statements.

 

 39 

 

 

Outlook

 

We believe that the addition of our Hospital Operations to our business model offers a more predictable and stable revenue base, as well as the potential for significant synergistic opportunities with our Clinical Laboratory Operations business segment. To date, our focus is on rural hospitals, which provide a much-needed service to their local communities. These hospitals reduce our reliance on commission based sales employees to generate sales. Our hospitals, CarePlus center and a doctor’s office practice are in the same general geographic location, which has created numerous efficiencies in purchasing, staffing and provision of needed services to the local communities. We are confident that this is a sustainable model we can continue to grow through acquisition and development and believe that we can benefit from the compliance and IT and software capabilities we already have in place. The Company is focusing on centralizing certain functions like ordering of supplies, revenue cycle management and financial management of the acquired facilities and is planning to share certain services that one facility alone could not sustain. Management believes that these actions when complete will enable the operations to be profitable and cash flow positive.

 

Our Clinical Laboratory Operations revenues have decreased significantly over the past number of years. This decline in revenues has had a material adverse impact on our liquidity, results of operations and financial condition, and is the result of lower third-party reimbursement and while we secured numerous in-network contracts with payers our status in many cases is as an “out of network” service provider. These trends have impacted our entire industry, and have been accompanied by allegations of irregularities in the practices of a number of our competitors and substance abuse facilities. In response, we have put in place a robust compliance program that we are implementing in all facets of our business.

 

We believe that our ability to grow our Clinical Laboratory Operations revenues inside our Hospital Operations and return this division to profitability is dependent on our ability to secure additional “in-network” contracts with insurance companies and other third-party payers, which will then ensure adequate and timely payment for the toxicology, clinical pharmacogenetics and other testing services we perform. These third-party payers are now generally unwilling to reimburse service providers who are not part of their network, a departure from prior industry practices and a trend that has accelerated during the past several years. However, we do anticipate that significant new opportunities to become credentialed with certain large third-party payers will arise in 2020 and 2021, which would have a significant positive impact on our future revenues. In addition, we have made a number of changes to our onboarding policies and procedures to ensure that, on a going forward basis, substantially all services that we perform will be reimbursable.

 

We believe that a successful spin off of AMSG and HTS as two independent publicly traded companies by way of tax-free distributions to the Company’s stockholders would allow each to focus on its own strengths and operational plans. In addition, after the spin offs, each company will provide a distinct and targeted investment opportunity. The Company believes it will be able to recognize the expenditures to date with regard to AMSG and HTS, which are in excess of $20 million, as an investment after the spinoff(s) are complete.

 

Our net loss from continuing operations for the three months ended September 30, 2019 was $12.1 million compared to net income of $97.4 million for the same period of a year ago. The change is primarily due to a gain of $109.3 million from the change in fair value of derivative instruments in the three months ended September 30, 2018 versus no change in the fair value of derivative instruments during the three months ended September 30, 2019. Also contributing to the change was other expense of $5.8 million in the three months ended September 30, 2019 compared to other income of $0.2 million in the comparable 2018 period. Partially offsetting these items was an improvement in the loss from continuing operations before other income (expense) and income taxes, which was $2.7 million in the three months ended September 30, 2019 compared to $2.8 million in the three months ended September 30, 2018 and interest expense of $3.6 million in the three months ended September 30, 2019 compared to $9.3 million in the three months ended September 30, 2018.

 

Our net loss from continuing operations for the nine months ended September 30, 2019 was $38.3 million compared to a net loss of $4.0 million for the same period of a year ago. The increase in the loss is primarily due to a gain of $13.7 million from the change in fair value of derivative instruments in the nine months ended September 30, 2018 compared to a loss of $0.1 million from the change in fair value of derivative instruments during the nine months ended September 30, 2019, other expense of $7.0 million in the nine months ended September 30, 2019 compared to other income of $0.6 million in the comparable 2018 period, loss from continuing operations before other income (expense) and income taxes of $12.3 million in the nine months ended September 30, 2019 compared to $8.9 million in the nine months ended September 30, 2018 and interest expense of $19.2 million in the nine months ended September 30, 2019 compared to $17.1 million in the nine months ended September 30, 2018.

 

 40 

 

 

Comparison for the three months ended September 30, 2019 and September 30, 2018

 

The following table summarizes the results of our consolidated continuing operations for the three months ended September 30, 2019 and 2018 (unaudited):

 

   Three Months Ended September 30, 
   2019   2018 
       %       % 
Net revenues  $3,885,977    100.0%  $5,039,112    100.0%
Operating expenses:                    
Direct costs of revenue   3,227,709    83.1%   3,350,286    66.5%
General and administrative expenses   3,163,624    81.4%   4,351,576    86.4%
Depreciation and amortization   199,996    5.1%   152,825    3.0%
Loss from operations before other income (expense) and income taxes   (2,705,352)   -69.6%   (2,815,575)   -55.9%

Other income (expense), net

   (5,874,873)   -151.2%   188,658    3.7%
Change in fair value of derivative instruments   -    0.0%   109,305,331    2169.1%
Interest expense   (3,637,467)   -93.6%   (9,322,333)   -185.0%
Provision for income taxes   -    0.0%   -    0.0%
Net (loss) income from continuing operations  $(12,217,692)   -314.4%  $97,356,081    1932.0%

 

Net Revenues

 

Consolidated net revenues were $3.9 million for the three months ended September 30, 2019 as compared to $5.0 million for the three months ended September 30, 2018. Our Hospital Operations net revenues decreased by $1.1 million, which reflect a decrease in net revenues from Jamestown Regional Medical Center of $3.9 million, partially offset by $1.8 million of net revenues from Jellico Community Hospital and CarePlus Center, which were acquired on March 5, 2019, and an increase in net revenues from Big South Fork Medical Center of $1.0 million. Operations at Jamestown Regional Medical Center were temporarily suspended beginning in June 2019 pending reinstatement of the hospital’s Medicare agreement, which the Company is hoping to get reinstated in the near future. Our Clinical Laboratory Operations net revenue decreased by $52,200 for the 2019 period compared to the 2018 period. Net revenues for the three months ended September 30, 2019 and 2018, include bad debt expense elimination of $0.9 million and $1.8 million, respectively, for doubtful accounts and $23.3 million and $22.9 million, respectively, for contractual allowances. In a continued effort to refine our revenue recognition estimates, the Company practices the full retrospective approach, evaluating and analyzing the realizability of gross service revenues monthly, to make certain that we are properly allowing for bad debt and contractual adjustments.

 

Direct Costs of Revenue

 

Direct costs of revenue decreased by $0.1 million compared to the three months ended September 30, 2018 due to a reduction in Clinical Laboratory Operations’ direct costs. As a percentage of net revenues, direct costs increased to 83.1% in the three months ended September 30, 2019 as compared to 66.6% in the comparable period. We attribute the increase in the percentage of net revenues primarily to the Company’s decision to suspend operations at Jamestown Regional Medical Center, which did not operate during the third quarter of 2019, following the termination of the Medicare program. Despite the suspension, we still incurred certain direct costs of revenue. On June 10, 2019, the Company hired a new CEO to oversee the reopening of the hospital and took steps to re-enter the Medicare program. Contributing to the increase in the direct costs as a percentage of net revenues for the three months ended September 30, 2019 compared to the comparable 2018 period was a decision to reassess our revenue rate at Big South Fork Medical Center to recognize revenue after contractual allowances at 10% based on the Company’s historical data compared to using an industry standard rate of 20% in the comparable 2018 period.

 

 41 

 

 

General and Administrative Expenses

 

General and administrative expenses decreased by $1.2 million, or 27%, in the three months ended September 30, 2019 compared to the same period a year ago. The decrease was primarily due to a $0.8 million decrease in our Hospital Operations’ general and administrative expenses as well as a $0.2 million decrease in our Clinical Laboratory Operation’s general and administrative expenses and a $0.3 million decrease in our Corporate’s general and administrative expense. We attribute the decrease in our Hospital Operations general and administrative expenses primarily to the suspension of operations at Jamestown Regional Medical Center during the 2019 period.

 

Depreciation and Amortization Expenses

 

Depreciation and amortization expense was $0.2 million and $0.2 million for the three months ended September 30, 2019 and 2018, respectively.

 

Loss from Continuing Operations Before Other Income (Expense) and Income Taxes

 

Loss from continuing operations before other income (expense) and income taxes decreased by $0.1 million for the three months ended September 30, 2019 as compared to same period a year ago. The loss from our Clinical Laboratory Operations decreased by approximately $0.3 million, and the loss from Corporate decreased by approximately $0.3 million, which were partially offset by an increase in the loss from our Hospital Operations of $0.5 million. Contributing to the increase in the loss from our Hospital Operations for the three months ended September 30, 2019 compared to the comparable 2018 period was a decision to reassess our revenue rate at Big South Fork Medical Center to recognize revenue after contractual allowances at 10% based on the Company’s historical data compared to using an industry standard rate of 20% in the comparable 2018 period.

 

Other Income (Expense)

 

Other expense was $5.8 million for the three months ended September 30, 2019, compared to other income of $0.2 million for the same period a year ago. The expense in the three months ended September 30, 2019 was due to the loss on sale of receivables under a factoring arrangement of $0.7 million and penalties for non-payment of debentures at maturity of $5.1 million.

 

Change in Fair Value of Derivative Instruments

 

For the three months ended September 30, 2018, the Company realized income of $109.3 million for the change in fair value of derivative instruments. On September 23, 2018, the Company’s board of directors approved a reverse split of its common stock, which would provide sufficient authorized and unissued shares to allow for otherwise equity classified instruments to be classified in equity. As of September 23, 2018, the fair value of these instruments was evaluated for reclassification. As a result of the evaluation, the Company reclassified the derivative liability previously reported as a current liability to derivative income. We did not incur a change in fair value of derivative instruments in the 2019 period.

 

Interest Expense

 

Interest expense for the three months ended September 30, 2019 was $3.6 million compared to $9.3 million for the three months ended September 30, 2018. Interest expense for the three months ended September 30, 2019 includes $1.8 million for interest on loans from a member of our board of directors, $1.4 million for the amortization of debt discount and deferred financing costs related to debentures and note payable and approximately $0.4 million of interest expense on debentures, notes payable and finance lease obligations. Interest expense for the three months ended September 30, 2018 included $9.0 million for the amortization of debt discount and deferred financing costs related to convertible debentures and warrants and $0.3 million for finance lease obligations.

 

Net Loss/Income From Continuing Operations

 

Our net loss from continuing operations for the three months ended September 30, 2019 was $12.1 million compared to net income of $97.4 million for the same period of a year ago. The change is primarily due to a gain of $109.3 million from the change in fair value of derivative instruments in the three months ended September 30, 2018 versus no change in the fair value of derivative instruments during the three months ended September 30, 2019. Also contributing to the change was other expense of $5.8 million in the three months ended September 30, 2019 compared to other income of $0.2 million in the comparable 2018 period. Partially offsetting these items was an improvement in the loss from continuing operations before other income (expense) and income taxes, which was $2.7 million in the three months ended September 30, 2019 compared to $2.8 million the three months ended September 30, 2018 and interest expense of $3.6 million in the three months ended September 30, 2019 compared to $9.3 million in the three months ended September 30, 2018.

 

 42 

 

 

The following table presents key financial metrics for our Hospital Operations segment:

 

   Three Months Ended September 30,         
   2019   2018   Change   % 
Hospital Operations                    
                     
Net revenues  $3,920,608   $5,021,543   $(1,100,935)   -21.9%
Operating expenses:                    
Direct costs of revenue   3,226,509    3,156,461    70,048    2.2%
General and administrative expenses   2,280,667    3,119,994    (839,327)   -26.9%
Depreciation and amortization   182,832    39,669    143,163    360.9%
                     
Loss from operations  $(1,769,400)  $(1,294,581)  $(474,819)   -36.7%
                     
                     
Number of Patients Served   9,607    3,044    6,563      
Key Operating Measures - Net revenues per patient served:  $408.10   $1,649.65    N/A      
                     
Key Operating Measures - Direct cost of revenue per patient:  $335.85   $1,036.95    N/A      

 

In the three months ended September 30, 2019, we reassessed our revenue rate at Big South Fork Medical Center to recognize revenue after contractual allowances at 10% based on the Company’s historical data compared to using an industry standard rate of 20% in the compared 2018 period.

 

The following table presents key financial and operating metrics for our Clinical Laboratory Operations segment:

 

   Three Months Ended September 30,         
   2019   2018   Change   % 
Clinical Laboratory Operations                    
                     
Net revenues (1)  $(34,631)  $17,569   $(52,200)   -297.1%
Operating expenses:                    
Direct costs of revenue   1,200    193,825    (192,625)   -99.4%
General and administrative expenses   250,041    257,877    (7,836)   -3.0%
Depreciation and amortization   10,036    112,908    (102,872)   -91.1%
                     
Loss from operations  $(295,908)  $(547,041)  $251,133    45.9%
                     
Key Operating Measures - Revenues: (1)                    
Insured tests performed   -    1,895    (1,895)   -100.0%
Net revenue per insured test  $-   $9.27   $(9.27)   -100.0%
Revenue recognition percent of gross billings        7.0%   -7.0%     
                     
Key Operating Measures - Direct Costs:                    
Total samples processed   -    1,259    (1,259)   -100.0%
Direct costs per sample  $-   $153.95   $(153.95)   -100.0%

 

  (1) No tests were performed in the three months ended September 30, 2019. The negative net revenue represents bad debt expense recorded in the period.

 

 43 

 

 

The following table presents key financial metrics for our Corporate group:

 

   Three Months Ended September 30,         
   2019   2018   Change   % 
Corporate                    
                     
Operating expenses:                    
General and administrative expenses  $632,916   $973,705   $(340,789)   -35.0%
Depreciation and amortization   7,128    248    6,880    2774.2%
                     
Loss from operations  $(640,044)  $(973,953)  $333,909    34.3%

 

Comparison for the nine months ended September 30, 2019 and September 30, 2018

 

The following table summarizes the results of our consolidated continuing operations for the nine months ended September 30, 2019 and 2018 (unaudited):

 

   Nine Months Ended September 30, 
   2019   2018 
   $   %   $   % 
Net revenues  $13,137,816    100.0%  $9,932,989    100.0%
Operating expenses:                    
Direct costs of revenue   12,072,442    91.9%   7,809,465    78.6%
General and administrative expenses   12,730,695    96.9%   10,240,434    103.1%
Depreciation and amortization   609,818    4.6%   804,074    8.1%
Loss from operations before other income (expense) and income taxes   (12,275,139)   -93.4%   (8,920,984)   -89.8%

Other income (expense)

   (6,980,616)   -53.1%   609,719    6.1%
Gain on bargain purchase   250,000    1.9%   7,732,302    77.8%
Change in fair value of derivative instruments   (105,076)   -0.8%   13,688,678    137.8%
Interest expense   (19,229,232)   -146.4%   (17,075,437)   -171.9%
Provision for income taxes   -    0.0%   (76)   0.0%
Net loss from continuing operations  $(38,340,063)   -291.8%  $(3,965,798)   -39.9%

 

Net Revenues

 

Consolidated net revenues were $13.1 million for the nine months ended September 30, 2019, as compared to $9.9 million for the nine months ended September 30, 2018, an increase of $3.2 million. The increase in net revenues was due to net revenue from Jellico Community Hospital and CarePlus Center of $4.8 million, which were acquired on March 5, 2019. In addition, our Big South Fork Medical Center’s net revenue increased by $0.7 million in the nine months ended September 30, 2019, as compared to the nine months ended September 30, 2018. The increases were partially offset by a decrease in net revenues from Jamestown Regional Medical Center of $2.2 million for the nine months ended September 30, 2019 compared to the 2018 period. Operations at Jamestown Regional Medical Center were temporarily suspended beginning in June 2019 pending reinstatement of the hospital’s Medicare agreement, which the Company is hoping to get reinstated in the near future. The increase in Hospital Operations net revenues was offset by an approximately $0.1 million decrease in Clinical Laboratory Operations net revenues for the 2019 period compared to 2018 period. Net revenues for the nine months ended September 30, 2019 and 2018, include bad debt expense elimination of $4.8 million and $3.1 million, respectively, for doubtful accounts and $81.9 million and $40.7 million, respectively, for contractual allowances. In a continued effort to refine our revenue recognition estimates, the Company practices the full retrospective approach, evaluating and analyzing the realizability of gross service revenues monthly, to make certain that we are properly allowing for bad debt and contractual adjustments.

 

 44 

 

 

Direct Costs of Revenue

 

Direct costs of revenue increased by $4.3 million in the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018. We attribute the increase to Jellico Community Hospital and CarePlus Center, which were acquired on March 5, 2019. As a percentage of net revenues, direct costs increased to 91.9% in the nine months ended September 30, 2019 as compared to 78.6% in the comparable period. We attribute the increase in the percentage of net revenues primarily to the Company’s decision to suspend operations at Jamestown Regional Medical Center, which did not operate during the third quarter of 2019, following the termination of the Medicare program. Despite the suspension, we still incurred certain direct costs of revenue. On June 10, 2019, the Company hired a new CEO to oversee the reopening of the hospital and took steps to re-enter the Medicare program. Also contributing to the increase in the direct costs as a percentage of revenue for the nine months ended September 30, 2019, was our decision to reassess our revenue rate at Big South Fork Medical Center to recognize revenue after contractual allowances at 10% based on the Company’s historical data compared to using an industry standard rate of 20% in the compared 2018 period.

 

General and Administrative Expenses

 

General and administrative increased by $2.5 million, or 24.5%, in the nine months ended September 30, 2019 compared to the same period a year ago. The increase was primarily due to a $3.4 million increase in our Hospital Operations’ general and administrative expenses, partially offset by a decrease of $0.4 million decrease in our Clinical Laboratory Operations and a $0.5 million decrease in Corporate’s general and administrative expense.

 

Depreciation and Amortization Expenses

 

Depreciation and amortization expense was $0.6 million for the nine months ended September 30, 2019 as compared to $0.8 million for the same period a year ago. The decrease is due to fully depreciating certain fixed assets in 2018. We expect our depreciation and amortization expense to increase going forward as a result of the fixed assets associated with our hospital acquisitions.

 

Loss from Continuing Operations Before Other Income (Expense) and Income Taxes

 

Our operating loss increased by $3.4 million for the nine months ended September 30, 2019 as compared to same period a year ago due to additional losses for our Hospital Operations. The increase in the loss from operations was due to the suspension of operations at Jamestown Regional Medical Center, which did not operate during the third quarter of 2019, following the termination of the Medicare program. Despite the suspension, we still incurred certain direct costs of revenue as well as general and administrative expenses. We also attribute the increase in the loss to the reassessment of our revenue rate at Big South Fork Medical Center to recognize revenue after contractual allowances at 10% based on the Company’s historical data compared to using an industry standard rate of 20% in the comparable 2018 period.

 

Other Income (Expense)

 

We incurred other loss of $7.0 million in the nine months ended September 30, 2019 as compared to income of $0.6 million in same period a year ago. The loss in the nine months ended September 30, 2019 was due to $5.7 million in penalties for non-payment of debentures on the maturity dates and $1.2 million of loss on sale under factoring arrangements.

 

Gain on Bargain Purchase

 

The gain on bargain purchase of $0.3 million for the nine months ended September 30, 2019 resulted primarily from intangible assets of Jellico Community Hospital and CarePlus Center, which were acquired on March 5, 2019. The gain on bargain purchase of $7.7 million for the nine months ended September 30, 2018 resulted primarily from real property of Jamestown Regional Medical Center, which was acquired on June 1, 2018.

 

Change in Fair Value of Derivative Instruments

 

For the nine months ended September 30, 2019, the Company realized a loss of $0.1 million for the change in fair value of derivative instruments, which represented the increase in the fair value of a derivative debenture due to the increase in the spread between the price of our common stock and the conversion price of the derivative in the nine months ended September 30, 2019. For the nine months ended September 30, 2018, the Company realized income of $13.7 million for the change in fair value of derivative instruments. On September 23, 2018, the Company’s board of directors approved a reverse split of its common stock, which would provide sufficient authorized and unissued shares to allow for otherwise equity classified instruments to be classified in equity. As of September 23, 2018, the fair value of these instruments was evaluated for reclassification. As a result of the evaluation, the Company reclassified the derivative liability previously reported as a current liability to derivative income.

 

 45 

 

 

Interest Expense

 

Interest expense for the nine months ended September 30, 2019 was $19.2 million compared to $17.1 million for the nine months ended September 30, 2018. Interest expense for the nine months ended September 30, 2019 includes $2.9 million for interest on loans from a member of our board of directors, $6.4 million for the amortization of debt discount and deferred financing costs related to debentures and note payable, $9.5 million for the modification of warrants and approximately $0.4 million of interest expense on debentures, notes payable and finance lease obligations. Interest expense for the nine months ended September 30, 2018 includes $16.1 million for the amortization of debt discount, including expense associated with the modification of warrants, and deferred financing costs related to convertible debentures and warrants and $1.0 million for interest on notes payable and finance lease obligations.

 

Net Loss From Continuing Operations

 

Our net loss from continuing operations for the nine months ended September 30, 2019 was $38.3 million compared to net loss of $4.0 million for the same period of a year ago. The increase in the loss is primarily due to a gain of $13.7 million from the change in fair value of derivative instruments in the nine months ended September 30, 2018 compared to a loss of $0.1 million from the change in fair value of derivative instruments during the nine months ended September 30, 2019, other expense of $7.0 million in the nine months ended September 30, 2019 compared to other income of $0.6 million in the comparable 2018 period, loss from continuing operations before other income (expense) and income taxes of $12.3 million in the nine months ended September 30, 2019 compared to $8.9 million in the nine months ended September 30, 2018 and interest expense of $19.2 million in the nine months ended September 30, 2019 compared to $17.1 million in the nine months ended September 30, 2018.

 

The following table presents key financial metrics for our Hospital segment:

 

   Nine Months Ended September 30,         
   2019   2018   Change   % 
Hospital Operations                    
                     
Net revenues  $13,081,647   $9,755,099   $3,326,548    34.1%
Operating expenses:                    
Direct costs of revenue   12,068,460    7,574,619    4,493,841    59.3%
General and administrative expenses   9,426,928    6,002,037    3,424,891    57.1%
Depreciation and amortization   532,979    177,386    355,593    200.5%
                     
Loss from operations  $(8,946,720)  $(3,998,943)  $(4,947,777)   -123.7%
                     
                     
Number of Patients Served   33,299    10,093    N/A      
                     
Key Operating Measures - Revenue per patient served:  $392.85   $966.52    N/A      
                     
Key Operating Measures - Direct costs of revenue per patient served:  $362.43   $750.48    N/A      

 

In the nine months ended September 30, 2019, we reassessed our revenue rate at Big South Fork Medical Center to recognize revenue after contractual allowances at 10% based on the Company’s historical data compared to using an industry standard rate of 20% in the compared 2018 period.

 

 46 

 

 

The following table presents key financial and operating metrics for our Clinical Laboratory Operations segment

 

   Nine Months Ended September 30,         
   2019   2018   Change   % 
Clinical Laboratory Operations                    
                     
Net revenues  $56,169   $177,890   $(121,721)   -68.4%
Operating expenses:                    
Direct costs of revenue   3,982    234,846    (230,864)   -98.3%
General and administrative expenses   684,272    1,082,562    (398,290)   -36.8%
Depreciation and amortization   69,381    625,877    (556,496)   -88.9%
                     
Loss from operations  $(701,466)  $(1,765,395)  $1,063,929    60.3%
                     
Key Operating Measures - Revenues: (1)                    
Insured tests performed   78    3,444    (3,366)   -97.7%
Net revenue per insured test    NM    $51.65           
Revenue recognition percent of gross billings        11.0%   -11.0%     
                     
Key Operating Measures - Direct Costs: (1)                    
Total samples processed   19    4,499    (4,480)   -99.6%
Direct costs per sample   NM    $52.20           

 

  (1) Net revenue per insured test and direct costs of insured tests are not meaningful for the nine months ended September 30, 2019 due to the impact of the recovery of $74,000 of bad debt in the nine months ended September 30, 2019, partially offset by additional bad debt expense recorded in the period.

 

The following table presents key financial metrics for our Corporate group:

 

   Nine Months Ended September 30,         
   2019   2018   Change   % 
Corporate                    
                     
Operating expenses:                    
General and administrative expenses  $2,619,495   $3,155,835   $(536,340)   -17.0%
Depreciation and amortization   7,458    811    6,647    819.6%
                     
Loss from operations  $(2,626,953)  $(3,156,646)  $529,693    16.8%

 

LIQUIDITY AND CAPITAL RESOURCES

 

For the nine months ended September 30, 2019 and the year ended December 31, 2018, we financed our operations primarily from the sale of our equity securities, the issuance of debentures and advances from related parties and in the nine months ended September 30, 2019 from the sale of accounts receivable to factors. Future cash needs for working capital, capital expenditures and potential acquisitions will require management to seek additional equity or obtain additional credit facilities. The sale of additional equity will result in additional dilution to our stockholders. A portion of our cash may be used to acquire or invest in complementary businesses or products or to obtain the right to use complementary technologies. From time-to-time, in the ordinary course of business, we evaluate potential acquisitions of such businesses, products or technologies.

 

 47 

 

 

Going Concern and Liquidity

 

Under Accounting Standards Update, or ASU, 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40) (“ASC 205-40”), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued. Management has assessed the Company’s ability to continue as a going concern in accordance with the requirement of ASC 205-40.

 

As reflected in the accompanying unaudited condensed consolidated financial statements, at September 30, 2019, we had $0.1 million cash on hand from continuing operations, a working capital deficit of $69.3 million, an accumulated deficit of $578.0 million and a stockholders’ deficit of $67.7 million. In addition, we incurred a loss from continuing operations of $39.1 million and cash used in operating activities of $14.4 million for the nine months ended September 30, 2019. As of the date of this report, our cash position is deficient and payments are not being made in the ordinary course. In addition, we have not repaid approximately $28.7 million of outstanding principal balance of debentures, including default penalties, which are past due. Our fixed operating expenses include payroll, rent, finance lease payments and other fixed expenses, as well as the costs required to operate our Hospital Operations. Our fixed operating expenses were approximately $2.0 million per month for the nine months ended September 30, 2019.

 

We need to raise additional funds immediately and continue to do so until we begin to realize positive cash flow from operations. There can be no assurance that we will be able to achieve our business plan, which is to acquire and operate clusters of rural hospitals, raise any additional capital or secure the additional financing necessary to implement our current operating plan. Our ability to continue as a going concern is dependent upon our ability to significantly reduce our operating costs, increase our revenues and eventually achieve profitable operations. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

We received approximately $3.8 million in cash from issuances of debentures and $1.5 million from the issuance of a note payable during the nine months ended September 30, 2019. In addition, during the nine months ended September 30, 2019, we entered into five accounts receivable factoring arrangements, as more fully discussed in Note 4 to the accompanying condensed consolidated financial statements, and Mr. Diamantis, a member of our board of directors, advanced the Company: (i) $0.7 million for the purchase of Jellico Community Hospital; (ii) $9.9 million, which was used to repay obligations under a prepaid forward purchase contract related to an accounts receivable financing; (iii) $1.9 million for fees and expenses incurred in connection with the settlement of the prepaid forward purchase contract; and (iv) $4.7 million for working capital purposes.

 

Subsequent to September 30, 2019 and through November 30, 2019, Mr. Diamantis advanced the Company $0.7 million, which was used for working capital purposes.

 

As of September 30, 2019, we were party to legal proceedings, which are presented in Note 15 to the accompanying unaudited condensed consolidated financial statements.

 

The following table presents our capital resources as of September 30, 2019 and December 31, 2018:

 

   September 30,   December 31,     
   2019   2018   Change 
             
Cash  $107,472   $6,870   $100,602 
Working capital deficit   (69,272,314)   (39,293,904)   (29,978,410)
Total debt, excluding discounts and derivative liabilities   47,636,055    26,418,305    21,217,750 
Finance lease obligations   618,278    762,208    (143,930)
Stockholders’ deficit  $(67,644,949)  $(39,167,864)  $(28,477,085)

 

 48 

 

 

The following table presents the major sources and uses of cash for the nine months ended September 30, 2019 and 2018:

 

   Nine Months Ended September 30,     
   2019   2018   Change 
             
Cash used in operations  $(14,420,826)  $(7,121,826)  $(7,299,000)
Cash (used in) provided by investing activities   (709,338)   461,242    (1,170,580)
Cash provided by financing activities   15,230,766    6,660,584    8,570,182 
                
Net change in cash   100,602    -    100,602 
Cash and cash equivalents, beginning of the year   6,870    -    6,870 
Cash and cash equivalents, end of the period  $107,472   $-   $107,472 

 

The components of cash used in operations for the nine months ended September 30, 2019 and 2018 are presented in the following table:

 

   Nine Months Ended September 30,     
   2019   2018   Change 
             
Net loss from continuing operations  $(38,340,063)  $(3,965,798)  $(34,374,265)
Non-cash adjustments to net loss   23,413,633    (4,346,430)   27,760,063 
Accounts receivable   (3,525,152)   (5,648,343)   2,123,191 
Inventory   82,010    -    82,010 
Accounts payable, checks issued in excess of               
 bank balance and accrued expenses   4,604,504    7,225,248    (2,620,744)
(Loss) income from discontinued operations   (791,936)   115,787    (907,723)
Other   (46,485)   125,864    (172,349)
Net cash used in operating activities   (14,603,489)   (6,493,672)   (8,109,817)
Cash provided by (used in) discontinued operations   182,663    (628,154)   810,817 
Cash used in operations  $(14,420,826)  $(7,121,826)  $(7,299,000)

 

Cash used in investing activities for the nine months ended September 30, 2019 was due primarily to $0.7 million for the acquisition of Jellico Community Hospital and CarePlus Center as well as $50,801 for purchases of property and equipment. Cash used in investing activities for the nine months ended September 30, 2018 was due to the acquisition of Jamestown Regional Medical Center for $0.7 million and the purchases of property and equipment of $0.1 million, partially offset by proceeds from the sale of equipment under finance leases of $0.4 million. Cash provided by investing activities of discontinued operations for the nine months ended September 30, 2018 consist of the $0.8 million received from the February 14, 2018 Common Stock Purchase Agreement with two investors pursuant to which the Company agreed to sell an aggregate of 200,000 shares of common stock of NanoVibronix, Inc. owned by the Company at a purchase price of $4.00 per share. The Company had acquired the shares as a result of an investment originally made in 2011.

 

Cash provided by financing activities in the nine months ended September 30, 2019 consists of $16.5 million for the issuance of related party notes payable and advances, $2.7 million in proceeds from the sale of accounts receivable to factors, $3.8 million from the issuances of debentures and $1.5 million from the issuance of a promissory note. Cash used in financing activities in the nine months ended September 30, 2019 include $1.8 million of payments to factors, $5.0 million in payments on notes payable, $2.3 million for payments of related party notes payable and advances and $0.1 million for payments of finance lease obligations. Cash provided by financing activities for the nine months ended September 30, 2018 consists of the $8.0 million received from the issuances of debentures, and $3.6 million from related party notes and advances, partially offset by payments of related party notes and advances of $4.0 million, $0.3 million in payments of notes payable and $0.7 million of payment of finance lease obligations.

 

We need to raise additional funds immediately and continue to do so until we begin to realize positive cash flow from operations.

 

 49 

 

 

The terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion price of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, the majority of these equity-based securities contain exercise/conversion prices that vary based upon the price of the Company’s common stock on the date of exercise/conversion (see Notes 8, 11, 12 and 13 to the accompanying unaudited condensed consolidated financial statements). These provisions have resulted in significant dilution of the Company’s common stock and have given rise to reverse splits of the Company’s common stock. As a result of these down round provisions, the potential common stock equivalents, including outstanding common stock, totaled 753.9 billion at December 26, 2019.

 

OTHER MATTERS

 

Inflation

 

We do not believe inflation has a significant effect on the Company’s operations at this time.

 

Off Balance Sheet Arrangements

 

Under SEC regulations, we are required to disclose the Company’s off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, results of operations, liquidity, capital expenditures or capital resources that are material to investors. Off-balance sheet arrangements consist of transactions, agreements or contractual arrangements to which any entity that is not consolidated with us is a party, under which we have:

 

  Any obligation under certain guarantee contracts.
     
  Any retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to that entity for such assets.
     
  Any obligation under a contract that would be accounted for as a derivative instrument, except that it is both indexed to the Company’s stock and classified in stockholder’s equity in the Company’s statement of financial position.
     
  Any obligation arising out of a material variable interest held by us in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to us, or engages in leasing, hedging or research and development services with us.

 

As of September 30, 2019, the Company had no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the Company’s financial condition, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable

 

Item 4. Controls and Procedures.

 

  (a) Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Interim Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure. Under the supervision and with the participation of our management, including our Chief Executive Officer and Interim Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures. Based on the foregoing evaluation, our management concluded that, as of September 30, 2019, our disclosure controls and procedures were not effective to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management, including our Chief Executive Officer (Principal Executive Officer) and Interim Chief Financial Officer (Principal Financial Officer), does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

 50 

 

 

In our Annual Report on Form 10-K for the year ended December 31, 2018, we identified material weaknesses in our internal control over financial reporting as a result of not properly performing an effective risk assessment or monitoring of our internal controls over financial reporting. With the acquisitions of Big South Fork, Jamestown and Jellico Hospitals, there are risks related to the timing and accuracy of the integration of information from various accounting systems whereby the Company has experienced delays in receiving information in a timely manner from its subsidiaries. As of September 30, 2019, we concluded that these material weaknesses continued to exist.

 

The Company expects to continue to make improvements on the integration of information issues in 2019 as we plan to move towards securing a prompt and accurate reporting system. The Company is continuing to further remediate the material weaknesses identified above as its resources permit. The Company is in the process of taking the following steps to remediate these material weaknesses: (i) increasing the staffing of its internal accounting department; (ii) beginning the process of converting to a new integrated accounting system to enhance controls and procedures for recording accounting transactions; and (iii) implementing enhanced documentation procedures to be followed by the internal accounting department, including independent review of material cash disbursements.

 

Notwithstanding such material weakness, management believes that the condensed consolidated financial statements included in this Form 10-Q fairly present in all material respects the Company’s financial condition, results of operations and cash flows for the periods and dates presented.

 

  (b) Changes in Internal Control over Financial Reporting

 

During the nine months ended September 30, 2019, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time-to-time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims, which are presented in Note 15 to the accompanying unaudited condensed consolidated financial statements.

 

Item 1A. Risk Factors.

 

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, Item 1A of the 2018 Form 10-K which could materially affect our business, financial condition, or future results. There have been no material changes to the risk factors previously disclosed in our 2018 Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None

 

Item 3. Defaults Upon Senior Securities.

 

The Company had $1,984,000 principal amount of March Debentures issued March 21, 2017 and due on March 21, 2019 outstanding on the maturity date. These debentures have not been paid and remain outstanding, accruing interest at the default rate of 18% per annum. Per the terms of the debentures, the Company accrued a default penalty of approximately $0.6 million as a result of the default.

 

 51 

 

 

The Company had $17,050,000 principal amount of debentures due September 19, 2019 outstanding on the maturity date. These debentures have not been paid and remain outstanding, accruing interest at the default rate of 18% per annum. In addition, the Company will incur a default penalty of approximately $5.1 million as a result of the payment default.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None

 

Item 6. Exhibits.

 

3.21 Certificate of Designation for Series K Convertible Preferred Stock (incorporated by reference to Exhibit 3.21 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2019)
   
10.170 Form of Promissory Note (incorporated by reference to Exhibit 10.176 to the Company’s Current Report on Form 8-K filed with the SEC on October 2, 2019)

 

 
10.171

Exchange Agreement, dated as of December 23, 2019, between Rennova Health, Inc. and Alcimede LLC (incorporated by reference to Exhibit 10.177 to the Company’s Current Report on Form 8-K filed with the SEC on December 27, 2019)

   
31.1 Rule 13a-14(a) Certification by the Principal Executive Officer.
   
31.2 Rule 13a-14(a) Certification by the Principal Financial Officer.
   
32.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
   
32.2 Certification by Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
   
101.INS XBRL Instance Document
   
101.SCH XBRL Schema Document
   
101.CAL XBRL Calculation Link base Document
   
101.DEF XBRL Definition Link base Document
   
101.LAB XBRL Label Link base Document
   
101.PRE XBRL Presentation Link base Document

 

*Furnished herewith

 

 52 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  RENNOVA HEALTH, INC.
     
Date: December 30, 2019 By: /s/ Seamus Lagan
    Seamus Lagan
   

Chief Executive Officer and Interim Chief Financial Officer

(Principal Executive Officer and Principal Financial Officer)

 

 53 

 

EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF

PRINICPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Seamus Lagan, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10-Q of Rennova Health, Inc.
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s), if any, and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s), if any, and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  /s/ Seamus Lagan
  Seamus Lagan
  Chief Executive Officer
  (Principal Executive Officer)
   
Dated: December 30, 2019  

 

   

 

 

EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Seamus Lagan, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10-Q of Rennova Health, Inc.
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s), if any, and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s), if any, and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  /s/ Seamus Lagan
  Seamus Lagan
  Interim Chief Financial Officer
  (Principal Financial Officer)
   
Dated: December 30, 2019  

 

   

 

EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Rennova Health, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the period ended September 30, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, Seamus Lagan, Chief Executive Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to the best of my knowledge:

 

  1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Seamus Lagan  
Seamus Lagan  
Chief Executive Officer  
Dated: December 30, 2019  

 

   

 

 

EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Rennova Health, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the period ended September 30, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, Seamus Lagan, Interim Chief Financial Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to the best of my knowledge:

 

  1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Seamus Lagan  
Seamus Lagan  
Interim Chief Financial Officer  
Dated: December 30, 2019  

 

   

 

 

EX-101.INS 6 rnva-20190930.xml XBRL INSTANCE FILE 0000931059 2019-01-01 2019-09-30 0000931059 2017-12-31 0000931059 us-gaap:SeriesGPreferredStockMember 2018-12-31 0000931059 us-gaap:SeriesHPreferredStockMember 2018-12-31 0000931059 2018-12-31 0000931059 us-gaap:CorporateMember 2018-01-01 2018-09-30 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2018-01-01 2018-09-30 0000931059 us-gaap:CorporateMember 2019-09-30 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2019-09-30 0000931059 RNVA:TCADebentureMember 2017-02-01 2017-02-02 0000931059 RNVA:TCADebentureMember 2017-03-20 2017-03-21 0000931059 RNVA:TCADebentureMember RNVA:AprilTwoThousandSeventeenThroughSeptemberTwoThousandSeventeenMember 2017-03-20 2017-03-21 0000931059 RNVA:TCADebentureMember 2017-03-21 0000931059 RNVA:SettlementAgreementMember RNVA:EpinexDiagnosticsLaboratoriesIncMember 2016-07-29 0000931059 RNVA:EpinexDiagnosticsLaboratoriesIncMember 2017-03-24 0000931059 us-gaap:InternalRevenueServiceIRSMember RNVA:MedytoxSolutionsIncMember 2016-02-01 2016-02-29 0000931059 us-gaap:InternalRevenueServiceIRSMember RNVA:MedytoxSolutionsIncMember 2016-09-30 0000931059 RNVA:FloridaDepartmentOfRevenueMember 2016-09-27 0000931059 RNVA:TCSFloridaLPMember 2017-01-02 2017-01-03 0000931059 RNVA:TCSFloridaLPMember RNVA:ForbearanceAgreementMember 2017-02-14 2017-02-15 0000931059 RNVA:DeLageLandenFinancialServicesIncMember 2017-01-23 2017-01-24 0000931059 RNVA:DeLageLandenFinancialServicesIncMember 2017-02-06 2017-02-08 0000931059 RNVA:HoldersOfTegalNotesMember 2016-12-07 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2019-01-01 2019-09-30 0000931059 RNVA:HospitaOperationsMember 2019-01-01 2019-09-30 0000931059 us-gaap:CorporateMember 2019-01-01 2019-09-30 0000931059 RNVA:HospitaOperationsMember 2018-01-01 2018-09-30 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2018-12-31 0000931059 RNVA:HospitaOperationsMember 2018-12-31 0000931059 us-gaap:CorporateMember 2018-12-31 0000931059 RNVA:EliminationsMember 2018-12-31 0000931059 RNVA:HospitaOperationsMember 2019-09-30 0000931059 us-gaap:SeriesFPreferredStockMember 2018-12-31 0000931059 RNVA:EpinexDiagnosticsLaboratoriesIncMember 2016-10-31 0000931059 RNVA:SeriesIOnePreferredStockMember 2017-10-29 2017-10-30 0000931059 RNVA:SeriesIOnePreferredStockMember 2017-10-30 0000931059 RNVA:SeriesIOnePreferredStockMember RNVA:PurchaseAgreementMember 2017-10-29 2017-10-30 0000931059 RNVA:SeriesIOnePreferredStockMember us-gaap:InvestorMember 2017-10-30 0000931059 us-gaap:InternalRevenueServiceIRSMember RNVA:MedytoxSolutionsIncMember 2016-03-31 0000931059 RNVA:AdvancedMolecularServicesGroupMember 2018-01-01 2018-09-30 0000931059 RNVA:AdvancedMolecularServicesGroupMember 2019-01-01 2019-09-30 0000931059 RNVA:HealthTechnologySolutionsIncMember 2019-01-01 2019-09-30 0000931059 RNVA:HealthTechnologySolutionsIncMember 2018-01-01 2018-09-30 0000931059 RNVA:FloridaDepartmentOfRevenueMember 2019-09-30 0000931059 RNVA:RedeemablePreferredStockIOneMember 2018-12-31 0000931059 RNVA:RedeemablePreferredStockITwoMember 2018-12-31 0000931059 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000931059 RNVA:HospitalsOperationsMember 2018-12-31 0000931059 RNVA:NotesPayableThirdPartiesOneMember 2018-12-31 0000931059 RNVA:NotesPayableThirdPartiesTwoMember 2018-12-31 0000931059 RNVA:NotesPayableThirdPartiesThreeMember 2018-12-31 0000931059 RNVA:NotesPayableThirdPartiesTwoMember 2018-01-01 2018-12-31 0000931059 RNVA:NotesPayableThirdPartiesThreeMember 2018-01-01 2018-12-31 0000931059 RNVA:NotesPayableRelatedPartiesMember 2018-12-31 0000931059 RNVA:EliminationsMember 2019-09-30 0000931059 RNVA:GenomasIncMember 2017-11-01 2017-11-30 0000931059 RNVA:MedytoxSolutionsIncMember 2019-01-01 2019-09-30 0000931059 RNVA:SeriesITwoConvertiblePreferredStockMember 2017-10-30 0000931059 RNVA:SeriesITwoConvertiblePreferredStockMember 2019-09-30 0000931059 RNVA:SeriesITwoConvertiblePreferredStockMember RNVA:SeptemberDebentureMember 2018-02-03 2018-02-09 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000931059 us-gaap:FairValueInputsLevel1Member 2018-12-31 0000931059 us-gaap:FairValueInputsLevel2Member 2018-12-31 0000931059 us-gaap:FairValueInputsLevel3Member 2018-12-31 0000931059 RNVA:EmbeddedConversionOptionsMember 2018-12-31 0000931059 us-gaap:InternalRevenueServiceIRSMember RNVA:MedytoxSolutionsIncMember 2016-11-01 2016-11-30 0000931059 RNVA:TCSFloridaLPMember 2019-09-30 0000931059 RNVA:DeLageLandenFinancialServicesIncMember 2019-09-30 0000931059 RNVA:SeriesITwoPreferredStockMember 2018-01-01 2018-12-31 0000931059 RNVA:SeptemberDebentureMember 2018-07-15 2018-07-16 0000931059 RNVA:SeriesITwoPreferredStockMember 2018-07-15 2018-07-16 0000931059 RNVA:ExchangeAgreementMember RNVA:AlcimedeLLCMember RNVA:SeriesJConvertiblePreferredStockMember 2018-07-22 2018-07-23 0000931059 2016-11-03 0000931059 RNVA:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0000931059 RNVA:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2018-09-30 0000931059 RNVA:SeriesJPreferredStockMember 2018-12-31 0000931059 2018-09-18 0000931059 RNVA:TCSFloridaLPMember 2017-01-01 2017-01-31 0000931059 RNVA:TCSFloridaLPMember 2017-02-01 2017-02-28 0000931059 RNVA:EmploymentAgreementsMember RNVA:FormerEmployeeOneMember 2019-01-01 2019-09-30 0000931059 RNVA:EmploymentAgreementsMember RNVA:FormerEmployeeTwoMember 2019-01-01 2019-09-30 0000931059 RNVA:EPICReferenceLaboratoriesIncMember 2018-09-12 2018-09-13 0000931059 2018-09-30 0000931059 2018-11-04 2018-11-05 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2018-12-31 0000931059 RNVA:JamestownRegionalMedicalCenterMember 2018-06-02 0000931059 RNVA:SettlementAgreementMember 2018-12-31 0000931059 us-gaap:IndividualMember RNVA:ChristopherDiamantisMember 2017-03-24 0000931059 us-gaap:IndividualMember 2017-03-24 0000931059 us-gaap:IndividualMember RNVA:ChristopherDiamantisMember 2019-05-19 2019-05-20 0000931059 us-gaap:IndividualMember RNVA:ChristopherDiamantisMember 2019-04-05 0000931059 RNVA:ChristopherDiamantisMember 2019-04-04 2019-04-05 0000931059 RNVA:ChristopherDiamantisMember 2019-05-30 2019-05-31 0000931059 us-gaap:IndividualMember RNVA:ChristopherDiamantisMember RNVA:FinalPaymentMember 2019-07-27 2019-07-28 0000931059 RNVA:ChristopherDiamantisMember 2019-01-01 2019-09-30 0000931059 RNVA:SeriesFConvertiblePreferredStockMember RNVA:GenomasIncMember 2017-09-01 2017-09-30 0000931059 RNVA:SeriesFConvertiblePreferredStockMember RNVA:GenomasIncMember 2017-09-30 0000931059 RNVA:ExchangeAgreementMember RNVA:AlcimedeLLCMember RNVA:SeriesJConvertiblePreferredStockMember 2018-07-23 0000931059 RNVA:TwoThousandAndSevenEquityPlanMember 2019-01-01 2019-09-30 0000931059 RNVA:WarrantsMember 2019-01-01 2019-09-30 0000931059 RNVA:AssetsOfAMSGAndHTSClassifiedAsHeldForSaleMember 2018-12-31 0000931059 RNVA:AssetsOfAMSGAndHTSClassifiedAsHeldForSaleMember 2019-09-30 0000931059 us-gaap:PreferredStockMember 2017-12-31 0000931059 us-gaap:PreferredStockMember 2018-12-31 0000931059 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000931059 us-gaap:CommonStockMember 2017-12-31 0000931059 us-gaap:CommonStockMember 2018-12-31 0000931059 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000931059 us-gaap:RetainedEarningsMember 2017-12-31 0000931059 us-gaap:RetainedEarningsMember 2018-12-31 0000931059 2018-01-01 2018-09-30 0000931059 us-gaap:SubsequentEventMember 2019-12-26 0000931059 RNVA:JamestownRegionalMedicalCenterMember 2018-06-01 2018-06-02 0000931059 us-gaap:IndividualMember RNVA:ChristopherDiamantisMember 2017-03-23 2017-03-24 0000931059 us-gaap:IndividualMember 2017-03-23 2017-03-24 0000931059 RNVA:AdvancedMolecularServicesGroupMember 2018-12-31 0000931059 RNVA:AdvancedMolecularServicesGroupMember 2019-09-30 0000931059 RNVA:HealthTechnologySolutionsIncMember 2018-12-31 0000931059 RNVA:HealthTechnologySolutionsIncMember 2019-09-30 0000931059 RNVA:EPICReferenceLaboratoriesIncMember 2019-05-01 2019-05-31 0000931059 RNVA:RocheDiagnosticsCorporationMember 2019-07-01 2019-07-31 0000931059 RNVA:BeckmanCoulterIncMember 2019-08-01 2019-08-31 0000931059 RNVA:MedytoxSolutionsIncMember 2019-07-01 2019-07-31 0000931059 RNVA:TechlogixIncMember 2019-02-01 2019-02-28 0000931059 RNVA:PreModificationMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2019-09-30 0000931059 2019-12-26 0000931059 2019-09-30 0000931059 RNVA:RedeemablePreferredStockIOneMember 2019-09-30 0000931059 RNVA:RedeemablePreferredStockITwoMember 2019-09-30 0000931059 us-gaap:SeriesGPreferredStockMember 2019-09-30 0000931059 us-gaap:SeriesHPreferredStockMember 2019-09-30 0000931059 us-gaap:SeriesFPreferredStockMember 2019-09-30 0000931059 RNVA:SeriesJPreferredStockMember 2019-09-30 0000931059 2018-06-30 0000931059 us-gaap:PreferredStockMember 2019-09-30 0000931059 us-gaap:PreferredStockMember 2018-09-30 0000931059 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0000931059 us-gaap:CommonStockMember 2019-09-30 0000931059 us-gaap:CommonStockMember 2018-09-30 0000931059 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000931059 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000931059 us-gaap:RetainedEarningsMember 2019-09-30 0000931059 us-gaap:RetainedEarningsMember 2018-09-30 0000931059 2018-01-01 2018-12-31 0000931059 us-gaap:WarrantMember 2019-01-01 2019-09-30 0000931059 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-09-30 0000931059 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-09-30 0000931059 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000931059 us-gaap:WarrantMember 2018-01-01 2018-09-30 0000931059 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-09-30 0000931059 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-09-30 0000931059 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0000931059 RNVA:DebenturesMember 2019-02-24 0000931059 RNVA:DebenturesMember 2019-03-27 0000931059 RNVA:DebenturesMember 2019-02-23 2019-02-24 0000931059 RNVA:DebenturesMember 2019-03-26 2019-03-27 0000931059 RNVA:DebenturesMember 2019-01-01 2019-09-30 0000931059 RNVA:DebenturesMember 2019-09-30 0000931059 RNVA:AlcimedeLLCMember 2019-01-01 2019-09-30 0000931059 RNVA:AlcimedeLLCMember 2018-01-01 2018-09-30 0000931059 RNVA:JamestownRegionalMedicalCenterMember RNVA:NonCompeteIntangibleAssetMember 2019-06-02 0000931059 RNVA:JamestownRegionalMedicalCenterMember RNVA:NonCompeteIntangibleAssetMember 2018-01-01 2018-12-31 0000931059 RNVA:JellicoCommunityHospitalAndCarePlusCenterMember 2019-03-04 2019-03-05 0000931059 RNVA:JellicoCommunityHospitalAndCarePlusCenterMember 2019-03-05 0000931059 RNVA:MrDiamantisMember 2019-09-30 0000931059 RNVA:NotesPayableThirdPartiesOneMember 2019-09-30 0000931059 RNVA:NotesPayableThirdPartiesTwoMember 2019-09-30 0000931059 RNVA:NotesPayableThirdPartiesThreeMember 2019-09-30 0000931059 RNVA:LoanPayabletToChristopherDiamantisMember 2019-09-30 0000931059 RNVA:NotesPayableRelatedPartiesMember 2019-09-30 0000931059 RNVA:LoanPayabletToChristopherDiamantisMember 2018-12-31 0000931059 us-gaap:DerivativeMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2019-09-30 0000931059 us-gaap:DerivativeMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2019-09-30 0000931059 us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2019-09-30 0000931059 us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2019-09-30 0000931059 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2019-01-01 2019-09-30 0000931059 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2019-01-01 2019-09-30 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel1Member 2019-09-30 0000931059 us-gaap:FairValueInputsLevel1Member 2019-09-30 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel2Member 2019-09-30 0000931059 us-gaap:FairValueInputsLevel2Member 2019-09-30 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel3Member 2019-09-30 0000931059 us-gaap:FairValueInputsLevel3Member 2019-09-30 0000931059 RNVA:EmbeddedConversionOptionsMember 2019-09-30 0000931059 RNVA:SeriesIOnePreferredStockMember RNVA:PurchaseAgreementMember 2017-10-30 0000931059 RNVA:SeriesITwoConvertiblePreferredStockMember RNVA:BoardOfDirectorsMember 2019-09-30 0000931059 RNVA:SeriesITwoPreferredStockMember 2019-01-01 2019-09-30 0000931059 RNVA:SeriesFConvertiblePreferredStockMember 2019-09-30 0000931059 RNVA:SeriesJConvertiblePreferredStockMember 2019-09-30 0000931059 us-gaap:SeriesGPreferredStockMember 2019-01-01 2019-09-30 0000931059 us-gaap:SeriesHPreferredStockMember 2019-01-01 2019-09-30 0000931059 RNVA:TwoThousandAndSevenEquityPlanMember 2018-01-01 2018-09-30 0000931059 RNVA:TwoThousandAndSevenEquityPlanMember 2019-09-30 0000931059 us-gaap:InternalRevenueServiceIRSMember RNVA:MedytoxSolutionsIncMember 2016-11-30 0000931059 RNVA:HoldersOfTegalNotesMember 2018-04-22 2018-04-23 0000931059 RNVA:OtherIncomeExpenseNetMember 2019-01-01 2019-09-30 0000931059 RNVA:OtherIncomeExpenseNetMember 2018-01-01 2018-09-30 0000931059 2017-12-30 2017-12-31 0000931059 us-gaap:IndividualMember RNVA:ChristopherDiamantisMember 2019-05-20 0000931059 RNVA:ChristopherDiamantisMember 2019-09-30 0000931059 RNVA:ChristopherDiamantisMember 2019-01-01 2019-09-30 0000931059 RNVA:DebentureOneMember 2019-09-30 0000931059 RNVA:DebentureOneMember 2019-01-01 2019-09-30 0000931059 2019-07-01 2019-09-30 0000931059 2018-07-01 2018-09-30 0000931059 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0000931059 us-gaap:PreferredStockMember 2019-07-01 2019-09-30 0000931059 us-gaap:PreferredStockMember 2018-07-01 2018-09-30 0000931059 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0000931059 us-gaap:PreferredStockMember 2019-06-30 0000931059 us-gaap:PreferredStockMember 2018-06-30 0000931059 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000931059 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000931059 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000931059 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000931059 us-gaap:CommonStockMember 2019-06-30 0000931059 us-gaap:CommonStockMember 2018-06-30 0000931059 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000931059 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000931059 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000931059 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000931059 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000931059 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000931059 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000931059 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000931059 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000931059 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000931059 us-gaap:RetainedEarningsMember 2019-06-30 0000931059 us-gaap:RetainedEarningsMember 2018-06-30 0000931059 2019-01-01 2019-03-31 0000931059 2018-01-01 2018-03-31 0000931059 2019-06-30 0000931059 2017-01-01 2017-03-31 0000931059 us-gaap:SubsequentEventMember 2019-12-25 2019-12-26 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2019-09-30 0000931059 RNVA:HospitalsOperationsMember 2019-09-30 0000931059 RNVA:OtherMember 2019-09-30 0000931059 RNVA:OtherMember 2018-12-31 0000931059 RNVA:JamestownRegionalMedicalCenterAndJellicoCommunityHospitalAndCareplusCenterMember 2018-07-01 2018-09-30 0000931059 RNVA:JamestownRegionalMedicalCenterAndJellicoCommunityHospitalAndCareplusCenterMember 2019-01-01 2019-09-30 0000931059 RNVA:MrDiamantisMember 2018-12-31 0000931059 RNVA:ChristopherDiamantisMember 2019-07-01 2019-09-30 0000931059 RNVA:DebenturesMember 2019-05-12 0000931059 RNVA:DebenturesMember RNVA:ChristopherDiamantisMember 2019-05-10 2019-05-12 0000931059 RNVA:DebenturesMember RNVA:ChristopherDiamantisMember 2019-06-05 0000931059 RNVA:DebenturesMember RNVA:ChristopherDiamantisMember 2019-06-07 0000931059 RNVA:BridgeDebentureAgreementMember RNVA:JuneThirteenTwoThousandAndNineteenOfferingsMember 2019-06-13 0000931059 RNVA:BridgeDebentureAgreementMember RNVA:JuneThirteenTwoThousandAndNineteenOfferingsMember 2019-06-10 2019-06-13 0000931059 RNVA:DebenturesMember 2019-06-21 0000931059 RNVA:DebenturesMember 2019-06-24 0000931059 RNVA:DebenturesMember 2019-06-19 2019-06-21 0000931059 RNVA:DebenturesMember 2019-06-22 2019-06-24 0000931059 RNVA:AlcimedeLLCMember 2019-07-01 2019-09-30 0000931059 RNVA:AlcimedeLLCMember 2018-07-01 2018-09-30 0000931059 2017-03-31 0000931059 RNVA:JamestownRegionalMedicalCenterAndJellicoCommunityHospitalAndCareplusCenterMember 2018-01-01 2018-09-30 0000931059 RNVA:PreModificationMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2019-09-30 0000931059 RNVA:PreModificationMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2019-09-30 0000931059 RNVA:PreModificationMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2019-09-30 0000931059 RNVA:PostModificationMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2019-09-30 0000931059 RNVA:PostModificationMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2019-09-30 0000931059 RNVA:PostModificationMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2019-09-30 0000931059 RNVA:PostModificationMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2019-09-30 0000931059 RNVA:TwoThousandAndSevenEquityPlanMember RNVA:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2017-08-01 2017-08-14 0000931059 RNVA:TwoThousandAndSevenEquityPlanMember us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0000931059 RNVA:WarrantsMember 2019-05-12 0000931059 RNVA:WarrantsMember 2019-03-01 2019-03-27 0000931059 RNVA:WarrantsMember 2019-05-01 2019-05-12 0000931059 RNVA:HospitaOperationsMember 2018-07-01 2018-09-30 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2019-07-01 2019-09-30 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2018-07-01 2018-09-30 0000931059 us-gaap:CorporateMember 2019-07-01 2019-09-30 0000931059 us-gaap:CorporateMember 2018-07-01 2018-09-30 0000931059 RNVA:OtherIncomeExpenseNetMember 2019-07-01 2019-09-30 0000931059 RNVA:OtherIncomeExpenseNetMember 2018-07-01 2018-09-30 0000931059 RNVA:HospitaOperationsMember 2019-07-01 2019-09-30 0000931059 RNVA:AdvancedMolecularServicesGroupMember 2019-07-01 2019-09-30 0000931059 RNVA:AdvancedMolecularServicesGroupMember 2018-07-01 2018-09-30 0000931059 RNVA:HealthTechnologySolutionsIncMember 2019-07-01 2019-09-30 0000931059 RNVA:HealthTechnologySolutionsIncMember 2018-07-01 2018-09-30 0000931059 us-gaap:SubsequentEventMember 2019-10-02 2019-10-04 0000931059 us-gaap:SubsequentEventMember 2019-12-31 0000931059 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0000931059 RNVA:JamestownRegionalMedicalCenterMember 2018-10-01 2018-12-31 0000931059 2018-06-02 0000931059 2016-03-30 2016-03-31 0000931059 2016-06-30 0000931059 us-gaap:SubsequentEventMember RNVA:DebenturesMember srt:MaximumMember 2019-10-12 0000931059 RNVA:PreModificationMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2019-09-30 0000931059 RNVA:PreModificationMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2019-09-30 0000931059 RNVA:PostModificationMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2019-09-30 0000931059 RNVA:PostModificationMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2019-09-30 0000931059 us-gaap:SubsequentEventMember RNVA:DebentureOneMember srt:MaximumMember 2019-10-12 0000931059 RNVA:BridgeDebentureAgreementMember RNVA:JuneThirteenTwoThousandAndNineteenOfferingsMember RNVA:InvestorsMember 2019-06-13 0000931059 us-gaap:SubsequentEventMember RNVA:DebentureTwoMember srt:MaximumMember 2019-10-12 0000931059 us-gaap:SubsequentEventMember RNVA:SeriesKPreferredStockMember 2019-10-04 0000931059 us-gaap:PreferredStockMember 2018-04-01 2018-06-30 0000931059 us-gaap:PreferredStockMember 2018-03-31 0000931059 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000931059 us-gaap:CommonStockMember 2018-03-31 0000931059 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000931059 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000931059 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000931059 us-gaap:RetainedEarningsMember 2018-03-31 0000931059 2018-04-01 2018-06-30 0000931059 2018-03-31 0000931059 us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0000931059 us-gaap:PreferredStockMember 2019-03-31 0000931059 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000931059 us-gaap:CommonStockMember 2019-03-31 0000931059 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000931059 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000931059 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000931059 us-gaap:RetainedEarningsMember 2019-03-31 0000931059 2019-04-01 2019-06-30 0000931059 2019-03-31 0000931059 us-gaap:SubsequentEventMember RNVA:ChristopherDiamantisMember 2019-10-01 2019-11-30 0000931059 us-gaap:DerivativeMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2018-09-30 0000931059 us-gaap:DerivativeMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2018-09-30 0000931059 us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2018-09-30 0000931059 us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2018-09-30 0000931059 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2018-01-01 2018-09-30 0000931059 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2018-01-01 2018-09-30 0000931059 RNVA:PreModificationMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2018-09-30 0000931059 RNVA:PreModificationMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2018-09-30 0000931059 RNVA:PreModificationMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2018-09-30 0000931059 RNVA:PreModificationMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2018-09-30 0000931059 RNVA:PostModificationMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2018-09-30 0000931059 RNVA:PostModificationMember RNVA:MeasurementInputRiskFreeInterestRateMemberMeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2018-09-30 0000931059 RNVA:PostModificationMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2018-09-30 0000931059 RNVA:PostModificationMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2018-09-30 0000931059 RNVA:PreModificationMember us-gaap:MeasurementInputExpectedTermMember 2018-09-30 0000931059 RNVA:PostModificationMember us-gaap:MeasurementInputExpectedTermMember 2018-09-30 0000931059 RNVA:SeriesITwoPreferredStockMember 2018-01-01 2018-09-30 0000931059 RNVA:WarrantsMember 2018-01-01 2018-09-30 0000931059 RNVA:DiamantisMember 2019-09-27 0000931059 RNVA:DiamantisMember 2019-09-26 2019-09-27 0000931059 RNVA:NotesPayableThirdPartiesFourMember 2019-09-30 0000931059 RNVA:NotesPayableThirdPartiesFourMember 2018-12-31 0000931059 RNVA:NotesPayableThirdPartiesTwoMember 2019-01-01 2019-09-30 0000931059 RNVA:NotesPayableThirdPartiesThreeMember 2019-01-01 2019-09-30 0000931059 RNVA:NotesPayableThirdPartiesFourMember 2019-01-01 2019-09-30 0000931059 RNVA:DebenturesMember 2019-08-17 0000931059 RNVA:DebentureOneMember 2019-08-17 0000931059 RNVA:DebenturesMember RNVA:PurchaseAgreementMember RNVA:JuneTwoThousandAndNineteenDebenturesMember 2019-08-28 2019-08-31 0000931059 RNVA:DebentureTwoMember 2019-08-17 0000931059 RNVA:DebenturesMember RNVA:PurchaseAgreementMember RNVA:JuneTwoThousandAndNineteenDebenturesMember 2019-08-31 0000931059 RNVA:FloridaDepartmentOfRevenueMember 2019-01-01 2019-09-30 0000931059 RNVA:AcquisitionsofHospitalsAndMedicalCenterMember 2019-09-30 0000931059 RNVA:AcquisitionsofHospitalsAndMedicalCenterMember 2018-09-30 0000931059 us-gaap:SubsequentEventMember RNVA:SeriesKPreferredStockMember RNVA:BoardOfDirectorsMember 2019-10-04 0000931059 us-gaap:SubsequentEventMember 2019-10-01 2019-12-26 0000931059 us-gaap:SubsequentEventMember us-gaap:SeriesGPreferredStockMember 2019-12-09 0000931059 us-gaap:SubsequentEventMember us-gaap:StockOptionMember 2019-10-01 2019-12-26 0000931059 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2019-10-01 2019-12-26 0000931059 us-gaap:SubsequentEventMember us-gaap:ConvertibleDebtMember 2019-10-01 2019-12-26 0000931059 us-gaap:SubsequentEventMember us-gaap:ConvertiblePreferredStockMember 2019-10-01 2019-12-26 0000931059 2018-09-17 0000931059 RNVA:DebentureTwoMember 2019-09-30 0000931059 RNVA:DebentureTwoMember 2019-01-01 2019-09-30 0000931059 RNVA:DebenturesMember 2018-09-30 0000931059 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2018-07-01 2018-09-30 0000931059 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2018-07-01 2018-09-30 0000931059 RNVA:WarrantsMember 2018-07-01 2018-09-30 0000931059 RNVA:SeptemberDebentureMember 2018-02-07 2018-02-09 0000931059 RNVA:SeriesJConvertiblePreferredStockMember 2018-07-20 0000931059 us-gaap:WarrantMember 2019-01-01 2019-09-30 0000931059 us-gaap:WarrantMember 2018-12-31 0000931059 us-gaap:WarrantMember 2019-09-30 0000931059 RNVA:NotesPayableThirdPartiesFourMember RNVA:NovemberEightTwoThousandNineteenMember 2019-09-30 0000931059 RNVA:NotesPayableThirdPartiesFourMember RNVA:DecemberTwentySixTwoThousandNineteenMember 2019-09-30 0000931059 us-gaap:SubsequentEventMember RNVA:ExchangeAgreementMember RNVA:AlcimedeLLCMember RNVA:SeriesKPreferredStockMember 2019-12-22 2019-12-23 0000931059 us-gaap:SubsequentEventMember RNVA:ExchangeAgreementMember RNVA:AlcimedeLLCMember RNVA:SeriesJPreferredStockMember 2019-12-22 2019-12-23 0000931059 us-gaap:SubsequentEventMember RNVA:SeriesJPreferredStockMember 2019-12-22 2019-12-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure RNVA:Segment Rennova Health, Inc. 0000931059 10-Q 2019-09-30 false --12-31 14199300 1821952 356854 271426 13568933 2707416 -2500646 16831443 -2809305 152171 373121 16574065 800000 800000 14968104 14968104 2 17500 2500 2 17500 2500 -40613461 -39167864 375845883 -30134731 17502 20002 4 12857 128549458 -169180425 -415046606 -67664949 -129945975 20002 20002 839894 737 509515347 160817543 -578040192 -190973013 20002 17502 600894 318 509506697 140263291 -565774424 -270227086 -55646831 17502 100 131619780 -315545007 -183907625 20002 350388 504078894 -552349597 -47900313 14000 14202 1750000 4960 5000000 250000 5000000 5000000 14000 14202 1750000 250000 21346 5000000 250000 0.01 0.01 0.01 1000 0.80 1.00 1000 0.01 0.01 0.01 0.01 0.01 0.01 0.01 1.00 215 60 1750000 250000 215 10 1750000 250000 215 60 1750000 250000 215 10 1750000 250000 1750000 250000 215 0.0001 0.0001 0.0001 0.01 10000000000 10000000000 10000000000 12500000000 10000000000 250000 128567273 8398936775 128567273 9648936775 8398936775 Non-accelerated Filer 609818 811 625877 69381 532979 7458 177386 804074 199996 152825 39669 10036 112908 7128 248 182832 -12275139 -8920984 -2705352 -2815575 9500000 5400000 -39131999 -3850011 -12265768 97196651 -13441404 -12265768 97196651 -146364582 -13441404 -146364582 45317921 45317921 -13424827 -13424827 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Selected financial information for the Company&#8217;s operating segments is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Nine Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Net revenues - External</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; padding-left: 10pt"><font style="font-size: 10pt">Hospital Operations</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">3,920,608</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">5,021,543</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">13,081,647</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">9,755,099</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Clinical Laboratory Operations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(34,631</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">17,569</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">56,169</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">177,890</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,885,977</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,039,112</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">13,137,816</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,932,989</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">(Loss) income from continuing operations before income taxes:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Hospital Operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(1,769,400</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(1,294,581</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(8,946,720</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(3,998,943</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Clinical Laboratory Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(295,908</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(547,041</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(701,466</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(1,765,395</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Corporate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(640,044</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(973,953</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(2,626,953</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(3,156,646</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Other income (expense), net</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(9,422,340</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">100,171,656</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(26,064,924</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">4,955,262</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(12,127,692</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">97,356,081</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(38,340,063</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(3,965,722</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Depreciation and amortization</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Hospital Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">182,832</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">39,669</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">532,979</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">177,386</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Clinical Laboratory Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">10,036</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">112,908</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">69,381</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">625,877</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Corporate</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,128</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">248</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,458</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">811</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">199,996</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">152,825</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">609,818</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">804,074</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Capital expenditures</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Hospital Operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">7,086</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">103,387</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">50,801</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">103,387</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Clinical Laboratory Operations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,086</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">103,387</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">50,801</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">103,387</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Total assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 62%; padding-left: 10pt"><font style="font-size: 10pt">Hospital Operations</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">16,831,443</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">13,568,933</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Clinical Laboratory Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">356,854</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">271,426</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Corporate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,821,952</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,707,416</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Assets of AMSG and HTS classified as held for sale</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">373,121</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">152,171</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Eliminations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,809,305</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,500,646</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,574,065</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">14,199,300</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 50801 50801 103387 103387 7086 103387 103387 7086 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Carrying amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the condensed consolidated balance sheets consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>AMSG Assets and Liabilities:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Cash</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">220</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">4,471</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts receivable, net</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">22,523</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,838</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Prepaid expenses and other current assets</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">25,477</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current assets classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>22,743</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>36,786</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts payable (includes related parties)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">514,415</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">532,858</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">493,356</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">418,932</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Income taxes payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Current portion of notes payable</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">268,851</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">278,836</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current liabilities classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,276,622</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,230,626</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Non-current liabilities classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>HTS Assets and Liabilities:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Cash</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">2,298</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">2,523</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts receivable, net</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">330,238</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">90,743</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Prepaid expenses and other current assets</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,867</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10,300</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current assets classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>339,403</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>103,566</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Property and equipment, net</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4,946</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,790</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deposits</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,029</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,029</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Non-current assets classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>10,975</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>11,819</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts payable (includes related parties)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">710,709</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">546,969</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">714,128</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">520,251</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Current portion of notes payable</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current liabilities classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,424,837</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,067,220</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Total Discontinued Assets and Liabilities:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Cash</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">2,518</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">6,994</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts receivable, net</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">352,761</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">97,581</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Prepaid expenses and other current assets</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,867</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">35,777</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current assets classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>362,146</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>140,352</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Property and equipment, net</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4,946</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,790</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deposits</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,029</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,029</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Non-current assets classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>10,975</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>11,819</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts payable (includes related parties)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,225,124</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,079,827</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,207,484</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">939,183</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Current portion of notes payable</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">268,851</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">278,836</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current liabilities classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>2,701,459</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>2,297,846</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Major line items constituting loss from discontinued operations in the condensed consolidated statements of operations for the three months ended September 30, 2019 and 2018 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>AMSG Loss from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">11,350</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">13,249</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,878</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">15,559</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit (loss)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,472</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(2,310</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">60,424</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">93,059</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other income (expenses)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,912</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(5,748</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Loss from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(57,864</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(89,621</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>HTS Loss from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">235,326</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">499,317</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">20,134</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">30,082</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">215,192</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">469,235</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">295,404</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">532,892</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other income</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,152</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Loss from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(80,212</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(69,809</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Consolidated Loss from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">246,676</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">512,566</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">26,012</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">45,641</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">220,664</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">466,925</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">355,828</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">625,951</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other expense</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,912</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">404</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Loss from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(138,076</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(159,430</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Major line items constituting (loss) income from discontinued operations in the condensed consolidated statements of operations for the nine months ended September 30, 2019 and 2018 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>AMSG (Loss) Income from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">59,832</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">92,090</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">29,638</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">37,773</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">30,194</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">54,317</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">237,042</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">363,944</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other (income) expense</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">31,874</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(819,258</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>(Loss) income from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(238,722</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>509,631</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>HTS Loss from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">706,795</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">1,291,288</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">83,628</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">95,965</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">623,167</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,195,323</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,176,381</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,577,046</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other income</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">12,121</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Loss from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(553,214</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(393,844</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Consolidated (Loss) Income from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">766,627</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">1,383,378</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">113,266</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">133,738</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">653,361</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,249,640</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,413,423</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,940,990</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other (income) expense</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">31,874</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(807,137</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>(Loss) income from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(791,936</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>115,787</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 1750000 119615384 119615384 768548 151200 572480 250000 120 1649059 666621 1571000 14625 991578 165 67 991413 3056607 3056674 157 4036932 4037089 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8211; Accounts Receivable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable at September 30, 2019 (unaudited) and December 31, 2018 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>September 30,</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Accounts receivable - Clinical Laboratory Operations</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">41,750</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">622,009</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts receivable - Hospital Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">45,804,056</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">31,607,644</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Accounts receivable - Other</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(52,296</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Total accounts receivable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">45,793,510</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">32,229,653</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Less:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Amount purchased by factors</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(1,572,000</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Allowance for discounts - Clinical Laboratory Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(26,182</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(573,584</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Allowance for discounts - Hospital Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(36,298,972</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(25,066,799</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Allowance for bad debts</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,787,894</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,777,521</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Accounts receivable, net</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>5,108,462</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>3,811,749</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Accounts Receivable Factoring Arrangements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended September 30, 2019, the Company entered into five accounts receivable factoring arrangements. Under the terms of the arrangements, the aggregate amount of accounts receivable sold on a non-recourse basis, was $3.9 million. The aggregate purchase price paid to the Company was $2.7 million, the total origination and other fees incurred by the Company were $0.1 million and the Company recorded a loss on sale of the receivables of $1.2 million. As of September 30, 2019, $1.6 million of the outstanding accounts receivable were purchased but not yet paid to the factors.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 7 &#8211; Notes Payable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At September 30, 2019 (unaudited) and December 31, 2018, notes payable consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Notes Payable &#8211; Third Parties</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>September 30,</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Loan payable under prepaid forward purchase contract (1)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">5,000,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Loan payable to TCA Global Master Fund, LP (&#8220;TCA&#8221;) in the original principal amount of $3 million at 16% interest (the &#8220;TCA Debenture&#8221;). Principal and interest payments due in various installments through December 31, 2017</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,741,893</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,741,893</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the &#8220;Tegal Notes&#8221;). Principal and interest payments due annually from July 12, 2015 through July 12, 2017</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">335,818</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">341,612</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Note payable to Anthony O&#8217;Killough dated September 27, 2019 in the original principal amount of $1.9 million. Interest is due only upon event of default. Issued net of $0.3 million of debt discount and $0.1 million of financing fees with $1.0 million of principal due on November 8, 2019 and $0.9 million of principal due December 26, 2019</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,527,821</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,605,532</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,083,505</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,605,532</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(7,083,505</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Notes payable - third parties, net of current portion</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify">&#160;</td> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">(1)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The loan payable under prepaid forward purchase contract has been fully settled during the nine months ended September 2019 as more fully discussed below under the heading &#8220;<i>Notes Payable &#8211;Related Party&#8221;.</i></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not make the required monthly principal and interest payments due under the TCA Debenture for the period from October 2016 through March 2017. On February 2, 2017, the Company made a payment to TCA in the amount of $0.4 million, which was applied to accrued and unpaid interest and fees, including default interest, as of the date of payment. On March 21, 2017, the Company made a payment to TCA in the amount of $0.75 million, of which approximately $0.1 million was applied to accrued and unpaid interest and fees in accordance with the terms of the TCA Debenture. Also on March 21, 2017, the Company entered into a letter agreement with TCA, which (i) waived any payment defaults through March 21, 2017; (ii) provided for the $0.75 million payment discussed above; (iii) set forth a revised repayment schedule whereby the remaining principal plus interest aggregating to approximately $2.6 million was to be repaid in various monthly installments from April of 2017 through September of 2017; and (iv) provided for payment of an additional service fee in the amount of $150,000, which was due on June 27, 2017, the day after the effective date of the registration statement filed by the Company; which amount is reflected in accrued expenses at December 31, 2018. In addition, TCA entered into an inter-creditor agreement with the purchasers of the convertible debentures (see Note 8) which sets forth rights, preferences and priorities with respect to the security interests in the Company&#8217;s assets. On September 19, 2017, the Company entered into a new agreement with TCA, which extended the repayment schedule through December 31, 2017. The remaining debt to TCA remains outstanding and TCA has made a demand for payment. The parties are currently working to amend the TCA Debenture to extend the maturity although there can be no assurance that the parties will agree to any such extension.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not make the principal payments under the Tegal Notes that were due on July 12, 2016. On November 3, 2016, the Company received a default notice from the holders of the Tegal Notes demanding immediate repayment of the outstanding principal of $341,612 and accrued interest of $43,000. On December 7, 2016, the Company received a breach of contract complaint with a request for the entry of a default judgment (see Note 15). On April 23, 2018, the holders of the Tegal Notes received a judgment against the Company. To date, the Company has yet to repay this amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 27, 2019, the Company issued a promissory note to a lender in the principal amount of $1.9 million and received proceeds of $1.5 million, which is net of a $0.3 million original issue discount and $0.1 million in financing fees. The first principal payment of $1.0 million was due on November 8, 2019 and has not yet been made and the remaining $0.9 million is due on December 26, 2019. The note does not bear interest except upon the occurrence of an event of default (as defined in the note). The note is unsecured and is guaranteed by Mr. Diamantis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Notes Payable &#8211; Related Party</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Loan payable to Christopher Diamantis</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"><font style="font-size: 10pt">14,968,104</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"><font style="font-size: 10pt">800,000</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Total notes payable, related party</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">14,968,104</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">800,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion of notes payable, related party</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(14,968,104</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(800,000</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total notes payable, related party, net of current portion</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2016, the Company entered into an agreement to pledge certain of its accounts receivable as collateral against a prepaid forward purchase contract whereby the Company received consideration in the amount of $5.0 million. The receivables had an estimated collectable value of $8.7 million which had been adjusted down to $0 as of December 31, 2017. In exchange for the consideration received, the counterparty received the right to: (i) a 20% per annum investment return from the Company on the consideration, with a minimum repayment term of six months and minimum return of $0.5 million, (ii) all payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty had not been paid $6.0 million, the Company was required to pay the difference. Christopher Diamantis, a director of the Company, guaranteed the Company&#8217;s obligation. On March 24, 2017, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into an amendment to extend the Company&#8217;s obligation to March 31, 2018. Also, what the counterparty was to receive was amended to equal (a) the $5,000,000 purchase price plus a 20% per annum investment return thereon, plus (b) $500,000, plus (c) the product of (i) the proceeds received from the accounts receivable, minus the amount set forth in clauses (a) and (b), multiplied by (ii) 40%. In connection with the extension, the counterparty received a fee of $1,000,000. On April 2, 2018, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into a second amendment to extend further the Company&#8217;s obligation to May 30, 2018. In connection with this further extension, the counterparty received a fee of $100,000. The counterparty instituted an arbitration proceeding under the agreement with regard to the outstanding balance. In December 2018, the Company, Mr. Diamantis and the counterparty entered into a preliminary settlement agreement in connection with the arbitration, with the terms of the settlement agreement revised on March 31, 2019. The Company and Mr. Diamantis agreed to pay the counterparty $2,000,000 on or before April 5, 2019 and an additional $7,694,685 plus interest at 10% per annum on or before May 20, 2019, which date was subsequently amended. On April 5, 2019 and May 31, 2019, Mr. Diamantis made payments totaling $5.0 million on behalf of the Company. The final payment of $4,937,105 was due on or before July 28, 2019. Mr. Diamantis made that payment on behalf of the Company on July 26, 2019. The Company and Mr. Diamantis have now complied with all of their obligations under the settlement agreement. As a result, the Company is obligated to repay Mr. Diamantis a total of $9,937,105.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended September 30, 2019, in addition to the $9,937,105 that Mr. Diamantis loaned the Company in connection with the settlement of the prepaid forward purchase contract discussed above, Mr. Diamantis advanced the Company: (i) $0.7 million for the purchase of Jellico Community Hospital as more fully discussed in Note 5; $1.9 million for fees and expenses incurred in connection with the settlement of the prepaid forward purchase contract; and $4.7 million for working capital purposes. During the three and nine months ended September 30, 2019, we accrued interest of $0.7 million and $1.5 million, respectively, on the advances from Mr. Diamantis. During the nine months ended September 30, 2019, we repaid $2.3 million of principal to Mr. Diamantis. Interest accrues on advances from Mr. Diamantis at a flat rate of 10%. Therefore, the total amount of loans and accrued interest payable to Mr. Diamantis at September 30, 2019 and December 31, 2018, were $16.7 million and $1.1 million, respectively. See Note 19 for the discussion of additional advances made by Mr. Diamantis to the Company subsequent to September 30, 2019.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8 &#8211; Debentures</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amount of all outstanding debentures as of September 30, 2019 (unaudited), and December 31, 2018 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Debentures</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">28,690,240</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">19,034,800</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Discount on Debentures</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(6,247,469</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deferred financing fees</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(11,015</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">28,690,240</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">12,776,316</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(28,690,240</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(12,776,316</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Debentures, long-term</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2019, $2.0 million of outstanding debentures issued in March 2017 were not paid as of March 21, 2019, the maturity date and $17.1 million of outstanding debentures issued during 2017 and 2018 were not paid as of September 19, 2019, the maturity date. The Company has accrued penalties in connection with these non-payments in the amount of $5.7 million as of September 30, 2019. These debentures have still not been paid and remain outstanding, and the Company has been accruing interest on these debentures at the default rate of 18% per annum since the dates of the payment defaults.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Debentures Issued in the Nine Months Ended September 30, 2019</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issued debentures on February 24, 2019 in the aggregate principal amount of $300,000 and on March 27, 2019 in the aggregate principal amount of $300,000. Both of these debentures were guaranteed by Mr. Diamantis and were originally due on June 3, 2019. The maturity dates of these debentures were extended to December 31, 2019 and the terms were changed so that commencing on August 17, 2019 the debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest shall entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issued debentures on May 12, 2019 in the aggregate principal amount of $500,000. These debentures were guaranteed by Mr. Diamantis and were due on June 3, 2019. In addition, the Company issued debentures on June 5, 2019 in the aggregate principal amount of $125,000 and on June 7, 2019 in the aggregate principal amount of $200,000. These debentures were also guaranteed by Mr. Diamantis and were due on July 20, 2019. The maturity dates of these debentures were extended to December 31, 2019 and the terms were changed so that commencing on August 17, 2019 the debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest shall entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 13, 2019, the Company closed an offering of $1,250,000 aggregate principal amount of debentures with certain existing institutional investors pursuant to the terms of a Bridge Debenture Agreement, dated as of June 13, 2019 (the &#8220;June 13 Agreement&#8221;) and received proceeds of $1,250,000. The June 13 Agreement provided that on or prior to June 30, 2019, at the mutual election of the Company and the investors, the investors could purchase an additional $1,250,000 principal amount on the same terms and conditions as provided in the June 13 Agreement. Under the June 13 Agreement, the maturity date of the debentures issued on February 24, 2019, March 27, 2019, May 12, 2019, June 5, 2019 and June 7, 2019 were extended to December 31, 2019 and the terms were changed such that they have the same interest terms as contained in the June 13, 2019 debentures, as more fully discussed below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 21, 2019, the Company and the investors agreed that the Company would issue, and the investors would purchase, $250,000 principal amount of debentures and on June 24, 2019 the Company and the investors agreed that the Company would issue, and the investors would purchase, an additional $1,020,000 aggregate principal amount of debentures. In connection with the issuances of the June 21, 2019 and June 24, 2019 debentures, the Company received total proceeds of $1,270,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The June 13, 2019, June 21, 2019 and June 24, 2019 debentures (collectively, the &#8220;June 2019 Debentures&#8221;) are secured and guaranteed by the Company&#8217;s subsidiaries on the same terms as provided in the Purchase Agreement, dated as of August 31, 2017, which is more fully described in Note 9 to the Company&#8217;s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2018. At the Company&#8217;s option, the June 2019 Debentures may also be exchanged for shares of the Company&#8217;s Series I-2 Convertible Preferred Stock under the terms of the previously-announced Exchange Agreement, dated as of October 30, 2017. Commencing on August 17, 2019, the June 2019 Debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law. Christopher Diamantis is a guarantor of the June 2019 Debentures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the debentures issued in the nine months ended September 30, 2019, during the years ending December 31, 2017 and 2018, the Company issued convertible debentures, which are more fully described in Note 9 to the Company&#8217;s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2018. Certain of these convertible debentures were issued with warrants to purchase shares of the Company&#8217;s common stock. Outstanding warrants are more fully discussed in Note 13.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The debentures issued during the nine months ended September 30, 2019 and 2018, were issued at discounts of $0.1 million and $2.9 million, respectively, and accordingly, the Company realized a total of $3.8 million and $8.0 million, respectively, in proceeds from the issuances of the debentures. At September 30, 2019, these discounts have been fully amortized. These discounts represented original issue discounts, the relative fair value of the warrants issued with the debentures and the relative fair value of the beneficial conversion features of the debentures. During the three months ended September 30, 2019 and 2018, the Company recorded approximately $1.4 million and approximately $9.0 million, respectively, of non-cash interest and amortization of debt discount expense in connection with the debentures and warrants. During the nine months ended September 30, 2019 and 2018, the Company recorded approximately $15.8 million and approximately $16.1 million, respectively, of non-cash interest and amortization of debt discount expense primarily in connection with the debentures and warrants. These amounts include non-cash interest expense and debt discount amortization, which resulted from the modification of warrants as more fully discussed in Notes 11 and 13.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 13 for summarized information related to warrants issued and the activity during the nine months ended September 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Notes 3, 13 and 19 for a discussion of the dilutive effect of the outstanding convertible debentures, warrants and convertible preferred stock as of September 30, 2019.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9 &#8211; Related Party Transactions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Alcimede billed $0.1 million and $0.1 million for consulting fees for the three months ended September 30, 2019 and 2018, respectively, and $0.3 million and $0.3 million for the nine months ended September 30, 2019 and 2018, respectively. Seamus Lagan, the Company&#8217;s President and Chief Executive Officer, is the sole manager of Alcimede (see Note 13).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Notes 5, 7 and 19 for a discussion of amounts advanced to the Company by Mr. Diamantis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms of the foregoing transactions, including those discussed in Notes 5, 7, 12 and 19, are not necessarily indicative of those that would have been agreed to with unrelated parties for similar transactions.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10 &#8211; Finance and Operating Lease Obligations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As more fully discussed in Note 1, we adopted ASU No. 2016-02, <i>Leases (Topic 842)</i>, which requires leases with durations greater than 12 months to be recognized on the balance sheet, effective January 1, 2019, using the modified retrospective approach.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Generally, we use our estimated weighted average cost of capital at lease commencement as our interest rate, as most of our operating leases do not provide a readily determinable implicit interest rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents our lease-related assets and liabilities at September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Balance Sheet Classification</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Assets:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; width: 43%"><font style="font-size: 10pt">Operating leases</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: bottom; width: 35%"><font style="font-size: 10pt">Right-of-use operating lease assets</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 18%; text-align: right"><font style="font-size: 10pt">328,615</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.5pt"><font style="font-size: 10pt">Finance leases</font></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 10pt">Property and equipment, net</font></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">618,278</font></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total lease assets</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">946,893</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Liabilities:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Current:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top"><font style="font-size: 10pt">Operating leases</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 10pt">Right-of-use operating lease assets</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">141,830</font></td> <td style="vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Finance leases</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">Current liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">589,457</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Noncurrent:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><font style="font-size: 10pt">Operating leases</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 10pt">Right-of-use operating lease obligations</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">186,785</font></td> <td style="vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Finance leases</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">Long-term debt</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">28,821</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total lease liabilities</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">946,893</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Weighted-average remaining term:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Operating leases</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.98 years </font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Finance leases</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.19 years </font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Weighted-average discount rate:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating leases (1)</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">13.0</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Finance leases</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5.122</font></td> <td><font style="font-size: 10pt">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 24px"><font style="font-size: 10pt">(1)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Upon adoption of the new lease standard, discount rates used for existing operating leases were established at January 1, 2019.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents certain information related to lease expense for finance and operating leases for the three and nine months ended September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30, 2019</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended<br /> September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Finance lease expense:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 52%; padding-left: 10pt"><font style="font-size: 10pt">Depreciation/amortization of leased assets (1)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 21%; text-align: right"><font style="font-size: 10pt">15,004</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 21%; text-align: right"><font style="font-size: 10pt">(30,055</font></td> <td style="width: 1%"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Interest on lease liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">704</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,804</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating leases:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 11.6pt"><font style="font-size: 10pt">Short-term lease expense (2)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">76,312</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">263,713</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total lease expense</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">92,020</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">239,462</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The depreciation for the nine months ended September 30, 2019 has been adjusted for depreciation recorded in the prior year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Expenses are included in general and administrative expenses in our condensed consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Other Information</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents supplemental cash flow information for the nine months ended September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right">&#160;</td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating cash flows for operating leases</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">214,357</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Operating cash flows for finance leases</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,800</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Financing cash flows for finance leases payments</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">143,930</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aggregate future minimum rentals under right-to-use operating and finance leases are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Right-to-Use</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Operating Leases</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Finance Leases</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">October 1, 2019 to September 30, 2020</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">107,457</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">604,080</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">October 1, 2020 to September 30, 2021</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">134,776</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">32,611</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">October 1, 2021 to September 30, 2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">110,062</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">October 1, 2022 to September 30, 2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">29,247</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">October 1, 2023 to September 30, 2024</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,437</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">383,979</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">636,691</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less interest</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(55,364</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(18,413</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><b>Present value of minimum lease payments</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt"><b>328,615</b></font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt"><b>618,278</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion of lease obligations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(141,830</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(589,457</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Lease obligations, net of current portion</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>186,785</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>28,821</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2019, the Company is in default of substantially all its finance lease obligations, therefore the aggregate future minimum rentals and accrued interest under finance leases in the amount of $0.6 million are deemed to be immediately due.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 13 &#8211; Stockholders&#8217; Deficit</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 35.8pt 0 0; text-align: justify"><b><u>Authorized Capital</u></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 35.8pt 0 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has 10,000,000,000 authorized shares of Common Stock at $0.0001 par value and 5,000,000 authorized shares of Preferred Stock at a par value of $0.01.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Preferred Stock</u></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company has 5,000,000 shares, par value $0.01, of preferred stock authorized. As of September 30, 2019, the Company had outstanding shares of preferred stock consisting of shares of its Series I-1 Preferred Stock and shares of Series I-2 Preferred Stock (both of which are more fully discussed in Note 12), 215 shares of its Series G Preferred Stock, 10 shares of its Series H Preferred Stock, 1,750,000 shares of its Series F Convertible Preferred Stock and 250,000 shares of its Series J Convertible Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The 215 shares of the Series G Preferred Stock have a stated value of $1,000 per share and are convertible into shares of the Company&#8217;s common stock at a price equal to 85% of the volume weighted average price of the Company&#8217;s common stock at the time of conversion. See Note 19 regarding the redemption of these shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Series H Preferred Stock has a stated value of $1,000 per share and is convertible into shares of the Company&#8217;s common stock at a conversion price of 85% of the volume weighted average price of the Company&#8217;s common stock at the time of conversion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2017, the Company issued 1,750,000 shares of its Series F Preferred Stock valued at $174,097 in connection with the acquisition of Genomas Inc. Genomas Inc. is included in the Company&#8217;s discontinued operations, which are discussed in Note 17. Each share of the Series F Preferred Stock is convertible into shares of our common stock (subject to adjustment as provided in the related certificate of designation) at any time after the first anniversary of the issuance date at the option of the holder at a conversion price equal to the greater of $14,625 or the average closing price of the Company&#8217;s common stock for the 10 trading days immediately preceding the conversion. The maximum number of shares of common stock issuable upon the conversion of the Series F Preferred Stock is 120. Any shares of Series F Preferred Stock outstanding on the fifth anniversary of the issuance date will be mandatorily converted into common stock at the applicable conversion price on such date. At any time, from time to time after the first anniversary of the issuance date, the Company has the right to redeem all or any portion of the outstanding Series F Preferred Stock at a price per share equal to $1.95 plus any accrued but unpaid dividends. The Series F Preferred Stock has voting rights. Each share of Series F Preferred Stock has one vote, and the holders of the Series F Preferred Stock shall vote together with the holders of the Company&#8217;s common stock as a single class.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 20, 2018, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware to authorize the issuance of up to 250,000 shares of its Series J Convertible Preferred Stock (the &#8220;Series J Preferred Stock&#8221;). On July 23, 2018, the Company entered into an Exchange Agreement (the &#8220;Agreement&#8221;) with Alcimede, of which Seamus Lagan, our Chief Executive Officer, is the sole manager. Pursuant to the Agreement, the Company issued to Alcimede 250,000 shares of the Series J Preferred Stock in exchange for the cancellation of the outstanding principal and interest owed by the Company to Alcimede under the Note, dated February 5, 2015, and the cancellation of certain amounts owed by the Company to Alcimede under a consulting agreement between the parties. The total amount of consideration paid by Alcimede to the Company equaled $250,000. Each share of the Series J Preferred Stock has a stated value of $1.00. The conversion price is equal to the average closing price of the Company&#8217;s common stock on the 10 trading days immediately prior to the conversion date. Each holder of the Series J Preferred Stock is entitled to vote on all matters submitted to a vote of the holders of the Company&#8217;s common stock. From and after October 1, 2018, each share of the Series J Preferred Stock is entitled to the whole number of votes equal to the number of common shares into which it is then convertible. The full terms of the Series J Preferred Stock are listed in the Certificate of Designations filed as Exhibit 3.16 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 24, 2018. The Series J Preferred Stock is entitled to 8% per annum cumulative dividends at the discretion of the Company&#8217;s board of directors. No dividends have been declared by the board as of September 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement, as more fully described in Note 19.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Common Stock</u></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has authorized 10,000,000,000 shares of Common Stock, par value $0.0001 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company had 8,398,936,775 and 128,567,273 shares of common stock issued and outstanding at September 30, 2019 and December 31, 2018, respectively. During the nine months ended September 30, 2019, the Company:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Issued 119,615,384 shares of common stock upon exercise of 755,000,000 warrants, on a cashless basis; and</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Issued 8,150,754,118 shares of common stock upon the conversion of 982.101 shares of its Series I-2 Preferred Stock;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Restricted Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On August 14, 2017, the Board of Directors, based on the recommendation of the Compensation Committee of the Board and in accordance with the provisions of the 2007 Equity Plan, approved grants to employees and directors of the Company of an aggregate of 364 shares of restricted common stock of the Company. The grants fully vested on the first anniversary of the date of grant, subject to the grantee&#8217;s continued status as an employee or director on the vesting date. During the nine months ended September 30, 2019, 123 shares of the restricted stock were forfeited by their terms and returned to treasury.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended September 30, 2018, the Company issued an aggregate of 142,667 shares of restricted stock to employees and directors, based upon the recommendation of the Compensation Committee of the Board of Directors. The grants fully vested immediately. During the nine months ended September 30, 2018, the Company recognized stock-based compensation in the amount of $477,933 for the grant of such restricted stock based on a valuation of $3.35 per share. The value of the common stock issued was based on the fair value of the stock at the time of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common Stock and Common Stock Equivalents</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has outstanding options, warrants, convertible preferred stock and convertible debentures. Exercise of the options and warrants, and conversions of the convertible preferred stock and debentures could result in substantial dilution of our common stock and a decline in its market price. In addition, the terms of certain of the warrants, convertible preferred stock and convertible debentures issued by us provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that we issue common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. These provisions, as well as the issuances of debentures and preferred stock with conversion prices that vary based upon the price of our common stock on the date of conversion, have resulted in significant dilution of our common stock and have given rise to reverse splits of our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement. The Series K Preferred Stock is more fully described in Note 19. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares. These potentially dilutive shares are presented in Note 19.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company maintained and sponsored the Tegal Corporation 2007 Incentive Award Plan (the &#8220;2007 Equity Plan&#8221;). Tegal Corporation is the prior name of the Company. The 2007 Equity Plan, as amended, provided for the issuance of stock options and other equity awards to the Company&#8217;s officers, directors, employees and consultants. The 2007 Equity Plan terminated pursuant to its terms in September 2017. The following table summarizes the stock option activity for the nine months ended September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Stock Options</u></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of options</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted-average exercise price</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted-average contractual term</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%"><font style="font-size: 10pt">Outstanding at December 31, 2018</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">77</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 17%; text-align: right"><font style="font-size: 10pt">1,036,375</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 17%; text-align: right"><font style="font-size: 10pt">7.33</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Granted </font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Expired</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeit</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at September 30, 2019</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">77</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,036,375</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6.50</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exercisable at September 30, 2019</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">68</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,152,616</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized stock option expense of approximately $25,950 and $72,590 for the nine months ended September 30, 2019 and 2018, respectively. As of September 30, 2019, the weighted average remaining contractual life was 6.50 years for options outstanding and exercisable. The intrinsic value of options exercisable at September 30, 2019 was $0. As of September 30, 2019, the remaining compensation expense of approximately $8,650 will be amortized over the remaining vesting period, which is approximately three months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Warrants</u></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company&#8217;s common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended September 30, 2019, the number of shares issuable pursuant to outstanding warrants increased by 582.2 billion as a result of the anti-dilution provisions of outstanding warrants that were issued in connection with the issuances of debentures as more fully discussed in Note 9 to the Company&#8217;s consolidated financial statements included in its Annual Report on Form 10-K. The number of shares issued and issuable as well as the exercise prices of the warrants reflected in the table below have been adjusted to reflect the full ratchet and other dilutive and down round provisions pursuant to the warrant agreements. As a result of the current exercise prices for the majority of the outstanding warrants (subject to a floor in some cases), as well as the full ratchet provisions of the majority of the outstanding warrants (again, subject to a floor in some cases), subsequent decreases in the price of the Company&#8217;s common stock and subsequent issuances of the Company&#8217;s common stock or common stock equivalents at prices below the current exercise prices of the warrants will result in increases in the number of shares issuable pursuant to the warrants and decreases in the exercise prices.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes the information related to warrants issued and the activity during the nine months ended September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of shares issuable pursuant to warrants</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted average exercise price</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Balance at December 31, 2018</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">53,130,510,439</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">0.00172</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Increase during the period as a result of down round provisions</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">582,209,844,938</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Shares issued pursuant to Warrants exercised during the period</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(755,000,000</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.00034</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at September 30, 2019</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">634,585,355,377</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.00014</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 27, 2019, the expiration dates of certain warrants issued in March 2017 and September 2017 with convertible debentures, referred to as the March 2017 Series B Warrants and the September 2017 Series B Warrants, were extended from June 2019 to September 2019. On May 12, 2019, the expiration date of these warrants was further extended to March 31, 2022. The Company used the Black Scholes model to calculate the fair value of the warrants as of the modification date. Using the pre-modification terms and related assumptions, and the post-modification terms and related assumptions, the Company determined that the change in fair value of the warrants as a result of the March 27<sup>th</sup> modification was $4.1 million and the May 12<sup>th</sup> modification was $5.4 million. Accordingly, the Company recorded the modification value of $5.4 and $9.5 million as interest expense in the three and nine months ended September 30, 2019, respectively. See Note 11 for the assumptions used in the Black Scholes valuation models.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and nine months ended September 30, 2018, the Company extended the exercise period of outstanding warrants twice, once to March 21, 2019 and the second time to June 21, 2019 and recorded an additional discount on the debenture issued in connection with the warrants of approximately $8.3 million and $0.3 million as a result of the extensions. The Company amortized approximately $6.4 million of the discount as non-cash interest expense in the nine months ended September 30, 2018. This amount was included in the cash flow statement for the nine months ended September 30, 2018 in amortization of debt discount. See Note 11 for the assumptions used in the Black Scholes valuation models.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 19 for a discussion of the dilutive effect of the outstanding warrants as of December 26, 2019.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 14 &#8211; Supplemental Disclosure of Cash Flow Information</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended September 30,</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%"><font style="font-size: 10pt">Cash paid for interest</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">303,208</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Cash paid for income taxes</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">45,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">20,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt"><b>Acquisitions of Hospitals and Medical Center:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Cash</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">375</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Inventory</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">317,427</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">450,682</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Prepaid expenses and other current assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">310,385</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Property and equipment</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">500,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,129,484</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Intangible assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">250,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">504,806</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Accrued expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">158,890</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">193,966</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt"><b>Non-cash investing and financing activities:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exchange of Series I-2 Preferred Stock for common stock</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,143,974</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">633,101</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Cashless exercise of warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">11,961</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,619,150</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Debentures converted into common stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">8,085,342</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Common stock issued in cashless exercise of warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">11,961</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exchange of debentures into Series I-2 Preferred Stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,420</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Conversions of Series H Preferred Stock into common stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">50,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Original issue discount of debentures and notes payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">400,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,920,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Deemed dividend for trigger of down round provision features</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">123,861,587</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">17,942,578</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Issuance of Series J Preferred Stock in settlement of note payable to related party</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">250,000</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 15 &#8211; Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base. The Company does have significant receivable balances with government payers and various insurance carriers. Generally, the Company does not require collateral or other security to support customer receivables. However, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid (CMS) reimbursements to hospitals and clinical laboratories. Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in revenues from Medicare and Medicaid (CMS), which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains its cash balances in high credit quality financial institutions. The Company&#8217;s cash balances may, at times, exceed the deposit insurance limits provided by the Federal Deposit Insurance Corporation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Legal Matters</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time-to-time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company&#8217;s financial position or results of operations. The Company&#8217;s policy is to expense legal fees and expenses incurred in connection with the legal proceedings in the period in which the expense is incurred. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Biohealth Medical Laboratory, Inc. and PB Laboratories, LLC (the &#8220;Companies&#8221;) filed suit against CIGNA Health in 2015 alleging that CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA - issued and CIGNA - administered plans. In 2016, the U.S. District Court dismissed part of the Companies&#8217; claims for lack of standing. The Companies appealed that decision to the Eleventh Circuit Court of Appeals, which in late 2017 reversed the District Court&#8217;s decision and found that the Companies have standing to raise claims arising out of traditional insurance plans as well as self-funded plans. In July 2019, the Companies and EPIC Reference Labs, Inc. filed suit against Cigna Health for failure to pay claims for laboratory services provided. Cigna Health, in turn, sued for improper billing practices. Both cases are in the early stages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Epinex Diagnostics Laboratories, Inc. subsidiary was sued in a California state court by two former employees who alleged that they were wrongfully terminated, as well as for a variety of unpaid wage claims. The parties entered into a settlement agreement of this matter on July 29, 2016 for approximately $0.2 million, and the settlement was consummated on August 25, 2016. In October of 2016, the plaintiffs in this matter filed a motion with the court seeking payment for attorneys&#8217; fees in the approximate amount of $0.7 million. On March 24, 2017, the court granted plaintiffs&#8217; motion for payment of attorneys&#8217; fees in the amount of $0.3 million, and the Company accrued this amount in its consolidated financial statements. Additionally, the Company is seeking indemnification for these amounts from Epinex Diagnostics, Inc., the seller of Epinex Diagnostic Laboratories, Inc., pursuant to a Stock Purchase Agreement entered into by and among the parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the Company received notice that the Internal Revenue Service (the &#8220;IRS&#8221;) placed a lien against Medytox Solutions, Inc. and its subsidiaries relating to unpaid 2014 taxes due, plus penalties and interest, in the amount of $5.0 million. The Company paid $0.1 million toward its 2014 tax liability in March 2016. The Company filed its 2015 Federal tax return on March 15, 2016 and the accompanying election to carryback the reported net operating losses was filed in April 2016. On August 24, 2016, the lien was released, and in September of 2016 the Company received a refund from the IRS in the amount of $1.9 million. In November of 2016, the IRS commenced an audit of the Company&#8217;s 2015 Federal tax return. Based upon the audit results, the Company has made provisions of approximately $1.0 million as a liability in its financial statements as well as an estimated $0.6 million of receivables for an additional refund that it believes is due.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 27, 2016, a tax warrant was issued against the Company by the Florida Department of Revenue (the &#8220;DOR&#8221;) for unpaid 2014 state income taxes in the approximate amount of $0.9 million, including penalties and interest. The Company entered into a Stipulation Agreement with the DOR allowing the Company to make monthly installments until July 2019. The Company has made payments to reduce the amount owed to approximately $$0.4 million as of September 30, 2019. The Company intends to renegotiate another Stipulation agreement. However, there can be no assurance the Company will be successful. The remaining balance accrued of approximately $0.4 million remained outstanding to the DOR at September 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December of 2016, TCS-Florida, L.P. (&#8220;Tetra&#8221;), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with Tetra (see Note 10). On January 3, 2017, Tetra received a Default Judgment against the Company in the amount of $2.6 million, representing the balance owed on the leases, as well as additional interest, penalties and fees. In January and February of 2017, the Company made payments to Tetra relating to this judgment aggregating $0.7 million, and on February 15, 2017, the Company entered into a forbearance agreement with Tetra whereby the remaining $1.9 million due would be paid in 24 equal monthly installments. The Company has not maintained the payment schedule to Tetra. As a result of this default, in May 2018, Tetra and the Company agreed to dispose of certain equipment and the proceeds from the sale have been applied to the outstanding balance. The balance owed to Tetra at September 30, 2019 was $0.3 million and the Company remains in default.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December of 2016, DeLage Landen Financial Services, Inc. (&#8220;DeLage&#8221;), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with DeLage (see Note 10). On January 24, 2017, DeLage received a default judgment against the Company in the approximate amount of $1.0 million, representing the balance owed on the lease, as well as additional interest, penalties and fees. The Company recognized this amount in its consolidated financial statements as of December 31, 2016. On February 8, 2017, a Stay of Execution was filed and under its terms the balance due was to be paid in variable monthly installments through January of 2019, with an implicit interest rate of 4.97%. The Company and DeLage have now disposed of certain equipment and reduced the balance owed to DeLage. A balance of $0.2 million remained outstanding at September 30, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 7, 2016, the holders of the Tegal Notes (see Note 7) filed suit against the Company seeking payment for the amounts due under the notes in the aggregate of the principal of $341,612, and accrued interest of $43,000. A request for entry of default judgment was filed on January 24, 2017. On April 23, 2018, the holders of the Tegal Notes received a judgment against the Company. To date, the Company has repaid $5,513 of this amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2017, a former shareholder of Genomas, Inc., Phenomas, LLC, filed suit against the Company for payment of a $200,000 note payable by the Company&#8217;s subsidiary, Genomas. This note is recorded in the financial statements of the subsidiary and is not payable directly from the Company. The Company has made payments totaling $120,000 against this note and agreed to a payment schedule in order to dismiss the legal action. On November 12, 2018, Phenomas, LLC filed a motion to voluntarily dismiss the suit without prejudice.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The counterparty to the prepaid forward purchase agreement entered into by the Company on March 31, 2016, as amended, filed an arbitration proceeding under the agreement with regard to the outstanding balance. During the nine months ended September 30, 2019, Mr. Diamantis advanced the Company $9.9 million, which was used to repay all obligations under the prepaid forward purchase agreement, as more fully discussed in Note 7.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two former employees of the Company&#8217;s CollabRx, Inc. subsidiary have filed suits in a California state court in connection with amounts claimed to be owed under their respective employment agreements with the subsidiary. One former employee received a judgment in October 2018 for approximately $253,000. The other former employee&#8217;s claim is for approximately $110,000. The Company is considering its options to refute these matters and believes the claims against the Company to be frivolous and outside of entitlement and contractual agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, as well as many of our subsidiaries, are defendants in a case filed in Broward County Circuit Court by TCA Global Credit Master Fund, L.P. The plaintiff alleges a breach by Medytox Solutions, Inc. of its obligations under a debenture and claims damages of approximately $2,030,000 plus interest, costs and fees. The Company and the other subsidiaries are sued as alleged guarantors of the debenture. The complaint was filed on August 1, 2018. The Company has recorded the principal balance and interest owed under the debenture agreement for the period ended September 30, 2019. The Company and all defendants have filed a motion to dismiss the complaint, but have not recorded any potential liability related to any further damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 13, 2018, Laboratory Corporation of America sued EPIC Reference Labs, Inc., a subsidiary of the Company, in Palm Beach County Circuit Court for amounts claimed to be owed of approximately $148,000. The Company has recorded the amount owed in accrued expenses at September 30, 2019. The court awarded a judgment against EPIC Reference Labs, Inc. in May 2019 for approximately $155,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2019, Roche Diagnostics Corporation sued EPIC Reference Labs, Inc. in the Circuit Court for Palm Beach County claiming approximately $240,000 under an agreement to purchase laboratory supplies. This suit is in the early stages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2019, EPIC Reference Labs, Inc. and Medytox Diagnostics, Inc. were sued by Beckman Coulter, Inc. in the same court under an agreement to purchase laboratory supplies. The plaintiff claims damages of approximately $106,000. This case is in the early stages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2019, the landlord of Medytox Solutions, Inc. received a judgment in the amount of approximately $413,000 in connection with failure to pay under an office lease in West Palm Beach, Florida.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2018, Techlogix, Inc. received a judgment of approximately $72,000 against the Company and HTS in the Superior Court of Middlesex County Massachusetts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the Company&#8217;s decision to suspend operations at Jamestown Regional Medical Center in June 2019 a number of vendors remain unpaid. A number have initiated or threatened legal actions. The Company believes it will come to satisfactory arrangements with these parties as it works towards reopening the hospital. On June 10, 2019, the Company hired a new CEO to oversee the reopening of the hospital and took steps to re-enter the Medicare program. The hospital received initial approval of its application to reactivate the Medicare agreement in August and is currently planning the reopening of the hospital. Negotiations with vendors are ongoing.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 16&#8211; Segment Reporting</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are defined under U.S. GAAP as components of an enterprise for which discrete financial information is available and are evaluated regularly by the enterprise&#8217;s chief operating decision maker in determining how to allocate resources and assess performance. The Company operates in two reportable business segments:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt"><b>Hospital Operations, </b>which reflects the operations of Jamestown Regional Medical Center, Big South Fork Medical Center and Jellico Community Hospital and CarePlus Center.</font></td></tr> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify">&#160;</td> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt"><b>Clinical Laboratory Operations</b>, which specializes in providing urine and blood toxicology and pain medication testing to physicians, clinics and rehabilitation facilities in the United States.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Corporate expenses reflect consolidated company-wide support services such as finance, legal counsel, human resources, and payroll.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Decision Support and Informatics segment and its Supportive Software Solutions segment are now included in discontinued operations as they have been classified as held for sale as of September 30, 2019. The accounting policies of the reportable segments are the same as those described in Note 1.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Selected financial information for the Company&#8217;s operating segments is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Nine Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Net revenues - External</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; padding-left: 10pt"><font style="font-size: 10pt">Hospital Operations</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">3,920,608</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">5,021,543</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">13,081,647</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">9,755,099</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Clinical Laboratory Operations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(34,631</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">17,569</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">56,169</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">177,890</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,885,977</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,039,112</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">13,137,816</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,932,989</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">(Loss) income from continuing operations before income taxes:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Hospital Operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(1,769,400</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(1,294,581</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(8,946,720</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(3,998,943</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Clinical Laboratory Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(295,908</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(547,041</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(701,466</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(1,765,395</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Corporate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(640,044</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(973,953</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(2,626,953</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(3,156,646</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Other income (expense), net</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(9,422,340</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">100,171,656</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(26,064,924</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">4,955,262</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(12,127,692</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">97,356,081</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(38,340,063</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(3,965,722</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Depreciation and amortization</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Hospital Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">182,832</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">39,669</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">532,979</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">177,386</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Clinical Laboratory Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">10,036</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">112,908</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">69,381</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">625,877</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Corporate</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,128</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">248</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,458</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">811</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">199,996</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">152,825</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">609,818</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">804,074</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Capital expenditures</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Hospital Operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">7,086</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">103,387</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">50,801</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">103,387</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Clinical Laboratory Operations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,086</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">103,387</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">50,801</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">103,387</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Total assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 62%; padding-left: 10pt"><font style="font-size: 10pt">Hospital Operations</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">16,831,443</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">13,568,933</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Clinical Laboratory Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">356,854</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">271,426</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Corporate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,821,952</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,707,416</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Assets of AMSG and HTS classified as held for sale</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">373,121</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">152,171</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Eliminations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,809,305</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,500,646</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">16,574,065</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">14,199,300</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 17 &#8211; Discontinued Operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 12, 2017, the Company announced plans to spin off AMSG and in the third quarter of 2017, the Company&#8217;s Board of Directors voted unanimously to spin off HTS as independent publicly traded companies by way of tax-free distributions to the Company&#8217;s stockholders. While the spin offs have taken longer than anticipated, completion of these spin offs is now expected to occur in the first quarter of 2020. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission, and consents, including under various funding agreements previously entered into by the Company. A record date to determine those stockholders entitled to receive shares in the spin offs should be approximately 30 to 60 days prior to the dates of the spin offs. The strategic goal of the spin offs is to create three public companies, each of which can focus on its own strengths and operational plans.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 205-20 and having met the criteria for &#8220;held for sale&#8221;, as the Company reached this decision prior to December 31, 2017, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. Prior to being classified as &#8220;held for sale,&#8221; AMSG had been the Company&#8217;s Decision Support and Informatics segment, except for the Company&#8217;s subsidiary, Alethea Laboratories, Inc., which had been included in the Clinical Laboratory Operations segment and now is part of AMSG, and HTS had been the Company&#8217;s Supportive Software Solutions segment. Segment disclosures in Note 16 no longer include amounts relating to AMSG and HTS following the reclassification to discontinued operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Carrying amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the condensed consolidated balance sheets consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>AMSG Assets and Liabilities:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Cash</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">220</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">4,471</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts receivable, net</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">22,523</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,838</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Prepaid expenses and other current assets</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">25,477</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current assets classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>22,743</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>36,786</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts payable (includes related parties)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">514,415</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">532,858</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">493,356</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">418,932</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Income taxes payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Current portion of notes payable</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">268,851</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">278,836</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current liabilities classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,276,622</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,230,626</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Non-current liabilities classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>HTS Assets and Liabilities:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Cash</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">2,298</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">2,523</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts receivable, net</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">330,238</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">90,743</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Prepaid expenses and other current assets</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,867</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10,300</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current assets classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>339,403</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>103,566</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Property and equipment, net</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4,946</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,790</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deposits</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,029</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,029</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Non-current assets classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>10,975</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>11,819</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts payable (includes related parties)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">710,709</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">546,969</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">714,128</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">520,251</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Current portion of notes payable</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current liabilities classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,424,837</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>1,067,220</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Total Discontinued Assets and Liabilities:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Cash</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">2,518</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">6,994</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts receivable, net</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">352,761</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">97,581</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Prepaid expenses and other current assets</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,867</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">35,777</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current assets classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>362,146</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>140,352</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Property and equipment, net</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4,946</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,790</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deposits</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,029</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6,029</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Non-current assets classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>10,975</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>11,819</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts payable (includes related parties)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,225,124</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,079,827</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,207,484</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">939,183</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Current portion of notes payable</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">268,851</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">278,836</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Current liabilities classified as held for sale</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>2,701,459</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>2,297,846</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Major line items constituting loss from discontinued operations in the condensed consolidated statements of operations for the three months ended September 30, 2019 and 2018 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>AMSG Loss from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">11,350</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">13,249</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,878</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">15,559</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit (loss)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,472</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(2,310</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">60,424</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">93,059</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other income (expenses)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,912</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(5,748</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Loss from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(57,864</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(89,621</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>HTS Loss from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">235,326</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">499,317</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">20,134</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">30,082</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">215,192</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">469,235</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">295,404</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">532,892</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other income</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,152</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Loss from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(80,212</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(69,809</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Consolidated Loss from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">246,676</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">512,566</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">26,012</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">45,641</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">220,664</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">466,925</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">355,828</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">625,951</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other expense</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,912</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">404</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Loss from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(138,076</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(159,430</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Major line items constituting (loss) income from discontinued operations in the condensed consolidated statements of operations for the nine months ended September 30, 2019 and 2018 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>AMSG (Loss) Income from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">59,832</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">92,090</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">29,638</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">37,773</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">30,194</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">54,317</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">237,042</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">363,944</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other (income) expense</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">31,874</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(819,258</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>(Loss) income from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(238,722</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>509,631</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>HTS Loss from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">706,795</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">1,291,288</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">83,628</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">95,965</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">623,167</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,195,323</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,176,381</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,577,046</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other income</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">12,121</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Loss from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(553,214</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(393,844</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Consolidated (Loss) Income from Discontinued Operations:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>(unaudited)</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Revenue from services</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">766,627</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">1,383,378</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of services</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">113,266</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">133,738</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Gross profit</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">653,361</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,249,640</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,413,423</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,940,990</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other (income) expense</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">31,874</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(807,137</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>(Loss) income from discontinued operations</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>(791,936</b></font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>)</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>115,787</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 19 &#8211; Subsequent Events</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Loans From Mr. Diamantis</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to September 30, 2019 and through November 30, 2019, Mr. Diamantis advanced the Company $0.7 million for working capital purposes. The Company incurred interest of $65,000 on the advance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Issuance of Common Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to September 30, 2019 and through December 26, 2019, the Company issued an aggregate of 1,250,000,000 shares of common stock for conversions of preferred stock. The following table presents the dilutive effect of our various potential common shares as of December 26, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 26, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Common shares outstanding</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">9,648,936,775</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Dilutive potential shares:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Stock options</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">77</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">634,525,355,377</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Convertible debt</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">30,634,784,339</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Convertible preferred stock</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">79,122,373,825</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total dilutive potential common shares, including outstanding common stock</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">753,931,450,393</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding. Following is a summary of certain terms of the Series K Preferred Stock:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>General</i>. The Company&#8217;s Board of Directors has designated 250,000 shares of the 5,000,000 authorized shares of preferred stock as the Series K Preferred Stock. Each share of the Series K Preferred Stock has a stated value of $1.00.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Voting Rights</i>. Each holder of the Series K Preferred Stock shall be entitled to vote on all matters submitted to a vote of the holders of the Company&#8217;s common stock. With respect to a vote of stockholders to approve either or both a reverse stock split of the Company&#8217;s common stock (and any reduction in the authorized shares) and an increase in the authorized shares of common stock from 10 billion shares to up to 12.5 billion shares, no later than December 31, 2019 only, each share of the Series K Preferred Stock shall be entitled to the whole number of votes equal to 40,000 shares of common stock. With respect to all other matters, and from and after December 31, 2019, each share of the Series K Preferred Stock shall be entitled to the whole number of votes equal to the number of shares of common stock into which it is then convertible. The Series K Preferred Stock shall vote with the common stock as if they were a single class of securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Dividends</i>. Holders of the Series K Preferred Stock shall be entitled to receive dividends on shares of the Series K Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of common stock when, as and if dividends are paid on shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Rank</i>. The Series K Preferred Stock ranks with respect to dividends or a liquidation, (i) on parity with the common stock, the Company&#8217;s Series G Convertible Preferred Stock and the Company&#8217;s Series H Convertible Preferred Stock, (ii) senior to the Company&#8217;s Series F Convertible Preferred Stock, and (iii) junior to the Company&#8217;s Series I-1 Convertible Preferred Stock and the Company&#8217;s Series 1-2 Convertible Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Conversion</i>. Each share of the Series K Preferred Stock is convertible into shares of the Company&#8217;s common stock at any time at the option of the holder, into that number of shares of common stock determined by dividing the stated value of such share of Preferred Stock plus any accrued and unpaid dividends thereon, by the conversion price. The conversion price is equal to the average closing price of the common stock on the 10 trading days immediately prior to the conversion date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Liquidation Preference</i>. Upon any liquidation, dissolution or winding up of the Company, the holders of the Series K Preferred Stock shall be entitled to receive an amount equal to the stated value of the Series K Preferred Stock, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon for each share of the Series K Preferred Stock before any distribution or payment shall be made on any junior securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Redemption</i>. At any time the Company shall have the right to redeem all, or any part, of the Series K Preferred Stock then outstanding. The Series K Preferred Stock subject to redemption shall be redeemed by the Company in cash in an amount equal to the stated value of the shares of the Series K Preferred Stock being redeemed plus all accrued and unpaid dividends.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Exchange of Series J Preferred Stock for Series K Preferred Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 23, 2019, the Company entered into an Exchange Agreement (the &#8220;Agreement&#8221;) with Alcimede. Pursuant to the Agreement, the Company issued to Alcimede 250,000 shares of its Series K Preferred Stock in exchange for the 250,000 shares of the Company&#8217;s Series J Preferred Stock. The holder of the Series J Preferred Stock was entitled to receive, when and as declared by the Board of Directors of the Company, but only out of funds that were legally available therefore, cumulative cash dividends at the rate of 8% of the stated value per annum on each share of Series J Preferred Stock. The Series J Preferred Stock had been issued to Alcimede on July 23, 2018 and upon the issuance of the Series K Preferred Stock to Alcimede, the shares of Series J Preferred Stock were cancelled. Under the Agreement, Alcimede relinquished all rights to any cumulative dividends on the Series J Preferred Stock. The terms of the Series K Preferred Stock do not provide for cumulative dividends.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Redemption of Series G Preferred Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 9, 2019, the Company redeemed all 215 shares of its Series G Preferred Stock that were outstanding.</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended September 30,</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%"><font style="font-size: 10pt">Cash paid for interest</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">303,208</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Cash paid for income taxes</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">45,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">20,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt"><b>Acquisitions of Hospitals and Medical Center:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Cash</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">375</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Inventory</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">317,427</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">450,682</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Prepaid expenses and other current assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">310,385</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Property and equipment</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">500,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,129,484</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Intangible assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">250,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">504,806</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Accrued expenses</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">158,890</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">193,966</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt"><b>Non-cash investing and financing activities:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exchange of Series I-2 Preferred Stock for common stock</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,143,974</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">633,101</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Cashless exercise of warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">11,961</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,619,150</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Debentures converted into common stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">8,085,342</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Common stock issued in cashless exercise of warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">11,961</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Exchange of debentures into Series I-2 Preferred Stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,420</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Conversions of Series H Preferred Stock into common stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">50,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Original issue discount of debentures and notes payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">400,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,920,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Deemed dividend for trigger of down round provision features</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">123,861,587</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">17,942,578</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Issuance of Series J Preferred Stock in settlement of note payable to related party</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">250,000</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> 400000 500000 142667 142667 364 25950 477933 739729 8650 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 &#8211; Accrued Expenses</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses at September 30, 2019 (unaudited) and December 31, 2018 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>September 30,</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Commissions payable</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">19,113</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">19,113</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Sales tax payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">8,009</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">8,016</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued payroll and related liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,761,173</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,400,052</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accrued property tax</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">41,784</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">47,396</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued interest</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,586,652</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,464,837</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Other accrued expenses</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,125,488</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,771,867</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Accrued expenses</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,542,219</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,711,281</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses at December 31, 2018 included $4.9 million of interest due under the terms of a settlement agreement for a prepaid forward purchase contract related to an accounts receivable financing, which was paid by Mr. Diamantis on behalf of the Company during the nine months ended September 30, 2019, as more fully discussed in Note 7. Accrued expenses at September 30, 2019 and December 31, 2018 included $1.8 million and $0.3 million, respectively, of accrued interest due to Mr. Diamantis related to loans made by Mr. Diamantis to the Company as more fully discussed in Note 7.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses at September 30, 2019 (unaudited) and December 31, 2018 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>September 30,</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Commissions payable</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">19,113</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">19,113</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Sales tax payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">8,009</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">8,016</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued payroll and related liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,761,173</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,400,052</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accrued property tax</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">41,784</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">47,396</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Accrued interest</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,586,652</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,464,837</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Other accrued expenses</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,125,488</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,771,867</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Accrued expenses</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,542,219</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,711,281</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> 12776316 28690240 5835294 3084153 5835294 1940179 6386305 16080270 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 18 &#8211; Recent Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Accounting Pronouncements Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the adoption of pronouncements related to derivative liabilities discussed in Note 1, and ASU 2018-02<i>, Leases (Topic 842)</i> discussed in Notes 1 and 10, the Company adopted the following pronouncements:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2018, the FASB issued ASU 2018-02, <i>Income Statement&#8212;Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. </i>This standard provides companies with an option to reclassify stranded tax effects resulting from enactment of the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) from accumulated other comprehensive income to retained earnings. Early adoption of this standard is permitted and may be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the tax rate as a result of TCJA is recognized. This ASU became effective for us for annual and interim periods beginning after December 15, 2018. The adoption of this ASU did not have a material impact on our results of operations, financial position and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2018, the FASB issued ASU 2018-03; <i>Technical Corrections and Improvements to Financial Instruments&#8212;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>. These technical corrections and improvements are intended to clarify certain aspects of the guidance on recognizing and measuring financial assets and liabilities in ASU 2016-01. This includes equity securities without a readily determinable fair value, forward contracts and purchased options, presentation requirements for certain fair value option liabilities, fair value option liabilities denominated in foreign currency and transition guidance for equity securities without a readily determinable fair value. We were required to adopt these standards starting in the first quarter of fiscal year 2019. The implementation did not have a material impact on our consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, the FASB issued ASU 2018-05; <i>&#8220;Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update)&#8221;, </i>which amended ASC 740 to incorporate the requirements of Staff Accounting Bulletin (&#8220;SAB&#8221;) 118. Issued in December 2017 by the SEC, SAB 118 addresses the application of U.S. GAAP in situations in which a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the TCJA which was signed into law on December 22, 2017. The adoption did not have a material impact on our consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07 to expand the scope of <i>ASC Topic 718, Compensation - Stock Compensation</i>, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The adoption did not have a material impact on our consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Accounting Pronouncements Not Yet Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued ASU 2018-13, <i>Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</i>. This standard will require entities to disclose the amount of total gains or losses for the period recognized in other comprehensive income that is attributable to fair value changes in assets and liabilities held as of the balance sheet date and categorized within Level 3 of the fair value hierarchy. This ASU will be effective for us for annual and interim periods beginning after December 31, 2020. Early adoption of this standard is permitted. We have not yet determined the impact of the adoption of this ASU on our results of operations, financial position and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued ASU 2018-15, <i>Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</i>. Under this standard customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. The adoption of this new guidance prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and additional quantitative and qualitative disclosures. This ASU will be effective for us for annual and interim periods beginning after December 30, 2020. Early adoption of this standard is permitted and may be applied either prospectively to eligible costs incurred on or after the date of the new guidance or retrospectively. We have not yet determined the impact of the adoption of this ASU on our results of operations, financial position and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other recent accounting standards issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statements.</p> 3845000 8000000 1270000 1270000 1500000 4960000 4000000 1250000 <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of options</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted-average exercise price</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted-average contractual term</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%"><font style="font-size: 10pt">Outstanding at December 31, 2018</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">77</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 17%; text-align: right"><font style="font-size: 10pt">1,036,375</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 17%; text-align: right"><font style="font-size: 10pt">7.33</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Granted </font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Expired</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeit</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at September 30, 2019</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">77</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,036,375</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6.50</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exercisable at September 30, 2019</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">68</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,152,616</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes the information related to warrants issued and the activity during the nine months ended September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of shares issuable pursuant to warrants</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted average exercise price</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Balance at December 31, 2018</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">53,130,510,439</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">0.00172</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Increase during the period as a result of down round provisions</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">582,209,844,938</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Shares issued pursuant to Warrants exercised during the period</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(755,000,000</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.00034</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at September 30, 2019</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">634,585,355,377</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.00014</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Reclassification</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the nine months ended September 30, 2018, the Company has presented the proceeds from related party notes payable and advances that were previously netted against payments on related party notes payable and advances as a separate line item on the Statement of Cash Flows. This reclassification did not have an effect on total cash flow from financing activities for the nine months ended September 30, 2018.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 11 &#8211; Derivative Financial Instruments and Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2019 and December 31, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Level 1</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Level 2</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Level 3</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><b>As of December 31, 2018:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Embedded conversion options</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right"><font style="font-size: 10pt">&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right"><font style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right"><font style="font-size: 10pt">350,260</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right"><font style="font-size: 10pt">350,260</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">350,260</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">350,260</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><b>As of September 30, 2019:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Embedded conversion options</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">455,336</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">455,336</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">455,336</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">455,336</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilized the following methods to value its derivative liabilities as of September 30, 2019 and December 31, 2018, for embedded conversion options valued at $455,336 and $350,260, respectively. The Company determined the fair value by comparing the discounted conversion price per share (85% of market price, subject to a floor in certain cases) multiplied by the number of shares issuable at the balance sheet date to the actual price per share of the Company&#8217;s common stock multiplied by the number of shares issuable at that date with the difference in value recorded as a liability. All inputs for the derivative liabilities are observable and, therefore, there is no sensitivity in the valuation to unobservable inputs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the nine months ended September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Balance at December 31, 2018</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">350,260</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Change in fair value of debentures</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">105,076</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at September 30, 2019</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">455,336</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended September 30, 2019 and the three and nine months ended September 30, 2018, the conversions of preferred stock triggered a further reduction in the exercise prices of any debentures and warrants containing ratchet features that had not already ratcheted down to their floor. In accordance with U.S. GAAP, the incremental fair value of the debentures and warrants was measured, ignoring the down round provision, using Black Scholes. The following assumptions were utilized in the Black Scholes valuation models in the nine months ended September 30, 2019: risk free rates ranging from 2.4% to 2.6% and volatility ranging from 189.5% to 273.1% and weighted average life of 0.3 to 3.2 years. The following assumptions were utilized in the Black Scholes valuation models in the three and nine months ended September 30, 2018: risk free rates ranging from 2.36% to 2.88% and volatility ranging from 163.8% to 234.7% and weighted average life of .73 to 3.5 years. The incremental value of $123.9 million was recorded as a deemed dividend for the nine months ended September 30, 2019 and the incremental value of $17.9 million and $17.9 million was recorded as a deemed dividend in the three and nine months ended September 30, 2018, respectively. Deemed dividends are also discussed in Notes 1 and 3.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended September 30, 2019, the Company recorded interest expense of $9.5 million, which represented the fair value of the modification of warrants during the period as more fully discussed in Note 13. The Company used the Black Scholes model to calculate the fair value of the warrants as of the modification dates. Using the pre-modification terms and related assumptions of risk free rates ranging from 2.44% to 2.46%, volatility ranging from 182.9% to 204.4% and weighted average remaining lives of .24 years to .36 years, and the post-modification terms and related assumptions of risk free rates ranging from 2.23% to 2.49%, volatility ranging from 198.3% to 259.4% and weighted average remaining lives of .48 years to 2.89 years, the changes in the fair value of the warrant instruments as a result of the modifications were estimated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and nine months ended September 30, 2018, the Company extended the exercise period of outstanding warrants twice, once to March 21, 2019 and the second time to June 21, 2019 and recorded an additional discount on the debenture issued in connection with the warrants of approximately $8.3 million and $0.3 million as a result of the extensions. The Company amortized approximately $6.4 million of the discount as non-cash interest expense in the nine months ended September 30, 2018. This amount was included in the cash flow statement for the nine months ended September 30, 2018 in amortization of debt discount. The Company used the Black Scholes model to calculate the fair value of the warrants as of the modification dates. Using the pre-modification term and related assumptions of risk free rates ranging from 1.91-2.32%, volatility ranging from 184.0-296.3% and weighted average remaining life of .33 years, and the post-modification term and related assumptions of risk free rates ranging from 2.09-2.56%, volatility ranging from 208.2-249.1% and weighted average remaining life of .65 years, the change in the fair value of the warrant instruments as a result of the modifications was estimated on each date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three and nine months ended September 30, 2018, the Company realized income of $109.3 million and $13.7 million, respectively, on instruments valued using Level 3 valuations. On September 23, 2018, the Company&#8217;s board of directors approved a reverse split of its common stock, which would provide sufficient authorized and unissued shares to allow for otherwise equity classified instruments to be classified in equity. As of September 23, 2018, the fair value of these instruments was evaluated for reclassification. As a result of the evaluation, the Company reclassified the derivative liability previously reported as a current liability to derivative income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All inputs for the derivative liabilities are observable and, therefore, there is no sensitivity in the valuation to unobservable inputs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding. The Series K Preferred Stock is more fully described in Note 19.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted loss per share as reflected in the table above excludes all dilutive potential shares if their effect is anti-dilutive. For the nine months ended September 30, 2019 and 2018, the following table sets forth the computation of the following potential common stock equivalents excluded from the calculation of diluted loss per share as their effect was anti-dilutive:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended September 30,</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Warrants</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">634,525,355,377</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">463,449,767</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Convertible preferred stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">82,901,785,590</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">68,344,495</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Convertible debentures</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">30,634,784,339</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">214,222,495</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Stock options</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">77</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">77</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">748,061,925,383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">746,016,834</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> 748061925383 746016834 634525355377 82901785590 30634784339 77 463449767 68344495 214222495 77 77 634525355377 30634784339 79122373825 2019 174097 661381 11961 77 15 -11961 661304 -15 57 3957710 3957767 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amount of all outstanding debentures as of September 30, 2019 (unaudited), and December 31, 2018 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Debentures</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">28,690,240</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">19,034,800</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Discount on Debentures</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(6,247,469</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deferred financing fees</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(11,015</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">28,690,240</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">12,776,316</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(28,690,240</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(12,776,316</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Debentures, long-term</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Notes Payable &#8211; Third Parties</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>September 30,</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Loan payable under prepaid forward purchase contract (1)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">5,000,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Loan payable to TCA Global Master Fund, LP (&#8220;TCA&#8221;) in the original principal amount of $3 million at 16% interest (the &#8220;TCA Debenture&#8221;). Principal and interest payments due in various installments through December 31, 2017</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,741,893</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,741,893</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the &#8220;Tegal Notes&#8221;). Principal and interest payments due annually from July 12, 2015 through July 12, 2017</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">335,818</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">341,612</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Note payable to Anthony O&#8217;Killough dated September 27, 2019 in the original principal amount of $1.9 million. Interest is due only upon event of default. Issued net of $0.3 million of debt discount and $0.1 million of financing fees with $1.0 million of principal due on November 8, 2019 and $0.9 million of principal due December 26, 2019</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,527,821</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,605,532</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,083,505</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,605,532</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(7,083,505</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Notes payable - third parties, net of current portion</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify">&#160;</td> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">(1)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">The loan payable under prepaid forward purchase contract has been fully settled during the nine months ended September 2019 as more fully discussed below under the heading &#8220;<i>Notes Payable &#8211;Related Party&#8221;.</i></font></td></tr> </table> <p style="margin: 0pt"></p> 350260 350260 350260 350260 455336 455336 455336 455336 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2019 and December 31, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Level 1</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Level 2</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Level 3</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><b>As of December 31, 2018:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Embedded conversion options</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right"><font style="font-size: 10pt">&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right"><font style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right"><font style="font-size: 10pt">350,260</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right"><font style="font-size: 10pt">350,260</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">350,260</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">350,260</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><b>As of September 30, 2019:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Embedded conversion options</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">455,336</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">455,336</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>-</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">455,336</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">455,336</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the nine months ended September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Balance at December 31, 2018</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">350,260</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Change in fair value of debentures</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">105,076</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at September 30, 2019</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">455,336</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 9464991 4056425 4056425 5408566 5408566 0.85 0.85 3.35 0 77 77 1036375 1036375 P7Y3M29D P6Y6M -38340063 -3965798 -12127692 97356081 1286.141 106335991 8150754118 982.101 1250000000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Use of Estimates</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include the estimates of fair values of assets acquired and liabilities assumed in business combinations, including hospital acquisitions, reserves, contractual allowances and write-downs related to receivables and inventories, the recoverability of long-lived assets, stock based compensation, the valuation allowance relating to the Company&#8217;s deferred tax assets, valuation of equity and derivative instruments, including modifications thereof, deemed dividends and debt discounts, among others. Actual results could differ from those estimates and would impact future results of operations and cash flows.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Earnings (Loss) Per Share</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reports earnings (loss) per share in accordance with ASC Topic 260, &#8220;Earnings Per Share&#8221;, which establishes standards for computing and presenting earnings per share. Basic earnings (loss) per share of common stock is calculated by dividing net (loss) earnings allocable to common shareholders by the weighted-average shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted earnings (loss) per share is calculated by adjusting the weighted-average shares of common stock outstanding for the dilutive effect of common stock equivalents, including stock options and warrants outstanding for the period as determined using the treasury stock method. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation when their effect would be anti-dilutive. Therefore, basic and diluted net loss per share applicable to common shareholders is the same for periods with a net loss. See Note 3 for the computation of earnings (loss) per share for the three and nine months ended September 30, 2019 and 2018.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the computation of the Company&#8217;s basic and diluted net income (loss) per share for each of the three and nine months ended September 30, 2019 and 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Nine Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Numerator:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%"><font style="font-size: 10pt">Net (loss) income from continuing operations</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">(12,127,692</font></td> <td style="width: 1%"><font style="font-size: 10pt">)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">97,356,081</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">(38,340,063</font></td> <td style="width: 1%"><font style="font-size: 10pt">)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">(3,965,798</font></td> <td style="width: 1%"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Net (loss) income from discontinued operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(138,076</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(159,430</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(791,936</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">115,787</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deemed dividends</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(17,942,578</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(123,861,587</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(17,942,578</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Net loss (income) to common shareholders -basic</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(12,265,768</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">79,254,073</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(162,993,586</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(21,792,589</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Adjustments for diluted calculations:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Deduct change in fair value of derivative liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(109,305,331</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Amortize discounts associated with conversion of dilutive convertible debentures</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(7,303,912</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Remove change in warrant value for diluted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(11,376</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Add back deemed dividends</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">17,942,578</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Net loss to common shareholders - diluted</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(12,265,768</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(19,423,968</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(162,993,586</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(21,792,589</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Denominator:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Weighted average number of common shares outstanding during the period:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,634,045,471</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,531,767</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,461,922,587</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,550,632</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Common stock equivalents:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">64,315,740</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Convertible preferred stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">9,505,156</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Convertible debentures</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">175,301,554</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Diluted</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,634,045,471</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">254,654,217</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,461,922,587</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,550,632</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Net (loss) income per common share- continuing operations:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">17.60</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(1.55</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Diluted</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.08</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(1.55</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Net (loss) income per common share- discontinued operations:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.03</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.05</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Diluted</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.05</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Total per share net (loss) income to common shareholders:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">14.33</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.04</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(8.54</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Diluted</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.08</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.04</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(8.54</font></td> <td><font style="font-size: 10pt">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the allocation of the purchase price of Jamestown Regional Medical Center to the acquired identifiable assets acquired, and liabilities assumed:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; padding-bottom: 1.5pt"><font style="font-size: 10pt"><b>Total purchase price</b></font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: right"><font style="font-size: 10pt"><b>635,096</b></font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt"><b>Tangible and intangible assets acquired, and liabilities assumed at fair value:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Cash</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">375</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Inventories</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">450,682</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Prepaids and deposits</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">310,385</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Property and equipment</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,129,484</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Intangible assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">504,806</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Accrued expenses</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(193,966</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Net tangible and intangible assets acquired</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">8,201,766</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Gain on bargain purchase <sup>(1)</sup></b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>7,566,670</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify">&#160;</td> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">(1)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Gain was adjusted in the fourth quarter of 2018 from $7,732,302 to $7,566,670 to reflect an adjustment of the value of the property and equipment acquired.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the preliminary allocation of the purchase price of Jellico Community Hospital and CarePlus Center to the acquired identifiable assets acquired, and liabilities assumed:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; padding-bottom: 1.5pt"><font style="font-size: 10pt"><b>Total purchase price</b></font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: right"><font style="font-size: 10pt"><b>658,537</b></font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt"><b>Tangible and intangible assets acquired, and liabilities assumed at estimated fair value:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Inventories</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">317,427</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Property and equipment</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">500,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Intangible asset- certificate of need</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">250,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Accrued expenses</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(158,890</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Net tangible and intangible assets acquired</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">908,537</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Gain on bargain purchase</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>250,000</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following presents the unaudited pro-forma combined results of operations of the Company and Jamestown Regional Medical Center and Jellico Community Hospital and CarePlus Center as if the acquisitions had occurred on January 1, 2018. The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the acquisitions been completed as of January 1, 2018 or to project potential operating results as of any future date or for any future periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Nine Months</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%"><font style="font-size: 10pt">Net revenue</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">8,276,112</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">14,855,436</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">25,499,677</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Net income (loss) from continuing operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">96,879,012</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(38,537,422</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(8,151,239</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Deemed dividend from trigger of down round provision feature</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(17,942,578</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(123,861,587</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(17,942,578</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Net (loss) income from discontinued operations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(159,430</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(791,936</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">115,787</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Net income (loss) to common shareholders - basic</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">78,777,004</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(163,190,945</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(25,978,030</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Adjustments for diluted loss to common shareholders</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(98,678,041</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt"><b>&#8212;</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt"><b>&#8212;</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Net loss to common shareholders - diluted</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(19,901,037</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(163,190,945</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(25,978,030</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><b>Net income (loss) per common share:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Basic continuing operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">17.51</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(3.20</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Diluted continuing operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.02</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(3.20</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Basic net income (loss) to common shareholders</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">14.24</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.04</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(10.18</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Diluted net loss to common shareholders</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.24</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.04</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(10.18</font></td> <td><font style="font-size: 10pt">)</font></td></tr> </table> <p style="margin: 0pt"></p> true false false 755000000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the dilutive effect of our various potential common shares as of December 26, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 26, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Common shares outstanding</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">9,648,936,775</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Dilutive potential shares:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Stock options</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">77</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">634,525,355,377</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Convertible debt</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">30,634,784,339</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Convertible preferred stock</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">79,122,373,825</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total dilutive potential common shares, including outstanding common stock</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">753,931,450,393</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> Yes Yes 3525152 5648343 -82010 -25066 4932457 3497210 -327953 3728038 -45000 -12243 -14603489 -6493672 182663 -628154 -709338 -338758 800000 -709338 461242 2310000 5000000 5000000 4937105 9937105 4011000 2300000 400000 143930 654435 15230766 6660584 15230766 6660584 100602 6870 107472 12072442 7809465 3227709 3350286 12730695 10240434 3163624 4351576 25412955 18853973 6591329 7854687 250000 7732302 7566670 250000 7732302 19229232 17075437 3637467 9322333 -123861587 -17942578 -17942578 6870 107472 3811749 5108462 453402 688819 78820 77646 631077 631077 5122270 6975622 8526904 8467887 259443 509443 278864 281523 8155955 13076160 10711281 4900000 10542219 1400651 1355651 7083505 3605532 44416174 76247935 44447717 76463541 12857 839894 375845883 509515347 14199300 16574065 109695 121947 76 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash and Cash Equivalents</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had minimal cash equivalents at September 30, 2019 and December 31, 2018.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Derivative Financial Instruments and Fair Value, Including the Adoption of ASU 2017-11</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for warrants issued in conjunction with the issuance of common stock and certain convertible debt instruments in accordance with the guidance contained in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815, Derivatives and Hedging (&#8220;ASC 815&#8221;) and ASC Topic 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;). For warrant instruments and conversion options embedded in promissory notes that are not deemed to be indexed to the Company&#8217;s own stock, we classified such instruments as liabilities at their fair values at the time of issuance and adjusted the instruments to fair value at each reporting period. These liabilities were subject to re-measurement at each balance sheet date until extinguished either through conversion or exercise, and any change in fair value was recognized in our statement of operations. The fair values of these derivative and other financial instruments had been estimated using a Black-Scholes model and other valuation techniques.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the FASB issued ASU 2017-11 &#8220;Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).&#8221; The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt&#8212;Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company&#8217;s first fiscal quarter of 2017. The remaining $16 million was offset to additional paid-in-capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million of which $51 million of the deemed dividend was recorded retrospectively as of the beginning of the issuance of the debentures issued in March 2017 where the initial derivative liability was recorded as a result of the down round provision feature. A deemed dividend of $231.8 million was recorded for the year ended December 31, 2018, a deemed dividend of $123.9 million was recorded during the nine months ended September 30, 2019 and a deemed dividend of $17.9 million and $17.9 million was recorded for the three and nine months ended September 30, 2018, respectively, as a result of down round provision features. See Note 11 for an additional discussion of derivative financial instruments.</p> -105076 13688678 109305331 7129484 500000 500000 7129484 450682 317427 317427 450682 504806 250000 250000 504806 193966 158890 158890 193966 1000 1000 1.95 0.08 25950 72590 582200000000 5005794 200000 256481 5513 1750275 2000225 39502 128567273 2000225 2000225 8398936775 7365881 2000225 1750225 6008936775 3183349 1750275 999985 2000225 3503882657 8650 78444 8650 8650 78444 24196 8650 24196 24197 24197 8650 8650 123861587 17942578 -123861587 -17942578 14 641096 641110 303208 45000 20000 8085342 123861587 17942578 13137816 177890 56169 13081647 9755099 9932989 3885977 5039112 5021543 -34631 17569 3920608 2022-03-31 400000 180000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 12 &#8211; Redeemable Preferred Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has 5,000,000 authorized shares of Preferred Stock at a par value of $0.01. Issuances of the Company&#8217;s Preferred Stock included as part of stockholders&#8217; deficit are discussed in Note 13. The following is a summary of the issuances of the Company&#8217;s Redeemable Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series I-1 Convertible Preferred Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2017, the Company closed an offering of $4,960,000 stated value of 4,960 shares of a newly-authorized Series I-1 Convertible Preferred Stock (the &#8220;Series I-1 Preferred Stock&#8221;). Each share of Series I-1 Preferred Stock has a stated value of $1,000. The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of October 30, 2017 (the &#8220;Purchase Agreement&#8221;), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $4.0 million from the offering. The Purchase Agreement gives the investors the right to participate in up to 50% of any offering of common stock or common stock equivalents by the Company. In the event of any such offering, the investors may also exchange all or some of their Series I-1 Preferred Stock for such new securities on an $0.80 stated value of Series I-1 Preferred Stock for $1.00 of new subscription amount basis. Each share of Series I-1 Preferred Stock is convertible into shares of the Company&#8217;s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to &#8220;full ratchet&#8221; and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-1 Preferred Stock. Upon the occurrence of certain Triggering Events, as defined in the Certificate of Designation of the Series I-1 Preferred Stock, the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-1 Preferred Stock in cash or in certain circumstances in shares of common stock at the redemption prices set forth in the Certificate of Designation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series I-2 Convertible Preferred Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2017, the Company entered into Exchange Agreements with the holders of the September Debentures to provide that the holders may, from time to time, exchange their September Debentures for shares of a newly-authorized Series I-2 Preferred Stock. The Exchange Agreements permitted the holders of the September Debentures to exchange specified principal amounts of the September Debentures on various closing dates starting on December 2, 2017 (debentures are more fully discussed in Note 9 to the consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K). At the holder&#8217;s option each holder could reduce the principal amount of September Debentures exchanged on any particular closing date, or elect not to exchange any September Debentures at all on a closing date. If a holder chose to exchange less principal amount of September Debentures, or no September Debentures at all, it could carry forward such lesser amount to a future closing date and then exchange more than the originally specified principal amount for that later closing date. For each $0.80 of principal amount of September Debenture surrendered to the Company at any closing date, the Company will issue the holder a share of Series I-2 Preferred Stock with a stated value of $1.00. Each share of Series I-2 Preferred Stock is convertible into shares of the Company&#8217;s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to &#8220;full ratchet&#8221; and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-2 Preferred Stock. From December 2, 2017 through March 1, 2018, any exchange under the Exchange Agreements was at the option of the holder. Subsequent to March 2018, any exchange is at the option of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s board of directors has designated up to 21,346 shares of the 5,000,000 authorized shares of preferred stock as the Series I-2 Preferred Stock. Each share of Series I-2 Preferred Stock has a stated value of $1,000. Upon the occurrence of certain Triggering Events (as defined in the Certificate of Designation of the Series I-2 Preferred Stock), the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-2 Preferred Stock in cash or in certain circumstances in shares of common stock at the redemption prices set forth in the Certificate of Designation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 9, 2018, the holders exercised their right to exchange a portion of the September Debentures for shares of the Series I-2 Preferred Stock for the first time. On that date, the holders exchanged an aggregate of $1,384,556 principal amount of September Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Preferred Stock. On July 16, 2018, under the Exchange Agreements with the holders of the September Debentures, the holders exchanged a portion of the September Debentures for shares of the Company&#8217;s Series I-2 Preferred Stock. On that date, the holders exchanged an aggregate of $1,741,580 principal amount of the September Debentures and the Company issued an aggregate of 2,176.975 shares of its Series I-2 Preferred Stock. During the nine months ended September 30, 2018, the Company recorded a loss on these exchanges of convertible debentures into shares of its Series I-2 Preferred Stock in the aggregate amount of $1.5 million. In 2018, the holder converted 1,286.141 shares of Series I-2 Preferred Stock into 106,335,991 shares of the Company&#8217;s common stock and during the nine months ended September 30, 2019, the holder converted 982.101 shares of Series I-2 Preferred Stock into 8,150,754,118 shares of the Company&#8217;s common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Notes 3 and 19 for a discussion of the dilutive effect of the Series I-1 Preferred Stock and the Series I-2 Preferred Stock as of September 30, 2019 and December 26, 2019, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 &#8211; Earnings (Loss) Per Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic and diluted earnings (loss) per share is computed by dividing (i) loss available to common shareholders, by (ii) the weighted-average number of shares of common stock outstanding during the period. Basic loss per share excludes dilution and is computed by dividing loss attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company. The loss per share for the three and nine months ended September 30, 2019 and the nine months ended September 30, 2018 excluded securities or other contracts to issue the Company&#8217;s common stock because the results were anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the computation of the Company&#8217;s basic and diluted net income (loss) per share for each of the three and nine months ended September 30, 2019 and 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Nine Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Numerator:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%"><font style="font-size: 10pt">Net (loss) income from continuing operations</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">(12,127,692</font></td> <td style="width: 1%"><font style="font-size: 10pt">)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">97,356,081</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">(38,340,063</font></td> <td style="width: 1%"><font style="font-size: 10pt">)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">(3,965,798</font></td> <td style="width: 1%"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Net (loss) income from discontinued operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(138,076</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(159,430</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(791,936</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">115,787</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deemed dividends</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(17,942,578</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(123,861,587</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(17,942,578</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Net loss (income) to common shareholders -basic</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(12,265,768</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">79,254,073</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(162,993,586</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(21,792,589</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Adjustments for diluted calculations:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Deduct change in fair value of derivative liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(109,305,331</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Amortize discounts associated with conversion of dilutive convertible debentures</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(7,303,912</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Remove change in warrant value for diluted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(11,376</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Add back deemed dividends</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">17,942,578</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Net loss to common shareholders - diluted</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(12,265,768</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(19,423,968</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(162,993,586</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(21,792,589</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Denominator:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Weighted average number of common shares outstanding during the period:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,634,045,471</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,531,767</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,461,922,587</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,550,632</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Common stock equivalents:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">64,315,740</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Convertible preferred stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">9,505,156</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Convertible debentures</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">175,301,554</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Diluted</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,634,045,471</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">254,654,217</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,461,922,587</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,550,632</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Net (loss) income per common share- continuing operations:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">17.60</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(1.55</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Diluted</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.08</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(1.55</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Net (loss) income per common share- discontinued operations:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.03</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.05</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Diluted</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.05</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Total per share net (loss) income to common shareholders:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">14.33</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.04</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(8.54</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Diluted</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.08</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.04</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(8.54</font></td> <td><font style="font-size: 10pt">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted loss per share as reflected in the table above excludes all dilutive potential shares if their effect is anti-dilutive. For the nine months ended September 30, 2019 and 2018, the following table sets forth the computation of the following potential common stock equivalents excluded from the calculation of diluted loss per share as their effect was anti-dilutive:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended September 30,</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Warrants</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">634,525,355,377</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">463,449,767</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Convertible preferred stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">82,901,785,590</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">68,344,495</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Convertible debentures</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">30,634,784,339</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">214,222,495</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Stock options</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">77</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">77</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">748,061,925,383</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">746,016,834</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, many of these equity-based securities contain exercise or conversion prices that vary based upon the price of the Company&#8217;s common stock on the date of exercise/conversion (see Notes 12 and 13). These provisions have resulted in significant dilution of the Company&#8217;s common stock and have given rise to reverse splits of the Company&#8217;s common stock. As a result of these down round provisions, the outstanding common stock and potential common stock equivalents totaled 753.9 billion at December 26, 2019. See Notes 13 and 19 regarding a discussion of the Company&#8217;s common stock and potential common stock equivalents.</p> 328615 141830 186785 5710440 1361053 1782614 -651562 -651562 651562 651562 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8211; Organization and Summary of Significant Accounting Policies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Description of Business</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rennova Health, Inc. (&#8220;Rennova&#8221;), together with its subsidiaries (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;), is a vertically integrated provider of healthcare related products and services. The Company&#8217;s principal lines of business are (i) Hospital Operations; and (ii) Clinical Laboratory Operations. The Company presents its financial results based upon these two business segments, which are more fully discussed in Note 16.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Reverse Stock Split</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 5, 2018, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s Certificate of Incorporation to effect a 1-for-500 reverse stock split effective November 12, 2018 (the &#8220;Reverse Stock Split&#8221;). The stockholders of the Company had approved the amendment to the Company&#8217;s Certificate of Incorporation on August 22, 2018 for the Reverse Stock Split. The Company&#8217;s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations, and the timing of the reverse split within certain specified effective dates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the Reverse Stock Split, every 500 shares of the Company&#8217;s then outstanding common stock was combined and automatically converted into one share of the Company&#8217;s common stock on November 12, 2018. In addition, the conversion and exercise prices of all of the Company&#8217;s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the applicable reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Split, other than as a result of cash paid in lieu of fractional shares as no fractional shares were issued in connection with the Reverse Stock Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All share, per share and capital stock amounts as of and for the three and nine months ended September 30, 2018 have been restated to give effect to the Reverse Stock Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, on September 18, 2018, the Company amended its Certificate of Incorporation to have the authority to issue 10,000,000,000 shares of common stock and the par value of the Company&#8217;s common stock was decreased from $0.01 per share to $0.0001 per share. No additional change was made to the terms of the Company&#8217;s common stock as a result of the November 12, 2018 reverse stock split and no change was made to the authorized preferred stock, which remains at 5,000,000 shares of preferred stock, par value $0.01 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Reverse Stock Split provided sufficient authorized and unissued shares to allow for the Company&#8217;s outstanding and otherwise equity classified instruments to be classified in equity. As a result, the fair value of these instruments was evaluated for reclassification and, as a result, during the third quarter of 2018, the Company reclassified its derivative liabilities previously reported as a current liability to derivative income. On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of its Series K Convertible Preferred Stock (&#8220;Series K Preferred Stock&#8221;) to Alcimede LLC (&#8220;Alcimede&#8221;), a related party, as more fully discussed in Note 19. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Jamestown Regional Medical Center Medicare Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following an inspection at Jamestown Regional Medical Center on February 5, 2019, the hospital was informed on February 15 that several conditions of participation in its Medicare agreement were deficient. The hospital was informed that if the deficiencies where not corrected by May 16 the Medicare agreement would terminate. A follow-up inspection on May 15 resulted in the determination that the hospital had failed to adequately correct the deficiencies highlighted and a notice of involuntary termination was issued that was effective on June 12, 2019. A significant percentage of patients at Jamestown Regional Medical Center are covered by Medicare and without any ability to get paid for these services the Company suspended operations at the hospital. The hospital received initial approval of its application to reactivate the Medicare agreement in August of 2019 and is currently planning the reopening of the hospital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Basis of Presentation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the consolidated financial statements as filed on the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on October 21, 2019. In the opinion of management, the unaudited condensed consolidated financial statements included herein contain all adjustments necessary to present fairly the Company&#8217;s consolidated financial position as of September 30, 2019, and the results of its operations, changes in stockholders&#8217; deficit and cash flows for the three and nine months ended September 30, 2019 and 2018. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2019 may not be indicative of results for the year ending December 31, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Principles of Consolidation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) include the accounts of Rennova and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in the consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Reclassification</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the nine months ended September 30, 2018, the Company has presented the proceeds from related party notes payable and advances that were previously netted against payments on related party notes payable and advances as a separate line item on the Statement of Cash Flows. This reclassification did not have an effect on total cash flow from financing activities for the nine months ended September 30, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Comprehensive Loss</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and nine months ended September 30, 2019 and 2018, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Use of Estimates</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include the estimates of fair values of assets acquired and liabilities assumed in business combinations, including hospital acquisitions, reserves, contractual allowances and write-downs related to receivables and inventories, the recoverability of long-lived assets, stock based compensation, the valuation allowance relating to the Company&#8217;s deferred tax assets, valuation of equity and derivative instruments, including modifications thereof, deemed dividends and debt discounts, among others. Actual results could differ from those estimates and would impact future results of operations and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash and Cash Equivalents</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had minimal cash equivalents at September 30, 2019 and December 31, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Revenue Recognition</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hospital Operations</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain government programs, primarily Medicare, this is generally referred to as the &#8220;cost report&#8221; filing and settlement process). There were no adjustments to estimated Medicare and Medicaid reimbursement amounts and disproportionate-share funds related primarily to cost reports filed during the three and nine months ended September 30, 2019 and 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Emergency Medical Treatment and Labor Act (&#8220;EMTALA&#8221;) requires any hospital participating in the Medicare program to conduct an appropriate medical screening examination of every person who presents to the hospital&#8217;s emergency room for treatment and, if the individual is suffering from an emergency medical condition, to either stabilize the condition or make an appropriate transfer of the individual to a facility able to handle the condition. The obligation to screen and stabilize emergency medical conditions exists regardless of an individual&#8217;s ability to pay for treatment. Federal and state laws and regulations require, and our commitment to providing quality patient care encourages, us to provide services to patients who are financially unable to pay for the health care services they receive. The federal poverty level is established by the federal government and is based on income and family size. The Company considers the poverty level in determining whether patients qualify for free or reduced cost of care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. We provide discounts to uninsured patients who do not qualify for Medicaid or charity care. In implementing the uninsured discount policy, we may first attempt to provide assistance to uninsured patients to help determine whether they may qualify for Medicaid, other federal or state assistance, or charity care. If an uninsured patient does not qualify for these programs, the uninsured discount is applied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management&#8217;s assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable (the &#8220;hindsight analysis&#8221;) as a primary source of information in estimating the collectability of our accounts receivable. We perform the hindsight analysis quarterly, utilizing rolling twelve-months accounts receivable collection and write-off data. We believe our quarterly updates to the estimated contractual allowance amounts at each of our hospital facilities provide reasonable estimates of our revenues and valuations of our accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical Laboratory Operations</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Laboratory testing services include chemical diagnostic tests such as blood analysis and urine analysis. Laboratory service revenues are recognized at the time the testing services are performed and billed and are reported at their estimated net realizable amounts. Net service revenues are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the U.S. have an agreement with a third-party payer such as a commercial insurance provider, Medicaid or Medicare to pay all or a portion of their healthcare expenses; most of the services provided by us are to patients covered under a third-party payer contract. In most cases, the Company is provided the third-party billing information and seeks payment from the third party in accordance with the terms and conditions of the third-party payer for health service providers like us. Each of these third-party payers may differ not only in terms of rates, but also with respect to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payer methods and trends. Despite follow up billing efforts, the Company does not currently anticipate collection of a significant portion of self-pay billings, including the patient responsibility portion of the billing for patients covered by third party payers. The Company currently does not have any capitated agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review our calculations for the realizability of gross service revenues monthly to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payer groups. The contractual allowance calculation is made based on historical allowance rates for the various specific payer groups monthly with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions. This calculation is routinely analyzed by us based on actual allowances issued by payers and the actual payments made to determine what adjustments, if any, are needed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Bad Debt and Contractual Allowances</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total gross revenues for Hospital and Clinical Laboratory Operations were reduced in the aggregate by approximately $0.9 million and $1.8 million for bad debt for the three months ended September 30, 2019 and 2018, respectively. After bad debt and contractual and related allowance adjustments to revenues of $21.9 million and $25.1 million, for the three months ended September 30, 2019 and 2018, respectively, we reported net revenues of $3.9 million and $5.0 million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total gross revenues for Hospital and Clinical Operations were reduced in the aggregate by approximately $4.8 million and $3.1 million for bad debt for the nine months ended September 30, 2019 and 2018, respectively. After bad debt and contractual and related allowance adjustments to revenues of $86.7 million and $43.8 million, for the nine months ended September 30, 2019 and 2018, respectively, we reported net revenues of $13.1 million and $9.9 million, respectively. We continue to review the provision for bad debt and contractual and related allowances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Leases, Including the Adoption of ASU No. 2016-02</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We adopted ASU No. 2016-02, <i>Leases (Topic 842)</i>, which requires leases with durations greater than 12 months to be recognized on the balance sheet, effective January 1, 2019, using the modified retrospective approach. Prior period financial statement amounts and disclosures have not been adjusted to reflect the provisions of the new standard. We elected the package of transition provisions available which allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. We lease property and equipment under finance and operating leases. For leases with terms greater than 12 months, we record the related right-of-use assets and right-of-use obligations at the present value of lease payments over the term. We do not separate lease and non-lease components of contracts. Our operating and finance leases are more fully discussed in Note 10.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Derivative Financial Instruments and Fair Value, Including the Adoption of ASU 2017-11</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for warrants issued in conjunction with the issuance of common stock and certain convertible debt instruments in accordance with the guidance contained in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815, Derivatives and Hedging (&#8220;ASC 815&#8221;) and ASC Topic 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;). For warrant instruments and conversion options embedded in promissory notes that are not deemed to be indexed to the Company&#8217;s own stock, we classified such instruments as liabilities at their fair values at the time of issuance and adjusted the instruments to fair value at each reporting period. These liabilities were subject to re-measurement at each balance sheet date until extinguished either through conversion or exercise, and any change in fair value was recognized in our statement of operations. The fair values of these derivative and other financial instruments had been estimated using a Black-Scholes model and other valuation techniques.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the FASB issued ASU 2017-11 &#8220;Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).&#8221; The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt&#8212;Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company&#8217;s first fiscal quarter of 2017. The remaining $16 million was offset to additional paid-in-capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million of which $51 million of the deemed dividend was recorded retrospectively as of the beginning of the issuance of the debentures issued in March 2017 where the initial derivative liability was recorded as a result of the down round provision feature. A deemed dividend of $231.8 million was recorded for the year ended December 31, 2018, a deemed dividend of $123.9 million was recorded during the nine months ended September 30, 2019 and a deemed dividend of $17.9 million and $17.9 million was recorded for the three and nine months ended September 30, 2018, respectively, as a result of down round provision features. See Note 11 for an additional discussion of derivative financial instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Earnings (Loss) Per Share</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reports earnings (loss) per share in accordance with ASC Topic 260, &#8220;Earnings Per Share&#8221;, which establishes standards for computing and presenting earnings per share. Basic earnings (loss) per share of common stock is calculated by dividing net (loss) earnings allocable to common shareholders by the weighted-average shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted earnings (loss) per share is calculated by adjusting the weighted-average shares of common stock outstanding for the dilutive effect of common stock equivalents, including stock options and warrants outstanding for the period as determined using the treasury stock method. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation when their effect would be anti-dilutive. Therefore, basic and diluted net loss per share applicable to common shareholders is the same for periods with a net loss. See Note 3 for the computation of earnings (loss) per share for the three and nine months ended September 30, 2019 and 2018.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8211; Liquidity and Financial Condition</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under ASU, 2014-15<i>, Presentation of Financial Statements&#8212;Going Concern (Subtopic 205-40)</i> (&#8220;ASC 205-40&#8221;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued. Management has assessed the Company&#8217;s ability to continue as a going concern in accordance with the requirement of ASC 205-40.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had a working capital deficit, an accumulated deficit and a stockholders&#8217; deficit of $69.3 million, $578.0 million and $67.7 million, respectively, at September 30, 2019. In addition, the Company had a net loss of approximately $39.1 million and cash used in operating activities of $14.4 million for the nine months ended September 30, 2019. The continued losses and other related factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern for twelve months from the filing date of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s unaudited condensed consolidated financial statements are prepared assuming the Company can continue as a going concern, which contemplates continuity of operations through realization of assets, and the settling of liabilities in the normal course of business. Initial cost savings were realized by reducing the number of laboratory facilities to one for most of its toxicology diagnostics, thereby reducing the number of employees and associated operating expenses. The Company intends to spin off its Advanced Molecular Services Group (&#8220;AMSG&#8221;) and Health Technology Solutions, Inc. (&#8220;HTS&#8221;), as independent publicly traded companies by way of tax-free distributions to its shareholders. While these spin offs have taken longer than anticipated, completion of these spin offs is now expected to occur during the first quarter of 2020. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission and consents, including under various funding agreements previously entered by the Company. The intent of the spin offs of AMSG and HTS is to create three public companies, each of which can focus on its own strengths and operational plans. In accordance with ASC 205-20 and having met the criteria for &#8220;held for sale&#8221;, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. AMSG and HTS are no longer included in the segment reporting following the reclassification to discontinued operations. The discontinued operations of AMSG and HTS are described further in Note 17.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s core business is now rural hospitals which is a specialized marketplace with a requirement for capable and knowledgeable management. The Company&#8217;s current financial condition may make it difficult to attract and maintain adequate expertise in its management team to successfully operate the Company&#8217;s hospitals.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There can be no assurance that the Company will be able to achieve its business plan, which is to acquire and operate clusters of rural hospitals, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to significantly reduce its operating costs, increase its revenues, and eventually achieve profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Description of Business</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rennova Health, Inc. (&#8220;Rennova&#8221;), together with its subsidiaries (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;), is a vertically integrated provider of healthcare related products and services. The Company&#8217;s principal lines of business are (i) Hospital Operations; and (ii) Clinical Laboratory Operations. The Company presents its financial results based upon these two business segments, which are more fully discussed in Note 16.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Reverse Stock Split</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 5, 2018, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s Certificate of Incorporation to effect a 1-for-500 reverse stock split effective November 12, 2018 (the &#8220;Reverse Stock Split&#8221;). The stockholders of the Company had approved the amendment to the Company&#8217;s Certificate of Incorporation on August 22, 2018 for the Reverse Stock Split. The Company&#8217;s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations, and the timing of the reverse split within certain specified effective dates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the Reverse Stock Split, every 500 shares of the Company&#8217;s then outstanding common stock was combined and automatically converted into one share of the Company&#8217;s common stock on November 12, 2018. In addition, the conversion and exercise prices of all of the Company&#8217;s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the applicable reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Split, other than as a result of cash paid in lieu of fractional shares as no fractional shares were issued in connection with the Reverse Stock Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All share, per share and capital stock amounts as of and for the three and nine months ended September 30, 2018 have been restated to give effect to the Reverse Stock Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, on September 18, 2018, the Company amended its Certificate of Incorporation to have the authority to issue 10,000,000,000 shares of common stock and the par value of the Company&#8217;s common stock was decreased from $0.01 per share to $0.0001 per share. No additional change was made to the terms of the Company&#8217;s common stock as a result of the November 12, 2018 reverse stock split and no change was made to the authorized preferred stock, which remains at 5,000,000 shares of preferred stock, par value $0.01 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Reverse Stock Split provided sufficient authorized and unissued shares to allow for the Company&#8217;s outstanding and otherwise equity classified instruments to be classified in equity. As a result, the fair value of these instruments was evaluated for reclassification and, as a result, during the third quarter of 2018, the Company reclassified its derivative liabilities previously reported as a current liability to derivative income. On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of its Series K Convertible Preferred Stock (&#8220;Series K Preferred Stock&#8221;) to Alcimede LLC (&#8220;Alcimede&#8221;), a related party, as more fully discussed in Note 19. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Basis of Presentation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the consolidated financial statements as filed on the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on October 21, 2019. In the opinion of management, the unaudited condensed consolidated financial statements included herein contain all adjustments necessary to present fairly the Company&#8217;s consolidated financial position as of September 30, 2019, and the results of its operations, changes in stockholders&#8217; deficit and cash flows for the three and nine months ended September 30, 2019 and 2018. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2019 may not be indicative of results for the year ending December 31, 2019.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Principles of Consolidation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) include the accounts of Rennova and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in the consolidation.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Revenue Recognition</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hospital Operations</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain government programs, primarily Medicare, this is generally referred to as the &#8220;cost report&#8221; filing and settlement process). There were no adjustments to estimated Medicare and Medicaid reimbursement amounts and disproportionate-share funds related primarily to cost reports filed during the three and nine months ended September 30, 2019 and 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Emergency Medical Treatment and Labor Act (&#8220;EMTALA&#8221;) requires any hospital participating in the Medicare program to conduct an appropriate medical screening examination of every person who presents to the hospital&#8217;s emergency room for treatment and, if the individual is suffering from an emergency medical condition, to either stabilize the condition or make an appropriate transfer of the individual to a facility able to handle the condition. The obligation to screen and stabilize emergency medical conditions exists regardless of an individual&#8217;s ability to pay for treatment. Federal and state laws and regulations require, and our commitment to providing quality patient care encourages, us to provide services to patients who are financially unable to pay for the health care services they receive. The federal poverty level is established by the federal government and is based on income and family size. The Company considers the poverty level in determining whether patients qualify for free or reduced cost of care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. We provide discounts to uninsured patients who do not qualify for Medicaid or charity care. In implementing the uninsured discount policy, we may first attempt to provide assistance to uninsured patients to help determine whether they may qualify for Medicaid, other federal or state assistance, or charity care. If an uninsured patient does not qualify for these programs, the uninsured discount is applied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management&#8217;s assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable (the &#8220;hindsight analysis&#8221;) as a primary source of information in estimating the collectability of our accounts receivable. We perform the hindsight analysis quarterly, utilizing rolling twelve-months accounts receivable collection and write-off data. We believe our quarterly updates to the estimated contractual allowance amounts at each of our hospital facilities provide reasonable estimates of our revenues and valuations of our accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical Laboratory Operations</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Laboratory testing services include chemical diagnostic tests such as blood analysis and urine analysis. Laboratory service revenues are recognized at the time the testing services are performed and billed and are reported at their estimated net realizable amounts. Net service revenues are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the U.S. have an agreement with a third-party payer such as a commercial insurance provider, Medicaid or Medicare to pay all or a portion of their healthcare expenses; most of the services provided by us are to patients covered under a third-party payer contract. In most cases, the Company is provided the third-party billing information and seeks payment from the third party in accordance with the terms and conditions of the third-party payer for health service providers like us. Each of these third-party payers may differ not only in terms of rates, but also with respect to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payer methods and trends. Despite follow up billing efforts, the Company does not currently anticipate collection of a significant portion of self-pay billings, including the patient responsibility portion of the billing for patients covered by third party payers. The Company currently does not have any capitated agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review our calculations for the realizability of gross service revenues monthly to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payer groups. The contractual allowance calculation is made based on historical allowance rates for the various specific payer groups monthly with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions. This calculation is routinely analyzed by us based on actual allowances issued by payers and the actual payments made to determine what adjustments, if any, are needed.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Notes Payable &#8211; Related Party</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Loan payable to Christopher Diamantis</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"><font style="font-size: 10pt">14,968,104</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"><font style="font-size: 10pt">800,000</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Total notes payable, related party</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">14,968,104</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">800,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion of notes payable, related party</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(14,968,104</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(800,000</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total notes payable, related party, net of current portion</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents our lease-related assets and liabilities at September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Balance Sheet Classification</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Assets:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; width: 43%"><font style="font-size: 10pt">Operating leases</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: bottom; width: 35%"><font style="font-size: 10pt">Right-of-use operating lease assets</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: bottom; width: 1%"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 18%; text-align: right"><font style="font-size: 10pt">328,615</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.5pt"><font style="font-size: 10pt">Finance leases</font></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"><font style="font-size: 10pt">Property and equipment, net</font></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">618,278</font></td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total lease assets</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">946,893</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Liabilities:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Current:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top"><font style="font-size: 10pt">Operating leases</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 10pt">Right-of-use operating lease assets</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">141,830</font></td> <td style="vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Finance leases</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">Current liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">589,457</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Noncurrent:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><font style="font-size: 10pt">Operating leases</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 10pt">Right-of-use operating lease obligations</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">186,785</font></td> <td style="vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Finance leases</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">Long-term debt</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">28,821</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total lease liabilities</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">946,893</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Weighted-average remaining term:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Operating leases</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.98 years </font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Finance leases</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.19 years </font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Weighted-average discount rate:</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating leases (1)</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">13.0</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Finance leases</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5.122</font></td> <td><font style="font-size: 10pt">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 24px"><font style="font-size: 10pt">(1)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Upon adoption of the new lease standard, discount rates used for existing operating leases were established at January 1, 2019.</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents certain information related to lease expense for finance and operating leases for the three and nine months ended September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30, 2019</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended<br /> September 30, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Finance lease expense:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 52%; padding-left: 10pt"><font style="font-size: 10pt">Depreciation/amortization of leased assets (1)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 21%; text-align: right"><font style="font-size: 10pt">15,004</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 21%; text-align: right"><font style="font-size: 10pt">(30,055</font></td> <td style="width: 1%"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Interest on lease liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">704</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,804</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating leases:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 11.6pt"><font style="font-size: 10pt">Short-term lease expense (2)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">76,312</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">263,713</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total lease expense</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">92,020</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">239,462</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The depreciation for the nine months ended September 30, 2019 has been adjusted for depreciation recorded in the prior year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Expenses are included in general and administrative expenses in our condensed consolidated statements of operations.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents supplemental cash flow information for the nine months ended September 30, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right">&#160;</td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating cash flows for operating leases</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">214,357</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Operating cash flows for finance leases</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,800</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Financing cash flows for finance leases payments</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">143,930</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aggregate future minimum rentals under right-to-use operating and finance leases are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Right-to-Use</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Operating Leases</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Finance Leases</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">October 1, 2019 to September 30, 2020</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">107,457</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">604,080</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">October 1, 2020 to September 30, 2021</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">134,776</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">32,611</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">October 1, 2021 to September 30, 2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">110,062</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">October 1, 2022 to September 30, 2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">29,247</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">October 1, 2023 to September 30, 2024</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,437</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">383,979</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">636,691</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less interest</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(55,364</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(18,413</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><b>Present value of minimum lease payments</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt"><b>328,615</b></font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt"><b>618,278</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion of lease obligations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(141,830</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(589,457</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Lease obligations, net of current portion</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>186,785</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>28,821</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> P6Y6M 68 1152616 1420 11961 -38340063 -3156646 -1765395 -701466 -8946720 -2626953 -3998943 -3965722 -26064924 4955262 -12127692 97356081 -1294581 -295908 -547041 -640044 -973953 -9422340 100171656 -1769400 -791936 509631 -238722 -553214 -393844 115787 -138076 -159430 -57864 -89621 -80212 -69809 -38340063 -3965798 -12127692 97356081 2650000 false -26064924 4955262 -9422340 100171656 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8211; Acquisitions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Purchase Agreement Re Jamestown Regional Medical Center</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 1, 2018, the Company acquired a business engaging in acute hospital care located in Jamestown, Tennessee under an asset purchase agreement. The acquisition also included a separate physician practice referred to as Mountain View Physician Practice, Inc. This acquisition was made as part of the Company&#8217;s business plan to acquire and operate clusters of rural hospitals.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the asset purchase agreement, by and among the Company and Jamestown TN Medical Center, Inc., and HMA Fentress County Hospital, LLC, Jamestown HMA Physician Management, LLC and CHS/Community Health Systems, Inc. (the &#8220;Sellers&#8221;), the purchase price paid for the transaction was an aggregate of $635,096, which includes closing costs of $35,735, legal costs of approximately $115,000, and other diligence related costs, which were expensed in 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the purchase consideration paid to the Sellers was allocated to the net tangible and intangible assets acquired. The Company accounted for the acquisition as a business combination under U.S. GAAP. In accordance with the acquisition method of accounting under ASC Topic 805, <i>&#8220;Business Combinations,&#8221;</i> (&#8220;ASC 805&#8221;) the assets acquired, and liabilities assumed were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the assets acquired, net of the liabilities assumed, was approximately $8.2 million. The excess of the aggregate fair value of the net tangible assets acquired over the purchase price was $7.6 million and has been treated as a gain on bargain purchase in accordance with ASC 805.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the allocation of the purchase price of Jamestown Regional Medical Center to the acquired identifiable assets acquired, and liabilities assumed:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; padding-bottom: 1.5pt"><font style="font-size: 10pt"><b>Total purchase price</b></font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: right"><font style="font-size: 10pt"><b>635,096</b></font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt"><b>Tangible and intangible assets acquired, and liabilities assumed at fair value:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Cash</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">375</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Inventories</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">450,682</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Prepaids and deposits</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">310,385</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Property and equipment</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,129,484</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Intangible assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">504,806</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Accrued expenses</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(193,966</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Net tangible and intangible assets acquired</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">8,201,766</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Gain on bargain purchase <sup>(1)</sup></b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>7,566,670</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify">&#160;</td> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">(1)</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Gain was adjusted in the fourth quarter of 2018 from $7,732,302 to $7,566,670 to reflect an adjustment of the value of the property and equipment acquired.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As reflected in the table above, the total value of intangible assets acquired in the Jamestown acquisition was $504,806, which included a certificate of need valued at $259,443 and a non-compete intangible asset valued at $245,363. The certificate of need has an indefinite life. During the year ended December 31, 2018, the Company determined that the fair value of the non-compete intangible asset, which was being amortized over two years, was fully impaired and, accordingly, the Company recorded an impairment of approximately $0.2 million in December 31, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Purchase Agreement re Jellico Community Hospital and CarePlus Center</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective March 5, 2019, the Company acquired certain assets related to Jellico Community Hospital and CarePlus Center. Jellico Community Hospital is a fully operational 54-bed acute care facility that offers comprehensive services, including diagnostic imaging, radiology, surgery (general, gynecological and vascular), nuclear medicine, wound care and hyperbaric medicine, intensive care, emergency care and physical therapy. The CarePlus Center offers sophisticated testing capabilities and compassionate care, all in a modern, patient-friendly environment. Services include diagnostic imaging services, x-ray, mammography, bone densitometry, computed tomography (CT), ultrasound, physical therapy and laboratory services on a walk-in basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price was $658,537. This purchase price was made available by Mr. Diamantis, a director of the Company. The total cost of the acquisition is estimated to be $908,537, including $250,000 of diligence, legal and other costs associated with the acquisition. The acquisition costs were fully expensed in 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preliminary fair value of the purchase consideration paid to the sellers was allocated to the net tangible and intangible assets acquired. The Company accounted for the acquisition as a business combination under U.S. GAAP. In accordance with the acquisition method of accounting under ASC 805 the assets acquired, and liabilities assumed were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is currently undertaking a valuation study to determine the fair value of the assets acquired. The preliminary estimated fair value of the assets acquired, net of the liabilities assumed, was approximately $0.9 million. The excess of the aggregate fair value of the net tangible assets acquired over the purchase price is currently estimated to be $0.3 million and has been treated as a gain on bargain purchase in accordance with ASC 805. The gain is primarily due to the value of the intangible assets acquired. In addition, the provisional amounts used for the purchase price allocation are subject to adjustments for a period not to exceed one year from the acquisition date. As a result, upon completion of a valuation study, the gain on bargain purchase presented below may be increased or decreased. The preliminary purchase price allocation was based, in part, on management&#8217;s knowledge of hospital operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the preliminary allocation of the purchase price of Jellico Community Hospital and CarePlus Center to the acquired identifiable assets acquired, and liabilities assumed:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; padding-bottom: 1.5pt"><font style="font-size: 10pt"><b>Total purchase price</b></font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: right"><font style="font-size: 10pt"><b>658,537</b></font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt"><b>Tangible and intangible assets acquired, and liabilities assumed at estimated fair value:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Inventories</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">317,427</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Property and equipment</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">500,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Intangible asset- certificate of need</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">250,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Accrued expenses</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(158,890</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Net tangible and intangible assets acquired</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">908,537</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Gain on bargain purchase</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>250,000</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following presents the unaudited pro-forma combined results of operations of the Company and Jamestown Regional Medical Center and Jellico Community Hospital and CarePlus Center as if the acquisitions had occurred on January 1, 2018. The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the acquisitions been completed as of January 1, 2018 or to project potential operating results as of any future date or for any future periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Nine Months</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%"><font style="font-size: 10pt">Net revenue</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">8,276,112</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">14,855,436</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">25,499,677</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Net income (loss) from continuing operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">96,879,012</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(38,537,422</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(8,151,239</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Deemed dividend from trigger of down round provision feature</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(17,942,578</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(123,861,587</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(17,942,578</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Net (loss) income from discontinued operations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(159,430</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(791,936</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">115,787</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Net income (loss) to common shareholders - basic</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">78,777,004</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(163,190,945</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(25,978,030</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Adjustments for diluted loss to common shareholders</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(98,678,041</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt"><b>&#8212;</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt"><b>&#8212;</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Net loss to common shareholders - diluted</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(19,901,037</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(163,190,945</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(25,978,030</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><b>Net income (loss) per common share:</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Basic continuing operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">17.51</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(3.20</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Diluted continuing operations</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.02</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(3.20</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Basic net income (loss) to common shareholders</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">14.24</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.04</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(10.18</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Diluted net loss to common shareholders</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.24</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.04</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(10.18</font></td> <td><font style="font-size: 10pt">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Leases, Including the Adoption of ASU No. 2016-02</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We adopted ASU No. 2016-02, <i>Leases (Topic 842)</i>, which requires leases with durations greater than 12 months to be recognized on the balance sheet, effective January 1, 2019, using the modified retrospective approach. Prior period financial statement amounts and disclosures have not been adjusted to reflect the provisions of the new standard. We elected the package of transition provisions available which allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. We lease property and equipment under finance and operating leases. For leases with terms greater than 12 months, we record the related right-of-use assets and right-of-use obligations at the present value of lease payments over the term. We do not separate lease and non-lease components of contracts. Our operating and finance leases are more fully discussed in Note 10.</p> Q3 9648936775 89 89 1331 1331 658537 668983 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable at September 30, 2019 (unaudited) and December 31, 2018 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>September 30,</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Accounts receivable - Clinical Laboratory Operations</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">41,750</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">622,009</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Accounts receivable - Hospital Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">45,804,056</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">31,607,644</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Accounts receivable - Other</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(52,296</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Total accounts receivable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">45,793,510</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">32,229,653</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Less:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Amount purchased by factors</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(1,572,000</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Allowance for discounts - Clinical Laboratory Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(26,182</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(573,584</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Allowance for discounts - Hospital Operations</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(36,298,972</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(25,066,799</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Allowance for bad debts</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,787,894</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,777,521</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Accounts receivable, net</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>5,108,462</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>3,811,749</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> -415046606 -578040192 -14420826 -7121826 -162993586 -21792589 -12265768 79254073 4461922587 2550632 6634045471 5531767 4461922587 2550632 6634045471 254654217 -0.01 -1.55 -0.00 17.6 -0.01 -1.55 -0.00 -0.08 -0.00 0.05 -0.00 -0.03 -0.00 0.05 -0.00 -0.00 -0.04 -8.54 -0.00 14.33 -0.04 -8.54 -0.00 -0.08 375 375 310385 310385 0.85 2.4 2.6 189.5 273.1 2.36 2.88 163.8 234.7 P3M19D P3Y2M12D P8M23D P3Y6M0D P8M23D P3Y6M0D 123900000 17900000 17900000 13700000 109300000 4100000 5400000 105076 0.50 1.00 1.00 1.00 0.85 0.85 0.80 1741580 250000 1500000 1384556 1730.7 2176.975 250000 16478104 3582500 123 50000 400000 1920000 730665 589457 31543 28821 4700000 700000 2.46 2.44 182.9 204.4 2.23 2.49 198.3 259.4 1.91 2.32 184.0 296.3 2.09 2.56 208.2 249.1 P2M27D P4M9D P5M23D P2Y10M21D P3M29D P7M24D <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Jamestown Regional Medical Center Medicare Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following an inspection at Jamestown Regional Medical Center on February 5, 2019, the hospital was informed on February 15 that several conditions of participation in its Medicare agreement were deficient. The hospital was informed that if the deficiencies where not corrected by May 16 the Medicare agreement would terminate. A follow-up inspection on May 15 resulted in the determination that the hospital had failed to adequately correct the deficiencies highlighted and a notice of involuntary termination was issued that was effective on June 12, 2019. A significant percentage of patients at Jamestown Regional Medical Center are covered by Medicare and without any ability to get paid for these services the Company suspended operations at the hospital. The hospital received initial approval of its application to reactivate the Medicare agreement in August of 2019 and is currently planning the reopening of the hospital.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Bad Debt and Contractual Allowances</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total gross revenues for Hospital and Clinical Laboratory Operations were reduced in the aggregate by approximately $0.9 million and $1.8 million for bad debt for the three months ended September 30, 2019 and 2018, respectively. After bad debt and contractual and related allowance adjustments to revenues of $21.9 million and $25.1 million, for the three months ended September 30, 2019 and 2018, respectively, we reported net revenues of $3.9 million and $5.0 million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total gross revenues for Hospital and Clinical Operations were reduced in the aggregate by approximately $4.8 million and $3.1 million for bad debt for the nine months ended September 30, 2019 and 2018, respectively. After bad debt and contractual and related allowance adjustments to revenues of $86.7 million and $43.8 million, for the nine months ended September 30, 2019 and 2018, respectively, we reported net revenues of $13.1 million and $9.9 million, respectively. We continue to review the provision for bad debt and contractual and related allowances.</p> 633101 177 632924 1764927 250000 250000 2500 247500 -2 433612 1500000 2 1-for-500 reverse stock split As a result of the Reverse Stock Split, every 500 shares of the Company's then outstanding common stock was combined and automatically converted into one share of the Company's common stock on November 12, 2018. 4800000 3100000 900000 1800000 86700000 43800000 21900000 25100000 56000000 41000000 6247469 16000000 53300000 123900000 17900000 231800000 17900000 17900000 51000000 69300000 753900000000 -791936 115787 -138076 -159430 -123861587 -17942578 -17942578 -7303912 -11376 17942578 -162993586 -21792589 -12265768 -19423968 64315740 9505156 175301554 3900000 2700000 100000 1200000 1600000 32229653 31607644 622009 45793510 41750 45804056 -52296 -1572000 25066799 573584 26182 36298972 2777521 2787894 635096 5000000 500000 658537 35735 115000 1900000 8201766 908537 504806 245363 259443 P2Y 200000 250000 5000000 8276112 14855436 25499677 96879012 -38537422 -8151239 -17942578 -123861587 -17942578 -159430 -791936 115787 78777004 -163190945 -25978030 -98678041 -19901037 -163190945 -25978030 17.51 -0.01 -3.20 -0.02 -0.01 -3.20 14.24 -0.04 -10.18 -0.24 -0.04 -10.18 5464837 2586652 1800000 300000 19113 19113 8016 8009 3400052 6761173 47396 41784 1771867 1125488 400000 100000 1500000 700000 750000 700000 500000 2600000 1000000 150000 1000000 100000 2017-06-27 2019-12-31 2019-12-31 2019-03-21 2019-06-03 2019-12-31 2019-11-08 2019-09-19 341612 500000 125000 200000 1250000 1250000 1900000 1000000 900000 300000 300000 11015 100000 100000 900000 2019-12-26 43000 43000 1100000 8700000 0 0.20 0.40 0.20 3000000 500000 2000000 3000000 500000 16700000 1900000 7694685 0.24 0.10 0.10 0.18 0.24 0.05 0.05 0.05 0.025 0.025 0.025 0.24 0.18 7083505 5000000 1741893 341612 3605532 1741893 335818 1527821 0.16 0.06 0.16 0.06 Principal and interest payments due in various installments through December 31, 2017 July 12, 2015 through July 12, 2017 Under the June 13 Agreement, the maturity date of the debentures issued on February 24, 2019, March 27, 2019, May 12, 2019, June 5, 2019 and June 7, 2019 were extended to December 31, 2019 and the terms were changed such that they have the same interest terms as contained in the June 13, 2019 debentures Principal and interest payments due in various installments through December 31, 2017 July 12, 2015 through July 12, 2017 800000 14968104 14968104 800000 12776316 28690240 2000000 250000 1020000 17100000 5700000 Commencing on August 17, 2019 the debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest shall entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law. The maturity dates of these debentures were extended to December 31, 2019 and the terms were changed so that commencing on August 17, 2019 the debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. Commencing on August 17, 2019, the June 2019 Debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. 15800000 16100000 1400000 900000 19034800 28690240 12776316 28690240 300000 300000 100000 100000 600000 618278 946893 946893 P1Y11M23D P0Y2M8D 0.130 0.05122 -30055 15004 5804 704 263713 76312 239462 92020 214357 143930 107457 134776 110062 29247 2437 383979 55364 604080 32611 636691 18413 618278 200000 100000 300000 700000 5000000 1900000 1000000 600000 900000 400000 300000 9900000 2600000 1000000 253000 110000 155000 700000 700000 1900000 0.0497 341612 200000 120000 2030000 148000 240000 106000 413000 72000 1143974 633101 11961 4619150 250000 2 6994 4471 220 2523 2298 2518 97581 6838 22523 90743 330238 352761 35777 25477 10300 6867 6867 140352 36786 22743 103566 339403 362146 5790 5790 4946 4946 6029 6029 6029 6029 11819 11819 10975 10975 1079827 532858 514415 546969 710709 1225124 939183 418932 493356 520251 714128 1207484 278836 278836 268851 268851 2297846 1230626 1276622 1067220 1424837 2701459 766627 92090 59832 706795 1291288 1383378 246676 512566 11350 13249 235326 499317 113266 37773 29638 83628 95965 133738 26012 45641 5878 15559 20134 30082 653361 54317 30194 623167 1195323 1249640 220664 466925 5472 -2310 215192 469235 1413423 363944 237042 1176381 1577046 1940990 355828 625951 60424 93059 295404 532892 31874 -819258 31874 12121 -807137 2912 404 2912 -5748 6152 65000 Each share of the Series K Preferred Stock shall be entitled to the whole number of votes equal to 40,000 shares of common stock. 753931450393 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Comprehensive Loss</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and nine months ended September 30, 2019 and 2018, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations.</p> -109305331 -6980616 609719 -5784873 188658 -28217 -28217 -5 -116 4 -4 239000 325570 239000 318310 643880 250506 10587 261093 -50 40000 3255700000 2390000000 2505054118 1485 -113042 549524 The consideration received, the counterparty received the right to: (i) a 20% per annum investment return from the Company on the consideration, with a minimum repayment term of six months and minimum return of $0.5 million, (ii) all payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty had not been paid $6.0 million, the Company was required to pay the difference. Christopher Diamantis, a director of the Company, guaranteed the Company's obligation. On March 24, 2017, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into an amendment to extend the Company's obligation to March 31, 2018. Also, what the counterparty was to receive was amended to equal (a) the $5,000,000 purchase price plus a 20% per annum investment return thereon, plus (b) $500,000, plus (c) the product of (i) the proceeds received from the accounts receivable, minus the amount set forth in clauses (a) and (b), multiplied by (ii) 40%. In connection with the extension, the counterparty received a fee of $1,000,000. 300000 300000 100000 2900000 1.00 300000 8300000 755000000 0.00034 53130510439 634585355377 0.00172 0.00014 582209844938 908537 250000 0.08 Gain was adjusted in the fourth quarter of 2018 from $7,732,302 to $7,566,670 to reflect an adjustment of the value of the property and equipment acquired. Upon adoption of the new lease standard, discount rates used for existing operating leases were established at January 1, 2019. Expenses are included in general and administrative expenses in our condensed consolidated statements of operations. The loan payable under prepaid forward purchase contract has been fully settled during the nine months ended September 2019 as more fully discussed below under the heading "Notes Payable - Related Party". The depreciation for the nine months ended September 30, 2019 has been adjusted for depreciation recorded in the prior year. EX-101.SCH 7 rnva-20190930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity and Financial Condition link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Debentures link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Finance and Operating Lease Obligations link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Derivative Financial Instruments and Fair Value link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Redeemable Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Supplemental Disclosure of Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Debentures (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Finance and Operating Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Derivative Financial Instruments and Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Supplemental Disclosure of Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Subsequent Events (Tables) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Liquidity and Financial Condition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Earnings (Loss) Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Earnings (Loss) Per Share - Schedule of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Earnings (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Accounts Receivable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Accounts Receivable - Schedule of Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Acquisitions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Acquisitions - Schedule of Unaudited Pro-forma of Results of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Accrued Expenses (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Notes Payable - Schedule of Notes Payable - Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Debentures (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Debentures - Schedule of Debentures (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Finance and Operating Lease Obligations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Finance and Operating Lease Obligations - Schedule of Lease-related Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Finance and Operating Lease Obligations - Schedule of Information Related to Lease Expense for Finance and Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Finance and Operating Lease Obligations - Schedule of Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Finance and Operating Lease Obligations - Schedule of Future Minimum Rentals Under Right-to-use Operating and Capital Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Derivative Financial Instruments and Fair Value (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Derivative Financial Instruments and Fair Value - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - Derivative Financial Instruments and Fair Value - Schedule of Changes in Liabilities with Level 3 of Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - Redeemable Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - Stockholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000070 - Disclosure - Stockholders' Deficit - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000071 - Disclosure - Stockholders' Deficit - Schedule of Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000072 - Disclosure - Supplemental Disclosure of Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000073 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000074 - Disclosure - Segment Reporting (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000075 - Disclosure - Segment Reporting - Schedule of Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000076 - Disclosure - Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) link:presentationLink link:calculationLink link:definitionLink 00000077 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000078 - Disclosure - Subsequent Events - Schedule of Dilutive Effect of Potential Common Shares (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 rnva-20190930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 rnva-20190930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 rnva-20190930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series G Preferred Stock [Member] Series H Preferred Stock [Member] Segments [Axis] Corporate [Member] Clinical Laboratory Operations [Member] Debt Instrument [Axis] TCA Debenture [Member] Award Type [Axis] April 2017 Through September 2017 [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Settlement Agreement [Member] Legal Entity [Axis] Epinex Diagnostics Laboratories, Inc. [Member] Income Tax Authority, Name [Axis] Internal Revenue Service (IRS) [Member] Medytox Solutions, Inc [Member] Florida Department of Revenue [Member] TCS-Florida, L.P [Member] Forbearance Agreement [Member] DeLage Landen Financial Services, Inc. [Member] Title of Individual [Axis] Holders of Tegal Notes [Member] Hospital Operations [Member] Eliminations [Member] Series F Preferred Stock [Member] Series I-1 Preferred Stock [Member] Purchase Agreement [Member] Investor [Member] Disposal Group Classification [Axis] Advanced Molecular Services Group [Member] Health Technology Solutions, Inc [Member] Redeemable Preferred Stock I-1 [Member] Redeemable Preferred Stock I-2 [Member] Equity Components [Axis] Additional Paid-in Capital [Member] Receivable Type [Axis] Hospitals Operations [Member] Notes Payable - Third Parties One [Member] Notes Payable Third Parties Two [Member] Notes Payable Third Parties Three [Member] Notes Payable Related Parties [Member] Genomas, Inc [Member] Series I-2 Convertible Preferred Stock [Member] September Debenture [Member] Liability Class [Axis] Embedded Conversion Options [Member] Fair Value, Hierarchy [Axis] Level 3 [Member] Level 1 [Member] Level 2 [Member] Series I-2 Preferred Stock [Member] Exchange Agreement [Member] Alcimede LLC [Member] Series J Convertible Preferred Stock [Member] Employees and Directors [Member] Restricted Stock [Member] Series J Preferred Stock [Member] Employment Agreements [Member] Former Employee 1 [Member] Former Employee 2 [Member] EPIC Reference Laboratories, Inc. [Member] Business Acquisition [Axis] Jamestown Regional Medical Center [Member] Legal Entity of Counterparty, Type [Axis] Counterparty [Member] Christopher Diamantis [Member] Final Payment [Member] Series F Convertible Preferred Stock [Member] Plan Name [Axis] 2007 Equity Plan [Member] Warrants [Member] Assets of AMSG And HTS Classified as Held for Sale [Member] Preferred Stock [Member] Common Stock [Member] Retained Earnings [Member] Accumulated Deficit [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Roche Diagnostics Corporation [Member] Beckman Coulter, Inc [Member] Techlogix, Inc [Member] Scenario [Axis] Pre-Modification [Member] Measurement Input Type [Axis] Risk Free Interest Rate [Member] Range [Axis] Maximum [Member] Antidilutive Securities [Axis] Warrants [Member] Convertible Preferred Stock [Member] Convertible Debentures [Member] Stock Options [Member] Debentures [Member] Related Party [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Non Compete Intangible [Member] Jellico Community Hospital and CarePlus Center [Member] Mr Diamantis [Member] Loan Payable to Christopher Diamantis [Member] Financial Instrument [Axis] Derivative Liabilities [Member] Minimum [Member] Volatility [Member] Expected Term [Member] Board of Directors [Member] Other Income (Expense), Net [Member] Debenture One [Member] Other [Member] Jamestown Regional Medical Center and Jellico Community Hospital and Careplus Center [Member] Bridge Debenture Agreement [Member] Short-term Debt, Type [Axis] June Thirteen Two Thousand And Nineteen Offerings [Member] Post-Modification [Member] Investors [Member] Debenture Two [Member] Series K Preferred Stock [Member] Diamantis [Member] Notes Payable Third Parties Four [Member] June 2019 Debentures [Member] Acquisitions of Hospitals and Medical Center [Member] Stock Options [Member] Convertible Debt [Member] November 8, 2019 [Member] December 26, 2019 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Accounts receivable, net Inventory Prepaid expenses and other current assets Income tax refunds receivable Current assets of AMSG and HTS classified as held for sale Total current assets Property and equipment, net Right-of-use operating lease assets Intangibles, net Deposits Non-current assets of AMSG and HTS classified as held for sale Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable (includes related parties amount of $0.5 million and $0.4 million, respectively) Checks issued in excess of bank account balance Accrued expenses (includes related parties amount of $1.8 million and $0.4 million, respectively) Income taxes payable Current portion of notes payable Current portion of notes payable, related party Current portion of right-of-use operating lease obligations Current portion of finance lease obligations Current portion of debentures Derivative liabilities Current liabilities of AMSG and HTS classified as held for sale Total current liabilities Other liabilities: Right-of-use operating lease obligations, net of current portion Finance lease obligations, net of current portion Total liabilities Commitments and contingencies Redeemable Preferred Stock Stockholders' deficit: Preferred stock value Common stock, $0.0001 par value, 10,000,000,000 shares authorized, 8,398,936,775 and 128,567,273 shares issued and outstanding Additional paid-in-capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Accounts payable related parties Accrued expenses related parties Preferred stock par value Preferred stock shares authorized Preferred stock shares issued Preferred stock shares outstanding Common stock par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Income Statement [Abstract] Net revenues Operating expenses: Direct costs of revenue General and administrative Depreciation and amortization Total operating expenses Loss from continuing operations before other income (expense) and income taxes Other (expense) income: Other (expense) income Gain on bargain purchase Change in fair value of derivative instruments Interest expense Total other(expense) income, net Net (loss) income from continuing operations before income taxes Provision for income taxes Net (loss) income from continuing operations Net (loss) income from discontinued operations Net (loss) income Deemed dividend from trigger of down round provision feature Net (loss) income to common shareholders Net (loss) income per common share: Basic continuing operations Diluted continuing operations Basic discontinued operations Diluted discontinued operations Basic net (loss) income Diluted net loss Weighted average number of common shares outstanding during the period: Basic Diluted Balance Balance, shares Common stock issued in cashless exercise of warrants Common stock issued in cashless exercise of warrants, shares Conversion of debentures into common stock Conversion of debentures into common stock, shares Stock-based compensation Restricted stock issued to employees Restricted stock issued to employees, shares Shares returned to treasury Shares returned to treasury, shares Beneficial conversion feature of preferred stock Conversion of Series H Preferred Stock into common stock Conversion of Series H Preferred Stock into common stock, shares Exchange of debentures into Series I-2 Preferred Stock Conversion of Series I-2 Preferred stock into common stock Conversion of Series I-2 Preferred stock into common stock, shares Deemed dividend from trigger of down round provision feature Modification of warrants Exchange of note payable and accrued expenses for Series J Preferred Stock Exchange of note payable and accrued expenses for Series J Preferred Stock, shares Common stock issued for conversion of Series I-2 Preferred Stock Common stock issued for conversion of Series I-2 Preferred Stock, shares Adjust treasury shares Adjust treasury shares, shares Net income (loss) Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss from continuing operations Adjustments to reconcile net loss to net cash (used in) provided by operations: Stock-based compensation Amortization of debt discount Penalty for non-payment of debentures Change in fair value of derivative instruments Loss on sale of receivables to factor Gain on disposal of equipment under finance leases Bargain purchase gain for hospitals and medical center (Loss) income from discontinued operations Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses and other current assets Accounts payable and checks issued in excess of bank balance Accrued expenses Income tax assets and liabilities Net cash used in operating activities of continuing operations Net cash provided by (used in) operating activities of discontinued operations Net cash used in operating activities Cash flows from investing activities: Purchase of hospitals and medical center Proceeds from the sale of equipment under finance leases Purchase of property and equipment Net cash used in investing activities of continuing operations Net cash provided by investing activities of discontinued operations Net cash (used in) provided by investing activities Cash flows from financing activities: Proceeds from issuance of related party note payable and advances Payments on related party note payable and advances Proceeds from issuance of debentures Payments on notes payable Proceeds from issuance of note payable Proceeds from receivables sold to factors Receivables paid to factors Payments on finance lease obligations Net cash provided by financing activities of continuing operations Net cash used in financing activities of discontinued operations Net cash provided by financing activities Net increase in cash Cash at beginning of period Cash at end of period Accounting Policies [Abstract] Organization and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Liquidity and Financial Condition Earnings Per Share [Abstract] Earnings (Loss) Per Share Receivables [Abstract] Accounts Receivable Business Combinations [Abstract] Acquisitions Payables and Accruals [Abstract] Accrued Expenses Debt Disclosure [Abstract] Notes Payable Debentures Related Party Transactions [Abstract] Related Party Transactions Leases [Abstract] Finance and Operating Lease Obligations Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Financial Instruments and Fair Value Equity [Abstract] Redeemable Preferred Stock Stockholders' Deficit Supplemental Cash Flow Elements [Abstract] Supplemental Disclosure of Cash Flow Information Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Segment Reporting [Abstract] Segment Reporting Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations Accounting Changes and Error Corrections [Abstract] Recent Accounting Pronouncements Subsequent Events [Abstract] Subsequent Events Description of Business Reverse Stock Split Jamestown Regional Medical Center Medicare Agreement Basis of Presentation Principles of Consolidation Reclassification Comprehensive Loss Use of Estimates Cash and Cash Equivalents Revenue Recognition Bad Debt and Contractual Allowances Leases, Including the Adoption of ASU No. 2016-02 Derivative Financial Instruments and Fair Value, Including the Adoption of ASU 2017-11 Earnings (Loss) Per Share Schedule of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Accounts Receivable Schedule of Assets Acquired and Liabilities Assumed Schedule of Unaudited Pro-forma of Results of Operations Schedule of Accrued Expenses Schedule of Notes Payable Schedule of Notes Payable - Related Parties Schedule of Debentures Schedule of Lease-related Assets and Liabilities Schedule of Information Related to Lease Expense for Finance and Operating Leases Schedule of Supplemental Cash Flow Information Schedule of Future Minimum Rentals Under Right-to-use Operating and Capital Leases Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis Schedule of Changes in Liabilities with Level 3 of Fair Value Schedule of Stock Option Activity Schedule of Warrants Activity Schedule of Supplemental Cash Flow Information Schedule of Segment Information Schedule of Discontinued Operation of Balance Sheet and Operation Statement Schedule of Dilutive Effect of Potential Common Shares Number of operating segment Reserve stock split, description Common stock conversion description Bad debts Allowance for adjustment of revenue Derivative liabilities Reversal of interest expense Discount on convertible debenture Deemed dividend, down round feature Deemed dividend Working capital deficit Stockholders' deficit Net loss Cash used in operating activities Total dilutive potential common shares, including outstanding common stock Numerator: Net (loss) income from continuing operations Numerator: Net (loss) income from discontinued operations Numerator: Deemed dividends Numerator: Net loss (income) to common shareholders -basic Adjustments for diluted calculations: Deduct change in fair value of derivative liabilities Adjustments for diluted calculations: Amortize discounts associated with conversion of dilutive convertible debentures Remove change in warrant value for diluted Add back deemed dividends Net (loss) income to common shareholders - diluted Denominator: Basic weighted average number of common shares outstanding Common stock equivalents: Warrants Common stock equivalents: Convertible preferred stock Common stock equivalents: Convertible debentures Net (loss) income per common share- continuing operations: Basic Net (loss) income per common share- continuing operations: Diluted Net (loss) income per common share- discontinued operations: Basic Net (loss) income per common share- discontinued operations: Diluted Total per share net (loss) income to common shareholders: Basic Total per share net (loss) income to common shareholders: Diluted Dilutive potential shares Accounts receivable sold Proceeds from sale of accounts receivable Origination and other fees Loss on sale of receivables Accounts receivable purchase Accounts receivable, gross Less: Amount purchased by factors Less: Allowance for discounts Less: Allowance for bad debts Accounts receivable, net Purchase price paid Closing costs of acquisition Legal costs Fair value of assets acquired and liabilities assumed Fair value of intangible assets acquired Remaining amortization period Impairment of intangible assets Total cost of acquisition Diligence, legal and other costs Total purchase price Cash Inventories Prepaids and deposits Property and equipment Intangible Assets - certificate of need Accrued expenses Net tangible and intangible assets acquired Net revenue Net income (loss) from continuing operations Deemed dividend from trigger of down round provision feature Net (loss) income from discontinued operations Net income (loss) to common shareholders - basic Adjustments for diluted loss to common shareholders Net loss to common shareholders - diluted Basic continuing operations Diluted continuing operations Basic net income (loss) to common shareholders Diluted net loss to common shareholders Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Accrued expenses Accrued interest Commissions payable Sales tax payable Accrued payroll and related liabilities Accrued property tax Other accrued expenses Accrued expenses Accrued and unpaid interest Repayment of debt Debt instrument periodic payment Amount of fee received Debt instrument maturity date Debt instrument face amount Proceeds from issuance of debt Original issue discount Financing fees debt Remaining periodic principal payment Remaining periodic principal payment, due date Accrued interest payable Estimated value of receivable Adjustment down value Investment return percentage Consideration received description Consideration received Purchase price Loan payable Additional payment for related party Debt instrument interest rate Payments for related party Fees and expenses Working capital Note payable Less current portion Notes payable - third parties, net of current portion Original principal amount Debt instruments interest rate Debt maturity description Total notes payable, related party Less current portion of notes payable, related party Total notes payable, related party, net of current portion Statistical Measurement [Axis] Outstanding debentures Accured penalty Interest percentage Debentures principal amount Realized gain loss Interest rate, description Proceeds from debt Debt instrument principal amount Proceeds from offerings Debt instrument maturity date description Non-cash interest and amortization of debt discount expense Debentures Discount on debentures Deferred financing fees Total debentures Less current portion Debentures, long-term Consulting fee Minimum rentals and accrued interest Operating leases, Assets Finance leases, Assets Total lease assets Operating leases Liabilities, Current Finance leases Liabilities, Current Operating leases Liabilities, Non-current Finance leases Liabilities, Non-current Total lease liabilities Weighted-average remaining term: Operating leases Weighted-average remaining term: Finance leases Weighted-average discount rate: Operating leases Weighted-average discount rate: Finance leases Finance lease expense: Depreciation/amortization of leased assets Finance lease expense: Interest on lease liabilities Operating leases: Short-term lease expense Total lease expense Operating cash flows for operating leases Operating cash flows for finance leases Financing cash flows for finance leases payments October 1, 2019 to September 30, 2020, Right-to-Use Operating Leases October 1, 2020 to September 30, 2021, Right-to-Use Operating Leases October 1, 2021 to September 30, 2022, Right-to-Use Operating Leases October 1, 2022 to September 30, 2023, Right-to-Use Operating Leases October 1, 2023 to September 30, 2024, Right-to-Use Operating Leases Total, Right-to-Use Operating Leases Less interest, Right-to-Use Operating Leases Present value of minimum lease payments, Right-to-Use Operating Leases Less current portion of lease obligations, Right-to-Use Operating Leases Lease obligations, net of current portion, Right-to-Use Operating Leases October 1, 2019 to September 30, 2020, Finance Leases October 1, 2020 to September 30, 2021, Finance Leases October 1, 2021 to September 30, 2022, Finance Leases October 1, 2022 to September 30, 2023, Finance Leases October 1, 2023 to September 30, 2024, Finance Leases Total, Finance Leases Less interest, Finance Leases Present value of minimum lease payments, Finance Leases Less current portion of lease obligations, Finance Leases Lease obligations, net of current portion, Finance Leases Conversion price percentage Fair value assumptions, measurement input, percentage Fair value assumptions, measurement input, weighted average remaining term Deemed dividends Interest expense Warrants, measurement input, percentage Warrants term Discount on debentures Gain loss realized on instrument Fair Value Hierarchy and NAV [Axis] Total Balance at December 31, 2018 Change in fair value of debentures Balance at June 30, 2019 Preferred stock, shares authorized Preferred stock, par value Proceeds from offering Ownership percentage Preferred stock subscription amount Common stock conversion price per share Common stock weighted average market price percentage Debenture surrender value Principal amount of debt converted into shares Number of shares issued for debenture exchange Number of shares converted Preferred stock, stated value Weighted average common stock price percentage Number of common stock issued Number of common stock issued, value Stock conversion share price Conversion of stock into shares Preferred stock price per share for unpaid dividend Number of shares issued upon conversion, value Number of shares issued upon conversion Conversion price, per share Cumulative dividends percentage Cashless exercise warrants Number of restricted stock issued Number of restricted stock issued were forfeited Recognized stock stock-based compensation Stock issued price per share Stock option expense Weighted average period Intrinsic value of options exercisable Number of warrants issued as anti-dilution provision Warrant expiration date Change in fair value of warrants Warrants and rights outstanding Number of Options Outstanding, Beginning balance Number of Options Outstanding, Granted Number of Options Outstanding, Expired Number of Options Outstanding, Forfeited Number of Options Outstanding, Ending balance Number of Options Exercisable, Ending balance Weighted-average exercise price, Outstanding Beginning balance Weighted-average exercise price, Granted Weighted-average exercise price, Expired Weighted-average exercise price, Forfeited Weighted-average exercise price, Outstanding, Ending balance Weighted-average exercise price, Exercisable, Endig balance Weighted-average contractual term, Beginning Weighted-average contractual term, Ending Number of shares issuable pursuant to warrants, outstanding, beginning balance Number of shares issuable pursuant to warrants, Increase during the period as a result of down round provisions Number of shares issuable pursuant to warrants, Shares issued pursuant to Warrants exercised during the period Number of shares issuable pursuant to warrants, outstanding, ending balance Weighted average exercise price, warrants outstanding, beginning balance Weighted average exercise price, Shares issued pursuant to Warrants exercised during the period Weighted average exercise price, warrants outstanding, ending balance Cash paid for interest Cash paid for income taxes Inventory Prepaid expenses and other current assets Intangible assets Accrued expenses Exchange of Series I-2 Preferred Stock for common stock Cashless exercise of warrants Debentures converted into common stock Common stock issued in cashless exercise of warrants Exchange of debentures for Series I-2 preferred stock Conversions of Series H preferred stock into common stock Original issue discount of debentures Deemed dividend for trigger of down round provision features Issuance of Series J Preferred Stock in settlement of note payable to related party Settlement payable Payment of attorneys' fees Income tax penalties and interest paid Income tax liability refund Provision for liability Commitments receivables Income tax penalties and interest accrued Payment for related party debt Due to related party Litigation settlement in judgment Payment in settlement of judgment Monthly installment payment Implicit interest rate Equipment lease outstanding balance Accrued interest Payment for notes payable Discharge of payment Amount awarded to other party in judgement Number of reportable segments Net revenues - External (Loss) income from continuing operations before income taxes: Capital expenditures Total assets Cash Accounts receivable, net Prepaid expenses and other current assets Current assets classified as held for sale Property and equipment, net Deposits Non-current assets classified as held for sale Accounts payable (includes related parties) Accrued expenses Income taxes payable Current portion of notes payable Current liabilities classified as held for sale Non-current liabilities classified as held for sale Revenue from services Cost of services Gross profit (loss) Operating expenses Other (income) expense Provision for income taxes Loss from discontinued operations Incurred interest expenses Aggregate shares of common stock for conversions of preferred stock Preferred stock, stated value Common stock, shares authorized Preferred stock voting rights term Number of shares issued Number of shares exchanged Preferred stock cumulative dividend percentage Common shares outstanding Total dilutive potential common shares, including outstanding common stock Advanced Molecular Services Group [Member] Alcimede LLC [Member] Alcimede Member April 2017 Through September 2017 [Member] Asset Purchase Agreement [Member] Cashless exercise warrants. Christopher Diamantis [Member] Clinical Laboratory Operations [Member]. Common stock conversion price per share. Common Stock Warrants [Member] Common stock weighted average market price percentage. DeLage Landen Financial Services, Inc. [Member] Debentures and Warrants [Member] Deemed dividend from trigger of down round provision feature. EPIC Reference Laboratories, Inc. [Member] Eliminations [Member] Embedded Conversion Options [Member] Employees and Directors [Member] Employment Agreements [Member] Epinex Diagnostics Laboratories, Inc. [Member] Exercise Price Range Four [Member] Exercise Price Range One [Member] Exercise Price Range Three [Member] Exercise Price Range Two [Member] February 2017 Offering [Member] Florida Department of Revenue [Member] Forbearance Agreement [Member] Genomas acquisition [Member] Genomas, Inc. [Member] Hartford Healthcare Corporation [Member] Health Technology Solutions, Inc [Member] Hospital Operations [Member] Hospitals Operations [Member] Issuance Agreements [Member] July Debentures [Member] July 2017 Offerings [Member] June Debentures [Member] June 2017 Offerings [Member] June Warrants [Member] March 2017 Debentures [Member] March 2017 Offerings [Member] March 2017 Series B Warrants [Member] March Warrants [Member] Medical Equipment [Member]. Medytox Solutions, Inc [Member] Modification of warrants. Monarch Capital LLC [Member] Mr Diamantis [Member] Mr Lagan [Member] Notes Payable Related Parties [Member] Notes Payable Related Parties One [Member] Schedule of notes payable - related parties [Table Text Block] Notes Payable Related Parties Two [Member] Notes Payable Third Parties One [Member] Notes Payable Third Parties Three [Member] Notes Payable Third Parties Two [Member] October 1, 2018 to November 9, 2018 [Member] Purchase Agreement [Member] Redeemable Preferred Stock I-1 [Member] Redeemable Preferred Stock I-2 [Member] Schedule of Dilutive Effect of Potential Common Shares [Table Text Block] September Debenture [Member] September 2017 Offerings [Member] September Warrants [Member] Series A Warrant [Member] Series B Warrant [Member] Series B Warrants [Member] Series C Warrant [Member] Series H Convertible Preferred Stock [Member] Series I-1 Preferred Stock [Member] Series I 2 Convertible Preferred Stock [Member] Series I-2 Preferred Stock [Member] Series J Convertible Preferred Stock [Member] Series J Preferred Stock [Member] Settlement Agreement [Member] Weighted average contractual term, Options Outstanding, beginning balance. Stock Purchase Agreement [Member] TCA Debenture [Member] TCS-Florida, L.P [Member] Tax Cuts and Jobs Act [Member] 2018 Offerings [Member] 2007 Equity Plan [Member] Warrants [Member] Weighted average common stock price percentage. Jamestown Regional Medical Center [Member] Jellico Community Hospital [Member] Oneida Asset [Member] Certificate of Need [Member] Total Intangibles [Member] Final Payment[Member] 2017 Diamantis Note [Member] March Debentures [Member] Monte Carlo Simulations [Member] Intangible Asset - Certificate of Need [Member] Preferred stock, stated value. Series F Convertible Preferred Stock [Member] Cumulative dividends percentage. Weighted average exercise price, warrants outstanding. Weighted average exercise price, Warrants exercised during the period. Assets of AMSG And HTS Classified as Held for Sale [Member] Series H Preferred Stock [Member] Preferred Stock [Member] Debentures converted into common stock Deemed dividend for trigger of down round provision feature. Jellico Community Hospital and CarePlus Center [Member] 2019 Debenture Offerings [Member] Bridge Debenture Agreement [Member] Institutional Investors [Member] June 13 Agreement [Member] Investors [Member] June 2019 Agreement [Member] Accounts Receivable Factoring Arrangements [Member] Accrued expenses related parties. Prepaid Forward Purchase Contract [Member] The June 2019 Debentures [Member] Series H Preferred Stock [Member] Preferred Stock [Member] Roche Diagnostics Corporation [Member] Beckman Coulter, Inc [Member] Techlogix, Inc [Member] Debentures [Member] Risk Free Interest Rate [Member] Fair value assumptions, measurement input, weighted average remaining term. Pre-Modification [Member] Post-Modification [Member] Penalty for non-payment of debenture. Loss on sale of receivables to factor. Receivables paid to factor. Beneficial conversion feature of Series 1-2 preferred stock. Description of Business [Policy Text Block] Reverse stock splits [Policy Text Block] Schedule of Our Lease-related Assets and Liabilities [Table Text Block] Schedule of Information Related to Lease Expense for Finance and Operating Leases [Table Text Block] Schedule of Supplemental Cash Flow Information [Table Text Block] Schedule of Future Minimum Rentals Under Right-to-use Operating and Capital Leases [Table Text Block] Jamestown Acquisition [Member] Non Compete Intangible [Member] Diamantis [Member] Working capital. Loan Payable to Christopher Diamantis [Member] Binomial Model and Monte Carlo Simulations [Member] Black-Scholes Option Pricing Model [Member] Weighted average remaining contractual life for options outstanding and exercisable. Exchange of Series I-2 Preferred Stock for convertible debentures. Value of common stock issued in cashless exercise of warrants. Holders of Tegal Notes [Member] Debenture Offerings [Member] February 24, 2019, March 27, 2019, May 12, 2019, June 5, 2019 and June 7, 2019 [Member] Proceeds from receivables sold to factor. Debenture One [Member] Other Income Expense Net [Member] Exchange of debentures into Preferred Stock. Other [Member]. Jamestown Regional Medical Center and Jellico Community Hospital and Careplus Center [Member]. June Thirteen Two Thousand And Nineteen Offerings [Member]. June 2019 Debentures [Member]. Change in fair value of debentures. Preferred stock subscription amount. Debenture surrender value. Exchange Agreement [Member]. Conversions of Series H preferred stock into common stock. Original issue discount of debentures. Series K Preferred Stock [Member]. Disclosure of accounting policy for assessing the timing and amount of uncollectible revenue recognized as bad debt expense. Debenture Two [Member] Exchange of note payable and accrued expenses for Series J Preferred Stock. Exchange of note payable and accrued expenses for Series J Preferred Stock, shares. Common stock issued for conversion of Series I-2 Preferred Stock. Common stock issued for conversion of Series I-2 Preferred Stock, shares. Stock issued during period value adjust treasury shares. Stock issued during period shares adjust treasury shares, shares. Proceeds from the sale of equipment under finance leases. Gain on disposal of equipment under finance leases. Allowance for adjustment of revenue. Reversal of interest expense. Deemed dividend, down round feature. Deemed dividend. Working capital deficit. Total dilutive potential common shares, including outstanding common stock. Deemed dividends. Amortize discounts associated with conversion of dilutive convertible debentures for diluted calculation. Remove change in warrant value for diluted. Add back deemed dividends. Proceeds from sale of accounts receivable. Origination and other fees. Amount purchased by factor. Allowance for discounts Closing costs of acquisition. Business acquisition diligence legal and other costs. Business acquisitions proforma deemed dividend from trigger of down round provision feature. Net (loss) income from discontinued operations. Net income (loss) to common shareholders - basic. Adjustments for diluted loss to common shareholders. Net loss to common shareholders - diluted. Accrued property tax, current. Amount of fee received. Remaining periodic principal payment. Remaining periodic principal payment, due date. Estimated value of receivable. Adjustment down value. Investment return percentage. Consideration received description. Additional payment for related party. Notes Payable Third Parties Four [Member] Accured penalty. Non-cash interest and amortization of debt discount expense. Minimum rentals and accrued interest. Lease assets. Provision for liability. Payment in settlement of judgment. Monthly installment payment. Implicit interest rate. Equiment lease outstanding balance. Acquisitions of Hospitals and Medical Center [Member] Exchange of Series I-2 Preferred Stock for common stock. Cashless exercise of warrants. Issuance of Series J Preferred Stock in settlement of note payable to related party. Disposal group including discontinued operation deposits noncurrent, Disposal goup including discontinued operation notes payable current. Amount of other (income) expense attributable to disposal group. Board of Directors [Member] Dilutive potential common shares, including outstanding common stock. Adjustments for diluted calculations deduct change in fair value of derivative liabilities. Shares returned to treasury, value. Shares returned to treasury, shares. Stock issued during period value conversion of convertible securities. Stock issued during period value conversion of convertible securities. Stock issued during period shares conversion of convertible securities. Stock issued during period shares conversion of convertible securities. Debentures principal amount. Discount on debentures. Number of shares issuable pursuant to warrants, Increase during the period as a result of down round provisions. Former Employee 1 [Member] Former Employee 2 [Member] November 8, 2019 [Member] December 26, 2019 [Member] Number of shares exchanged. Warrant [Member] Equity Option [Member] Assets, Current Liabilities, Current Liabilities Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Other Nonoperating Income (Expense) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Adjustments to Additional Paid in Capital, Other GainOnDisposalOfEquipmentUnderFinanceLeases Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Net Cash Provided by (Used in) Operating Activities, Continuing Operations Payments to Acquire Businesses, Net of Cash Acquired Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net Cash Provided by (Used in) Investing Activities ReceivablesPaidToFactor Repayments of Debt and Lease Obligation Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Preferred Stock [Text Block] Earnings Per Share, Policy [Policy Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Derivative Liability AllowanceForDiscounts Accounts Receivable, Allowance for Credit Loss Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other BusinessAcquisitionsProFormaDeemedDividendFromTriggerOfDownRoundProvisionFeature BusinessAcquisitionsProFormaNetIncomeFromDiscontinuedOperations Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax, Per Share, Basic Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax, Per Share, Diluted Long-term Debt, Gross Long-term Debt, Current Maturities Long-term Debt, Excluding Current Maturities Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, Payment, Due Finance Lease, Liability, Undiscounted Excess Amount Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice ValueOfCommonStockIssuedInCashlessExerciseOfWarrants Disposal Group, Including Discontinued Operation, Cash Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent DisposalGroupIncludingDiscontinuedOperationDepositsNoncurrent Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current Disposal Group, Including Discontinued Operation, Accrued Income Tax Payable, Current DisposalGroupIncludingDiscontinuedOperationNotesPayableCurrent Discontinued Operation, Tax Effect of Discontinued Operation DilutivePotentialCommonSharesIncludingOutstandingCommonStock EX-101.PRE 11 rnva-20190930_pre.xml XBRL PRESENTATION FILE XML 12 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Supplemental Disclosure of Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($)
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash paid for interest $ 303,208
Cash paid for income taxes 45,000 20,000
Exchange of Series I-2 Preferred Stock for common stock 1,143,974 633,101
Cashless exercise of warrants 11,961 4,619,150
Debentures converted into common stock 8,085,342
Common stock issued in cashless exercise of warrants 11,961
Exchange of debentures for Series I-2 preferred stock 1,420
Conversions of Series H preferred stock into common stock 50,000
Original issue discount of debentures 400,000 1,920,000
Deemed dividend for trigger of down round provision features 123,861,587 17,942,578
Issuance of Series J Preferred Stock in settlement of note payable to related party 250,000
Acquisitions of Hospitals and Medical Center [Member]    
Cash 375
Inventory 317,427 450,682
Prepaid expenses and other current assets 310,385
Property and equipment 500,000 7,129,484
Intangible assets 250,000 504,806
Accrued expenses $ 158,890 $ 193,966
XML 13 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Cash $ 2,518   $ 2,518   $ 6,994
Accounts receivable, net 352,761   352,761   97,581
Prepaid expenses and other current assets 6,867   6,867   35,777
Current assets classified as held for sale 362,146   362,146   140,352
Property and equipment, net 4,946   4,946   5,790
Deposits 6,029   6,029   6,029
Non-current assets classified as held for sale 10,975   10,975   11,819
Accounts payable (includes related parties) 1,225,124   1,225,124   1,079,827
Accrued expenses 1,207,484   1,207,484   939,183
Current portion of notes payable 268,851   268,851   278,836
Current liabilities classified as held for sale 2,701,459   2,701,459   2,297,846
Revenue from services 246,676 $ 512,566 766,627 $ 1,383,378  
Cost of services 26,012 45,641 113,266 133,738  
Gross profit (loss) 220,664 466,925 653,361 1,249,640  
Operating expenses 355,828 625,951 1,413,423 1,940,990  
Other (income) expense 2,912 404 31,874 (807,137)  
Provision for income taxes  
Loss from discontinued operations (138,076) (159,430) (791,936) 115,787  
Advanced Molecular Services Group [Member]          
Cash 220   220   4,471
Accounts receivable, net 22,523   22,523   6,838
Prepaid expenses and other current assets     25,477
Current assets classified as held for sale 22,743   22,743   36,786
Non-current assets classified as held for sale    
Accounts payable (includes related parties) 514,415   514,415   532,858
Accrued expenses 493,356   493,356   418,932
Income taxes payable    
Current portion of notes payable 268,851   268,851   278,836
Current liabilities classified as held for sale 1,276,622   1,276,622   1,230,626
Non-current liabilities classified as held for sale    
Revenue from services 11,350 13,249 59,832 92,090  
Cost of services 5,878 15,559 29,638 37,773  
Gross profit (loss) 5,472 (2,310) 30,194 54,317  
Operating expenses 60,424 93,059 237,042 363,944  
Other (income) expense 2,912 (5,748) 31,874 (819,258)  
Provision for income taxes  
Loss from discontinued operations (57,864) (89,621) (238,722) 509,631  
Health Technology Solutions, Inc [Member]          
Cash 2,298   2,298   2,523
Accounts receivable, net 330,238   330,238   90,743
Prepaid expenses and other current assets 6,867   6,867   10,300
Current assets classified as held for sale 339,403   339,403   103,566
Property and equipment, net 4,946   4,946   5,790
Deposits 6,029   6,029   6,029
Non-current assets classified as held for sale 10,975   10,975   11,819
Accounts payable (includes related parties) 710,709   710,709   546,969
Accrued expenses 714,128   714,128   520,251
Current portion of notes payable    
Current liabilities classified as held for sale 1,424,837   1,424,837   $ 1,067,220
Revenue from services 235,326 499,317 706,795 1,291,288  
Cost of services 20,134 30,082 83,628 95,965  
Gross profit (loss) 215,192 469,235 623,167 1,195,323  
Operating expenses 295,404 532,892 1,176,381 1,577,046  
Other (income) expense 6,152 12,121  
Provision for income taxes  
Loss from discontinued operations $ (80,212) $ (69,809) $ (553,214) $ (393,844)  
XML 14 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Alcimede LLC [Member]        
Consulting fee $ 100,000 $ 100,000 $ 300,000 $ 300,000
XML 15 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Nov. 03, 2016
Financing fees debt $ 11,015  
Debt instrument face amount     $ 341,612
Notes Payable Third Parties Two [Member]      
Original principal amount $ 3,000,000 $ 3,000,000  
Debt instruments interest rate 16.00% 16.00%  
Debt maturity description Principal and interest payments due in various installments through December 31, 2017 Principal and interest payments due in various installments through December 31, 2017  
Notes Payable Third Parties Three [Member]      
Original principal amount $ 500,000 $ 500,000  
Debt instruments interest rate 6.00% 6.00%  
Debt maturity description July 12, 2015 through July 12, 2017 July 12, 2015 through July 12, 2017  
Notes Payable Third Parties Four [Member]      
Original principal amount $ 1,900,000    
Original issue discount 300,000    
Financing fees debt 100,000    
Notes Payable Third Parties Four [Member] | November 8, 2019 [Member]      
Debt instrument face amount 1,000,000    
Notes Payable Third Parties Four [Member] | December 26, 2019 [Member]      
Debt instrument face amount $ 900,000    
XML 16 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accrued Expenses (Details Narrative) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Accrued expenses $ 10,542,219 $ 10,711,281
Accrued interest 2,586,652 5,464,837
Mr Diamantis [Member]    
Accrued interest $ 1,800,000 300,000
Settlement Agreement [Member]    
Accrued expenses   $ 4,900,000
XML 17 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2019
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses at September 30, 2019 (unaudited) and December 31, 2018 consisted of the following:

 

    September 30,     December 31,  
    2019     2018  
Commissions payable   $ 19,113     $ 19,113  
Sales tax payable     8,009       8,016  
Accrued payroll and related liabilities     6,761,173       3,400,052  
Accrued property tax     41,784       47,396  
Accrued interest     2,586,652       5,464,837  
Other accrued expenses     1,125,488       1,771,867  
Accrued expenses   $ 10,542,219     $ 10,711,281  

XML 18 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Income Statement [Abstract]        
Net revenues $ 3,885,977 $ 5,039,112 $ 13,137,816 $ 9,932,989
Operating expenses:        
Direct costs of revenue 3,227,709 3,350,286 12,072,442 7,809,465
General and administrative 3,163,624 4,351,576 12,730,695 10,240,434
Depreciation and amortization 199,996 152,825 609,818 804,074
Total operating expenses 6,591,329 7,854,687 25,412,955 18,853,973
Loss from continuing operations before other income (expense) and income taxes (2,705,352) (2,815,575) (12,275,139) (8,920,984)
Other (expense) income:        
Other (expense) income (5,784,873) 188,658 (6,980,616) 609,719
Gain on bargain purchase 250,000 7,732,302
Change in fair value of derivative instruments 109,305,331 (105,076) 13,688,678
Interest expense (3,637,467) (9,322,333) (19,229,232) (17,075,437)
Total other(expense) income, net (9,422,340) 100,171,656 (26,064,924) 4,955,262
Net (loss) income from continuing operations before income taxes (12,127,692) 97,356,081 (38,340,063) (3,965,722)
Provision for income taxes 76
Net (loss) income from continuing operations (12,127,692) 97,356,081 (38,340,063) (3,965,798)
Net (loss) income from discontinued operations (138,076) (159,430) (791,936) 115,787
Net (loss) income (12,265,768) 97,196,651 (39,131,999) (3,850,011)
Deemed dividend from trigger of down round provision feature (17,942,578) (123,861,587) (17,942,578)
Net (loss) income to common shareholders $ (12,265,768) $ 79,254,073 $ (162,993,586) $ (21,792,589)
Net (loss) income per common share:        
Basic continuing operations $ (0.00) $ 17.6 $ (0.01) $ (1.55)
Diluted continuing operations (0.00) (0.08) (0.01) (1.55)
Basic discontinued operations (0.00) (0.03) (0.00) 0.05
Diluted discontinued operations (0.00) (0.00) (0.00) 0.05
Basic net (loss) income (0.00) 14.33 (0.04) (8.54)
Diluted net loss $ (0.00) $ (0.08) $ (0.04) $ (8.54)
Weighted average number of common shares outstanding during the period:        
Basic 6,634,045,471 5,531,767 4,461,922,587 2,550,632
Diluted 6,634,045,471 254,654,217 4,461,922,587 2,550,632
XML 19 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Derivative Financial Instruments and Fair Value (Tables)
9 Months Ended
Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis

The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2019 and December 31, 2018:

 

    Level 1     Level 2     Level 3     Total  
As of December 31, 2018:                                
Embedded conversion options   $     -     $      -     $ 350,260     $ 350,260  
Total   $ -     $ -     $ 350,260     $ 350,260  
                                 
As of September 30, 2019:                                
Embedded conversion options   $ -     $ -     $ 455,336     $ 455,336  
Total   $ -     $ -     $ 455,336     $ 455,336  

Schedule of Changes in Liabilities with Level 3 of Fair Value

The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the nine months ended September 30, 2019:

 

Balance at December 31, 2018   $ 350,260  
Change in fair value of debentures     105,076  
Balance at September 30, 2019   $ 455,336  

XML 20 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Discontinued Operations (Tables)
9 Months Ended
Sep. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Discontinued Operation of Balance Sheet and Operation Statement

Carrying amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the condensed consolidated balance sheets consisted of the following:

 

AMSG Assets and Liabilities:

 

    September 30, 2019     December 31, 2018  
    (unaudited)     (unaudited)  
Cash   $ 220     $ 4,471  
Accounts receivable, net     22,523       6,838  
Prepaid expenses and other current assets     -       25,477  
Current assets classified as held for sale   $ 22,743     $ 36,786  
                 
Accounts payable (includes related parties)   $ 514,415     $ 532,858  
Accrued expenses     493,356       418,932  
Income taxes payable     -       -  
Current portion of notes payable     268,851       278,836  
Current liabilities classified as held for sale   $ 1,276,622     $ 1,230,626  
                 
Non-current liabilities classified as held for sale   $ -     $ -  

 

HTS Assets and Liabilities:

 

    September 30, 2019     December 31, 2018  
    (unaudited)     (unaudited)  
Cash   $ 2,298     $ 2,523  
Accounts receivable, net     330,238       90,743  
Prepaid expenses and other current assets     6,867       10,300  
Current assets classified as held for sale   $ 339,403     $ 103,566  
                 
Property and equipment, net   $ 4,946     $ 5,790  
Deposits     6,029       6,029  
Non-current assets classified as held for sale   $ 10,975     $ 11,819  
                 
Accounts payable (includes related parties)   $ 710,709     $ 546,969  
Accrued expenses     714,128       520,251  
Current portion of notes payable     -       -  
Current liabilities classified as held for sale   $ 1,424,837     $ 1,067,220  

 

Total Discontinued Assets and Liabilities:

 

    September 30, 2019     December 31, 2018  
    (unaudited)     (unaudited)  
Cash   $ 2,518     $ 6,994  
Accounts receivable, net     352,761       97,581  
Prepaid expenses and other current assets     6,867       35,777  
Current assets classified as held for sale   $ 362,146     $ 140,352  
                 
Property and equipment, net   $ 4,946     $ 5,790  
Deposits     6,029       6,029  
Non-current assets classified as held for sale   $ 10,975     $ 11,819  
                 
Accounts payable (includes related parties)   $ 1,225,124     $ 1,079,827  
Accrued expenses     1,207,484       939,183  
Current portion of notes payable     268,851       278,836  
Current liabilities classified as held for sale   $ 2,701,459     $ 2,297,846  

 

Major line items constituting loss from discontinued operations in the condensed consolidated statements of operations for the three months ended September 30, 2019 and 2018 consisted of the following:

 

AMSG Loss from Discontinued Operations:

 

    Three Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 11,350     $ 13,249  
Cost of services     5,878       15,559  
Gross profit (loss)     5,472       (2,310 )
Operating expenses     60,424       93,059  
Other income (expenses)     2,912       (5,748 )
Provision for income taxes     -       -  
Loss from discontinued operations   $ (57,864 )   $ (89,621 )

 

HTS Loss from Discontinued Operations:

 

    Three Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 235,326     $ 499,317  
Cost of services     20,134       30,082  
Gross profit     215,192       469,235  
Operating expenses     295,404       532,892  
Other income     -       6,152  
Provision for income taxes     -       -  
Loss from discontinued operations   $ (80,212 )   $ (69,809 )

 

Consolidated Loss from Discontinued Operations:

 

    Three Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 246,676     $ 512,566  
Cost of services     26,012       45,641  
Gross profit     220,664       466,925  
Operating expenses     355,828       625,951  
Other expense     2,912       404  
Provision for income taxes     -       -  
Loss from discontinued operations   $ (138,076 )   $ (159,430 )

 

Major line items constituting (loss) income from discontinued operations in the condensed consolidated statements of operations for the nine months ended September 30, 2019 and 2018 consisted of the following:

 

AMSG (Loss) Income from Discontinued Operations:

 

    Nine Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 59,832     $ 92,090  
Cost of services     29,638       37,773  
Gross profit     30,194       54,317  
Operating expenses     237,042       363,944  
Other (income) expense     31,874       (819,258 )
Provision for income taxes     -       -  
(Loss) income from discontinued operations   $ (238,722 )   $ 509,631  

 

HTS Loss from Discontinued Operations:

 

    Nine Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 706,795     $ 1,291,288  
Cost of services     83,628       95,965  
Gross profit     623,167       1,195,323  
Operating expenses     1,176,381       1,577,046  
Other income     -       12,121  
Provision for income taxes     -       -  
Loss from discontinued operations   $ (553,214 )   $ (393,844 )

 

Consolidated (Loss) Income from Discontinued Operations:

 

    Nine Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 766,627     $ 1,383,378  
Cost of services     113,266       133,738  
Gross profit     653,361       1,249,640  
Operating expenses     1,413,423       1,940,990  
Other (income) expense     31,874       (807,137 )
Provision for income taxes     -       -  
(Loss) income from discontinued operations   $ (791,936 )   $ 115,787  

XML 21 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Liquidity and Financial Condition
9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Liquidity and Financial Condition

Note 2 – Liquidity and Financial Condition

 

Under ASU, 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40) (“ASC 205-40”), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued. Management has assessed the Company’s ability to continue as a going concern in accordance with the requirement of ASC 205-40.

 

The Company had a working capital deficit, an accumulated deficit and a stockholders’ deficit of $69.3 million, $578.0 million and $67.7 million, respectively, at September 30, 2019. In addition, the Company had a net loss of approximately $39.1 million and cash used in operating activities of $14.4 million for the nine months ended September 30, 2019. The continued losses and other related factors raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the filing date of this report.

 

The Company’s unaudited condensed consolidated financial statements are prepared assuming the Company can continue as a going concern, which contemplates continuity of operations through realization of assets, and the settling of liabilities in the normal course of business. Initial cost savings were realized by reducing the number of laboratory facilities to one for most of its toxicology diagnostics, thereby reducing the number of employees and associated operating expenses. The Company intends to spin off its Advanced Molecular Services Group (“AMSG”) and Health Technology Solutions, Inc. (“HTS”), as independent publicly traded companies by way of tax-free distributions to its shareholders. While these spin offs have taken longer than anticipated, completion of these spin offs is now expected to occur during the first quarter of 2020. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission and consents, including under various funding agreements previously entered by the Company. The intent of the spin offs of AMSG and HTS is to create three public companies, each of which can focus on its own strengths and operational plans. In accordance with ASC 205-20 and having met the criteria for “held for sale”, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. AMSG and HTS are no longer included in the segment reporting following the reclassification to discontinued operations. The discontinued operations of AMSG and HTS are described further in Note 17.

 

The Company’s core business is now rural hospitals which is a specialized marketplace with a requirement for capable and knowledgeable management. The Company’s current financial condition may make it difficult to attract and maintain adequate expertise in its management team to successfully operate the Company’s hospitals.

 

There can be no assurance that the Company will be able to achieve its business plan, which is to acquire and operate clusters of rural hospitals, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to significantly reduce its operating costs, increase its revenues, and eventually achieve profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

XML 22 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Derivative Financial Instruments and Fair Value
9 Months Ended
Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments and Fair Value

Note 11 – Derivative Financial Instruments and Fair Value

 

The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2019 and December 31, 2018:

 

    Level 1     Level 2     Level 3     Total  
As of December 31, 2018:                                
Embedded conversion options   $     -     $      -     $ 350,260     $ 350,260  
Total   $ -     $ -     $ 350,260     $ 350,260  
                                 
As of September 30, 2019:                                
Embedded conversion options   $ -     $ -     $ 455,336     $ 455,336  
Total   $ -     $ -     $ 455,336     $ 455,336  

 

The Company utilized the following methods to value its derivative liabilities as of September 30, 2019 and December 31, 2018, for embedded conversion options valued at $455,336 and $350,260, respectively. The Company determined the fair value by comparing the discounted conversion price per share (85% of market price, subject to a floor in certain cases) multiplied by the number of shares issuable at the balance sheet date to the actual price per share of the Company’s common stock multiplied by the number of shares issuable at that date with the difference in value recorded as a liability. All inputs for the derivative liabilities are observable and, therefore, there is no sensitivity in the valuation to unobservable inputs.

 

The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the nine months ended September 30, 2019:

 

Balance at December 31, 2018   $ 350,260  
Change in fair value of debentures     105,076  
Balance at September 30, 2019   $ 455,336  

 

During the nine months ended September 30, 2019 and the three and nine months ended September 30, 2018, the conversions of preferred stock triggered a further reduction in the exercise prices of any debentures and warrants containing ratchet features that had not already ratcheted down to their floor. In accordance with U.S. GAAP, the incremental fair value of the debentures and warrants was measured, ignoring the down round provision, using Black Scholes. The following assumptions were utilized in the Black Scholes valuation models in the nine months ended September 30, 2019: risk free rates ranging from 2.4% to 2.6% and volatility ranging from 189.5% to 273.1% and weighted average life of 0.3 to 3.2 years. The following assumptions were utilized in the Black Scholes valuation models in the three and nine months ended September 30, 2018: risk free rates ranging from 2.36% to 2.88% and volatility ranging from 163.8% to 234.7% and weighted average life of .73 to 3.5 years. The incremental value of $123.9 million was recorded as a deemed dividend for the nine months ended September 30, 2019 and the incremental value of $17.9 million and $17.9 million was recorded as a deemed dividend in the three and nine months ended September 30, 2018, respectively. Deemed dividends are also discussed in Notes 1 and 3.

 

During the nine months ended September 30, 2019, the Company recorded interest expense of $9.5 million, which represented the fair value of the modification of warrants during the period as more fully discussed in Note 13. The Company used the Black Scholes model to calculate the fair value of the warrants as of the modification dates. Using the pre-modification terms and related assumptions of risk free rates ranging from 2.44% to 2.46%, volatility ranging from 182.9% to 204.4% and weighted average remaining lives of .24 years to .36 years, and the post-modification terms and related assumptions of risk free rates ranging from 2.23% to 2.49%, volatility ranging from 198.3% to 259.4% and weighted average remaining lives of .48 years to 2.89 years, the changes in the fair value of the warrant instruments as a result of the modifications were estimated.

 

During the three and nine months ended September 30, 2018, the Company extended the exercise period of outstanding warrants twice, once to March 21, 2019 and the second time to June 21, 2019 and recorded an additional discount on the debenture issued in connection with the warrants of approximately $8.3 million and $0.3 million as a result of the extensions. The Company amortized approximately $6.4 million of the discount as non-cash interest expense in the nine months ended September 30, 2018. This amount was included in the cash flow statement for the nine months ended September 30, 2018 in amortization of debt discount. The Company used the Black Scholes model to calculate the fair value of the warrants as of the modification dates. Using the pre-modification term and related assumptions of risk free rates ranging from 1.91-2.32%, volatility ranging from 184.0-296.3% and weighted average remaining life of .33 years, and the post-modification term and related assumptions of risk free rates ranging from 2.09-2.56%, volatility ranging from 208.2-249.1% and weighted average remaining life of .65 years, the change in the fair value of the warrant instruments as a result of the modifications was estimated on each date.

 

For the three and nine months ended September 30, 2018, the Company realized income of $109.3 million and $13.7 million, respectively, on instruments valued using Level 3 valuations. On September 23, 2018, the Company’s board of directors approved a reverse split of its common stock, which would provide sufficient authorized and unissued shares to allow for otherwise equity classified instruments to be classified in equity. As of September 23, 2018, the fair value of these instruments was evaluated for reclassification. As a result of the evaluation, the Company reclassified the derivative liability previously reported as a current liability to derivative income.

 

All inputs for the derivative liabilities are observable and, therefore, there is no sensitivity in the valuation to unobservable inputs.

 

On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding. The Series K Preferred Stock is more fully described in Note 19.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Notes Payable
9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Notes Payable

Note 7 – Notes Payable

 

The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At September 30, 2019 (unaudited) and December 31, 2018, notes payable consisted of the following:

 

Notes Payable – Third Parties

 

    September 30,     December 31,  
    2019     2018  
Loan payable under prepaid forward purchase contract (1)   $ -     $ 5,000,000  
                 
Loan payable to TCA Global Master Fund, LP (“TCA”) in the original principal amount of $3 million at 16% interest (the “TCA Debenture”). Principal and interest payments due in various installments through December 31, 2017     1,741,893       1,741,893  
                 
Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the “Tegal Notes”). Principal and interest payments due annually from July 12, 2015 through July 12, 2017     335,818       341,612  
                 
Note payable to Anthony O’Killough dated September 27, 2019 in the original principal amount of $1.9 million. Interest is due only upon event of default. Issued net of $0.3 million of debt discount and $0.1 million of financing fees with $1.0 million of principal due on November 8, 2019 and $0.9 million of principal due December 26, 2019     1,527,821       -  
      3,605,532       7,083,505  
Less current portion     (3,605,532 )     (7,083,505 )
Notes payable - third parties, net of current portion   $ -     $ -  

 

  (1) The loan payable under prepaid forward purchase contract has been fully settled during the nine months ended September 2019 as more fully discussed below under the heading “Notes Payable –Related Party”.

 

The Company did not make the required monthly principal and interest payments due under the TCA Debenture for the period from October 2016 through March 2017. On February 2, 2017, the Company made a payment to TCA in the amount of $0.4 million, which was applied to accrued and unpaid interest and fees, including default interest, as of the date of payment. On March 21, 2017, the Company made a payment to TCA in the amount of $0.75 million, of which approximately $0.1 million was applied to accrued and unpaid interest and fees in accordance with the terms of the TCA Debenture. Also on March 21, 2017, the Company entered into a letter agreement with TCA, which (i) waived any payment defaults through March 21, 2017; (ii) provided for the $0.75 million payment discussed above; (iii) set forth a revised repayment schedule whereby the remaining principal plus interest aggregating to approximately $2.6 million was to be repaid in various monthly installments from April of 2017 through September of 2017; and (iv) provided for payment of an additional service fee in the amount of $150,000, which was due on June 27, 2017, the day after the effective date of the registration statement filed by the Company; which amount is reflected in accrued expenses at December 31, 2018. In addition, TCA entered into an inter-creditor agreement with the purchasers of the convertible debentures (see Note 8) which sets forth rights, preferences and priorities with respect to the security interests in the Company’s assets. On September 19, 2017, the Company entered into a new agreement with TCA, which extended the repayment schedule through December 31, 2017. The remaining debt to TCA remains outstanding and TCA has made a demand for payment. The parties are currently working to amend the TCA Debenture to extend the maturity although there can be no assurance that the parties will agree to any such extension.

 

The Company did not make the principal payments under the Tegal Notes that were due on July 12, 2016. On November 3, 2016, the Company received a default notice from the holders of the Tegal Notes demanding immediate repayment of the outstanding principal of $341,612 and accrued interest of $43,000. On December 7, 2016, the Company received a breach of contract complaint with a request for the entry of a default judgment (see Note 15). On April 23, 2018, the holders of the Tegal Notes received a judgment against the Company. To date, the Company has yet to repay this amount.

 

On September 27, 2019, the Company issued a promissory note to a lender in the principal amount of $1.9 million and received proceeds of $1.5 million, which is net of a $0.3 million original issue discount and $0.1 million in financing fees. The first principal payment of $1.0 million was due on November 8, 2019 and has not yet been made and the remaining $0.9 million is due on December 26, 2019. The note does not bear interest except upon the occurrence of an event of default (as defined in the note). The note is unsecured and is guaranteed by Mr. Diamantis.

 

Notes Payable – Related Party

 

    September 30, 2019     December 31, 2018  
             
Loan payable to Christopher Diamantis   $ 14,968,104     $ 800,000  
                 
Total notes payable, related party     14,968,104       800,000  
                 
Less current portion of notes payable, related party     (14,968,104 )     (800,000 )
Total notes payable, related party, net of current portion   $ -     $ -  

 

On March 31, 2016, the Company entered into an agreement to pledge certain of its accounts receivable as collateral against a prepaid forward purchase contract whereby the Company received consideration in the amount of $5.0 million. The receivables had an estimated collectable value of $8.7 million which had been adjusted down to $0 as of December 31, 2017. In exchange for the consideration received, the counterparty received the right to: (i) a 20% per annum investment return from the Company on the consideration, with a minimum repayment term of six months and minimum return of $0.5 million, (ii) all payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty had not been paid $6.0 million, the Company was required to pay the difference. Christopher Diamantis, a director of the Company, guaranteed the Company’s obligation. On March 24, 2017, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into an amendment to extend the Company’s obligation to March 31, 2018. Also, what the counterparty was to receive was amended to equal (a) the $5,000,000 purchase price plus a 20% per annum investment return thereon, plus (b) $500,000, plus (c) the product of (i) the proceeds received from the accounts receivable, minus the amount set forth in clauses (a) and (b), multiplied by (ii) 40%. In connection with the extension, the counterparty received a fee of $1,000,000. On April 2, 2018, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into a second amendment to extend further the Company’s obligation to May 30, 2018. In connection with this further extension, the counterparty received a fee of $100,000. The counterparty instituted an arbitration proceeding under the agreement with regard to the outstanding balance. In December 2018, the Company, Mr. Diamantis and the counterparty entered into a preliminary settlement agreement in connection with the arbitration, with the terms of the settlement agreement revised on March 31, 2019. The Company and Mr. Diamantis agreed to pay the counterparty $2,000,000 on or before April 5, 2019 and an additional $7,694,685 plus interest at 10% per annum on or before May 20, 2019, which date was subsequently amended. On April 5, 2019 and May 31, 2019, Mr. Diamantis made payments totaling $5.0 million on behalf of the Company. The final payment of $4,937,105 was due on or before July 28, 2019. Mr. Diamantis made that payment on behalf of the Company on July 26, 2019. The Company and Mr. Diamantis have now complied with all of their obligations under the settlement agreement. As a result, the Company is obligated to repay Mr. Diamantis a total of $9,937,105.

 

During the nine months ended September 30, 2019, in addition to the $9,937,105 that Mr. Diamantis loaned the Company in connection with the settlement of the prepaid forward purchase contract discussed above, Mr. Diamantis advanced the Company: (i) $0.7 million for the purchase of Jellico Community Hospital as more fully discussed in Note 5; $1.9 million for fees and expenses incurred in connection with the settlement of the prepaid forward purchase contract; and $4.7 million for working capital purposes. During the three and nine months ended September 30, 2019, we accrued interest of $0.7 million and $1.5 million, respectively, on the advances from Mr. Diamantis. During the nine months ended September 30, 2019, we repaid $2.3 million of principal to Mr. Diamantis. Interest accrues on advances from Mr. Diamantis at a flat rate of 10%. Therefore, the total amount of loans and accrued interest payable to Mr. Diamantis at September 30, 2019 and December 31, 2018, were $16.7 million and $1.1 million, respectively. See Note 19 for the discussion of additional advances made by Mr. Diamantis to the Company subsequent to September 30, 2019.

XML 24 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions (Tables)
9 Months Ended
Sep. 30, 2019
Business Combinations [Abstract]  
Schedule of Assets Acquired and Liabilities Assumed

The following table shows the allocation of the purchase price of Jamestown Regional Medical Center to the acquired identifiable assets acquired, and liabilities assumed:

 

Total purchase price   $ 635,096  
Tangible and intangible assets acquired, and liabilities assumed at fair value:        
Cash   $ 375  
Inventories     450,682  
Prepaids and deposits     310,385  
Property and equipment     7,129,484  
Intangible assets     504,806  
Accrued expenses     (193,966 )
Net tangible and intangible assets acquired   $ 8,201,766  
Gain on bargain purchase (1)   $ 7,566,670  

 

  (1) Gain was adjusted in the fourth quarter of 2018 from $7,732,302 to $7,566,670 to reflect an adjustment of the value of the property and equipment acquired.

 

The following table shows the preliminary allocation of the purchase price of Jellico Community Hospital and CarePlus Center to the acquired identifiable assets acquired, and liabilities assumed:

 

Total purchase price   $ 658,537  
Tangible and intangible assets acquired, and liabilities assumed at estimated fair value:        
Inventories   $ 317,427  
Property and equipment     500,000  
Intangible asset- certificate of need     250,000  
Accrued expenses     (158,890 )
Net tangible and intangible assets acquired   $ 908,537  
Gain on bargain purchase   $ 250,000  

Schedule of Unaudited Pro-forma of Results of Operations

The following presents the unaudited pro-forma combined results of operations of the Company and Jamestown Regional Medical Center and Jellico Community Hospital and CarePlus Center as if the acquisitions had occurred on January 1, 2018. The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the acquisitions been completed as of January 1, 2018 or to project potential operating results as of any future date or for any future periods.

 

    Three Months Ended September 30, 2018    

Nine Months

Ended

September 30,

2019

    Nine Months Ended September 30, 2018  
                   
Net revenue   $ 8,276,112     $ 14,855,436     $ 25,499,677  
Net income (loss) from continuing operations     96,879,012       (38,537,422 )     (8,151,239 )
Deemed dividend from trigger of down round provision feature     (17,942,578 )     (123,861,587 )     (17,942,578 )
Net (loss) income from discontinued operations     (159,430 )     (791,936 )     115,787  
Net income (loss) to common shareholders - basic     78,777,004       (163,190,945 )     (25,978,030 )
Adjustments for diluted loss to common shareholders     (98,678,041 )            
Net loss to common shareholders - diluted   $ (19,901,037 )   $ (163,190,945 )   $ (25,978,030 )
                         
Net income (loss) per common share:                        
Basic continuing operations   $ 17.51     $ (0.01 )   $ (3.20 )
Diluted continuing operations   $ (0.02 )   $ (0.01 )   $ (3.20 )
Basic net income (loss) to common shareholders   $ 14.24     $ (0.04 )   $ (10.18 )
Diluted net loss to common shareholders   $ (0.24 )   $ (0.04 )   $ (10.18 )

XML 25 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events
9 Months Ended
Sep. 30, 2019
Subsequent Events [Abstract]  
Subsequent Events

Note 19 – Subsequent Events

 

Loans From Mr. Diamantis

 

Subsequent to September 30, 2019 and through November 30, 2019, Mr. Diamantis advanced the Company $0.7 million for working capital purposes. The Company incurred interest of $65,000 on the advance.

 

Issuance of Common Stock

 

Subsequent to September 30, 2019 and through December 26, 2019, the Company issued an aggregate of 1,250,000,000 shares of common stock for conversions of preferred stock. The following table presents the dilutive effect of our various potential common shares as of December 26, 2019.

 

    December 26, 2019  
Common shares outstanding     9,648,936,775  
Dilutive potential shares:        
Stock options     77  
Warrants     634,525,355,377  
Convertible debt     30,634,784,339  
Convertible preferred stock     79,122,373,825  
Total dilutive potential common shares, including outstanding common stock     753,931,450,393  

 

On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding. Following is a summary of certain terms of the Series K Preferred Stock:

 

General. The Company’s Board of Directors has designated 250,000 shares of the 5,000,000 authorized shares of preferred stock as the Series K Preferred Stock. Each share of the Series K Preferred Stock has a stated value of $1.00.

 

Voting Rights. Each holder of the Series K Preferred Stock shall be entitled to vote on all matters submitted to a vote of the holders of the Company’s common stock. With respect to a vote of stockholders to approve either or both a reverse stock split of the Company’s common stock (and any reduction in the authorized shares) and an increase in the authorized shares of common stock from 10 billion shares to up to 12.5 billion shares, no later than December 31, 2019 only, each share of the Series K Preferred Stock shall be entitled to the whole number of votes equal to 40,000 shares of common stock. With respect to all other matters, and from and after December 31, 2019, each share of the Series K Preferred Stock shall be entitled to the whole number of votes equal to the number of shares of common stock into which it is then convertible. The Series K Preferred Stock shall vote with the common stock as if they were a single class of securities.

 

Dividends. Holders of the Series K Preferred Stock shall be entitled to receive dividends on shares of the Series K Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of common stock when, as and if dividends are paid on shares of common stock.

 

Rank. The Series K Preferred Stock ranks with respect to dividends or a liquidation, (i) on parity with the common stock, the Company’s Series G Convertible Preferred Stock and the Company’s Series H Convertible Preferred Stock, (ii) senior to the Company’s Series F Convertible Preferred Stock, and (iii) junior to the Company’s Series I-1 Convertible Preferred Stock and the Company’s Series 1-2 Convertible Preferred Stock.

 

Conversion. Each share of the Series K Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder, into that number of shares of common stock determined by dividing the stated value of such share of Preferred Stock plus any accrued and unpaid dividends thereon, by the conversion price. The conversion price is equal to the average closing price of the common stock on the 10 trading days immediately prior to the conversion date.

 

Liquidation Preference. Upon any liquidation, dissolution or winding up of the Company, the holders of the Series K Preferred Stock shall be entitled to receive an amount equal to the stated value of the Series K Preferred Stock, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon for each share of the Series K Preferred Stock before any distribution or payment shall be made on any junior securities.

 

Redemption. At any time the Company shall have the right to redeem all, or any part, of the Series K Preferred Stock then outstanding. The Series K Preferred Stock subject to redemption shall be redeemed by the Company in cash in an amount equal to the stated value of the shares of the Series K Preferred Stock being redeemed plus all accrued and unpaid dividends.

 

Exchange of Series J Preferred Stock for Series K Preferred Stock

 

On December 23, 2019, the Company entered into an Exchange Agreement (the “Agreement”) with Alcimede. Pursuant to the Agreement, the Company issued to Alcimede 250,000 shares of its Series K Preferred Stock in exchange for the 250,000 shares of the Company’s Series J Preferred Stock. The holder of the Series J Preferred Stock was entitled to receive, when and as declared by the Board of Directors of the Company, but only out of funds that were legally available therefore, cumulative cash dividends at the rate of 8% of the stated value per annum on each share of Series J Preferred Stock. The Series J Preferred Stock had been issued to Alcimede on July 23, 2018 and upon the issuance of the Series K Preferred Stock to Alcimede, the shares of Series J Preferred Stock were cancelled. Under the Agreement, Alcimede relinquished all rights to any cumulative dividends on the Series J Preferred Stock. The terms of the Series K Preferred Stock do not provide for cumulative dividends.

 

Redemption of Series G Preferred Stock

 

On December 9, 2019, the Company redeemed all 215 shares of its Series G Preferred Stock that were outstanding.

XML 26 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 15 – Commitments and Contingencies

 

Concentration of Credit Risk

 

Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base. The Company does have significant receivable balances with government payers and various insurance carriers. Generally, the Company does not require collateral or other security to support customer receivables. However, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.

 

A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid (CMS) reimbursements to hospitals and clinical laboratories. Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in revenues from Medicare and Medicaid (CMS), which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

 

The Company maintains its cash balances in high credit quality financial institutions. The Company’s cash balances may, at times, exceed the deposit insurance limits provided by the Federal Deposit Insurance Corporation.

 

Legal Matters

 

From time-to-time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. The Company’s policy is to expense legal fees and expenses incurred in connection with the legal proceedings in the period in which the expense is incurred. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.

 

Biohealth Medical Laboratory, Inc. and PB Laboratories, LLC (the “Companies”) filed suit against CIGNA Health in 2015 alleging that CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA - issued and CIGNA - administered plans. In 2016, the U.S. District Court dismissed part of the Companies’ claims for lack of standing. The Companies appealed that decision to the Eleventh Circuit Court of Appeals, which in late 2017 reversed the District Court’s decision and found that the Companies have standing to raise claims arising out of traditional insurance plans as well as self-funded plans. In July 2019, the Companies and EPIC Reference Labs, Inc. filed suit against Cigna Health for failure to pay claims for laboratory services provided. Cigna Health, in turn, sued for improper billing practices. Both cases are in the early stages.

 

The Company’s Epinex Diagnostics Laboratories, Inc. subsidiary was sued in a California state court by two former employees who alleged that they were wrongfully terminated, as well as for a variety of unpaid wage claims. The parties entered into a settlement agreement of this matter on July 29, 2016 for approximately $0.2 million, and the settlement was consummated on August 25, 2016. In October of 2016, the plaintiffs in this matter filed a motion with the court seeking payment for attorneys’ fees in the approximate amount of $0.7 million. On March 24, 2017, the court granted plaintiffs’ motion for payment of attorneys’ fees in the amount of $0.3 million, and the Company accrued this amount in its consolidated financial statements. Additionally, the Company is seeking indemnification for these amounts from Epinex Diagnostics, Inc., the seller of Epinex Diagnostic Laboratories, Inc., pursuant to a Stock Purchase Agreement entered into by and among the parties.

 

In February 2016, the Company received notice that the Internal Revenue Service (the “IRS”) placed a lien against Medytox Solutions, Inc. and its subsidiaries relating to unpaid 2014 taxes due, plus penalties and interest, in the amount of $5.0 million. The Company paid $0.1 million toward its 2014 tax liability in March 2016. The Company filed its 2015 Federal tax return on March 15, 2016 and the accompanying election to carryback the reported net operating losses was filed in April 2016. On August 24, 2016, the lien was released, and in September of 2016 the Company received a refund from the IRS in the amount of $1.9 million. In November of 2016, the IRS commenced an audit of the Company’s 2015 Federal tax return. Based upon the audit results, the Company has made provisions of approximately $1.0 million as a liability in its financial statements as well as an estimated $0.6 million of receivables for an additional refund that it believes is due.

 

On September 27, 2016, a tax warrant was issued against the Company by the Florida Department of Revenue (the “DOR”) for unpaid 2014 state income taxes in the approximate amount of $0.9 million, including penalties and interest. The Company entered into a Stipulation Agreement with the DOR allowing the Company to make monthly installments until July 2019. The Company has made payments to reduce the amount owed to approximately $$0.4 million as of September 30, 2019. The Company intends to renegotiate another Stipulation agreement. However, there can be no assurance the Company will be successful. The remaining balance accrued of approximately $0.4 million remained outstanding to the DOR at September 30, 2019.

 

In December of 2016, TCS-Florida, L.P. (“Tetra”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with Tetra (see Note 10). On January 3, 2017, Tetra received a Default Judgment against the Company in the amount of $2.6 million, representing the balance owed on the leases, as well as additional interest, penalties and fees. In January and February of 2017, the Company made payments to Tetra relating to this judgment aggregating $0.7 million, and on February 15, 2017, the Company entered into a forbearance agreement with Tetra whereby the remaining $1.9 million due would be paid in 24 equal monthly installments. The Company has not maintained the payment schedule to Tetra. As a result of this default, in May 2018, Tetra and the Company agreed to dispose of certain equipment and the proceeds from the sale have been applied to the outstanding balance. The balance owed to Tetra at September 30, 2019 was $0.3 million and the Company remains in default.

 

In December of 2016, DeLage Landen Financial Services, Inc. (“DeLage”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with DeLage (see Note 10). On January 24, 2017, DeLage received a default judgment against the Company in the approximate amount of $1.0 million, representing the balance owed on the lease, as well as additional interest, penalties and fees. The Company recognized this amount in its consolidated financial statements as of December 31, 2016. On February 8, 2017, a Stay of Execution was filed and under its terms the balance due was to be paid in variable monthly installments through January of 2019, with an implicit interest rate of 4.97%. The Company and DeLage have now disposed of certain equipment and reduced the balance owed to DeLage. A balance of $0.2 million remained outstanding at September 30, 2019.

 

On December 7, 2016, the holders of the Tegal Notes (see Note 7) filed suit against the Company seeking payment for the amounts due under the notes in the aggregate of the principal of $341,612, and accrued interest of $43,000. A request for entry of default judgment was filed on January 24, 2017. On April 23, 2018, the holders of the Tegal Notes received a judgment against the Company. To date, the Company has repaid $5,513 of this amount.

 

In November 2017, a former shareholder of Genomas, Inc., Phenomas, LLC, filed suit against the Company for payment of a $200,000 note payable by the Company’s subsidiary, Genomas. This note is recorded in the financial statements of the subsidiary and is not payable directly from the Company. The Company has made payments totaling $120,000 against this note and agreed to a payment schedule in order to dismiss the legal action. On November 12, 2018, Phenomas, LLC filed a motion to voluntarily dismiss the suit without prejudice.

 

The counterparty to the prepaid forward purchase agreement entered into by the Company on March 31, 2016, as amended, filed an arbitration proceeding under the agreement with regard to the outstanding balance. During the nine months ended September 30, 2019, Mr. Diamantis advanced the Company $9.9 million, which was used to repay all obligations under the prepaid forward purchase agreement, as more fully discussed in Note 7.

 

Two former employees of the Company’s CollabRx, Inc. subsidiary have filed suits in a California state court in connection with amounts claimed to be owed under their respective employment agreements with the subsidiary. One former employee received a judgment in October 2018 for approximately $253,000. The other former employee’s claim is for approximately $110,000. The Company is considering its options to refute these matters and believes the claims against the Company to be frivolous and outside of entitlement and contractual agreements.

 

The Company, as well as many of our subsidiaries, are defendants in a case filed in Broward County Circuit Court by TCA Global Credit Master Fund, L.P. The plaintiff alleges a breach by Medytox Solutions, Inc. of its obligations under a debenture and claims damages of approximately $2,030,000 plus interest, costs and fees. The Company and the other subsidiaries are sued as alleged guarantors of the debenture. The complaint was filed on August 1, 2018. The Company has recorded the principal balance and interest owed under the debenture agreement for the period ended September 30, 2019. The Company and all defendants have filed a motion to dismiss the complaint, but have not recorded any potential liability related to any further damages.

 

On September 13, 2018, Laboratory Corporation of America sued EPIC Reference Labs, Inc., a subsidiary of the Company, in Palm Beach County Circuit Court for amounts claimed to be owed of approximately $148,000. The Company has recorded the amount owed in accrued expenses at September 30, 2019. The court awarded a judgment against EPIC Reference Labs, Inc. in May 2019 for approximately $155,000.

 

In July 2019, Roche Diagnostics Corporation sued EPIC Reference Labs, Inc. in the Circuit Court for Palm Beach County claiming approximately $240,000 under an agreement to purchase laboratory supplies. This suit is in the early stages.

 

In August 2019, EPIC Reference Labs, Inc. and Medytox Diagnostics, Inc. were sued by Beckman Coulter, Inc. in the same court under an agreement to purchase laboratory supplies. The plaintiff claims damages of approximately $106,000. This case is in the early stages.

 

In July 2019, the landlord of Medytox Solutions, Inc. received a judgment in the amount of approximately $413,000 in connection with failure to pay under an office lease in West Palm Beach, Florida.

 

In February 2018, Techlogix, Inc. received a judgment of approximately $72,000 against the Company and HTS in the Superior Court of Middlesex County Massachusetts.

 

Following the Company’s decision to suspend operations at Jamestown Regional Medical Center in June 2019 a number of vendors remain unpaid. A number have initiated or threatened legal actions. The Company believes it will come to satisfactory arrangements with these parties as it works towards reopening the hospital. On June 10, 2019, the Company hired a new CEO to oversee the reopening of the hospital and took steps to re-enter the Medicare program. The hospital received initial approval of its application to reactivate the Medicare agreement in August and is currently planning the reopening of the hospital. Negotiations with vendors are ongoing.

XML 27 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Derivative Financial Instruments and Fair Value - Schedule of Changes in Liabilities with Level 3 of Fair Value (Details)
9 Months Ended
Sep. 30, 2019
USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Balance at December 31, 2018 $ 350,260
Change in fair value of debentures 105,076
Balance at June 30, 2019 $ 455,336
XML 28 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Finance and Operating Lease Obligations - Schedule of Supplemental Cash Flow Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2019
Leases [Abstract]    
Operating cash flows for operating leases   $ 214,357
Operating cash flows for finance leases $ 704 5,804
Financing cash flows for finance leases payments   $ 143,930
XML 29 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Summary of Significant Accounting Policies (Details Narrative)
3 Months Ended 9 Months Ended 12 Months Ended
Nov. 05, 2018
Sep. 30, 2019
USD ($)
$ / shares
shares
Sep. 30, 2018
USD ($)
Mar. 31, 2017
USD ($)
Sep. 30, 2019
USD ($)
Segment
$ / shares
shares
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
$ / shares
shares
Sep. 18, 2018
$ / shares
shares
Sep. 17, 2018
$ / shares
Number of operating segment | Segment         2        
Reserve stock split, description 1-for-500 reverse stock split                
Common stock conversion description As a result of the Reverse Stock Split, every 500 shares of the Company's then outstanding common stock was combined and automatically converted into one share of the Company's common stock on November 12, 2018.                
Common stock shares authorized | shares   10,000,000,000     10,000,000,000   10,000,000,000 10,000,000,000  
Common stock par value | $ / shares   $ 0.0001     $ 0.0001   $ 0.0001 $ 0.0001 $ 0.01
Preferred stock shares authorized | shares   5,000,000     5,000,000     5,000,000  
Preferred stock par value | $ / shares   $ 0.01     $ 0.01     $ 0.01  
Bad debts   $ 900,000 $ 1,800,000   $ 4,800,000 $ 3,100,000      
Allowance for adjustment of revenue   21,900,000 25,100,000   86,700,000 43,800,000      
Net revenues   3,885,977 5,039,112   13,137,816 9,932,989      
Derivative liabilities       $ 56,000,000          
Reversal of interest expense       41,000,000          
Discount on convertible debenture         $ 6,247,469    
Deemed dividend, down round feature       53,300,000          
Deemed dividend   $ 17,900,000 $ 17,900,000 51,000,000 $ 123,900,000 $ 17,900,000 $ 231,800,000    
Additional Paid-in Capital [Member]                  
Discount on convertible debenture       $ 16,000,000          
XML 30 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Dilutive potential shares 748,061,925,383 746,016,834
Warrants [Member]    
Dilutive potential shares 634,525,355,377 463,449,767
Convertible Preferred Stock [Member]    
Dilutive potential shares 82,901,785,590 68,344,495
Convertible Debentures [Member]    
Dilutive potential shares 30,634,784,339 214,222,495
Stock Options [Member]    
Dilutive potential shares 77 77
XML 31 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)
3 Months Ended 9 Months Ended
Mar. 05, 2019
Jun. 02, 2018
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Gain on bargain purchase       $ 250,000 $ 7,732,302
Jamestown Regional Medical Center [Member]              
Total purchase price   $ 635,096          
Cash   375          
Inventories   450,682          
Prepaids and deposits   310,385          
Property and equipment   7,129,484          
Intangible Assets - certificate of need   504,806          
Accrued expenses   (193,966)          
Net tangible and intangible assets acquired   8,201,766          
Gain on bargain purchase   $ 7,566,670 [1]   $ 7,732,302      
Jellico Community Hospital and CarePlus Center [Member]              
Total purchase price $ 658,537            
Inventories 317,427            
Property and equipment 500,000            
Intangible Assets - certificate of need 250,000            
Accrued expenses (158,890)            
Net tangible and intangible assets acquired 908,537            
Gain on bargain purchase $ 250,000            
[1] Gain was adjusted in the fourth quarter of 2018 from $7,732,302 to $7,566,670 to reflect an adjustment of the value of the property and equipment acquired.
XML 32 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Recent Accounting Pronouncements
9 Months Ended
Sep. 30, 2019
Accounting Changes and Error Corrections [Abstract]  
Recent Accounting Pronouncements

Note 18 – Recent Accounting Pronouncements

 

Accounting Pronouncements Adopted

 

In addition to the adoption of pronouncements related to derivative liabilities discussed in Note 1, and ASU 2018-02, Leases (Topic 842) discussed in Notes 1 and 10, the Company adopted the following pronouncements:

 

In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This standard provides companies with an option to reclassify stranded tax effects resulting from enactment of the Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income to retained earnings. Early adoption of this standard is permitted and may be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the tax rate as a result of TCJA is recognized. This ASU became effective for us for annual and interim periods beginning after December 15, 2018. The adoption of this ASU did not have a material impact on our results of operations, financial position and cash flows.

 

In February 2018, the FASB issued ASU 2018-03; Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. These technical corrections and improvements are intended to clarify certain aspects of the guidance on recognizing and measuring financial assets and liabilities in ASU 2016-01. This includes equity securities without a readily determinable fair value, forward contracts and purchased options, presentation requirements for certain fair value option liabilities, fair value option liabilities denominated in foreign currency and transition guidance for equity securities without a readily determinable fair value. We were required to adopt these standards starting in the first quarter of fiscal year 2019. The implementation did not have a material impact on our consolidated financial statements.

 

In March 2018, the FASB issued ASU 2018-05; “Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update)”, which amended ASC 740 to incorporate the requirements of Staff Accounting Bulletin (“SAB”) 118. Issued in December 2017 by the SEC, SAB 118 addresses the application of U.S. GAAP in situations in which a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the TCJA which was signed into law on December 22, 2017. The adoption did not have a material impact on our consolidated financial statements.

 

In June 2018, the FASB issued ASU 2018-07 to expand the scope of ASC Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The adoption did not have a material impact on our consolidated financial statements.

 

Accounting Pronouncements Not Yet Adopted

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard will require entities to disclose the amount of total gains or losses for the period recognized in other comprehensive income that is attributable to fair value changes in assets and liabilities held as of the balance sheet date and categorized within Level 3 of the fair value hierarchy. This ASU will be effective for us for annual and interim periods beginning after December 31, 2020. Early adoption of this standard is permitted. We have not yet determined the impact of the adoption of this ASU on our results of operations, financial position and cash flows.

 

In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. Under this standard customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. The adoption of this new guidance prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and additional quantitative and qualitative disclosures. This ASU will be effective for us for annual and interim periods beginning after December 30, 2020. Early adoption of this standard is permitted and may be applied either prospectively to eligible costs incurred on or after the date of the new guidance or retrospectively. We have not yet determined the impact of the adoption of this ASU on our results of operations, financial position and cash flows.

 

Other recent accounting standards issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

XML 33 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Supplemental Disclosure of Cash Flow Information
9 Months Ended
Sep. 30, 2019
Supplemental Cash Flow Elements [Abstract]  
Supplemental Disclosure of Cash Flow Information

Note 14 – Supplemental Disclosure of Cash Flow Information

 

    Nine Months Ended September 30,  
    2019     2018  
Cash paid for interest   $ -     $ 303,208  
Cash paid for income taxes     45,000       20,000  
                 
Acquisitions of Hospitals and Medical Center:                
Cash   $ -     $ 375  
Inventory     317,427       450,682  
Prepaid expenses and other current assets     -       310,385  
Property and equipment     500,000       7,129,484  
Intangible assets     250,000       504,806  
Accrued expenses     158,890       193,966  
                 
Non-cash investing and financing activities:                
Exchange of Series I-2 Preferred Stock for common stock   $ 1,143,974     $ 633,101  
Cashless exercise of warrants     11,961       4,619,150  
Debentures converted into common stock     -       8,085,342  
Common stock issued in cashless exercise of warrants     11,961       -  
Exchange of debentures into Series I-2 Preferred Stock     -       1,420  
Conversions of Series H Preferred Stock into common stock     -       50,000  
Original issue discount of debentures and notes payable     400,000       1,920,000  
Deemed dividend for trigger of down round provision features     123,861,587       17,942,578  
Issuance of Series J Preferred Stock in settlement of note payable to related party     -       250,000  

XML 34 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accounts Receivable (Tables)
9 Months Ended
Sep. 30, 2019
Receivables [Abstract]  
Schedule of Accounts Receivable

Accounts receivable at September 30, 2019 (unaudited) and December 31, 2018 consisted of the following:

 

    September 30,     December 31,  
    2019     2018  
Accounts receivable - Clinical Laboratory Operations   $ 41,750     $ 622,009  
Accounts receivable - Hospital Operations     45,804,056       31,607,644  
Accounts receivable - Other     (52,296 )     -  
Total accounts receivable     45,793,510       32,229,653  
Less:                
Amount purchased by factors     (1,572,000 )     -  
Allowance for discounts - Clinical Laboratory Operations     (26,182 )     (573,584 )
Allowance for discounts - Hospital Operations     (36,298,972 )     (25,066,799 )
Allowance for bad debts     (2,787,894 )     (2,777,521 )
Accounts receivable, net   $ 5,108,462     $ 3,811,749  

ZIP 35 0001493152-19-019860-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-019860-xbrl.zip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�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�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end
XML 36 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Derivative Financial Instruments and Fair Value - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Total $ 455,336 $ 350,260
Level 1 [Member]    
Total
Level 2 [Member]    
Total
Level 3 [Member]    
Total 455,336 350,260
Embedded Conversion Options [Member]    
Total 455,336 350,260
Embedded Conversion Options [Member] | Level 1 [Member]    
Total
Embedded Conversion Options [Member] | Level 2 [Member]    
Total
Embedded Conversion Options [Member] | Level 3 [Member]    
Total $ 455,336 $ 350,260
XML 37 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Finance and Operating Lease Obligations - Schedule of Information Related to Lease Expense for Finance and Operating Leases (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2019
Leases [Abstract]    
Finance lease expense: Depreciation/amortization of leased assets [1] $ 15,004 $ (30,055)
Finance lease expense: Interest on lease liabilities 704 5,804
Operating leases: Short-term lease expense [2] 76,312 263,713
Total lease expense $ 92,020 $ 239,462
[1] The depreciation for the nine months ended September 30, 2019 has been adjusted for depreciation recorded in the prior year.
[2] Expenses are included in general and administrative expenses in our condensed consolidated statements of operations.
XML 38 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) - USD ($)
3 Months Ended 9 Months Ended
Jun. 02, 2018
[1]
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Gain on bargain purchase     $ 250,000 $ 7,732,302
Jamestown Regional Medical Center [Member]            
Gain on bargain purchase $ 7,566,670   $ 7,732,302      
[1] Gain was adjusted in the fourth quarter of 2018 from $7,732,302 to $7,566,670 to reflect an adjustment of the value of the property and equipment acquired.
XML 39 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Liquidity and Financial Condition (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]                    
Working capital deficit $ 69,300,000           $ 69,300,000      
Accumulated deficit (578,040,192)           (578,040,192)   $ (415,046,606)  
Stockholders' deficit (67,664,949) $ (55,646,831) $ (47,900,313) $ (30,134,731) $ (129,945,975) $ (183,907,625) (67,664,949) $ (30,134,731) $ (39,167,864) $ (40,613,461)
Net loss $ (12,265,768) $ (13,424,827) $ (13,441,404) $ 97,196,651 $ 45,317,921 $ (146,364,582) (39,131,999) (3,850,011)    
Cash used in operating activities             $ (14,420,826) $ (7,121,826)    
XML 40 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accounts Receivable (Details Narrative)
9 Months Ended
Sep. 30, 2019
USD ($)
Receivables [Abstract]  
Accounts receivable sold $ 3,900,000
Proceeds from sale of accounts receivable 2,700,000
Origination and other fees 100,000
Loss on sale of receivables 1,200,000
Accounts receivable purchase $ 1,600,000
XML 41 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended
Sep. 13, 2018
Apr. 23, 2018
Feb. 15, 2017
Feb. 08, 2017
Jan. 24, 2017
Jan. 03, 2017
Aug. 31, 2019
Jul. 31, 2019
May 31, 2019
Feb. 28, 2019
Nov. 30, 2017
Feb. 28, 2017
Jan. 31, 2017
Nov. 30, 2016
Feb. 29, 2016
Sep. 30, 2019
Sep. 30, 2018
Mar. 24, 2017
Dec. 07, 2016
Nov. 03, 2016
Oct. 31, 2016
Sep. 30, 2016
Sep. 27, 2016
Jul. 29, 2016
Mar. 31, 2016
Payment for related party debt                               $ 2,310,000 $ 4,011,000                
Accrued interest                                       $ 43,000          
Payment for notes payable                               5,005,794 $ 256,481                
Holders of Tegal Notes [Member]                                                  
Equipment lease outstanding balance                                     $ 341,612            
Accrued interest                                     $ 43,000            
Payment for notes payable   $ 5,513                                              
Mr Diamantis [Member]                                                  
Due to related party                               9,900,000                  
Florida Department of Revenue [Member]                                                  
Income tax penalties and interest accrued                                             $ 900,000    
Payment for related party debt                               400,000                  
Due to related party                               400,000                  
TCS-Florida, L.P [Member]                                                  
Due to related party                               300,000                  
Litigation settlement in judgment           $ 2,600,000                                      
Payment in settlement of judgment                       $ 700,000 $ 700,000                        
DeLage Landen Financial Services, Inc. [Member]                                                  
Litigation settlement in judgment         $ 1,000,000                                        
Implicit interest rate       4.97%                                          
Equipment lease outstanding balance                               200,000                  
Epinex Diagnostics Laboratories, Inc. [Member]                                                  
Payment of attorneys' fees                                   $ 300,000     $ 700,000        
Medytox Solutions, Inc [Member]                                                  
Discharge of payment                               2,030,000                  
Amount awarded to other party in judgement               $ 413,000                                  
Medytox Solutions, Inc [Member] | Internal Revenue Service (IRS) [Member]                                                  
Settlement payable                                                 $ 100,000
Income tax penalties and interest paid                             $ 5,000,000                    
Income tax liability refund                                           $ 1,900,000      
Provision for liability                           $ 1,000,000                      
Commitments receivables                           $ 600,000                      
Genomas, Inc [Member]                                                  
Payment for notes payable                     $ 200,000                            
Discharge of payment                     $ 120,000                            
EPIC Reference Laboratories, Inc. [Member]                                                  
Litigation settlement in judgment                 $ 155,000                                
Discharge of payment $ 148,000                                                
Roche Diagnostics Corporation [Member]                                                  
Discharge of payment               $ 240,000                                  
Beckman Coulter, Inc [Member]                                                  
Discharge of payment             $ 106,000                                    
Techlogix, Inc [Member]                                                  
Amount awarded to other party in judgement                   $ 72,000                              
Settlement Agreement [Member] | Epinex Diagnostics Laboratories, Inc. [Member]                                                  
Settlement payable                                               $ 200,000  
Forbearance Agreement [Member] | TCS-Florida, L.P [Member]                                                  
Monthly installment payment     $ 1,900,000                                            
Employment Agreements [Member] | Former Employee 1 [Member]                                                  
Litigation settlement in judgment                               253,000                  
Employment Agreements [Member] | Former Employee 2 [Member]                                                  
Litigation settlement in judgment                               $ 110,000                  
XML 42 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events (Details Narrative) - USD ($)
2 Months Ended 3 Months Ended
Dec. 23, 2019
Oct. 04, 2019
Nov. 30, 2019
Dec. 26, 2019
Dec. 31, 2019
Dec. 09, 2019
Sep. 30, 2019
Dec. 31, 2018
Sep. 18, 2018
Preferred stock, shares authorized             5,000,000   5,000,000
Preferred stock, stated value             $ 0.01   $ 0.01
Common stock, shares authorized             10,000,000,000 10,000,000,000 10,000,000,000
Series J Preferred Stock [Member]                  
Preferred stock, shares authorized             250,000 250,000  
Preferred stock, stated value             $ 0.01 $ 0.01  
Preferred stock shares outstanding             250,000 250,000  
Series G Preferred Stock [Member]                  
Preferred stock, shares authorized             14,000 14,000  
Preferred stock, stated value             $ 0.01 $ 0.01  
Preferred stock shares outstanding             215 215  
Subsequent Event [Member]                  
Aggregate shares of common stock for conversions of preferred stock       1,250,000,000          
Common stock, shares authorized         12,500,000,000        
Preferred stock voting rights term   Each share of the Series K Preferred Stock shall be entitled to the whole number of votes equal to 40,000 shares of common stock.              
Subsequent Event [Member] | Series K Preferred Stock [Member]                  
Preferred stock, shares authorized   5,000,000              
Preferred stock, stated value   $ 1.00              
Common stock, shares authorized   10,000,000,000              
Subsequent Event [Member] | Series K Preferred Stock [Member] | Exchange Agreement [Member] | Alcimede LLC [Member]                  
Number of shares issued 250,000                
Subsequent Event [Member] | Series J Preferred Stock [Member]                  
Preferred stock cumulative dividend percentage 8.00%                
Subsequent Event [Member] | Series J Preferred Stock [Member] | Exchange Agreement [Member] | Alcimede LLC [Member]                  
Number of shares exchanged 250,000                
Subsequent Event [Member] | Series G Preferred Stock [Member]                  
Preferred stock shares outstanding           215      
Subsequent Event [Member] | Christopher Diamantis [Member]                  
Working capital     $ 700,000            
Incurred interest expenses     $ 65,000            
Subsequent Event [Member] | Board of Directors [Member] | Series K Preferred Stock [Member]                  
Preferred stock, shares authorized   250,000              
XML 43 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Notes Payable - Schedule of Notes Payable (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Note payable $ 3,605,532 $ 7,083,505
Less current portion (3,605,532) (7,083,505)
Notes payable - third parties, net of current portion
Notes Payable - Third Parties One [Member]    
Note payable [1] 5,000,000
Notes Payable Third Parties Two [Member]    
Note payable 1,741,893 1,741,893
Notes Payable Third Parties Three [Member]    
Note payable 335,818 341,612
Notes Payable Third Parties Four [Member]    
Note payable $ 1,527,821
[1] The loan payable under prepaid forward purchase contract has been fully settled during the nine months ended September 2019 as more fully discussed below under the heading "Notes Payable - Related Party".
XML 44 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Schedule of Unaudited Pro-forma of Results of Operations (Details) - Jamestown Regional Medical Center and Jellico Community Hospital and Careplus Center [Member] - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Net revenue $ 8,276,112 $ 14,855,436 $ 25,499,677
Net income (loss) from continuing operations 96,879,012 (38,537,422) (8,151,239)
Deemed dividend from trigger of down round provision feature (17,942,578) (123,861,587) (17,942,578)
Net (loss) income from discontinued operations $ (159,430) $ (791,936) $ 115,787
Net income (loss) to common shareholders - basic 78,777,004 (163,190,945) (25,978,030)
Adjustments for diluted loss to common shareholders (98,678,041)
Net loss to common shareholders - diluted (19,901,037) (163,190,945) (25,978,030)
Basic continuing operations $ 17.51 $ (0.01) $ (3.20)
Diluted continuing operations (0.02) (0.01) (3.20)
Basic net income (loss) to common shareholders 14.24 (0.04) (10.18)
Diluted net loss to common shareholders $ (0.24) $ (0.04) $ (10.18)
XML 46 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debentures - Schedule of Debentures (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Debt Disclosure [Abstract]    
Debentures $ 28,690,240 $ 19,034,800
Discount on debentures (6,247,469)
Deferred financing fees (11,015)
Total debentures 28,690,240 12,776,316
Less current portion (28,690,240) (12,776,316)
Debentures, long-term
EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

3P >&PO=V]R:W-H M965T&UL4$L! M A0#% @ V8">3[$2M3_" 0 -P0 !D ( !YE, 'AL M+W=O&PO=V]R:W-H965TP@$ #<$ 9 " M <]7 !X;"]W;W)K&UL4$L! A0#% @ V8"> M3R+Z ,JW 0 T@, !D ( !R%D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ V8">3U]V0S7= 0 04 M !D ( !GU\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ V8">3W/,P'JX 0 T@, !D M ( !J64 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ V8">3[A"W6ZW 0 T@, !D ( !&PO=V]R:W-H965T'.?9P( (<' 9 " 1M[ !X;"]W;W)K&UL4$L! A0#% @ V8">3^<[2&+_ 0 >P4 !D M ( !N7T 'AL+W=O8#&ZD" !U"0 &0 @ 'O?P >&PO M=V]R:W-H965T&UL4$L! A0#% @ V8">3Q5X/6AB P & X !D ( ! M>88 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ V8">3\ZE?U8$ @ I04 !D ( ! 9 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ V8">3ROG4#O$! 1!L !D M ( !5Z( 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ V8">3PV8;A"@ 0 70, !D ( ![*L M 'AL+W=OBJ M!\8" ("@ &0 @ '#K0 >&PO=V]R:W-H965T'< ( ,4' 9 M " <"P !X;"]W;W)K&UL4$L! A0#% @ MV8">3ZW,3\3_ 0 /04 !D ( !9[, 'AL+W=O&UL4$L! A0#% @ V8">3R9GMG]6 @ M/ D !D ( !0;X 'AL+W=O&PO=V]R:W-H965TK" !X;"]W;W)K&UL4$L! A0#% @ V8">3R&3MQU*!P BBL !D M ( !U<8 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ V8">3^Z35NQ5 P 8 T !D ( !;], 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ V8"> M3\[H#)D$!0 !1@ !D ( !E]X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ V8">3_T8WJ,# P )@L M !D ( ! O 'AL+W=O/0, % @ $\\P M>&PO&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #9 M@)Y/BP!PMAX" "$+0 $P @ &BS $ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 5P!7 -,7 #QS@$ ! end XML 48 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events (Tables)
9 Months Ended
Sep. 30, 2019
Subsequent Events [Abstract]  
Schedule of Dilutive Effect of Potential Common Shares

The following table presents the dilutive effect of our various potential common shares as of December 26, 2019.

 

    December 26, 2019  
Common shares outstanding     9,648,936,775  
Dilutive potential shares:        
Stock options     77  
Warrants     634,525,355,377  
Convertible debt     30,634,784,339  
Convertible preferred stock     79,122,373,825  
Total dilutive potential common shares, including outstanding common stock     753,931,450,393  

XML 49 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings (Loss) Per Share
9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Earnings (Loss) Per Share

Note 3 – Earnings (Loss) Per Share

 

Basic and diluted earnings (loss) per share is computed by dividing (i) loss available to common shareholders, by (ii) the weighted-average number of shares of common stock outstanding during the period. Basic loss per share excludes dilution and is computed by dividing loss attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company. The loss per share for the three and nine months ended September 30, 2019 and the nine months ended September 30, 2018 excluded securities or other contracts to issue the Company’s common stock because the results were anti-dilutive.

 

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share for each of the three and nine months ended September 30, 2019 and 2018:

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
    2019     2018     2019     2018  
Numerator:                                
Net (loss) income from continuing operations   $ (12,127,692 )   $ 97,356,081     $ (38,340,063 )   $ (3,965,798 )
Net (loss) income from discontinued operations     (138,076 )     (159,430 )     (791,936 )     115,787  
Deemed dividends           (17,942,578 )     (123,861,587 )     (17,942,578 )
Net loss (income) to common shareholders -basic   $ (12,265,768 )   $ 79,254,073     $ (162,993,586 )   $ (21,792,589 )
Adjustments for diluted calculations:                                
Deduct change in fair value of derivative liabilities           (109,305,331 )            
Amortize discounts associated with conversion of dilutive convertible debentures           (7,303,912 )            
Remove change in warrant value for diluted           (11,376 )            
Add back deemed dividends           17,942,578              
Net loss to common shareholders - diluted   $ (12,265,768 )   $ (19,423,968 )   $ (162,993,586 )   $ (21,792,589 )
Denominator:                                
Weighted average number of common shares outstanding during the period:                                
Basic     6,634,045,471       5,531,767       4,461,922,587       2,550,632  
Common stock equivalents:                                
Warrants           64,315,740              
Convertible preferred stock           9,505,156              
Convertible debentures           175,301,554              
Diluted     6,634,045,471       254,654,217       4,461,922,587       2,550,632  
Net (loss) income per common share- continuing operations:                                
Basic   $ (0.00 )   $ 17.60     $ (0.01 )   $ (1.55 )
Diluted   $ (0.00 )   $ (0.08 )   $ (0.01 )   $ (1.55 )
Net (loss) income per common share- discontinued operations:                                
Basic   $ (0.00 )   $ (0.03 )   $ (0.00 )   $ 0.05  
Diluted   $ (0.00 )   $ (0.00 )   $ (0.00 )   $ 0.05  
Total per share net (loss) income to common shareholders:                                
Basic   $ (0.00 )   $ 14.33     $ (0.04 )   $ (8.54 )
Diluted   $ (0.00 )   $ (0.08 )   $ (0.04 )   $ (8.54 )

 

Diluted loss per share as reflected in the table above excludes all dilutive potential shares if their effect is anti-dilutive. For the nine months ended September 30, 2019 and 2018, the following table sets forth the computation of the following potential common stock equivalents excluded from the calculation of diluted loss per share as their effect was anti-dilutive:

 

    Nine Months Ended September 30,  
    2019     2018  
Warrants     634,525,355,377       463,449,767  
Convertible preferred stock     82,901,785,590       68,344,495  
Convertible debentures     30,634,784,339       214,222,495  
Stock options     77       77  
      748,061,925,383       746,016,834  

 

The terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, many of these equity-based securities contain exercise or conversion prices that vary based upon the price of the Company’s common stock on the date of exercise/conversion (see Notes 12 and 13). These provisions have resulted in significant dilution of the Company’s common stock and have given rise to reverse splits of the Company’s common stock. As a result of these down round provisions, the outstanding common stock and potential common stock equivalents totaled 753.9 billion at December 26, 2019. See Notes 13 and 19 regarding a discussion of the Company’s common stock and potential common stock equivalents.

XML 50 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2019
Dec. 26, 2019
Document And Entity Information    
Entity Registrant Name Rennova Health, Inc.  
Entity Central Index Key 0000931059  
Document Type 10-Q  
Document Period End Date Sep. 30, 2019  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business Flag true  
Entity Emerging Growth Company false  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   9,648,936,775
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2019  
XML 51 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Notes Payable (Tables)
9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Schedule of Notes Payable

Notes Payable – Third Parties

 

    September 30,     December 31,  
    2019     2018  
Loan payable under prepaid forward purchase contract (1)   $ -     $ 5,000,000  
                 
Loan payable to TCA Global Master Fund, LP (“TCA”) in the original principal amount of $3 million at 16% interest (the “TCA Debenture”). Principal and interest payments due in various installments through December 31, 2017     1,741,893       1,741,893  
                 
Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the “Tegal Notes”). Principal and interest payments due annually from July 12, 2015 through July 12, 2017     335,818       341,612  
                 
Note payable to Anthony O’Killough dated September 27, 2019 in the original principal amount of $1.9 million. Interest is due only upon event of default. Issued net of $0.3 million of debt discount and $0.1 million of financing fees with $1.0 million of principal due on November 8, 2019 and $0.9 million of principal due December 26, 2019     1,527,821       -  
      3,605,532       7,083,505  
Less current portion     (3,605,532 )     (7,083,505 )
Notes payable - third parties, net of current portion   $ -     $ -  

 

  (1) The loan payable under prepaid forward purchase contract has been fully settled during the nine months ended September 2019 as more fully discussed below under the heading “Notes Payable –Related Party”.

Schedule of Notes Payable - Related Parties

Notes Payable – Related Party

 

    September 30, 2019     December 31, 2018  
             
Loan payable to Christopher Diamantis   $ 14,968,104     $ 800,000  
                 
Total notes payable, related party     14,968,104       800,000  
                 
Less current portion of notes payable, related party     (14,968,104 )     (800,000 )
Total notes payable, related party, net of current portion   $ -     $ -  

XML 52 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2017 $ 17,502 $ 4 $ 128,549,458 $ (169,180,425) $ (40,613,461)
Balance, shares at Dec. 31, 2017 1,750,275 39,502      
Common stock issued in cashless exercise of warrants $ 15 (15)
Common stock issued in cashless exercise of warrants, shares 151,200      
Conversion of debentures into common stock $ 67 3,056,607 3,056,674
Conversion of debentures into common stock, shares 666,621      
Stock-based compensation 24,196 24,196
Restricted stock issued to employees $ 14 641,096 641,110
Restricted stock issued to employees, shares 142,667      
Shares returned to treasury
Shares returned to treasury, shares (5)      
Beneficial conversion feature of preferred stock (651,562) (651,562)
Net income (loss) (146,364,582) (146,364,582)
Balance at Mar. 31, 2018 $ 17,502 $ 100 131,619,780 (315,545,007) (183,907,625)
Balance, shares at Mar. 31, 2018 1,750,275 999,985      
Balance at Dec. 31, 2017 $ 17,502 $ 4 128,549,458 (169,180,425) (40,613,461)
Balance, shares at Dec. 31, 2017 1,750,275 39,502      
Modification of warrants        
Net income (loss)         (3,850,011)
Balance at Sep. 30, 2018 $ 20,002 $ 737 160,817,543 (190,973,013) (30,134,731)
Balance, shares at Sep. 30, 2018 2,000,225 7,365,881      
Balance at Mar. 31, 2018 $ 17,502 $ 100 131,619,780 (315,545,007) (183,907,625)
Balance, shares at Mar. 31, 2018 1,750,275 999,985      
Common stock issued in cashless exercise of warrants $ 57 3,957,710 3,957,767
Common stock issued in cashless exercise of warrants, shares 572,480      
Conversion of debentures into common stock $ 157 4,036,932 4,037,089
Conversion of debentures into common stock, shares 1,571,000      
Stock-based compensation 24,197 24,197
Shares returned to treasury (28,217) (28,217)
Shares returned to treasury, shares (116)      
Beneficial conversion feature of preferred stock 651,562 651,562
Conversion of Series H Preferred Stock into common stock $ 4 (4)
Conversion of Series H Preferred Stock into common stock, shares (50) 40,000      
Exchange of debentures into Series I-2 Preferred Stock 1,331 1,331
Net income (loss) 45,317,921 45,317,921
Balance at Jun. 30, 2018 $ 17,502 $ 318 140,263,291 (270,227,086) (129,945,975)
Balance, shares at Jun. 30, 2018 1,750,225 3,183,349      
Common stock issued in cashless exercise of warrants $ 77 661,304 661,381
Common stock issued in cashless exercise of warrants, shares 768,548      
Conversion of debentures into common stock $ 165 991,413 991,578
Conversion of debentures into common stock, shares 1,649,059      
Stock-based compensation 78,444 78,444
Exchange of debentures into Series I-2 Preferred Stock 89 89
Deemed dividend from trigger of down round provision feature 17,942,578 (17,942,578)
Exchange of note payable and accrued expenses for Series J Preferred Stock $ 2,500 247,500 250,000
Exchange of note payable and accrued expenses for Series J Preferred Stock, shares 250,000      
Common stock issued for conversion of Series I-2 Preferred Stock $ 177 632,924 633,101
Common stock issued for conversion of Series I-2 Preferred Stock, shares 1,764,927      
Adjust treasury shares
Adjust treasury shares, shares (2)      
Net income (loss) 97,196,651 97,196,651
Balance at Sep. 30, 2018 $ 20,002 $ 737 160,817,543 (190,973,013) (30,134,731)
Balance, shares at Sep. 30, 2018 2,000,225 7,365,881      
Balance at Dec. 31, 2018 $ 20,002 $ 12,857 375,845,883 (415,046,606) (39,167,864)
Balance, shares at Dec. 31, 2018 2,000,225 128,567,273      
Common stock issued in cashless exercise of warrants $ 11,961 (11,961)
Common stock issued in cashless exercise of warrants, shares 119,615,384      
Stock-based compensation 8,650 8,650
Conversion of Series I-2 Preferred stock into common stock $ 325,570 318,310 643,880
Conversion of Series I-2 Preferred stock into common stock, shares 3,255,700,000      
Deemed dividend from trigger of down round provision feature 123,861,587 (123,861,587)
Modification of warrants 4,056,425 4,056,425
Net income (loss) (13,441,404) (13,441,404)
Balance at Mar. 31, 2019 $ 20,002 $ 350,388 504,078,894 (552,349,597) (47,900,313)
Balance, shares at Mar. 31, 2019 2,000,225 3,503,882,657      
Balance at Dec. 31, 2018 $ 20,002 $ 12,857 375,845,883 (415,046,606) (39,167,864)
Balance, shares at Dec. 31, 2018 2,000,225 128,567,273      
Common stock issued in cashless exercise of warrants, shares   119,615,384      
Modification of warrants         9,464,991
Net income (loss)         (39,131,999)
Balance at Sep. 30, 2019 $ 20,002 $ 839,894 509,515,347 (578,040,192) (67,664,949)
Balance, shares at Sep. 30, 2019 2,000,225 8,398,936,775      
Balance at Mar. 31, 2019 $ 20,002 $ 350,388 504,078,894 (552,349,597) (47,900,313)
Balance, shares at Mar. 31, 2019 2,000,225 3,503,882,657      
Stock-based compensation 8,650 8,650
Conversion of Series I-2 Preferred stock into common stock $ 250,506 10,587 261,093
Conversion of Series I-2 Preferred stock into common stock, shares 2,505,054,118      
Modification of warrants 5,408,566 5,408,566
Net income (loss) (13,424,827) (13,424,827)
Balance at Jun. 30, 2019 $ 20,002 $ 600,894 509,506,697 (565,774,424) (55,646,831)
Balance, shares at Jun. 30, 2019 2,000,225 6,008,936,775      
Stock-based compensation 8,650 8,650
Conversion of Series I-2 Preferred stock into common stock $ 239,000 239,000
Conversion of Series I-2 Preferred stock into common stock, shares 2,390,000,000      
Net income (loss) (12,265,768) (12,265,768)
Balance at Sep. 30, 2019 $ 20,002 $ 839,894 $ 509,515,347 $ (578,040,192) $ (67,664,949)
Balance, shares at Sep. 30, 2019 2,000,225 8,398,936,775      
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Deficit (Tables)
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Schedule of Stock Option Activity

    Number of options     Weighted-average exercise price     Weighted-average contractual term  
Outstanding at December 31, 2018     77     $ 1,036,375       7.33  
Granted     -                  
Expired     -                  
Forfeit     -                  
Outstanding at September 30, 2019     77     $ 1,036,375       6.50  
                         
Exercisable at September 30, 2019     68     $ 1,152,616          

Schedule of Warrants Activity

The following summarizes the information related to warrants issued and the activity during the nine months ended September 30, 2019:

 

    Number of shares issuable pursuant to warrants     Weighted average exercise price  
Balance at December 31, 2018     53,130,510,439     $ 0.00172  
Increase during the period as a result of down round provisions     582,209,844,938          
Shares issued pursuant to Warrants exercised during the period     (755,000,000 )   $ 0.00034  
Balance at September 30, 2019     634,585,355,377     $ 0.00014  

XML 54 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Finance and Operating Lease Obligations
9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Finance and Operating Lease Obligations

Note 10 – Finance and Operating Lease Obligations

 

As more fully discussed in Note 1, we adopted ASU No. 2016-02, Leases (Topic 842), which requires leases with durations greater than 12 months to be recognized on the balance sheet, effective January 1, 2019, using the modified retrospective approach.

 

Generally, we use our estimated weighted average cost of capital at lease commencement as our interest rate, as most of our operating leases do not provide a readily determinable implicit interest rate.

 

The following table presents our lease-related assets and liabilities at September 30, 2019:

 

    Balance Sheet Classification   September 30, 2019  
Assets:            
Operating leases   Right-of-use operating lease assets   $ 328,615  
Finance leases   Property and equipment, net     618,278  
Total lease assets       $ 946,893  
             
Liabilities:            
Current:            
Operating leases   Right-of-use operating lease assets   $ 141,830  
Finance leases   Current liabilities     589,457  
Noncurrent:            
Operating leases   Right-of-use operating lease obligations     186,785  
Finance leases   Long-term debt     28,821  
             
Total lease liabilities       $ 946,893  
             
Weighted-average remaining term:            
Operating leases         1.98 years  
Finance leases         0.19 years  
Weighted-average discount rate:            
Operating leases (1)         13.0 %
Finance leases         5.122 %

 

(1) Upon adoption of the new lease standard, discount rates used for existing operating leases were established at January 1, 2019.

 

The following table presents certain information related to lease expense for finance and operating leases for the three and nine months ended September 30, 2019:

 

   

Three Months Ended

September 30, 2019

    Nine Months Ended
September 30, 2019
 
Finance lease expense:                
Depreciation/amortization of leased assets (1)   $ 15,004     $ (30,055 )
Interest on lease liabilities     704       5,804  
Operating leases:                
Short-term lease expense (2)     76,312       263,713  
Total lease expense   $ 92,020     $ 239,462  

 

(1) The depreciation for the nine months ended September 30, 2019 has been adjusted for depreciation recorded in the prior year.

(2) Expenses are included in general and administrative expenses in our condensed consolidated statements of operations.

 

Other Information

 

The following table presents supplemental cash flow information for the nine months ended September 30, 2019:

 

    2019  
Cash paid for amounts included in the measurement of lease liabilities:        
Operating cash flows for operating leases   $ 214,357  
Operating cash flows for finance leases   $ 5,800  
Financing cash flows for finance leases payments   $ 143,930  

 

Aggregate future minimum rentals under right-to-use operating and finance leases are as follows:

 

    Right-to-Use        
    Operating Leases     Finance Leases  
October 1, 2019 to September 30, 2020   $ 107,457     $ 604,080  
October 1, 2020 to September 30, 2021     134,776       32,611  
October 1, 2021 to September 30, 2022     110,062        
October 1, 2022 to September 30, 2023     29,247        
October 1, 2023 to September 30, 2024     2,437        
Total     383,979       636,691  
                 
Less interest     (55,364 )     (18,413 )
Present value of minimum lease payments     328,615       618,278  
                 
Less current portion of lease obligations     (141,830 )     (589,457 )
Lease obligations, net of current portion   $ 186,785     $ 28,821  

 

As of September 30, 2019, the Company is in default of substantially all its finance lease obligations, therefore the aggregate future minimum rentals and accrued interest under finance leases in the amount of $0.6 million are deemed to be immediately due.

XML 55 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accrued Expenses
9 Months Ended
Sep. 30, 2019
Payables and Accruals [Abstract]  
Accrued Expenses

Note 6 – Accrued Expenses

 

Accrued expenses at September 30, 2019 (unaudited) and December 31, 2018 consisted of the following:

 

    September 30,     December 31,  
    2019     2018  
Commissions payable   $ 19,113     $ 19,113  
Sales tax payable     8,009       8,016  
Accrued payroll and related liabilities     6,761,173       3,400,052  
Accrued property tax     41,784       47,396  
Accrued interest     2,586,652       5,464,837  
Other accrued expenses     1,125,488       1,771,867  
Accrued expenses   $ 10,542,219     $ 10,711,281  

 

Accrued expenses at December 31, 2018 included $4.9 million of interest due under the terms of a settlement agreement for a prepaid forward purchase contract related to an accounts receivable financing, which was paid by Mr. Diamantis on behalf of the Company during the nine months ended September 30, 2019, as more fully discussed in Note 7. Accrued expenses at September 30, 2019 and December 31, 2018 included $1.8 million and $0.3 million, respectively, of accrued interest due to Mr. Diamantis related to loans made by Mr. Diamantis to the Company as more fully discussed in Note 7.

XML 56 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Description of Business

Description of Business

 

Rennova Health, Inc. (“Rennova”), together with its subsidiaries (the “Company”, “we”, “us” or “our”), is a vertically integrated provider of healthcare related products and services. The Company’s principal lines of business are (i) Hospital Operations; and (ii) Clinical Laboratory Operations. The Company presents its financial results based upon these two business segments, which are more fully discussed in Note 16.

Reverse Stock Split

Reverse Stock Split

 

On November 5, 2018, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-500 reverse stock split effective November 12, 2018 (the “Reverse Stock Split”). The stockholders of the Company had approved the amendment to the Company’s Certificate of Incorporation on August 22, 2018 for the Reverse Stock Split. The Company’s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations, and the timing of the reverse split within certain specified effective dates.

 

As a result of the Reverse Stock Split, every 500 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock on November 12, 2018. In addition, the conversion and exercise prices of all of the Company’s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the applicable reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Split, other than as a result of cash paid in lieu of fractional shares as no fractional shares were issued in connection with the Reverse Stock Split.

 

All share, per share and capital stock amounts as of and for the three and nine months ended September 30, 2018 have been restated to give effect to the Reverse Stock Split.

 

In addition, on September 18, 2018, the Company amended its Certificate of Incorporation to have the authority to issue 10,000,000,000 shares of common stock and the par value of the Company’s common stock was decreased from $0.01 per share to $0.0001 per share. No additional change was made to the terms of the Company’s common stock as a result of the November 12, 2018 reverse stock split and no change was made to the authorized preferred stock, which remains at 5,000,000 shares of preferred stock, par value $0.01 per share.

 

The Reverse Stock Split provided sufficient authorized and unissued shares to allow for the Company’s outstanding and otherwise equity classified instruments to be classified in equity. As a result, the fair value of these instruments was evaluated for reclassification and, as a result, during the third quarter of 2018, the Company reclassified its derivative liabilities previously reported as a current liability to derivative income. On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of its Series K Convertible Preferred Stock (“Series K Preferred Stock”) to Alcimede LLC (“Alcimede”), a related party, as more fully discussed in Note 19. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding.

Jamestown Regional Medical Center Medicare Agreement

Jamestown Regional Medical Center Medicare Agreement

 

Following an inspection at Jamestown Regional Medical Center on February 5, 2019, the hospital was informed on February 15 that several conditions of participation in its Medicare agreement were deficient. The hospital was informed that if the deficiencies where not corrected by May 16 the Medicare agreement would terminate. A follow-up inspection on May 15 resulted in the determination that the hospital had failed to adequately correct the deficiencies highlighted and a notice of involuntary termination was issued that was effective on June 12, 2019. A significant percentage of patients at Jamestown Regional Medical Center are covered by Medicare and without any ability to get paid for these services the Company suspended operations at the hospital. The hospital received initial approval of its application to reactivate the Medicare agreement in August of 2019 and is currently planning the reopening of the hospital.

Basis of Presentation

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the consolidated financial statements as filed on the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on October 21, 2019. In the opinion of management, the unaudited condensed consolidated financial statements included herein contain all adjustments necessary to present fairly the Company’s consolidated financial position as of September 30, 2019, and the results of its operations, changes in stockholders’ deficit and cash flows for the three and nine months ended September 30, 2019 and 2018. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2019 may not be indicative of results for the year ending December 31, 2019.

Principles of Consolidation

Principles of Consolidation

 

The accompanying condensed consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) include the accounts of Rennova and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in the consolidation.

Reclassification

Reclassification

 

For the nine months ended September 30, 2018, the Company has presented the proceeds from related party notes payable and advances that were previously netted against payments on related party notes payable and advances as a separate line item on the Statement of Cash Flows. This reclassification did not have an effect on total cash flow from financing activities for the nine months ended September 30, 2018.

Comprehensive Loss

Comprehensive Loss

 

During the three and nine months ended September 30, 2019 and 2018, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations.

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include the estimates of fair values of assets acquired and liabilities assumed in business combinations, including hospital acquisitions, reserves, contractual allowances and write-downs related to receivables and inventories, the recoverability of long-lived assets, stock based compensation, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and derivative instruments, including modifications thereof, deemed dividends and debt discounts, among others. Actual results could differ from those estimates and would impact future results of operations and cash flows.

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had minimal cash equivalents at September 30, 2019 and December 31, 2018.

Revenue Recognition

Revenue Recognition

 

Hospital Operations

 

Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.

 

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain government programs, primarily Medicare, this is generally referred to as the “cost report” filing and settlement process). There were no adjustments to estimated Medicare and Medicaid reimbursement amounts and disproportionate-share funds related primarily to cost reports filed during the three and nine months ended September 30, 2019 and 2018.

 

The Emergency Medical Treatment and Labor Act (“EMTALA”) requires any hospital participating in the Medicare program to conduct an appropriate medical screening examination of every person who presents to the hospital’s emergency room for treatment and, if the individual is suffering from an emergency medical condition, to either stabilize the condition or make an appropriate transfer of the individual to a facility able to handle the condition. The obligation to screen and stabilize emergency medical conditions exists regardless of an individual’s ability to pay for treatment. Federal and state laws and regulations require, and our commitment to providing quality patient care encourages, us to provide services to patients who are financially unable to pay for the health care services they receive. The federal poverty level is established by the federal government and is based on income and family size. The Company considers the poverty level in determining whether patients qualify for free or reduced cost of care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. We provide discounts to uninsured patients who do not qualify for Medicaid or charity care. In implementing the uninsured discount policy, we may first attempt to provide assistance to uninsured patients to help determine whether they may qualify for Medicaid, other federal or state assistance, or charity care. If an uninsured patient does not qualify for these programs, the uninsured discount is applied.

 

The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management’s assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable (the “hindsight analysis”) as a primary source of information in estimating the collectability of our accounts receivable. We perform the hindsight analysis quarterly, utilizing rolling twelve-months accounts receivable collection and write-off data. We believe our quarterly updates to the estimated contractual allowance amounts at each of our hospital facilities provide reasonable estimates of our revenues and valuations of our accounts receivable.

 

Clinical Laboratory Operations

 

Laboratory testing services include chemical diagnostic tests such as blood analysis and urine analysis. Laboratory service revenues are recognized at the time the testing services are performed and billed and are reported at their estimated net realizable amounts. Net service revenues are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the U.S. have an agreement with a third-party payer such as a commercial insurance provider, Medicaid or Medicare to pay all or a portion of their healthcare expenses; most of the services provided by us are to patients covered under a third-party payer contract. In most cases, the Company is provided the third-party billing information and seeks payment from the third party in accordance with the terms and conditions of the third-party payer for health service providers like us. Each of these third-party payers may differ not only in terms of rates, but also with respect to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payer methods and trends. Despite follow up billing efforts, the Company does not currently anticipate collection of a significant portion of self-pay billings, including the patient responsibility portion of the billing for patients covered by third party payers. The Company currently does not have any capitated agreements.

 

We review our calculations for the realizability of gross service revenues monthly to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payer groups. The contractual allowance calculation is made based on historical allowance rates for the various specific payer groups monthly with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions. This calculation is routinely analyzed by us based on actual allowances issued by payers and the actual payments made to determine what adjustments, if any, are needed.

Bad Debt and Contractual Allowances

Bad Debt and Contractual Allowances

 

Total gross revenues for Hospital and Clinical Laboratory Operations were reduced in the aggregate by approximately $0.9 million and $1.8 million for bad debt for the three months ended September 30, 2019 and 2018, respectively. After bad debt and contractual and related allowance adjustments to revenues of $21.9 million and $25.1 million, for the three months ended September 30, 2019 and 2018, respectively, we reported net revenues of $3.9 million and $5.0 million, respectively.

 

Total gross revenues for Hospital and Clinical Operations were reduced in the aggregate by approximately $4.8 million and $3.1 million for bad debt for the nine months ended September 30, 2019 and 2018, respectively. After bad debt and contractual and related allowance adjustments to revenues of $86.7 million and $43.8 million, for the nine months ended September 30, 2019 and 2018, respectively, we reported net revenues of $13.1 million and $9.9 million, respectively. We continue to review the provision for bad debt and contractual and related allowances.

Leases, Including the Adoption of ASU No. 2016-02

Leases, Including the Adoption of ASU No. 2016-02

 

We adopted ASU No. 2016-02, Leases (Topic 842), which requires leases with durations greater than 12 months to be recognized on the balance sheet, effective January 1, 2019, using the modified retrospective approach. Prior period financial statement amounts and disclosures have not been adjusted to reflect the provisions of the new standard. We elected the package of transition provisions available which allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. We lease property and equipment under finance and operating leases. For leases with terms greater than 12 months, we record the related right-of-use assets and right-of-use obligations at the present value of lease payments over the term. We do not separate lease and non-lease components of contracts. Our operating and finance leases are more fully discussed in Note 10.

Derivative Financial Instruments and Fair Value, Including the Adoption of ASU 2017-11

Derivative Financial Instruments and Fair Value, Including the Adoption of ASU 2017-11

 

We account for warrants issued in conjunction with the issuance of common stock and certain convertible debt instruments in accordance with the guidance contained in Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). For warrant instruments and conversion options embedded in promissory notes that are not deemed to be indexed to the Company’s own stock, we classified such instruments as liabilities at their fair values at the time of issuance and adjusted the instruments to fair value at each reporting period. These liabilities were subject to re-measurement at each balance sheet date until extinguished either through conversion or exercise, and any change in fair value was recognized in our statement of operations. The fair values of these derivative and other financial instruments had been estimated using a Black-Scholes model and other valuation techniques.

 

In July 2017, the FASB issued ASU 2017-11 “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.

 

When the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis.

 

The Company has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company’s first fiscal quarter of 2017. The remaining $16 million was offset to additional paid-in-capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million of which $51 million of the deemed dividend was recorded retrospectively as of the beginning of the issuance of the debentures issued in March 2017 where the initial derivative liability was recorded as a result of the down round provision feature. A deemed dividend of $231.8 million was recorded for the year ended December 31, 2018, a deemed dividend of $123.9 million was recorded during the nine months ended September 30, 2019 and a deemed dividend of $17.9 million and $17.9 million was recorded for the three and nine months ended September 30, 2018, respectively, as a result of down round provision features. See Note 11 for an additional discussion of derivative financial instruments.

Earnings (Loss) Per Share

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC Topic 260, “Earnings Per Share”, which establishes standards for computing and presenting earnings per share. Basic earnings (loss) per share of common stock is calculated by dividing net (loss) earnings allocable to common shareholders by the weighted-average shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted earnings (loss) per share is calculated by adjusting the weighted-average shares of common stock outstanding for the dilutive effect of common stock equivalents, including stock options and warrants outstanding for the period as determined using the treasury stock method. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation when their effect would be anti-dilutive. Therefore, basic and diluted net loss per share applicable to common shareholders is the same for periods with a net loss. See Note 3 for the computation of earnings (loss) per share for the three and nine months ended September 30, 2019 and 2018.

XML 57 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Reporting
9 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Segment Reporting

Note 16– Segment Reporting

 

Operating segments are defined under U.S. GAAP as components of an enterprise for which discrete financial information is available and are evaluated regularly by the enterprise’s chief operating decision maker in determining how to allocate resources and assess performance. The Company operates in two reportable business segments:

 

  Hospital Operations, which reflects the operations of Jamestown Regional Medical Center, Big South Fork Medical Center and Jellico Community Hospital and CarePlus Center.
  Clinical Laboratory Operations, which specializes in providing urine and blood toxicology and pain medication testing to physicians, clinics and rehabilitation facilities in the United States.

 

The Company’s Corporate expenses reflect consolidated company-wide support services such as finance, legal counsel, human resources, and payroll.

 

The Company’s Decision Support and Informatics segment and its Supportive Software Solutions segment are now included in discontinued operations as they have been classified as held for sale as of September 30, 2019. The accounting policies of the reportable segments are the same as those described in Note 1.

 

Selected financial information for the Company’s operating segments is as follows:

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
    2019     2018     2019     2018  
Net revenues - External                                
Hospital Operations   $ 3,920,608     $ 5,021,543     $ 13,081,647     $ 9,755,099  
Clinical Laboratory Operations     (34,631 )     17,569       56,169       177,890  
    $ 3,885,977     $ 5,039,112     $ 13,137,816     $ 9,932,989  
(Loss) income from continuing operations before income taxes:                                
Hospital Operations   $ (1,769,400 )   $ (1,294,581 )   $ (8,946,720 )     (3,998,943 )
Clinical Laboratory Operations     (295,908 )     (547,041 )     (701,466 )     (1,765,395 )
Corporate     (640,044 )     (973,953 )     (2,626,953 )     (3,156,646 )
Other income (expense), net     (9,422,340 )     100,171,656       (26,064,924 )     4,955,262  
    $ (12,127,692 )   $ 97,356,081     $ (38,340,063 )   $ (3,965,722 )
Depreciation and amortization                                
Hospital Operations     182,832     $ 39,669     $ 532,979     $ 177,386  
Clinical Laboratory Operations     10,036       112,908       69,381       625,877  
Corporate     7,128       248       7,458       811  
    $ 199,996     $ 152,825     $ 609,818     $ 804,074  
Capital expenditures                                
Hospital Operations   $ 7,086     $ 103,387     $ 50,801     $ 103,387  
Clinical Laboratory Operations     -       -       -       -  
    $ 7,086     $ 103,387     $ 50,801     $ 103,387  

 

    As of  
    September 30, 2019     December 31, 2018  
Total assets                
Hospital Operations   $ 16,831,443     $ 13,568,933  
Clinical Laboratory Operations     356,854       271,426  
Corporate     1,821,952       2,707,416  
Assets of AMSG and HTS classified as held for sale     373,121       152,171  
Eliminations     (2,809,305 )     (2,500,646 )
    $ 16,574,065     $ 14,199,300  

XML 58 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings (Loss) Per Share - Schedule of Earnings Per Share (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Earnings Per Share [Abstract]        
Numerator: Net (loss) income from continuing operations $ (12,127,692) $ 97,356,081 $ (38,340,063) $ (3,965,798)
Numerator: Net (loss) income from discontinued operations (138,076) (159,430) (791,936) 115,787
Numerator: Deemed dividends (17,942,578) (123,861,587) (17,942,578)
Numerator: Net loss (income) to common shareholders -basic (12,265,768) 79,254,073 (162,993,586) (21,792,589)
Adjustments for diluted calculations: Deduct change in fair value of derivative liabilities (109,305,331)  
Adjustments for diluted calculations: Amortize discounts associated with conversion of dilutive convertible debentures (7,303,912)  
Remove change in warrant value for diluted (11,376)
Add back deemed dividends 17,942,578
Net (loss) income to common shareholders - diluted $ (12,265,768) $ (19,423,968) $ (162,993,586) $ (21,792,589)
Denominator: Basic weighted average number of common shares outstanding 6,634,045,471 5,531,767 4,461,922,587 2,550,632
Common stock equivalents: Warrants 64,315,740  
Common stock equivalents: Convertible preferred stock 9,505,156  
Common stock equivalents: Convertible debentures 175,301,554  
Diluted 6,634,045,471 254,654,217 4,461,922,587 2,550,632
Net (loss) income per common share- continuing operations: Basic $ (0.00) $ 17.6 $ (0.01) $ (1.55)
Net (loss) income per common share- continuing operations: Diluted (0.00) (0.08) (0.01) (1.55)
Net (loss) income per common share- discontinued operations: Basic (0.00) (0.03) (0.00) 0.05
Net (loss) income per common share- discontinued operations: Diluted (0.00) (0.00) (0.00) 0.05
Total per share net (loss) income to common shareholders: Basic (0.00) 14.33 (0.04) (8.54)
Total per share net (loss) income to common shareholders: Diluted $ (0.00) $ (0.08) $ (0.04) $ (8.54)
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 05, 2019
Jun. 02, 2018
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Jun. 02, 2019
Gain on bargain purchase       $ 250,000 $ 7,732,302    
Fair value of intangible assets acquired   $ 259,443              
Jamestown Regional Medical Center [Member]                  
Purchase price paid   635,096              
Closing costs of acquisition   35,735              
Legal costs   115,000              
Fair value of assets acquired and liabilities assumed   8,201,766              
Gain on bargain purchase   7,566,670 [1]   $ 7,732,302          
Fair value of intangible assets acquired   $ 504,806              
Jamestown Regional Medical Center [Member] | Non Compete Intangible [Member]                  
Fair value of intangible assets acquired                 $ 245,363
Remaining amortization period               2 years  
Impairment of intangible assets               $ 200,000  
Jellico Community Hospital and CarePlus Center [Member]                  
Purchase price paid $ 658,537                
Fair value of assets acquired and liabilities assumed 908,537                
Gain on bargain purchase 250,000                
Total cost of acquisition 908,537                
Diligence, legal and other costs $ 250,000                
[1] Gain was adjusted in the fourth quarter of 2018 from $7,732,302 to $7,566,670 to reflect an adjustment of the value of the property and equipment acquired.
XML 60 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Redeemable Preferred Stock (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Jul. 16, 2018
Feb. 09, 2018
Feb. 09, 2018
Oct. 30, 2017
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Sep. 18, 2018
Preferred stock, shares authorized         5,000,000     5,000,000
Preferred stock, par value         $ 0.01     $ 0.01
Common Stock [Member]                
Number of shares converted         8,150,754,118   106,335,991  
September Debenture [Member]                
Principal amount of debt converted into shares $ 1,741,580 $ 1,384,556            
Series I-1 Preferred Stock [Member]                
Preferred stock, shares authorized       4,960        
Preferred stock, par value       $ 1,000        
Proceeds from offering       $ 4,960,000        
Series I-1 Preferred Stock [Member] | Investor [Member]                
Preferred stock, par value       $ 0.80        
Preferred stock subscription amount       1.00        
Common stock conversion price per share       $ 1.00        
Common stock weighted average market price percentage       85.00%        
Series I-1 Preferred Stock [Member] | Purchase Agreement [Member]                
Proceeds from offering       $ 4,000,000        
Ownership percentage       50.00%        
Series I-2 Convertible Preferred Stock [Member]                
Preferred stock, shares authorized         5,000,000      
Preferred stock, par value       $ 1.00 $ 1,000      
Common stock conversion price per share       $ 1.00        
Common stock weighted average market price percentage       85.00%        
Debenture surrender value       $ 0.80        
Series I-2 Convertible Preferred Stock [Member] | September Debenture [Member]                
Number of shares issued for debenture exchange     1,730.7          
Series I-2 Convertible Preferred Stock [Member] | Board of Directors [Member]                
Preferred stock, shares authorized         21,346      
Series I-2 Preferred Stock [Member]                
Principal amount of debt converted into shares           $ 1,500,000    
Number of shares issued for debenture exchange 2,176.975              
Number of shares converted         982.101   1,286.141  
XML 61 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Finance and Operating Lease Obligations - Schedule of Future Minimum Rentals Under Right-to-use Operating and Capital Leases (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Leases [Abstract]    
October 1, 2019 to September 30, 2020, Right-to-Use Operating Leases $ 107,457  
October 1, 2020 to September 30, 2021, Right-to-Use Operating Leases 134,776  
October 1, 2021 to September 30, 2022, Right-to-Use Operating Leases 110,062  
October 1, 2022 to September 30, 2023, Right-to-Use Operating Leases 29,247  
October 1, 2023 to September 30, 2024, Right-to-Use Operating Leases 2,437  
Total, Right-to-Use Operating Leases 383,979  
Less interest, Right-to-Use Operating Leases (55,364)  
Present value of minimum lease payments, Right-to-Use Operating Leases 946,893  
Less current portion of lease obligations, Right-to-Use Operating Leases (141,830)
Lease obligations, net of current portion, Right-to-Use Operating Leases 186,785
October 1, 2019 to September 30, 2020, Finance Leases 604,080  
October 1, 2020 to September 30, 2021, Finance Leases 32,611  
October 1, 2021 to September 30, 2022, Finance Leases  
October 1, 2022 to September 30, 2023, Finance Leases  
October 1, 2023 to September 30, 2024, Finance Leases  
Total, Finance Leases 636,691  
Less interest, Finance Leases (18,413)  
Present value of minimum lease payments, Finance Leases 618,278  
Less current portion of lease obligations, Finance Leases (589,457) (730,665)
Lease obligations, net of current portion, Finance Leases $ 28,821 $ 31,543
XML 62 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Finance and Operating Lease Obligations (Details Narrative)
Sep. 30, 2019
USD ($)
Leases [Abstract]  
Minimum rentals and accrued interest $ 600,000
XML 63 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Notes Payable - Schedule of Notes Payable - Related Parties (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Less current portion of notes payable, related party $ (14,968,104) $ (800,000)
Loan Payable to Christopher Diamantis [Member]    
Total notes payable, related party 14,968,104 800,000
Notes Payable Related Parties [Member]    
Total notes payable, related party 14,968,104 800,000
Less current portion of notes payable, related party (14,968,104) (800,000)
Total notes payable, related party, net of current portion
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Payables and Accruals [Abstract]    
Commissions payable $ 19,113 $ 19,113
Sales tax payable 8,009 8,016
Accrued payroll and related liabilities 6,761,173 3,400,052
Accrued property tax 41,784 47,396
Accrued interest 2,586,652 5,464,837
Other accrued expenses 1,125,488 1,771,867
Accrued expenses $ 10,542,219 $ 10,711,281
XML 65 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Deficit - Schedule of Warrants Activity (Details) - Warrants [Member]
9 Months Ended
Sep. 30, 2019
$ / shares
shares
Number of shares issuable pursuant to warrants, outstanding, beginning balance 53,130,510,439
Number of shares issuable pursuant to warrants, Increase during the period as a result of down round provisions 582,209,844,938
Number of shares issuable pursuant to warrants, Shares issued pursuant to Warrants exercised during the period (755,000,000)
Number of shares issuable pursuant to warrants, outstanding, ending balance 634,585,355,377
Weighted average exercise price, warrants outstanding, beginning balance | $ / shares $ 0.00172
Weighted average exercise price, Shares issued pursuant to Warrants exercised during the period | $ / shares 0.00034
Weighted average exercise price, warrants outstanding, ending balance | $ / shares $ 0.00014
XML 66 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Reporting - Schedule of Segment Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Net revenues - External $ 3,885,977 $ 5,039,112 $ 13,137,816 $ 9,932,989  
(Loss) income from continuing operations before income taxes: (12,127,692) 97,356,081 (38,340,063) (3,965,722)  
Depreciation and amortization 199,996 152,825 609,818 804,074  
Capital expenditures 7,086 103,387 50,801 103,387  
Total assets 16,574,065   16,574,065   $ 14,199,300
Hospital Operations [Member]          
Net revenues - External 3,920,608 5,021,543 13,081,647 9,755,099  
(Loss) income from continuing operations before income taxes: (1,769,400) (1,294,581) (8,946,720) (3,998,943)  
Depreciation and amortization 182,832 39,669 532,979 177,386  
Capital expenditures 7,086 103,387 50,801 103,387  
Total assets 16,831,443   16,831,443   13,568,933
Clinical Laboratory Operations [Member]          
Net revenues - External (34,631) 17,569 56,169 177,890  
(Loss) income from continuing operations before income taxes: (295,908) (547,041) (701,466) (1,765,395)  
Depreciation and amortization 10,036 112,908 69,381 625,877  
Capital expenditures  
Total assets 356,854   356,854   271,426
Corporate [Member]          
(Loss) income from continuing operations before income taxes: (640,044) (973,953) (2,626,953) (3,156,646)  
Depreciation and amortization 7,128 248 7,458 811  
Total assets 1,821,952   1,821,952   2,707,416
Other Income (Expense), Net [Member]          
(Loss) income from continuing operations before income taxes: (9,422,340) $ 100,171,656 (26,064,924) $ 4,955,262  
Assets of AMSG And HTS Classified as Held for Sale [Member]          
Total assets 373,121   373,121   152,171
Eliminations [Member]          
Total assets $ (2,809,305)   $ (2,809,305)   $ (2,500,646)
XML 67 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Redeemable Preferred Stock
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Redeemable Preferred Stock

Note 12 – Redeemable Preferred Stock

 

The Company has 5,000,000 authorized shares of Preferred Stock at a par value of $0.01. Issuances of the Company’s Preferred Stock included as part of stockholders’ deficit are discussed in Note 13. The following is a summary of the issuances of the Company’s Redeemable Preferred Stock.

 

Series I-1 Convertible Preferred Stock

 

On October 30, 2017, the Company closed an offering of $4,960,000 stated value of 4,960 shares of a newly-authorized Series I-1 Convertible Preferred Stock (the “Series I-1 Preferred Stock”). Each share of Series I-1 Preferred Stock has a stated value of $1,000. The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of October 30, 2017 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $4.0 million from the offering. The Purchase Agreement gives the investors the right to participate in up to 50% of any offering of common stock or common stock equivalents by the Company. In the event of any such offering, the investors may also exchange all or some of their Series I-1 Preferred Stock for such new securities on an $0.80 stated value of Series I-1 Preferred Stock for $1.00 of new subscription amount basis. Each share of Series I-1 Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-1 Preferred Stock. Upon the occurrence of certain Triggering Events, as defined in the Certificate of Designation of the Series I-1 Preferred Stock, the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-1 Preferred Stock in cash or in certain circumstances in shares of common stock at the redemption prices set forth in the Certificate of Designation.

 

Series I-2 Convertible Preferred Stock

 

On October 30, 2017, the Company entered into Exchange Agreements with the holders of the September Debentures to provide that the holders may, from time to time, exchange their September Debentures for shares of a newly-authorized Series I-2 Preferred Stock. The Exchange Agreements permitted the holders of the September Debentures to exchange specified principal amounts of the September Debentures on various closing dates starting on December 2, 2017 (debentures are more fully discussed in Note 9 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K). At the holder’s option each holder could reduce the principal amount of September Debentures exchanged on any particular closing date, or elect not to exchange any September Debentures at all on a closing date. If a holder chose to exchange less principal amount of September Debentures, or no September Debentures at all, it could carry forward such lesser amount to a future closing date and then exchange more than the originally specified principal amount for that later closing date. For each $0.80 of principal amount of September Debenture surrendered to the Company at any closing date, the Company will issue the holder a share of Series I-2 Preferred Stock with a stated value of $1.00. Each share of Series I-2 Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-2 Preferred Stock. From December 2, 2017 through March 1, 2018, any exchange under the Exchange Agreements was at the option of the holder. Subsequent to March 2018, any exchange is at the option of the Company.

 

The Company’s board of directors has designated up to 21,346 shares of the 5,000,000 authorized shares of preferred stock as the Series I-2 Preferred Stock. Each share of Series I-2 Preferred Stock has a stated value of $1,000. Upon the occurrence of certain Triggering Events (as defined in the Certificate of Designation of the Series I-2 Preferred Stock), the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-2 Preferred Stock in cash or in certain circumstances in shares of common stock at the redemption prices set forth in the Certificate of Designation.

 

On February 9, 2018, the holders exercised their right to exchange a portion of the September Debentures for shares of the Series I-2 Preferred Stock for the first time. On that date, the holders exchanged an aggregate of $1,384,556 principal amount of September Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Preferred Stock. On July 16, 2018, under the Exchange Agreements with the holders of the September Debentures, the holders exchanged a portion of the September Debentures for shares of the Company’s Series I-2 Preferred Stock. On that date, the holders exchanged an aggregate of $1,741,580 principal amount of the September Debentures and the Company issued an aggregate of 2,176.975 shares of its Series I-2 Preferred Stock. During the nine months ended September 30, 2018, the Company recorded a loss on these exchanges of convertible debentures into shares of its Series I-2 Preferred Stock in the aggregate amount of $1.5 million. In 2018, the holder converted 1,286.141 shares of Series I-2 Preferred Stock into 106,335,991 shares of the Company’s common stock and during the nine months ended September 30, 2019, the holder converted 982.101 shares of Series I-2 Preferred Stock into 8,150,754,118 shares of the Company’s common stock.

 

See Notes 3 and 19 for a discussion of the dilutive effect of the Series I-1 Preferred Stock and the Series I-2 Preferred Stock as of September 30, 2019 and December 26, 2019, respectively.

XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 376 508 1 true 104 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://rennovahealth.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://rennovahealth.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://rennovahealth.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://rennovahealth.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Sheet http://rennovahealth.com/role/StatementsOfChangesInStockholdersDeficit Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://rennovahealth.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://rennovahealth.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity and Financial Condition Sheet http://rennovahealth.com/role/LiquidityAndFinancialCondition Liquidity and Financial Condition Notes 8 false false R9.htm 00000009 - Disclosure - Earnings (Loss) Per Share Sheet http://rennovahealth.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 9 false false R10.htm 00000010 - Disclosure - Accounts Receivable Sheet http://rennovahealth.com/role/AccountsReceivable Accounts Receivable Notes 10 false false R11.htm 00000011 - Disclosure - Acquisitions Sheet http://rennovahealth.com/role/Acquisitions Acquisitions Notes 11 false false R12.htm 00000012 - Disclosure - Accrued Expenses Sheet http://rennovahealth.com/role/AccruedExpenses Accrued Expenses Notes 12 false false R13.htm 00000013 - Disclosure - Notes Payable Notes http://rennovahealth.com/role/NotesPayable Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Debentures Sheet http://rennovahealth.com/role/Debentures Debentures Notes 14 false false R15.htm 00000015 - Disclosure - Related Party Transactions Sheet http://rennovahealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 00000016 - Disclosure - Finance and Operating Lease Obligations Sheet http://rennovahealth.com/role/FinanceAndOperatingLeaseObligations Finance and Operating Lease Obligations Notes 16 false false R17.htm 00000017 - Disclosure - Derivative Financial Instruments and Fair Value Sheet http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValue Derivative Financial Instruments and Fair Value Notes 17 false false R18.htm 00000018 - Disclosure - Redeemable Preferred Stock Sheet http://rennovahealth.com/role/RedeemablePreferredStock Redeemable Preferred Stock Notes 18 false false R19.htm 00000019 - Disclosure - Stockholders' Deficit Sheet http://rennovahealth.com/role/StockholdersDeficit Stockholders' Deficit Notes 19 false false R20.htm 00000020 - Disclosure - Supplemental Disclosure of Cash Flow Information Sheet http://rennovahealth.com/role/SupplementalDisclosureOfCashFlowInformation Supplemental Disclosure of Cash Flow Information Notes 20 false false R21.htm 00000021 - Disclosure - Commitments and Contingencies Sheet http://rennovahealth.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 21 false false R22.htm 00000022 - Disclosure - Segment Reporting Sheet http://rennovahealth.com/role/SegmentReporting Segment Reporting Notes 22 false false R23.htm 00000023 - Disclosure - Discontinued Operations Sheet http://rennovahealth.com/role/DiscontinuedOperations Discontinued Operations Notes 23 false false R24.htm 00000024 - Disclosure - Recent Accounting Pronouncements Sheet http://rennovahealth.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 24 false false R25.htm 00000025 - Disclosure - Subsequent Events Sheet http://rennovahealth.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://rennovahealth.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://rennovahealth.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 26 false false R27.htm 00000027 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://rennovahealth.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) Tables http://rennovahealth.com/role/EarningsLossPerShare 27 false false R28.htm 00000028 - Disclosure - Accounts Receivable (Tables) Sheet http://rennovahealth.com/role/AccountsReceivableTables Accounts Receivable (Tables) Tables http://rennovahealth.com/role/AccountsReceivable 28 false false R29.htm 00000029 - Disclosure - Acquisitions (Tables) Sheet http://rennovahealth.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://rennovahealth.com/role/Acquisitions 29 false false R30.htm 00000030 - Disclosure - Accrued Expenses (Tables) Sheet http://rennovahealth.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://rennovahealth.com/role/AccruedExpenses 30 false false R31.htm 00000031 - Disclosure - Notes Payable (Tables) Notes http://rennovahealth.com/role/NotesPayableTables Notes Payable (Tables) Tables http://rennovahealth.com/role/NotesPayable 31 false false R32.htm 00000032 - Disclosure - Debentures (Tables) Sheet http://rennovahealth.com/role/DebenturesTables Debentures (Tables) Tables http://rennovahealth.com/role/Debentures 32 false false R33.htm 00000033 - Disclosure - Finance and Operating Lease Obligations (Tables) Sheet http://rennovahealth.com/role/FinanceAndOperatingLeaseObligationsTables Finance and Operating Lease Obligations (Tables) Tables http://rennovahealth.com/role/FinanceAndOperatingLeaseObligations 33 false false R34.htm 00000034 - Disclosure - Derivative Financial Instruments and Fair Value (Tables) Sheet http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValueTables Derivative Financial Instruments and Fair Value (Tables) Tables http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValue 34 false false R35.htm 00000035 - Disclosure - Stockholders' Deficit (Tables) Sheet http://rennovahealth.com/role/StockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://rennovahealth.com/role/StockholdersDeficit 35 false false R36.htm 00000036 - Disclosure - Supplemental Disclosure of Cash Flow Information (Tables) Sheet http://rennovahealth.com/role/SupplementalDisclosureOfCashFlowInformationTables Supplemental Disclosure of Cash Flow Information (Tables) Tables http://rennovahealth.com/role/SupplementalDisclosureOfCashFlowInformation 36 false false R37.htm 00000037 - Disclosure - Segment Reporting (Tables) Sheet http://rennovahealth.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://rennovahealth.com/role/SegmentReporting 37 false false R38.htm 00000038 - Disclosure - Discontinued Operations (Tables) Sheet http://rennovahealth.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://rennovahealth.com/role/DiscontinuedOperations 38 false false R39.htm 00000039 - Disclosure - Subsequent Events (Tables) Sheet http://rennovahealth.com/role/SubsequentEventsTables Subsequent Events (Tables) Tables http://rennovahealth.com/role/SubsequentEvents 39 false false R40.htm 00000040 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://rennovahealth.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://rennovahealth.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies 40 false false R41.htm 00000041 - Disclosure - Liquidity and Financial Condition (Details Narrative) Sheet http://rennovahealth.com/role/LiquidityAndFinancialConditionDetailsNarrative Liquidity and Financial Condition (Details Narrative) Details http://rennovahealth.com/role/LiquidityAndFinancialCondition 41 false false R42.htm 00000042 - Disclosure - Earnings (Loss) Per Share (Details Narrative) Sheet http://rennovahealth.com/role/EarningsLossPerShareDetailsNarrative Earnings (Loss) Per Share (Details Narrative) Details http://rennovahealth.com/role/EarningsLossPerShareTables 42 false false R43.htm 00000043 - Disclosure - Earnings (Loss) Per Share - Schedule of Earnings Per Share (Details) Sheet http://rennovahealth.com/role/EarningsLossPerShare-ScheduleOfEarningsPerShareDetails Earnings (Loss) Per Share - Schedule of Earnings Per Share (Details) Details http://rennovahealth.com/role/EarningsLossPerShareTables 43 false false R44.htm 00000044 - Disclosure - Earnings (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://rennovahealth.com/role/EarningsLossPerShare-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Earnings (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details http://rennovahealth.com/role/EarningsLossPerShareTables 44 false false R45.htm 00000045 - Disclosure - Accounts Receivable (Details Narrative) Sheet http://rennovahealth.com/role/AccountsReceivableDetailsNarrative Accounts Receivable (Details Narrative) Details http://rennovahealth.com/role/AccountsReceivableTables 45 false false R46.htm 00000046 - Disclosure - Accounts Receivable - Schedule of Accounts Receivable (Details) Sheet http://rennovahealth.com/role/AccountsReceivable-ScheduleOfAccountsReceivableDetails Accounts Receivable - Schedule of Accounts Receivable (Details) Details 46 false false R47.htm 00000047 - Disclosure - Acquisitions (Details Narrative) Sheet http://rennovahealth.com/role/AcquisitionsDetailsNarrative Acquisitions (Details Narrative) Details http://rennovahealth.com/role/AcquisitionsTables 47 false false R48.htm 00000048 - Disclosure - Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) Sheet http://rennovahealth.com/role/Acquisitions-ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) Details 48 false false R49.htm 00000049 - Disclosure - Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) Sheet http://rennovahealth.com/role/Acquisitions-ScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) (Parenthetical) Details 49 false false R50.htm 00000050 - Disclosure - Acquisitions - Schedule of Unaudited Pro-forma of Results of Operations (Details) Sheet http://rennovahealth.com/role/Acquisitions-ScheduleOfUnauditedPro-formaOfResultsOfOperationsDetails Acquisitions - Schedule of Unaudited Pro-forma of Results of Operations (Details) Details 50 false false R51.htm 00000051 - Disclosure - Accrued Expenses (Details Narrative) Sheet http://rennovahealth.com/role/AccruedExpensesDetailsNarrative Accrued Expenses (Details Narrative) Details http://rennovahealth.com/role/AccruedExpensesTables 51 false false R52.htm 00000052 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://rennovahealth.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails Accrued Expenses - Schedule of Accrued Expenses (Details) Details 52 false false R53.htm 00000053 - Disclosure - Notes Payable (Details Narrative) Notes http://rennovahealth.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://rennovahealth.com/role/NotesPayableTables 53 false false R54.htm 00000054 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) Notes http://rennovahealth.com/role/NotesPayable-ScheduleOfNotesPayableDetails Notes Payable - Schedule of Notes Payable (Details) Details 54 false false R55.htm 00000055 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Notes http://rennovahealth.com/role/NotesPayable-ScheduleOfNotesPayableDetailsParenthetical Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Details 55 false false R56.htm 00000056 - Disclosure - Notes Payable - Schedule of Notes Payable - Related Parties (Details) Notes http://rennovahealth.com/role/NotesPayable-ScheduleOfNotesPayable-RelatedPartiesDetails Notes Payable - Schedule of Notes Payable - Related Parties (Details) Details 56 false false R57.htm 00000057 - Disclosure - Debentures (Details Narrative) Sheet http://rennovahealth.com/role/DebenturesDetailsNarrative Debentures (Details Narrative) Details http://rennovahealth.com/role/DebenturesTables 57 false false R58.htm 00000058 - Disclosure - Debentures - Schedule of Debentures (Details) Sheet http://rennovahealth.com/role/Debentures-ScheduleOfDebenturesDetails Debentures - Schedule of Debentures (Details) Details 58 false false R59.htm 00000059 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://rennovahealth.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://rennovahealth.com/role/RelatedPartyTransactions 59 false false R60.htm 00000060 - Disclosure - Finance and Operating Lease Obligations (Details Narrative) Sheet http://rennovahealth.com/role/FinanceAndOperatingLeaseObligationsDetailsNarrative Finance and Operating Lease Obligations (Details Narrative) Details http://rennovahealth.com/role/FinanceAndOperatingLeaseObligationsTables 60 false false R61.htm 00000061 - Disclosure - Finance and Operating Lease Obligations - Schedule of Lease-related Assets and Liabilities (Details) Sheet http://rennovahealth.com/role/FinanceAndOperatingLeaseObligations-ScheduleOfLease-relatedAssetsAndLiabilitiesDetails Finance and Operating Lease Obligations - Schedule of Lease-related Assets and Liabilities (Details) Details 61 false false R62.htm 00000062 - Disclosure - Finance and Operating Lease Obligations - Schedule of Information Related to Lease Expense for Finance and Operating Leases (Details) Sheet http://rennovahealth.com/role/FinanceAndOperatingLeaseObligations-ScheduleOfInformationRelatedToLeaseExpenseForFinanceAndOperatingLeasesDetails Finance and Operating Lease Obligations - Schedule of Information Related to Lease Expense for Finance and Operating Leases (Details) Details 62 false false R63.htm 00000063 - Disclosure - Finance and Operating Lease Obligations - Schedule of Supplemental Cash Flow Information (Details) Sheet http://rennovahealth.com/role/FinanceAndOperatingLeaseObligations-ScheduleOfSupplementalCashFlowInformationDetails Finance and Operating Lease Obligations - Schedule of Supplemental Cash Flow Information (Details) Details 63 false false R64.htm 00000064 - Disclosure - Finance and Operating Lease Obligations - Schedule of Future Minimum Rentals Under Right-to-use Operating and Capital Leases (Details) Sheet http://rennovahealth.com/role/FinanceAndOperatingLeaseObligations-ScheduleOfFutureMinimumRentalsUnderRight-to-useOperatingAndCapitalLeasesDetails Finance and Operating Lease Obligations - Schedule of Future Minimum Rentals Under Right-to-use Operating and Capital Leases (Details) Details 64 false false R65.htm 00000065 - Disclosure - Derivative Financial Instruments and Fair Value (Details Narrative) Sheet http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValueDetailsNarrative Derivative Financial Instruments and Fair Value (Details Narrative) Details http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValueTables 65 false false R66.htm 00000066 - Disclosure - Derivative Financial Instruments and Fair Value - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValue-ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Derivative Financial Instruments and Fair Value - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) Details 66 false false R67.htm 00000067 - Disclosure - Derivative Financial Instruments and Fair Value - Schedule of Changes in Liabilities with Level 3 of Fair Value (Details) Sheet http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValue-ScheduleOfChangesInLiabilitiesWithLevel3OfFairValueDetails Derivative Financial Instruments and Fair Value - Schedule of Changes in Liabilities with Level 3 of Fair Value (Details) Details 67 false false R68.htm 00000068 - Disclosure - Redeemable Preferred Stock (Details Narrative) Sheet http://rennovahealth.com/role/RedeemablePreferredStockDetailsNarrative Redeemable Preferred Stock (Details Narrative) Details http://rennovahealth.com/role/RedeemablePreferredStock 68 false false R69.htm 00000069 - Disclosure - Stockholders' Deficit (Details Narrative) Sheet http://rennovahealth.com/role/StockholdersDeficitDetailsNarrative Stockholders' Deficit (Details Narrative) Details http://rennovahealth.com/role/StockholdersDeficitTables 69 false false R70.htm 00000070 - Disclosure - Stockholders' Deficit - Schedule of Stock Option Activity (Details) Sheet http://rennovahealth.com/role/StockholdersDeficit-ScheduleOfStockOptionActivityDetails Stockholders' Deficit - Schedule of Stock Option Activity (Details) Details 70 false false R71.htm 00000071 - Disclosure - Stockholders' Deficit - Schedule of Warrants Activity (Details) Sheet http://rennovahealth.com/role/StockholdersDeficit-ScheduleOfWarrantsActivityDetails Stockholders' Deficit - Schedule of Warrants Activity (Details) Details 71 false false R72.htm 00000072 - Disclosure - Supplemental Disclosure of Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) Sheet http://rennovahealth.com/role/SupplementalDisclosureOfCashFlowInformation-ScheduleOfSupplementalCashFlowInformationDetails Supplemental Disclosure of Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) Details 72 false false R73.htm 00000073 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://rennovahealth.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://rennovahealth.com/role/CommitmentsAndContingencies 73 false false R74.htm 00000074 - Disclosure - Segment Reporting (Details Narrative) Sheet http://rennovahealth.com/role/SegmentReportingDetailsNarrative Segment Reporting (Details Narrative) Details http://rennovahealth.com/role/SegmentReportingTables 74 false false R75.htm 00000075 - Disclosure - Segment Reporting - Schedule of Segment Information (Details) Sheet http://rennovahealth.com/role/SegmentReporting-ScheduleOfSegmentInformationDetails Segment Reporting - Schedule of Segment Information (Details) Details 75 false false R76.htm 00000076 - Disclosure - Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) Sheet http://rennovahealth.com/role/DiscontinuedOperations-ScheduleOfDiscontinuedOperationOfBalanceSheetAndOperationStatementDetails Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) Details 76 false false R77.htm 00000077 - Disclosure - Subsequent Events (Details Narrative) Sheet http://rennovahealth.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://rennovahealth.com/role/SubsequentEventsTables 77 false false R78.htm 00000078 - Disclosure - Subsequent Events - Schedule of Dilutive Effect of Potential Common Shares (Details) Sheet http://rennovahealth.com/role/SubsequentEvents-ScheduleOfDilutiveEffectOfPotentialCommonSharesDetails Subsequent Events - Schedule of Dilutive Effect of Potential Common Shares (Details) Details 78 false false All Reports Book All Reports rnva-20190930.xml rnva-20190930.xsd rnva-20190930_cal.xml rnva-20190930_def.xml rnva-20190930_lab.xml rnva-20190930_pre.xml http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 69 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debentures
9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Debentures

Note 8 – Debentures

 

The carrying amount of all outstanding debentures as of September 30, 2019 (unaudited), and December 31, 2018 is as follows:

 

    September 30, 2019     December 31, 2018  
Debentures   $ 28,690,240     $ 19,034,800  
Discount on Debentures     -       (6,247,469 )
Deferred financing fees     -       (11,015 )
      28,690,240       12,776,316  
Less current portion     (28,690,240 )     (12,776,316 )
Debentures, long-term   $ -     $ -  

 

As of September 30, 2019, $2.0 million of outstanding debentures issued in March 2017 were not paid as of March 21, 2019, the maturity date and $17.1 million of outstanding debentures issued during 2017 and 2018 were not paid as of September 19, 2019, the maturity date. The Company has accrued penalties in connection with these non-payments in the amount of $5.7 million as of September 30, 2019. These debentures have still not been paid and remain outstanding, and the Company has been accruing interest on these debentures at the default rate of 18% per annum since the dates of the payment defaults.

 

Debentures Issued in the Nine Months Ended September 30, 2019

 

The Company issued debentures on February 24, 2019 in the aggregate principal amount of $300,000 and on March 27, 2019 in the aggregate principal amount of $300,000. Both of these debentures were guaranteed by Mr. Diamantis and were originally due on June 3, 2019. The maturity dates of these debentures were extended to December 31, 2019 and the terms were changed so that commencing on August 17, 2019 the debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest shall entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law.

 

The Company issued debentures on May 12, 2019 in the aggregate principal amount of $500,000. These debentures were guaranteed by Mr. Diamantis and were due on June 3, 2019. In addition, the Company issued debentures on June 5, 2019 in the aggregate principal amount of $125,000 and on June 7, 2019 in the aggregate principal amount of $200,000. These debentures were also guaranteed by Mr. Diamantis and were due on July 20, 2019. The maturity dates of these debentures were extended to December 31, 2019 and the terms were changed so that commencing on August 17, 2019 the debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest shall entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law.

 

On June 13, 2019, the Company closed an offering of $1,250,000 aggregate principal amount of debentures with certain existing institutional investors pursuant to the terms of a Bridge Debenture Agreement, dated as of June 13, 2019 (the “June 13 Agreement”) and received proceeds of $1,250,000. The June 13 Agreement provided that on or prior to June 30, 2019, at the mutual election of the Company and the investors, the investors could purchase an additional $1,250,000 principal amount on the same terms and conditions as provided in the June 13 Agreement. Under the June 13 Agreement, the maturity date of the debentures issued on February 24, 2019, March 27, 2019, May 12, 2019, June 5, 2019 and June 7, 2019 were extended to December 31, 2019 and the terms were changed such that they have the same interest terms as contained in the June 13, 2019 debentures, as more fully discussed below.

 

On June 21, 2019, the Company and the investors agreed that the Company would issue, and the investors would purchase, $250,000 principal amount of debentures and on June 24, 2019 the Company and the investors agreed that the Company would issue, and the investors would purchase, an additional $1,020,000 aggregate principal amount of debentures. In connection with the issuances of the June 21, 2019 and June 24, 2019 debentures, the Company received total proceeds of $1,270,000.

 

The June 13, 2019, June 21, 2019 and June 24, 2019 debentures (collectively, the “June 2019 Debentures”) are secured and guaranteed by the Company’s subsidiaries on the same terms as provided in the Purchase Agreement, dated as of August 31, 2017, which is more fully described in Note 9 to the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2018. At the Company’s option, the June 2019 Debentures may also be exchanged for shares of the Company’s Series I-2 Convertible Preferred Stock under the terms of the previously-announced Exchange Agreement, dated as of October 30, 2017. Commencing on August 17, 2019, the June 2019 Debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law. Christopher Diamantis is a guarantor of the June 2019 Debentures.

 

In addition to the debentures issued in the nine months ended September 30, 2019, during the years ending December 31, 2017 and 2018, the Company issued convertible debentures, which are more fully described in Note 9 to the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2018. Certain of these convertible debentures were issued with warrants to purchase shares of the Company’s common stock. Outstanding warrants are more fully discussed in Note 13.

 

The debentures issued during the nine months ended September 30, 2019 and 2018, were issued at discounts of $0.1 million and $2.9 million, respectively, and accordingly, the Company realized a total of $3.8 million and $8.0 million, respectively, in proceeds from the issuances of the debentures. At September 30, 2019, these discounts have been fully amortized. These discounts represented original issue discounts, the relative fair value of the warrants issued with the debentures and the relative fair value of the beneficial conversion features of the debentures. During the three months ended September 30, 2019 and 2018, the Company recorded approximately $1.4 million and approximately $9.0 million, respectively, of non-cash interest and amortization of debt discount expense in connection with the debentures and warrants. During the nine months ended September 30, 2019 and 2018, the Company recorded approximately $15.8 million and approximately $16.1 million, respectively, of non-cash interest and amortization of debt discount expense primarily in connection with the debentures and warrants. These amounts include non-cash interest expense and debt discount amortization, which resulted from the modification of warrants as more fully discussed in Notes 11 and 13.

 

See Note 13 for summarized information related to warrants issued and the activity during the nine months ended September 30, 2019.

 

See Notes 3, 13 and 19 for a discussion of the dilutive effect of the outstanding convertible debentures, warrants and convertible preferred stock as of September 30, 2019.

XML 70 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accounts Receivable
9 Months Ended
Sep. 30, 2019
Receivables [Abstract]  
Accounts Receivable

Note 4 – Accounts Receivable

 

Accounts receivable at September 30, 2019 (unaudited) and December 31, 2018 consisted of the following:

 

    September 30,     December 31,  
    2019     2018  
Accounts receivable - Clinical Laboratory Operations   $ 41,750     $ 622,009  
Accounts receivable - Hospital Operations     45,804,056       31,607,644  
Accounts receivable - Other     (52,296 )     -  
Total accounts receivable     45,793,510       32,229,653  
Less:                
Amount purchased by factors     (1,572,000 )     -  
Allowance for discounts - Clinical Laboratory Operations     (26,182 )     (573,584 )
Allowance for discounts - Hospital Operations     (36,298,972 )     (25,066,799 )
Allowance for bad debts     (2,787,894 )     (2,777,521 )
Accounts receivable, net   $ 5,108,462     $ 3,811,749  

 

Accounts Receivable Factoring Arrangements

 

During the nine months ended September 30, 2019, the Company entered into five accounts receivable factoring arrangements. Under the terms of the arrangements, the aggregate amount of accounts receivable sold on a non-recourse basis, was $3.9 million. The aggregate purchase price paid to the Company was $2.7 million, the total origination and other fees incurred by the Company were $0.1 million and the Company recorded a loss on sale of the receivables of $1.2 million. As of September 30, 2019, $1.6 million of the outstanding accounts receivable were purchased but not yet paid to the factors.

XML 71 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Finance and Operating Lease Obligations (Tables)
9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Schedule of Lease-related Assets and Liabilities

The following table presents our lease-related assets and liabilities at September 30, 2019:

 

    Balance Sheet Classification   September 30, 2019  
Assets:            
Operating leases   Right-of-use operating lease assets   $ 328,615  
Finance leases   Property and equipment, net     618,278  
Total lease assets       $ 946,893  
             
Liabilities:            
Current:            
Operating leases   Right-of-use operating lease assets   $ 141,830  
Finance leases   Current liabilities     589,457  
Noncurrent:            
Operating leases   Right-of-use operating lease obligations     186,785  
Finance leases   Long-term debt     28,821  
             
Total lease liabilities       $ 946,893  
             
Weighted-average remaining term:            
Operating leases         1.98 years  
Finance leases         0.19 years  
Weighted-average discount rate:            
Operating leases (1)         13.0 %
Finance leases         5.122 %

 

(1) Upon adoption of the new lease standard, discount rates used for existing operating leases were established at January 1, 2019.

Schedule of Information Related to Lease Expense for Finance and Operating Leases

The following table presents certain information related to lease expense for finance and operating leases for the three and nine months ended September 30, 2019:

 

   

Three Months Ended

September 30, 2019

    Nine Months Ended
September 30, 2019
 
Finance lease expense:                
Depreciation/amortization of leased assets (1)   $ 15,004     $ (30,055 )
Interest on lease liabilities     704       5,804  
Operating leases:                
Short-term lease expense (2)     76,312       263,713  
Total lease expense   $ 92,020     $ 239,462  

 

(1) The depreciation for the nine months ended September 30, 2019 has been adjusted for depreciation recorded in the prior year.

(2) Expenses are included in general and administrative expenses in our condensed consolidated statements of operations.

Schedule of Supplemental Cash Flow Information

The following table presents supplemental cash flow information for the nine months ended September 30, 2019:

 

    2019  
Cash paid for amounts included in the measurement of lease liabilities:        
Operating cash flows for operating leases   $ 214,357  
Operating cash flows for finance leases   $ 5,800  
Financing cash flows for finance leases payments   $ 143,930  

Schedule of Future Minimum Rentals Under Right-to-use Operating and Capital Leases

Aggregate future minimum rentals under right-to-use operating and finance leases are as follows:

 

    Right-to-Use        
    Operating Leases     Finance Leases  
October 1, 2019 to September 30, 2020   $ 107,457     $ 604,080  
October 1, 2020 to September 30, 2021     134,776       32,611  
October 1, 2021 to September 30, 2022     110,062        
October 1, 2022 to September 30, 2023     29,247        
October 1, 2023 to September 30, 2024     2,437        
Total     383,979       636,691  
                 
Less interest     (55,364 )     (18,413 )
Present value of minimum lease payments     328,615       618,278  
                 
Less current portion of lease obligations     (141,830 )     (589,457 )
Lease obligations, net of current portion   $ 186,785     $ 28,821  

XML 72 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Accounts payable related parties $ 500,000 $ 400,000
Accrued expenses related parties $ 180,000 $ 400,000
Preferred stock par value $ 0.01  
Preferred stock shares authorized 5,000,000  
Common stock par value $ 0.0001 $ 0.0001
Common stock shares authorized 10,000,000,000 10,000,000,000
Common stock shares issued 8,398,936,775 128,567,273
Common stock shares outstanding 8,398,936,775 128,567,273
Series G Preferred Stock [Member]    
Preferred stock par value $ 0.01 $ 0.01
Preferred stock shares authorized 14,000 14,000
Preferred stock shares issued 215 215
Preferred stock shares outstanding 215 215
Series H Preferred Stock [Member]    
Preferred stock par value $ 0.01 $ 0.01
Preferred stock shares authorized 14,202 14,202
Preferred stock shares issued 10 60
Preferred stock shares outstanding 10 60
Series F Preferred Stock [Member]    
Preferred stock par value $ 0.01 $ 0.01
Preferred stock shares authorized 1,750,000 1,750,000
Preferred stock shares issued 1,750,000 1,750,000
Preferred stock shares outstanding 1,750,000 1,750,000
Series J Preferred Stock [Member]    
Preferred stock par value $ 0.01 $ 0.01
Preferred stock shares authorized 250,000 250,000
Preferred stock shares issued 250,000 250,000
Preferred stock shares outstanding 250,000 250,000
XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Schedule of Segment Information

Selected financial information for the Company’s operating segments is as follows:

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
    2019     2018     2019     2018  
Net revenues - External                                
Hospital Operations   $ 3,920,608     $ 5,021,543     $ 13,081,647     $ 9,755,099  
Clinical Laboratory Operations     (34,631 )     17,569       56,169       177,890  
    $ 3,885,977     $ 5,039,112     $ 13,137,816     $ 9,932,989  
(Loss) income from continuing operations before income taxes:                                
Hospital Operations   $ (1,769,400 )   $ (1,294,581 )   $ (8,946,720 )     (3,998,943 )
Clinical Laboratory Operations     (295,908 )     (547,041 )     (701,466 )     (1,765,395 )
Corporate     (640,044 )     (973,953 )     (2,626,953 )     (3,156,646 )
Other income (expense), net     (9,422,340 )     100,171,656       (26,064,924 )     4,955,262  
    $ (12,127,692 )   $ 97,356,081     $ (38,340,063 )   $ (3,965,722 )
Depreciation and amortization                                
Hospital Operations     182,832     $ 39,669     $ 532,979     $ 177,386  
Clinical Laboratory Operations     10,036       112,908       69,381       625,877  
Corporate     7,128       248       7,458       811  
    $ 199,996     $ 152,825     $ 609,818     $ 804,074  
Capital expenditures                                
Hospital Operations   $ 7,086     $ 103,387     $ 50,801     $ 103,387  
Clinical Laboratory Operations     -       -       -       -  
    $ 7,086     $ 103,387     $ 50,801     $ 103,387  

 

    As of  
    September 30, 2019     December 31, 2018  
Total assets                
Hospital Operations   $ 16,831,443     $ 13,568,933  
Clinical Laboratory Operations     356,854       271,426  
Corporate     1,821,952       2,707,416  
Assets of AMSG and HTS classified as held for sale     373,121       152,171  
Eliminations     (2,809,305 )     (2,500,646 )
    $ 16,574,065     $ 14,199,300  

XML 75 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Organization and Summary of Significant Accounting Policies

Note 1 – Organization and Summary of Significant Accounting Policies

 

Description of Business

 

Rennova Health, Inc. (“Rennova”), together with its subsidiaries (the “Company”, “we”, “us” or “our”), is a vertically integrated provider of healthcare related products and services. The Company’s principal lines of business are (i) Hospital Operations; and (ii) Clinical Laboratory Operations. The Company presents its financial results based upon these two business segments, which are more fully discussed in Note 16.

 

Reverse Stock Split

 

On November 5, 2018, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-500 reverse stock split effective November 12, 2018 (the “Reverse Stock Split”). The stockholders of the Company had approved the amendment to the Company’s Certificate of Incorporation on August 22, 2018 for the Reverse Stock Split. The Company’s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations, and the timing of the reverse split within certain specified effective dates.

 

As a result of the Reverse Stock Split, every 500 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock on November 12, 2018. In addition, the conversion and exercise prices of all of the Company’s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the applicable reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Split, other than as a result of cash paid in lieu of fractional shares as no fractional shares were issued in connection with the Reverse Stock Split.

 

All share, per share and capital stock amounts as of and for the three and nine months ended September 30, 2018 have been restated to give effect to the Reverse Stock Split.

 

In addition, on September 18, 2018, the Company amended its Certificate of Incorporation to have the authority to issue 10,000,000,000 shares of common stock and the par value of the Company’s common stock was decreased from $0.01 per share to $0.0001 per share. No additional change was made to the terms of the Company’s common stock as a result of the November 12, 2018 reverse stock split and no change was made to the authorized preferred stock, which remains at 5,000,000 shares of preferred stock, par value $0.01 per share.

 

The Reverse Stock Split provided sufficient authorized and unissued shares to allow for the Company’s outstanding and otherwise equity classified instruments to be classified in equity. As a result, the fair value of these instruments was evaluated for reclassification and, as a result, during the third quarter of 2018, the Company reclassified its derivative liabilities previously reported as a current liability to derivative income. On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of its Series K Convertible Preferred Stock (“Series K Preferred Stock”) to Alcimede LLC (“Alcimede”), a related party, as more fully discussed in Note 19. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding.

 

Jamestown Regional Medical Center Medicare Agreement

 

Following an inspection at Jamestown Regional Medical Center on February 5, 2019, the hospital was informed on February 15 that several conditions of participation in its Medicare agreement were deficient. The hospital was informed that if the deficiencies where not corrected by May 16 the Medicare agreement would terminate. A follow-up inspection on May 15 resulted in the determination that the hospital had failed to adequately correct the deficiencies highlighted and a notice of involuntary termination was issued that was effective on June 12, 2019. A significant percentage of patients at Jamestown Regional Medical Center are covered by Medicare and without any ability to get paid for these services the Company suspended operations at the hospital. The hospital received initial approval of its application to reactivate the Medicare agreement in August of 2019 and is currently planning the reopening of the hospital.

  

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the consolidated financial statements as filed on the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on October 21, 2019. In the opinion of management, the unaudited condensed consolidated financial statements included herein contain all adjustments necessary to present fairly the Company’s consolidated financial position as of September 30, 2019, and the results of its operations, changes in stockholders’ deficit and cash flows for the three and nine months ended September 30, 2019 and 2018. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2019 may not be indicative of results for the year ending December 31, 2019.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) include the accounts of Rennova and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in the consolidation.

 

Reclassification

 

For the nine months ended September 30, 2018, the Company has presented the proceeds from related party notes payable and advances that were previously netted against payments on related party notes payable and advances as a separate line item on the Statement of Cash Flows. This reclassification did not have an effect on total cash flow from financing activities for the nine months ended September 30, 2018.

 

Comprehensive Loss

 

During the three and nine months ended September 30, 2019 and 2018, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include the estimates of fair values of assets acquired and liabilities assumed in business combinations, including hospital acquisitions, reserves, contractual allowances and write-downs related to receivables and inventories, the recoverability of long-lived assets, stock based compensation, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and derivative instruments, including modifications thereof, deemed dividends and debt discounts, among others. Actual results could differ from those estimates and would impact future results of operations and cash flows.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had minimal cash equivalents at September 30, 2019 and December 31, 2018.

 

Revenue Recognition

 

Hospital Operations

 

Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.

 

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain government programs, primarily Medicare, this is generally referred to as the “cost report” filing and settlement process). There were no adjustments to estimated Medicare and Medicaid reimbursement amounts and disproportionate-share funds related primarily to cost reports filed during the three and nine months ended September 30, 2019 and 2018.

 

The Emergency Medical Treatment and Labor Act (“EMTALA”) requires any hospital participating in the Medicare program to conduct an appropriate medical screening examination of every person who presents to the hospital’s emergency room for treatment and, if the individual is suffering from an emergency medical condition, to either stabilize the condition or make an appropriate transfer of the individual to a facility able to handle the condition. The obligation to screen and stabilize emergency medical conditions exists regardless of an individual’s ability to pay for treatment. Federal and state laws and regulations require, and our commitment to providing quality patient care encourages, us to provide services to patients who are financially unable to pay for the health care services they receive. The federal poverty level is established by the federal government and is based on income and family size. The Company considers the poverty level in determining whether patients qualify for free or reduced cost of care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. We provide discounts to uninsured patients who do not qualify for Medicaid or charity care. In implementing the uninsured discount policy, we may first attempt to provide assistance to uninsured patients to help determine whether they may qualify for Medicaid, other federal or state assistance, or charity care. If an uninsured patient does not qualify for these programs, the uninsured discount is applied.

 

The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management’s assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable (the “hindsight analysis”) as a primary source of information in estimating the collectability of our accounts receivable. We perform the hindsight analysis quarterly, utilizing rolling twelve-months accounts receivable collection and write-off data. We believe our quarterly updates to the estimated contractual allowance amounts at each of our hospital facilities provide reasonable estimates of our revenues and valuations of our accounts receivable.

 

Clinical Laboratory Operations

 

Laboratory testing services include chemical diagnostic tests such as blood analysis and urine analysis. Laboratory service revenues are recognized at the time the testing services are performed and billed and are reported at their estimated net realizable amounts. Net service revenues are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the U.S. have an agreement with a third-party payer such as a commercial insurance provider, Medicaid or Medicare to pay all or a portion of their healthcare expenses; most of the services provided by us are to patients covered under a third-party payer contract. In most cases, the Company is provided the third-party billing information and seeks payment from the third party in accordance with the terms and conditions of the third-party payer for health service providers like us. Each of these third-party payers may differ not only in terms of rates, but also with respect to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payer methods and trends. Despite follow up billing efforts, the Company does not currently anticipate collection of a significant portion of self-pay billings, including the patient responsibility portion of the billing for patients covered by third party payers. The Company currently does not have any capitated agreements.

 

We review our calculations for the realizability of gross service revenues monthly to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payer groups. The contractual allowance calculation is made based on historical allowance rates for the various specific payer groups monthly with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions. This calculation is routinely analyzed by us based on actual allowances issued by payers and the actual payments made to determine what adjustments, if any, are needed.

 

Bad Debt and Contractual Allowances

 

Total gross revenues for Hospital and Clinical Laboratory Operations were reduced in the aggregate by approximately $0.9 million and $1.8 million for bad debt for the three months ended September 30, 2019 and 2018, respectively. After bad debt and contractual and related allowance adjustments to revenues of $21.9 million and $25.1 million, for the three months ended September 30, 2019 and 2018, respectively, we reported net revenues of $3.9 million and $5.0 million, respectively.

 

Total gross revenues for Hospital and Clinical Operations were reduced in the aggregate by approximately $4.8 million and $3.1 million for bad debt for the nine months ended September 30, 2019 and 2018, respectively. After bad debt and contractual and related allowance adjustments to revenues of $86.7 million and $43.8 million, for the nine months ended September 30, 2019 and 2018, respectively, we reported net revenues of $13.1 million and $9.9 million, respectively. We continue to review the provision for bad debt and contractual and related allowances.

 

Leases, Including the Adoption of ASU No. 2016-02

 

We adopted ASU No. 2016-02, Leases (Topic 842), which requires leases with durations greater than 12 months to be recognized on the balance sheet, effective January 1, 2019, using the modified retrospective approach. Prior period financial statement amounts and disclosures have not been adjusted to reflect the provisions of the new standard. We elected the package of transition provisions available which allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. We lease property and equipment under finance and operating leases. For leases with terms greater than 12 months, we record the related right-of-use assets and right-of-use obligations at the present value of lease payments over the term. We do not separate lease and non-lease components of contracts. Our operating and finance leases are more fully discussed in Note 10.

 

Derivative Financial Instruments and Fair Value, Including the Adoption of ASU 2017-11

 

We account for warrants issued in conjunction with the issuance of common stock and certain convertible debt instruments in accordance with the guidance contained in Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). For warrant instruments and conversion options embedded in promissory notes that are not deemed to be indexed to the Company’s own stock, we classified such instruments as liabilities at their fair values at the time of issuance and adjusted the instruments to fair value at each reporting period. These liabilities were subject to re-measurement at each balance sheet date until extinguished either through conversion or exercise, and any change in fair value was recognized in our statement of operations. The fair values of these derivative and other financial instruments had been estimated using a Black-Scholes model and other valuation techniques.

 

In July 2017, the FASB issued ASU 2017-11 “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.

 

When the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis.

 

The Company has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company’s first fiscal quarter of 2017. The remaining $16 million was offset to additional paid-in-capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million of which $51 million of the deemed dividend was recorded retrospectively as of the beginning of the issuance of the debentures issued in March 2017 where the initial derivative liability was recorded as a result of the down round provision feature. A deemed dividend of $231.8 million was recorded for the year ended December 31, 2018, a deemed dividend of $123.9 million was recorded during the nine months ended September 30, 2019 and a deemed dividend of $17.9 million and $17.9 million was recorded for the three and nine months ended September 30, 2018, respectively, as a result of down round provision features. See Note 11 for an additional discussion of derivative financial instruments.

 

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC Topic 260, “Earnings Per Share”, which establishes standards for computing and presenting earnings per share. Basic earnings (loss) per share of common stock is calculated by dividing net (loss) earnings allocable to common shareholders by the weighted-average shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted earnings (loss) per share is calculated by adjusting the weighted-average shares of common stock outstanding for the dilutive effect of common stock equivalents, including stock options and warrants outstanding for the period as determined using the treasury stock method. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation when their effect would be anti-dilutive. Therefore, basic and diluted net loss per share applicable to common shareholders is the same for periods with a net loss. See Note 3 for the computation of earnings (loss) per share for the three and nine months ended September 30, 2019 and 2018.

XML 76 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debentures (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Aug. 31, 2019
Jun. 24, 2019
Jun. 21, 2019
Jun. 13, 2019
May 12, 2019
Mar. 27, 2019
Feb. 24, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Oct. 12, 2019
Aug. 17, 2019
Jun. 07, 2019
Jun. 05, 2019
Dec. 31, 2018
Nov. 03, 2016
Outstanding debentures               $ 28,690,240   $ 28,690,240           $ 12,776,316  
Accured penalty                   5,700,000              
Proceeds from debt                   3,845,000 $ 8,000,000            
Debt instrument principal amount                                 $ 341,612
Non-cash interest and amortization of debt discount expense               1,400,000 $ 900,000 15,800,000 16,100,000            
Bridge Debenture Agreement [Member] | June Thirteen Two Thousand And Nineteen Offerings [Member]                                  
Debt instrument maturity date       Dec. 31, 2019                          
Debt instrument principal amount       $ 1,250,000                          
Proceeds from offerings       $ 1,250,000                          
Debt instrument maturity date description       Under the June 13 Agreement, the maturity date of the debentures issued on February 24, 2019, March 27, 2019, May 12, 2019, June 5, 2019 and June 7, 2019 were extended to December 31, 2019 and the terms were changed such that they have the same interest terms as contained in the June 13, 2019 debentures                          
Investors [Member] | Bridge Debenture Agreement [Member] | June Thirteen Two Thousand And Nineteen Offerings [Member]                                  
Debt instrument principal amount       $ 1,250,000                          
Debenture One [Member]                                  
Outstanding debentures               $ 2,000,000   $ 2,000,000              
Debt instrument maturity date                   Mar. 21, 2019              
Interest percentage               18.00%   18.00%     2.50%        
Debenture One [Member] | Subsequent Event [Member] | Maximum [Member]                                  
Interest percentage                       5.00%          
Debenture Two [Member]                                  
Outstanding debentures               $ 17,100,000   $ 17,100,000              
Debt instrument maturity date                   Sep. 19, 2019              
Interest percentage               18.00%   18.00%     2.50%        
Debenture Two [Member] | Subsequent Event [Member] | Maximum [Member]                                  
Interest percentage                       5.00%          
Debentures [Member]                                  
Outstanding debentures   $ 1,020,000 $ 250,000                            
Debt instrument maturity date           Dec. 31, 2019 Dec. 31, 2019                    
Interest percentage         24.00%     24.00%   24.00%     2.50%        
Debentures principal amount           $ 300,000 $ 300,000 $ 100,000 $ 2,900,000 $ 100,000 $ 2,900,000            
Interest rate, description                   Commencing on August 17, 2019 the debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019. All overdue accrued and unpaid interest shall entail a late fee equal to the lesser of 24% per annum or the maximum rate permitted by applicable law.              
Proceeds from debt   $ 1,270,000 $ 1,270,000                            
Debt instrument principal amount         $ 500,000                        
Debentures [Member] | Purchase Agreement [Member] | June 2019 Debentures [Member]                                  
Interest percentage 24.00%                                
Interest rate, description Commencing on August 17, 2019, the June 2019 Debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019.                                
Debentures [Member] | Christopher Diamantis [Member]                                  
Debt instrument maturity date         Jun. 03, 2019                        
Interest rate, description         The maturity dates of these debentures were extended to December 31, 2019 and the terms were changed so that commencing on August 17, 2019 the debentures bear interest on the outstanding principal amount at a rate of 2.5% per month (increasing to 5% per month on October 12, 2019), payable quarterly beginning on October 1, 2019.                        
Debt instrument principal amount                           $ 200,000 $ 125,000    
Debentures [Member] | Subsequent Event [Member] | Maximum [Member]                                  
Interest percentage                       5.00%          
XML 77 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Notes Payable (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 27, 2019
Jul. 28, 2019
May 31, 2019
May 20, 2019
Apr. 05, 2019
Dec. 31, 2017
Mar. 24, 2017
Mar. 21, 2017
Feb. 02, 2017
Mar. 31, 2016
Sep. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Nov. 03, 2016
Jun. 30, 2016
Repayment of debt                   $ 500,000            
Debt instrument face amount                             $ 341,612  
Proceeds from issuance of debt                       $ 3,845,000 $ 8,000,000      
Financing fees debt                       $ 11,015    
Accrued interest payable                             $ 43,000  
Estimated value of receivable           $ 8,700,000                    
Adjustment down value           $ 0                    
Investment return percentage                               20.00%
Consideration received description                   The consideration received, the counterparty received the right to: (i) a 20% per annum investment return from the Company on the consideration, with a minimum repayment term of six months and minimum return of $0.5 million, (ii) all payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty had not been paid $6.0 million, the Company was required to pay the difference. Christopher Diamantis, a director of the Company, guaranteed the Company's obligation. On March 24, 2017, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into an amendment to extend the Company's obligation to March 31, 2018. Also, what the counterparty was to receive was amended to equal (a) the $5,000,000 purchase price plus a 20% per annum investment return thereon, plus (b) $500,000, plus (c) the product of (i) the proceeds received from the accounts receivable, minus the amount set forth in clauses (a) and (b), multiplied by (ii) 40%. In connection with the extension, the counterparty received a fee of $1,000,000.            
Consideration received                   $ 5,000,000            
Payments for related party                       2,310,000 $ 4,011,000      
Christopher Diamantis [Member]                                
Accrued and unpaid interest                     700,000 1,500,000        
Repayment of debt                       700,000        
Accrued interest payable                     1,100,000 1,100,000        
Loan payable                     $ 16,700,000 $ 16,700,000        
Debt instrument interest rate                     10.00% 10.00%        
Payments for related party                       $ 2,300,000        
Fees and expenses                       1,900,000        
Working capital                       4,700,000        
Counterparty [Member]                                
Amount of fee received             $ 100,000                  
Investment return percentage             40.00%                  
Purchase price             $ 500,000                  
Diamantis [Member]                                
Debt instrument periodic payment $ 1,000,000                              
Debt instrument maturity date Nov. 08, 2019                              
Debt instrument face amount $ 1,900,000                              
Proceeds from issuance of debt 1,500,000                              
Original issue discount 300,000                              
Financing fees debt 100,000                              
Remaining periodic principal payment $ 900,000                              
Remaining periodic principal payment, due date Dec. 26, 2019                              
Christopher Diamantis [Member]                                
Payments for related party     $ 5,000,000   $ 5,000,000             $ 9,937,105        
Christopher Diamantis [Member] | Counterparty [Member]                                
Amount of fee received             $ 1,000,000                  
Investment return percentage             20.00%                  
Purchase price             $ 5,000,000                  
Loan payable         $ 2,000,000                      
Additional payment for related party       $ 7,694,685                        
Debt instrument interest rate       10.00%                        
Final Payment [Member] | Christopher Diamantis [Member] | Counterparty [Member]                                
Payments for related party   $ 4,937,105                            
TCA Debenture [Member]                                
Accrued and unpaid interest               $ 100,000 $ 400,000              
Repayment of debt               750,000                
Amount of fee received               $ 150,000                
Debt instrument maturity date               Jun. 27, 2017                
TCA Debenture [Member] | April 2017 Through September 2017 [Member]                                
Debt instrument periodic payment               $ 2,600,000                
XML 78 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events - Schedule of Dilutive Effect of Potential Common Shares (Details) - shares
3 Months Ended 9 Months Ended
Dec. 26, 2019
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Common shares outstanding   8,398,936,775   128,567,273
Dilutive potential shares   748,061,925,383 746,016,834  
Warrants [Member]        
Dilutive potential shares   634,525,355,377 463,449,767  
Convertible Preferred Stock [Member]        
Dilutive potential shares   82,901,785,590 68,344,495  
Subsequent Event [Member]        
Common shares outstanding 9,648,936,775      
Total dilutive potential common shares, including outstanding common stock 753,931,450,393      
Subsequent Event [Member] | Stock Options [Member]        
Dilutive potential shares 77      
Subsequent Event [Member] | Warrants [Member]        
Dilutive potential shares 634,525,355,377      
Subsequent Event [Member] | Convertible Debt [Member]        
Dilutive potential shares 30,634,784,339      
Subsequent Event [Member] | Convertible Preferred Stock [Member]        
Dilutive potential shares 79,122,373,825      
XML 79 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Deficit - Schedule of Stock Option Activity (Details)
9 Months Ended
Sep. 30, 2019
$ / shares
shares
Equity [Abstract]  
Number of Options Outstanding, Beginning balance | shares 77
Number of Options Outstanding, Granted | shares
Number of Options Outstanding, Expired | shares
Number of Options Outstanding, Forfeited | shares
Number of Options Outstanding, Ending balance | shares 77
Number of Options Exercisable, Ending balance | shares 68
Weighted-average exercise price, Outstanding Beginning balance | $ / shares $ 1,036,375
Weighted-average exercise price, Granted | $ / shares
Weighted-average exercise price, Expired | $ / shares
Weighted-average exercise price, Forfeited | $ / shares
Weighted-average exercise price, Outstanding, Ending balance | $ / shares 1,036,375
Weighted-average exercise price, Exercisable, Endig balance | $ / shares $ 1,152,616
Weighted-average contractual term, Beginning 7 years 3 months 29 days
Weighted-average contractual term, Ending 6 years 6 months
XML 80 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Reporting (Details Narrative)
9 Months Ended
Sep. 30, 2019
Segment
Segment Reporting [Abstract]  
Number of reportable segments 2
XML 81 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Related Party Transactions
9 Months Ended
Sep. 30, 2019
Related Party Transactions [Abstract]  
Related Party Transactions

Note 9 – Related Party Transactions

 

Alcimede billed $0.1 million and $0.1 million for consulting fees for the three months ended September 30, 2019 and 2018, respectively, and $0.3 million and $0.3 million for the nine months ended September 30, 2019 and 2018, respectively. Seamus Lagan, the Company’s President and Chief Executive Officer, is the sole manager of Alcimede (see Note 13).

 

See Notes 5, 7 and 19 for a discussion of amounts advanced to the Company by Mr. Diamantis.

 

The terms of the foregoing transactions, including those discussed in Notes 5, 7, 12 and 19, are not necessarily indicative of those that would have been agreed to with unrelated parties for similar transactions.

XML 82 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions
9 Months Ended
Sep. 30, 2019
Business Combinations [Abstract]  
Acquisitions

Note 5 – Acquisitions

 

Purchase Agreement Re Jamestown Regional Medical Center

 

On June 1, 2018, the Company acquired a business engaging in acute hospital care located in Jamestown, Tennessee under an asset purchase agreement. The acquisition also included a separate physician practice referred to as Mountain View Physician Practice, Inc. This acquisition was made as part of the Company’s business plan to acquire and operate clusters of rural hospitals.

 

Pursuant to the asset purchase agreement, by and among the Company and Jamestown TN Medical Center, Inc., and HMA Fentress County Hospital, LLC, Jamestown HMA Physician Management, LLC and CHS/Community Health Systems, Inc. (the “Sellers”), the purchase price paid for the transaction was an aggregate of $635,096, which includes closing costs of $35,735, legal costs of approximately $115,000, and other diligence related costs, which were expensed in 2018.

 

The fair value of the purchase consideration paid to the Sellers was allocated to the net tangible and intangible assets acquired. The Company accounted for the acquisition as a business combination under U.S. GAAP. In accordance with the acquisition method of accounting under ASC Topic 805, “Business Combinations,” (“ASC 805”) the assets acquired, and liabilities assumed were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company.

 

The fair value of the assets acquired, net of the liabilities assumed, was approximately $8.2 million. The excess of the aggregate fair value of the net tangible assets acquired over the purchase price was $7.6 million and has been treated as a gain on bargain purchase in accordance with ASC 805.

 

The following table shows the allocation of the purchase price of Jamestown Regional Medical Center to the acquired identifiable assets acquired, and liabilities assumed:

 

Total purchase price   $ 635,096  
Tangible and intangible assets acquired, and liabilities assumed at fair value:        
Cash   $ 375  
Inventories     450,682  
Prepaids and deposits     310,385  
Property and equipment     7,129,484  
Intangible assets     504,806  
Accrued expenses     (193,966 )
Net tangible and intangible assets acquired   $ 8,201,766  
Gain on bargain purchase (1)   $ 7,566,670  

 

  (1) Gain was adjusted in the fourth quarter of 2018 from $7,732,302 to $7,566,670 to reflect an adjustment of the value of the property and equipment acquired.

 

As reflected in the table above, the total value of intangible assets acquired in the Jamestown acquisition was $504,806, which included a certificate of need valued at $259,443 and a non-compete intangible asset valued at $245,363. The certificate of need has an indefinite life. During the year ended December 31, 2018, the Company determined that the fair value of the non-compete intangible asset, which was being amortized over two years, was fully impaired and, accordingly, the Company recorded an impairment of approximately $0.2 million in December 31, 2018.

 

Purchase Agreement re Jellico Community Hospital and CarePlus Center

 

Effective March 5, 2019, the Company acquired certain assets related to Jellico Community Hospital and CarePlus Center. Jellico Community Hospital is a fully operational 54-bed acute care facility that offers comprehensive services, including diagnostic imaging, radiology, surgery (general, gynecological and vascular), nuclear medicine, wound care and hyperbaric medicine, intensive care, emergency care and physical therapy. The CarePlus Center offers sophisticated testing capabilities and compassionate care, all in a modern, patient-friendly environment. Services include diagnostic imaging services, x-ray, mammography, bone densitometry, computed tomography (CT), ultrasound, physical therapy and laboratory services on a walk-in basis.

 

The purchase price was $658,537. This purchase price was made available by Mr. Diamantis, a director of the Company. The total cost of the acquisition is estimated to be $908,537, including $250,000 of diligence, legal and other costs associated with the acquisition. The acquisition costs were fully expensed in 2019.

 

The preliminary fair value of the purchase consideration paid to the sellers was allocated to the net tangible and intangible assets acquired. The Company accounted for the acquisition as a business combination under U.S. GAAP. In accordance with the acquisition method of accounting under ASC 805 the assets acquired, and liabilities assumed were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company.

 

The Company is currently undertaking a valuation study to determine the fair value of the assets acquired. The preliminary estimated fair value of the assets acquired, net of the liabilities assumed, was approximately $0.9 million. The excess of the aggregate fair value of the net tangible assets acquired over the purchase price is currently estimated to be $0.3 million and has been treated as a gain on bargain purchase in accordance with ASC 805. The gain is primarily due to the value of the intangible assets acquired. In addition, the provisional amounts used for the purchase price allocation are subject to adjustments for a period not to exceed one year from the acquisition date. As a result, upon completion of a valuation study, the gain on bargain purchase presented below may be increased or decreased. The preliminary purchase price allocation was based, in part, on management’s knowledge of hospital operations.

 

The following table shows the preliminary allocation of the purchase price of Jellico Community Hospital and CarePlus Center to the acquired identifiable assets acquired, and liabilities assumed:

 

Total purchase price   $ 658,537  
Tangible and intangible assets acquired, and liabilities assumed at estimated fair value:        
Inventories   $ 317,427  
Property and equipment     500,000  
Intangible asset- certificate of need     250,000  
Accrued expenses     (158,890 )
Net tangible and intangible assets acquired   $ 908,537  
Gain on bargain purchase   $ 250,000  

 

The following presents the unaudited pro-forma combined results of operations of the Company and Jamestown Regional Medical Center and Jellico Community Hospital and CarePlus Center as if the acquisitions had occurred on January 1, 2018. The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the acquisitions been completed as of January 1, 2018 or to project potential operating results as of any future date or for any future periods.

 

    Three Months Ended September 30, 2018    

Nine Months

Ended

September 30,

2019

    Nine Months Ended September 30, 2018  
                   
Net revenue   $ 8,276,112     $ 14,855,436     $ 25,499,677  
Net income (loss) from continuing operations     96,879,012       (38,537,422 )     (8,151,239 )
Deemed dividend from trigger of down round provision feature     (17,942,578 )     (123,861,587 )     (17,942,578 )
Net (loss) income from discontinued operations     (159,430 )     (791,936 )     115,787  
Net income (loss) to common shareholders - basic     78,777,004       (163,190,945 )     (25,978,030 )
Adjustments for diluted loss to common shareholders     (98,678,041 )            
Net loss to common shareholders - diluted   $ (19,901,037 )   $ (163,190,945 )   $ (25,978,030 )
                         
Net income (loss) per common share:                        
Basic continuing operations   $ 17.51     $ (0.01 )   $ (3.20 )
Diluted continuing operations   $ (0.02 )   $ (0.01 )   $ (3.20 )
Basic net income (loss) to common shareholders   $ 14.24     $ (0.04 )   $ (10.18 )
Diluted net loss to common shareholders   $ (0.24 )   $ (0.04 )   $ (10.18 )

XML 83 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Deficit
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Stockholders' Deficit

Note 13 – Stockholders’ Deficit

 

Authorized Capital

 

The Company has 10,000,000,000 authorized shares of Common Stock at $0.0001 par value and 5,000,000 authorized shares of Preferred Stock at a par value of $0.01.

 

Preferred Stock

 

The Company has 5,000,000 shares, par value $0.01, of preferred stock authorized. As of September 30, 2019, the Company had outstanding shares of preferred stock consisting of shares of its Series I-1 Preferred Stock and shares of Series I-2 Preferred Stock (both of which are more fully discussed in Note 12), 215 shares of its Series G Preferred Stock, 10 shares of its Series H Preferred Stock, 1,750,000 shares of its Series F Convertible Preferred Stock and 250,000 shares of its Series J Convertible Preferred Stock.

 

The 215 shares of the Series G Preferred Stock have a stated value of $1,000 per share and are convertible into shares of the Company’s common stock at a price equal to 85% of the volume weighted average price of the Company’s common stock at the time of conversion. See Note 19 regarding the redemption of these shares.

 

The Series H Preferred Stock has a stated value of $1,000 per share and is convertible into shares of the Company’s common stock at a conversion price of 85% of the volume weighted average price of the Company’s common stock at the time of conversion.

 

In September 2017, the Company issued 1,750,000 shares of its Series F Preferred Stock valued at $174,097 in connection with the acquisition of Genomas Inc. Genomas Inc. is included in the Company’s discontinued operations, which are discussed in Note 17. Each share of the Series F Preferred Stock is convertible into shares of our common stock (subject to adjustment as provided in the related certificate of designation) at any time after the first anniversary of the issuance date at the option of the holder at a conversion price equal to the greater of $14,625 or the average closing price of the Company’s common stock for the 10 trading days immediately preceding the conversion. The maximum number of shares of common stock issuable upon the conversion of the Series F Preferred Stock is 120. Any shares of Series F Preferred Stock outstanding on the fifth anniversary of the issuance date will be mandatorily converted into common stock at the applicable conversion price on such date. At any time, from time to time after the first anniversary of the issuance date, the Company has the right to redeem all or any portion of the outstanding Series F Preferred Stock at a price per share equal to $1.95 plus any accrued but unpaid dividends. The Series F Preferred Stock has voting rights. Each share of Series F Preferred Stock has one vote, and the holders of the Series F Preferred Stock shall vote together with the holders of the Company’s common stock as a single class.

 

On July 20, 2018, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware to authorize the issuance of up to 250,000 shares of its Series J Convertible Preferred Stock (the “Series J Preferred Stock”). On July 23, 2018, the Company entered into an Exchange Agreement (the “Agreement”) with Alcimede, of which Seamus Lagan, our Chief Executive Officer, is the sole manager. Pursuant to the Agreement, the Company issued to Alcimede 250,000 shares of the Series J Preferred Stock in exchange for the cancellation of the outstanding principal and interest owed by the Company to Alcimede under the Note, dated February 5, 2015, and the cancellation of certain amounts owed by the Company to Alcimede under a consulting agreement between the parties. The total amount of consideration paid by Alcimede to the Company equaled $250,000. Each share of the Series J Preferred Stock has a stated value of $1.00. The conversion price is equal to the average closing price of the Company’s common stock on the 10 trading days immediately prior to the conversion date. Each holder of the Series J Preferred Stock is entitled to vote on all matters submitted to a vote of the holders of the Company’s common stock. From and after October 1, 2018, each share of the Series J Preferred Stock is entitled to the whole number of votes equal to the number of common shares into which it is then convertible. The full terms of the Series J Preferred Stock are listed in the Certificate of Designations filed as Exhibit 3.16 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 24, 2018. The Series J Preferred Stock is entitled to 8% per annum cumulative dividends at the discretion of the Company’s board of directors. No dividends have been declared by the board as of September 30, 2019.

 

On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement, as more fully described in Note 19.

 

Common Stock

 

The Company has authorized 10,000,000,000 shares of Common Stock, par value $0.0001 per share.

 

The Company had 8,398,936,775 and 128,567,273 shares of common stock issued and outstanding at September 30, 2019 and December 31, 2018, respectively. During the nine months ended September 30, 2019, the Company:

 

Issued 119,615,384 shares of common stock upon exercise of 755,000,000 warrants, on a cashless basis; and
   
Issued 8,150,754,118 shares of common stock upon the conversion of 982.101 shares of its Series I-2 Preferred Stock;

 

Restricted Stock

 

On August 14, 2017, the Board of Directors, based on the recommendation of the Compensation Committee of the Board and in accordance with the provisions of the 2007 Equity Plan, approved grants to employees and directors of the Company of an aggregate of 364 shares of restricted common stock of the Company. The grants fully vested on the first anniversary of the date of grant, subject to the grantee’s continued status as an employee or director on the vesting date. During the nine months ended September 30, 2019, 123 shares of the restricted stock were forfeited by their terms and returned to treasury.

 

During the nine months ended September 30, 2018, the Company issued an aggregate of 142,667 shares of restricted stock to employees and directors, based upon the recommendation of the Compensation Committee of the Board of Directors. The grants fully vested immediately. During the nine months ended September 30, 2018, the Company recognized stock-based compensation in the amount of $477,933 for the grant of such restricted stock based on a valuation of $3.35 per share. The value of the common stock issued was based on the fair value of the stock at the time of issuance.

 

Common Stock and Common Stock Equivalents

 

The Company has outstanding options, warrants, convertible preferred stock and convertible debentures. Exercise of the options and warrants, and conversions of the convertible preferred stock and debentures could result in substantial dilution of our common stock and a decline in its market price. In addition, the terms of certain of the warrants, convertible preferred stock and convertible debentures issued by us provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that we issue common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. These provisions, as well as the issuances of debentures and preferred stock with conversion prices that vary based upon the price of our common stock on the date of conversion, have resulted in significant dilution of our common stock and have given rise to reverse splits of our common stock.

 

On October 4, 2019, the Board of Directors authorized the issuance and sale of certain shares of Series K Preferred Stock to Alcimede LLC pursuant to the terms of an Exchange Agreement. The Series K Preferred Stock is more fully described in Note 19. The Board considered all options to secure additional financing required to continue operations and determined this authorization to be necessary to secure needed financing in the required time frame. As a result of this authorization, as of the date of filing this report, the Company believes that it has the ability to have sufficient authorized shares of its common stock to cover all potentially dilutive common shares. These potentially dilutive shares are presented in Note 19.

 

The Company maintained and sponsored the Tegal Corporation 2007 Incentive Award Plan (the “2007 Equity Plan”). Tegal Corporation is the prior name of the Company. The 2007 Equity Plan, as amended, provided for the issuance of stock options and other equity awards to the Company’s officers, directors, employees and consultants. The 2007 Equity Plan terminated pursuant to its terms in September 2017. The following table summarizes the stock option activity for the nine months ended September 30, 2019:

 

Stock Options

 

    Number of options     Weighted-average exercise price     Weighted-average contractual term  
Outstanding at December 31, 2018     77     $ 1,036,375       7.33  
Granted     -                  
Expired     -                  
Forfeit     -                  
Outstanding at September 30, 2019     77     $ 1,036,375       6.50  
                         
Exercisable at September 30, 2019     68     $ 1,152,616          

 

The Company recognized stock option expense of approximately $25,950 and $72,590 for the nine months ended September 30, 2019 and 2018, respectively. As of September 30, 2019, the weighted average remaining contractual life was 6.50 years for options outstanding and exercisable. The intrinsic value of options exercisable at September 30, 2019 was $0. As of September 30, 2019, the remaining compensation expense of approximately $8,650 will be amortized over the remaining vesting period, which is approximately three months.

 

Warrants

 

The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company’s common stock.

 

During the nine months ended September 30, 2019, the number of shares issuable pursuant to outstanding warrants increased by 582.2 billion as a result of the anti-dilution provisions of outstanding warrants that were issued in connection with the issuances of debentures as more fully discussed in Note 9 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K. The number of shares issued and issuable as well as the exercise prices of the warrants reflected in the table below have been adjusted to reflect the full ratchet and other dilutive and down round provisions pursuant to the warrant agreements. As a result of the current exercise prices for the majority of the outstanding warrants (subject to a floor in some cases), as well as the full ratchet provisions of the majority of the outstanding warrants (again, subject to a floor in some cases), subsequent decreases in the price of the Company’s common stock and subsequent issuances of the Company’s common stock or common stock equivalents at prices below the current exercise prices of the warrants will result in increases in the number of shares issuable pursuant to the warrants and decreases in the exercise prices.

 

The following summarizes the information related to warrants issued and the activity during the nine months ended September 30, 2019:

 

    Number of shares issuable pursuant to warrants     Weighted average exercise price  
Balance at December 31, 2018     53,130,510,439     $ 0.00172  
Increase during the period as a result of down round provisions     582,209,844,938          
Shares issued pursuant to Warrants exercised during the period     (755,000,000 )   $ 0.00034  
Balance at September 30, 2019     634,585,355,377     $ 0.00014  

 

On March 27, 2019, the expiration dates of certain warrants issued in March 2017 and September 2017 with convertible debentures, referred to as the March 2017 Series B Warrants and the September 2017 Series B Warrants, were extended from June 2019 to September 2019. On May 12, 2019, the expiration date of these warrants was further extended to March 31, 2022. The Company used the Black Scholes model to calculate the fair value of the warrants as of the modification date. Using the pre-modification terms and related assumptions, and the post-modification terms and related assumptions, the Company determined that the change in fair value of the warrants as a result of the March 27th modification was $4.1 million and the May 12th modification was $5.4 million. Accordingly, the Company recorded the modification value of $5.4 and $9.5 million as interest expense in the three and nine months ended September 30, 2019, respectively. See Note 11 for the assumptions used in the Black Scholes valuation models.

 

During the three and nine months ended September 30, 2018, the Company extended the exercise period of outstanding warrants twice, once to March 21, 2019 and the second time to June 21, 2019 and recorded an additional discount on the debenture issued in connection with the warrants of approximately $8.3 million and $0.3 million as a result of the extensions. The Company amortized approximately $6.4 million of the discount as non-cash interest expense in the nine months ended September 30, 2018. This amount was included in the cash flow statement for the nine months ended September 30, 2018 in amortization of debt discount. See Note 11 for the assumptions used in the Black Scholes valuation models.

 

See Note 19 for a discussion of the dilutive effect of the outstanding warrants as of December 26, 2019.

XML 84 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debentures (Tables)
9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Schedule of Debentures

The carrying amount of all outstanding debentures as of September 30, 2019 (unaudited), and December 31, 2018 is as follows:

 

    September 30, 2019     December 31, 2018  
Debentures   $ 28,690,240     $ 19,034,800  
Discount on Debentures     -       (6,247,469 )
Deferred financing fees     -       (11,015 )
      28,690,240       12,776,316  
Less current portion     (28,690,240 )     (12,776,316 )
Debentures, long-term   $ -     $ -  

XML 85 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash $ 107,472 $ 6,870
Accounts receivable, net 5,108,462 3,811,749
Inventory 688,819 453,402
Prepaid expenses and other current assets 77,646 78,820
Income tax refunds receivable 631,077 631,077
Current assets of AMSG and HTS classified as held for sale 362,146 140,352
Total current assets 6,975,622 5,122,270
Property and equipment, net 8,467,887 8,526,904
Right-of-use operating lease assets 328,615  
Intangibles, net 509,443 259,443
Deposits 281,523 278,864
Non-current assets of AMSG and HTS classified as held for sale 10,975 11,819
Total assets 16,574,065 14,199,300
Current liabilities:    
Accounts payable (includes related parties amount of $0.5 million and $0.4 million, respectively) 13,076,160 8,155,955
Checks issued in excess of bank account balance 121,947 109,695
Accrued expenses (includes related parties amount of $1.8 million and $0.4 million, respectively) 10,542,219 10,711,281
Income taxes payable 1,355,651 1,400,651
Current portion of notes payable 3,605,532 7,083,505
Current portion of notes payable, related party 14,968,104 800,000
Current portion of right-of-use operating lease obligations 141,830
Current portion of finance lease obligations 589,457 730,665
Current portion of debentures 28,690,240 12,776,316
Derivative liabilities 455,336 350,260
Current liabilities of AMSG and HTS classified as held for sale 2,701,459 2,297,846
Total current liabilities 76,247,935 44,416,174
Other liabilities:    
Right-of-use operating lease obligations, net of current portion 186,785
Finance lease obligations, net of current portion 28,821 31,543
Total liabilities 76,463,541 44,447,717
Commitments and contingencies
Stockholders' deficit:    
Common stock, $0.0001 par value, 10,000,000,000 shares authorized, 8,398,936,775 and 128,567,273 shares issued and outstanding 839,894 12,857
Additional paid-in-capital 509,515,347 375,845,883
Accumulated deficit (578,040,192) (415,046,606)
Total stockholders' deficit (67,664,949) (39,167,864)
Total liabilities and stockholders' deficit 16,574,065 14,199,300
Redeemable Preferred Stock I-1 [Member]    
Other liabilities:    
Redeemable Preferred Stock 5,835,294 5,835,294
Redeemable Preferred Stock I-2 [Member]    
Other liabilities:    
Redeemable Preferred Stock 1,940,179 3,084,153
Series G Preferred Stock [Member]    
Stockholders' deficit:    
Preferred stock value 2 2
Series H Preferred Stock [Member]    
Stockholders' deficit:    
Preferred stock value
Series F Preferred Stock [Member]    
Stockholders' deficit:    
Preferred stock value 17,500 17,500
Series J Preferred Stock [Member]    
Stockholders' deficit:    
Preferred stock value $ 2,500 $ 2,500
XML 86 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Supplemental Disclosure of Cash Flow Information (Tables)
9 Months Ended
Sep. 30, 2019
Supplemental Cash Flow Elements [Abstract]  
Schedule of Supplemental Cash Flow Information

    Nine Months Ended September 30,  
    2019     2018  
Cash paid for interest   $ -     $ 303,208  
Cash paid for income taxes     45,000       20,000  
                 
Acquisitions of Hospitals and Medical Center:                
Cash   $ -     $ 375  
Inventory     317,427       450,682  
Prepaid expenses and other current assets     -       310,385  
Property and equipment     500,000       7,129,484  
Intangible assets     250,000       504,806  
Accrued expenses     158,890       193,966  
                 
Non-cash investing and financing activities:                
Exchange of Series I-2 Preferred Stock for common stock   $ 1,143,974     $ 633,101  
Cashless exercise of warrants     11,961       4,619,150  
Debentures converted into common stock     -       8,085,342  
Common stock issued in cashless exercise of warrants     11,961       -  
Exchange of debentures into Series I-2 Preferred Stock     -       1,420  
Conversions of Series H Preferred Stock into common stock     -       50,000  
Original issue discount of debentures and notes payable     400,000       1,920,000  
Deemed dividend for trigger of down round provision features     123,861,587       17,942,578  
Issuance of Series J Preferred Stock in settlement of note payable to related party     -       250,000  

XML 87 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash flows from operating activities:    
Net loss from continuing operations $ (38,340,063) $ (3,965,798)
Adjustments to reconcile net loss to net cash (used in) provided by operations:    
Depreciation and amortization 609,818 804,074
Stock-based compensation 25,950 739,729
Amortization of debt discount 6,386,305 16,080,270
Modification of warrants 9,464,991
Penalty for non-payment of debentures 5,710,440
Change in fair value of derivative instruments 105,076 (13,688,678)
Loss on sale of receivables to factor 1,361,053
Gain on disposal of equipment under finance leases (549,524)
Bargain purchase gain for hospitals and medical center (250,000) (7,732,302)
(Loss) income from discontinued operations (791,936) 115,787
Changes in operating assets and liabilities:    
Accounts receivable (3,525,152) (5,648,343)
Inventory 82,010 25,066
Prepaid expenses and other current assets (1,485) 113,042
Accounts payable and checks issued in excess of bank balance 4,932,457 3,497,210
Accrued expenses (327,953) 3,728,038
Income tax assets and liabilities (45,000) (12,243)
Net cash used in operating activities of continuing operations (14,603,489) (6,493,672)
Net cash provided by (used in) operating activities of discontinued operations 182,663 (628,154)
Net cash used in operating activities (14,420,826) (7,121,826)
Cash flows from investing activities:    
Purchase of hospitals and medical center (658,537) (668,983)
Proceeds from the sale of equipment under finance leases 433,612
Purchase of property and equipment (50,801) (103,387)
Net cash used in investing activities of continuing operations (709,338) (338,758)
Net cash provided by investing activities of discontinued operations 800,000
Net cash (used in) provided by investing activities (709,338) 461,242
Cash flows from financing activities:    
Proceeds from issuance of related party note payable and advances 16,478,104 3,582,500
Payments on related party note payable and advances (2,310,000) (4,011,000)
Proceeds from issuance of debentures 3,845,000 8,000,000
Payments on notes payable (5,005,794) (256,481)
Proceeds from issuance of note payable 1,500,000
Proceeds from receivables sold to factors 2,650,000
Receivables paid to factors (1,782,614)
Payments on finance lease obligations (143,930) (654,435)
Net cash provided by financing activities of continuing operations 15,230,766 6,660,584
Net cash used in financing activities of discontinued operations
Net cash provided by financing activities 15,230,766 6,660,584
Net increase in cash 100,602
Cash at beginning of period 6,870
Cash at end of period $ 107,472
XML 88 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings (Loss) Per Share (Tables)
9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share for each of the three and nine months ended September 30, 2019 and 2018:

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
    2019     2018     2019     2018  
Numerator:                                
Net (loss) income from continuing operations   $ (12,127,692 )   $ 97,356,081     $ (38,340,063 )   $ (3,965,798 )
Net (loss) income from discontinued operations     (138,076 )     (159,430 )     (791,936 )     115,787  
Deemed dividends           (17,942,578 )     (123,861,587 )     (17,942,578 )
Net loss (income) to common shareholders -basic   $ (12,265,768 )   $ 79,254,073     $ (162,993,586 )   $ (21,792,589 )
Adjustments for diluted calculations:                                
Deduct change in fair value of derivative liabilities           (109,305,331 )            
Amortize discounts associated with conversion of dilutive convertible debentures           (7,303,912 )            
Remove change in warrant value for diluted           (11,376 )            
Add back deemed dividends           17,942,578              
Net loss to common shareholders - diluted   $ (12,265,768 )   $ (19,423,968 )   $ (162,993,586 )   $ (21,792,589 )
Denominator:                                
Weighted average number of common shares outstanding during the period:                                
Basic     6,634,045,471       5,531,767       4,461,922,587       2,550,632  
Common stock equivalents:                                
Warrants           64,315,740              
Convertible preferred stock           9,505,156              
Convertible debentures           175,301,554              
Diluted     6,634,045,471       254,654,217       4,461,922,587       2,550,632  
Net (loss) income per common share- continuing operations:                                
Basic   $ (0.00 )   $ 17.60     $ (0.01 )   $ (1.55 )
Diluted   $ (0.00 )   $ (0.08 )   $ (0.01 )   $ (1.55 )
Net (loss) income per common share- discontinued operations:                                
Basic   $ (0.00 )   $ (0.03 )   $ (0.00 )   $ 0.05  
Diluted   $ (0.00 )   $ (0.00 )   $ (0.00 )   $ 0.05  
Total per share net (loss) income to common shareholders:                                
Basic   $ (0.00 )   $ 14.33     $ (0.04 )   $ (8.54 )
Diluted   $ (0.00 )   $ (0.08 )   $ (0.04 )   $ (8.54 )

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Diluted loss per share as reflected in the table above excludes all dilutive potential shares if their effect is anti-dilutive. For the nine months ended September 30, 2019 and 2018, the following table sets forth the computation of the following potential common stock equivalents excluded from the calculation of diluted loss per share as their effect was anti-dilutive:

 

    Nine Months Ended September 30,  
    2019     2018  
Warrants     634,525,355,377       463,449,767  
Convertible preferred stock     82,901,785,590       68,344,495  
Convertible debentures     30,634,784,339       214,222,495  
Stock options     77       77  
      748,061,925,383       746,016,834  

XML 89 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Discontinued Operations
9 Months Ended
Sep. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations

Note 17 – Discontinued Operations

 

On July 12, 2017, the Company announced plans to spin off AMSG and in the third quarter of 2017, the Company’s Board of Directors voted unanimously to spin off HTS as independent publicly traded companies by way of tax-free distributions to the Company’s stockholders. While the spin offs have taken longer than anticipated, completion of these spin offs is now expected to occur in the first quarter of 2020. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission, and consents, including under various funding agreements previously entered into by the Company. A record date to determine those stockholders entitled to receive shares in the spin offs should be approximately 30 to 60 days prior to the dates of the spin offs. The strategic goal of the spin offs is to create three public companies, each of which can focus on its own strengths and operational plans.

 

In accordance with ASC 205-20 and having met the criteria for “held for sale”, as the Company reached this decision prior to December 31, 2017, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. Prior to being classified as “held for sale,” AMSG had been the Company’s Decision Support and Informatics segment, except for the Company’s subsidiary, Alethea Laboratories, Inc., which had been included in the Clinical Laboratory Operations segment and now is part of AMSG, and HTS had been the Company’s Supportive Software Solutions segment. Segment disclosures in Note 16 no longer include amounts relating to AMSG and HTS following the reclassification to discontinued operations.

 

Carrying amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the condensed consolidated balance sheets consisted of the following:

 

AMSG Assets and Liabilities:

 

    September 30, 2019     December 31, 2018  
    (unaudited)     (unaudited)  
Cash   $ 220     $ 4,471  
Accounts receivable, net     22,523       6,838  
Prepaid expenses and other current assets     -       25,477  
Current assets classified as held for sale   $ 22,743     $ 36,786  
                 
Accounts payable (includes related parties)   $ 514,415     $ 532,858  
Accrued expenses     493,356       418,932  
Income taxes payable     -       -  
Current portion of notes payable     268,851       278,836  
Current liabilities classified as held for sale   $ 1,276,622     $ 1,230,626  
                 
Non-current liabilities classified as held for sale   $ -     $ -  

 

HTS Assets and Liabilities:

 

    September 30, 2019     December 31, 2018  
    (unaudited)     (unaudited)  
Cash   $ 2,298     $ 2,523  
Accounts receivable, net     330,238       90,743  
Prepaid expenses and other current assets     6,867       10,300  
Current assets classified as held for sale   $ 339,403     $ 103,566  
                 
Property and equipment, net   $ 4,946     $ 5,790  
Deposits     6,029       6,029  
Non-current assets classified as held for sale   $ 10,975     $ 11,819  
                 
Accounts payable (includes related parties)   $ 710,709     $ 546,969  
Accrued expenses     714,128       520,251  
Current portion of notes payable     -       -  
Current liabilities classified as held for sale   $ 1,424,837     $ 1,067,220  

 

Total Discontinued Assets and Liabilities:

 

    September 30, 2019     December 31, 2018  
    (unaudited)     (unaudited)  
Cash   $ 2,518     $ 6,994  
Accounts receivable, net     352,761       97,581  
Prepaid expenses and other current assets     6,867       35,777  
Current assets classified as held for sale   $ 362,146     $ 140,352  
                 
Property and equipment, net   $ 4,946     $ 5,790  
Deposits     6,029       6,029  
Non-current assets classified as held for sale   $ 10,975     $ 11,819  
                 
Accounts payable (includes related parties)   $ 1,225,124     $ 1,079,827  
Accrued expenses     1,207,484       939,183  
Current portion of notes payable     268,851       278,836  
Current liabilities classified as held for sale   $ 2,701,459     $ 2,297,846  

 

Major line items constituting loss from discontinued operations in the condensed consolidated statements of operations for the three months ended September 30, 2019 and 2018 consisted of the following:

 

AMSG Loss from Discontinued Operations:

 

    Three Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 11,350     $ 13,249  
Cost of services     5,878       15,559  
Gross profit (loss)     5,472       (2,310 )
Operating expenses     60,424       93,059  
Other income (expenses)     2,912       (5,748 )
Provision for income taxes     -       -  
Loss from discontinued operations   $ (57,864 )   $ (89,621 )

 

HTS Loss from Discontinued Operations:

 

    Three Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 235,326     $ 499,317  
Cost of services     20,134       30,082  
Gross profit     215,192       469,235  
Operating expenses     295,404       532,892  
Other income     -       6,152  
Provision for income taxes     -       -  
Loss from discontinued operations   $ (80,212 )   $ (69,809 )

 

Consolidated Loss from Discontinued Operations:

 

    Three Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 246,676     $ 512,566  
Cost of services     26,012       45,641  
Gross profit     220,664       466,925  
Operating expenses     355,828       625,951  
Other expense     2,912       404  
Provision for income taxes     -       -  
Loss from discontinued operations   $ (138,076 )   $ (159,430 )

 

Major line items constituting (loss) income from discontinued operations in the condensed consolidated statements of operations for the nine months ended September 30, 2019 and 2018 consisted of the following:

 

AMSG (Loss) Income from Discontinued Operations:

 

    Nine Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 59,832     $ 92,090  
Cost of services     29,638       37,773  
Gross profit     30,194       54,317  
Operating expenses     237,042       363,944  
Other (income) expense     31,874       (819,258 )
Provision for income taxes     -       -  
(Loss) income from discontinued operations   $ (238,722 )   $ 509,631  

 

HTS Loss from Discontinued Operations:

 

    Nine Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 706,795     $ 1,291,288  
Cost of services     83,628       95,965  
Gross profit     623,167       1,195,323  
Operating expenses     1,176,381       1,577,046  
Other income     -       12,121  
Provision for income taxes     -       -  
Loss from discontinued operations   $ (553,214 )   $ (393,844 )

 

Consolidated (Loss) Income from Discontinued Operations:

 

    Nine Months Ended  
    September 30, 2019     September 30, 2018  
    (unaudited)     (unaudited)  
Revenue from services   $ 766,627     $ 1,383,378  
Cost of services     113,266       133,738  
Gross profit     653,361       1,249,640  
Operating expenses     1,413,423       1,940,990  
Other (income) expense     31,874       (807,137 )
Provision for income taxes     -       -  
(Loss) income from discontinued operations   $ (791,936 )   $ 115,787  

XML 90 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 91 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings (Loss) Per Share (Details Narrative)
Dec. 26, 2019
shares
Subsequent Event [Member]  
Total dilutive potential common shares, including outstanding common stock 753,900,000,000
XML 92 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accounts Receivable - Schedule of Accounts Receivable (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Accounts receivable, gross $ 45,793,510 $ 32,229,653
Less: Amount purchased by factors (1,572,000)
Less: Allowance for discounts
Less: Allowance for bad debts (2,787,894) (2,777,521)
Accounts receivable, net 5,108,462 3,811,749
Clinical Laboratory Operations [Member]    
Accounts receivable, gross 41,750 622,009
Less: Allowance for discounts (26,182) (573,584)
Hospitals Operations [Member]    
Accounts receivable, gross 45,804,056 31,607,644
Less: Allowance for discounts (36,298,972) (25,066,799)
Other [Member]    
Accounts receivable, gross $ (52,296)
XML 93 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Derivative Financial Instruments and Fair Value (Details Narrative)
3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Segment
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Segment
Dec. 31, 2018
USD ($)
Derivative liabilities $ 455,336   $ 455,336   $ 350,260
Conversion price percentage     85.00%    
Deemed dividends   $ 17,900,000 $ 123,900,000 $ 17,900,000  
Interest expense $ 5,400,000   9,500,000    
Amortization of debt discount     $ 6,386,305 16,080,270  
Gain loss realized on instrument   109,300,000   13,700,000  
Warrants [Member]          
Discount on debentures   $ 8,300,000   $ 300,000  
Risk Free Interest Rate [Member] | Minimum [Member] | Pre-Modification [Member]          
Warrants, measurement input, percentage 2.44 1.91 2.44 1.91  
Risk Free Interest Rate [Member] | Minimum [Member] | Post-Modification [Member]          
Warrants, measurement input, percentage 2.23 2.09 2.23 2.09  
Risk Free Interest Rate [Member] | Maximum [Member] | Pre-Modification [Member]          
Warrants, measurement input, percentage 2.46 2.32 2.46 2.32  
Risk Free Interest Rate [Member] | Maximum [Member] | Post-Modification [Member]          
Warrants, measurement input, percentage 2.49 2.56 2.49 2.56  
Volatility [Member] | Minimum [Member] | Pre-Modification [Member]          
Warrants, measurement input, percentage 182.9 184.0 182.9 184.0  
Volatility [Member] | Minimum [Member] | Post-Modification [Member]          
Warrants, measurement input, percentage 198.3 208.2 198.3 208.2  
Volatility [Member] | Maximum [Member] | Pre-Modification [Member]          
Warrants, measurement input, percentage 204.4 296.3 204.4 296.3  
Volatility [Member] | Maximum [Member] | Post-Modification [Member]          
Warrants, measurement input, percentage 259.4 249.1 259.4 249.1  
Expected Term [Member] | Pre-Modification [Member]          
Warrants term   3 months 29 days   3 months 29 days  
Expected Term [Member] | Post-Modification [Member]          
Warrants term   7 months 24 days   7 months 24 days  
Expected Term [Member] | Minimum [Member] | Pre-Modification [Member]          
Warrants term 2 months 27 days   2 months 27 days    
Expected Term [Member] | Minimum [Member] | Post-Modification [Member]          
Warrants term 5 months 23 days   5 months 23 days    
Expected Term [Member] | Maximum [Member] | Pre-Modification [Member]          
Warrants term 4 months 9 days   4 months 9 days    
Expected Term [Member] | Maximum [Member] | Post-Modification [Member]          
Warrants term 2 years 10 months 21 days   2 years 10 months 21 days    
Derivative Liabilities [Member] | Risk Free Interest Rate [Member] | Minimum [Member]          
Fair value assumptions, measurement input, percentage 2.4 2.36 2.4 2.36  
Derivative Liabilities [Member] | Risk Free Interest Rate [Member] | Maximum [Member]          
Fair value assumptions, measurement input, percentage 2.6 2.88 2.6 2.88  
Derivative Liabilities [Member] | Volatility [Member] | Minimum [Member]          
Fair value assumptions, measurement input, percentage 189.5 163.8 189.5 163.8  
Derivative Liabilities [Member] | Volatility [Member] | Maximum [Member]          
Fair value assumptions, measurement input, percentage 273.1 234.7 273.1 234.7  
Derivative Liabilities [Member] | Expected Term [Member] | Minimum [Member]          
Fair value assumptions, measurement input, weighted average remaining term   8 months 23 days 3 months 19 days 8 months 23 days  
Derivative Liabilities [Member] | Expected Term [Member] | Maximum [Member]          
Fair value assumptions, measurement input, weighted average remaining term   3 years 6 months 3 years 2 months 12 days 3 years 6 months  
XML 94 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Finance and Operating Lease Obligations - Schedule of Lease-related Assets and Liabilities (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Leases [Abstract]    
Operating leases, Assets $ 328,615  
Finance leases, Assets 618,278  
Total lease assets 946,893  
Operating leases Liabilities, Current 141,830
Finance leases Liabilities, Current 589,457 730,665
Operating leases Liabilities, Non-current 186,785
Finance leases Liabilities, Non-current 28,821 $ 31,543
Total lease liabilities $ 946,893  
Weighted-average remaining term: Operating leases 1 year 11 months 23 days  
Weighted-average remaining term: Finance leases 2 months 8 days  
Weighted-average discount rate: Operating leases [1] 13.00%  
Weighted-average discount rate: Finance leases 5.122%  
[1] Upon adoption of the new lease standard, discount rates used for existing operating leases were established at January 1, 2019.
XML 95 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Deficit (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 12, 2019
Jul. 23, 2018
Jul. 16, 2018
Aug. 14, 2017
Mar. 27, 2019
Sep. 30, 2017
Sep. 30, 2019
Mar. 31, 2019
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Sep. 18, 2018
Sep. 17, 2018
Jul. 20, 2018
Common stock shares authorized             10,000,000,000         10,000,000,000   10,000,000,000 10,000,000,000    
Common stock par value             $ 0.0001         $ 0.0001   $ 0.0001 $ 0.0001 $ 0.01  
Preferred stock shares authorized             5,000,000         5,000,000     5,000,000    
Preferred stock par value             $ 0.01         $ 0.01     $ 0.01    
Number of common stock issued, value               $ 661,381 $ 3,957,767            
Stock conversion share price                 $ 991,578 $ 4,037,089 $ 3,056,674            
Common stock shares issued             8,398,936,775         8,398,936,775   128,567,273      
Common stock shares outstanding             8,398,936,775         8,398,936,775   128,567,273      
Recognized stock stock-based compensation             $ 8,650         $ 25,950 $ 739,729        
Interest expense             5,400,000         9,500,000          
Amortization of debt discount                       6,386,305 $ 16,080,270        
Employees and Directors [Member] | Restricted Stock [Member]                                  
Number of restricted stock issued                         142,667        
Recognized stock stock-based compensation                         $ 477,933        
Stock issued price per share                 $ 3.35       $ 3.35        
2007 Equity Plan [Member]                                  
Stock option expense                       $ 25,950 $ 72,590        
Weighted average period                       6 years 6 months          
Intrinsic value of options exercisable             $ 0         $ 0          
2007 Equity Plan [Member] | Restricted Stock [Member]                                  
Number of restricted stock issued were forfeited                       123          
2007 Equity Plan [Member] | Employees and Directors [Member] | Restricted Stock [Member]                                  
Number of restricted stock issued       364                          
Common Stock [Member]                                  
Number of common stock issued               119,615,384 768,548 572,480 151,200 119,615,384          
Number of common stock issued, value               $ 11,961 $ 77 $ 57 $ 15            
Stock conversion share price                 $ 165 $ 157 $ 67            
Conversion of stock into shares                 1,649,059 1,571,000 666,621            
Cashless exercise warrants             755,000,000         755,000,000          
Number of shares converted                       8,150,754,118   106,335,991      
Number of restricted stock issued                     142,667            
Warrants [Member]                                  
Number of warrants issued as anti-dilution provision                       582,200,000,000          
Warrant expiration date Mar. 31, 2022                                
Change in fair value of warrants $ 5,400,000       $ 4,100,000                        
Discount on debentures                 $ 8,300,000       300,000        
Series G Preferred Stock [Member]                                  
Preferred stock shares authorized             14,000         14,000   14,000      
Preferred stock par value             $ 0.01         $ 0.01   $ 0.01      
Preferred stock shares outstanding             215         215   215      
Preferred stock, stated value             $ 1,000         $ 1,000          
Weighted average common stock price percentage                       85.00%          
Series H Preferred Stock [Member]                                  
Preferred stock shares authorized             14,202         14,202   14,202      
Preferred stock par value             $ 0.01         $ 0.01   $ 0.01      
Preferred stock shares outstanding             10         10   60      
Preferred stock, stated value             $ 1,000         $ 1,000          
Weighted average common stock price percentage                       85.00%          
Series F Convertible Preferred Stock [Member]                                  
Preferred stock shares outstanding             1,750,000         1,750,000          
Series F Convertible Preferred Stock [Member] | Genomas, Inc [Member]                                  
Number of common stock issued           1,750,000                      
Number of common stock issued, value           $ 174,097                      
Stock conversion share price           $ 14,625                      
Conversion of stock into shares           120                      
Preferred stock price per share for unpaid dividend           $ 1.95                      
Series J Convertible Preferred Stock [Member]                                  
Common stock shares authorized                                 250,000
Preferred stock shares outstanding             250,000         250,000          
Series J Convertible Preferred Stock [Member] | Exchange Agreement [Member] | Alcimede LLC [Member]                                  
Number of shares issued upon conversion, value   $ 250,000                              
Number of shares issued upon conversion   250,000                              
Conversion price, per share   $ 1.00                              
Cumulative dividends percentage   8.00%                              
Series I-2 Preferred Stock [Member]                                  
Number of shares issued upon conversion, value                         $ 1,500,000        
Number of shares issued upon conversion     2,176.975                            
Number of shares converted                       982.101   1,286.141      

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